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Abstract	Steven	C.	Hair	Determining	the	role	of	the	LPI/GPR55	system	in	the	development	of	obesity	and	associated	cardiovascular	consequences.	A	thesis	submitted	in	partial	fulfilment	for	the	degree	of	Doctor	of	Philosophy.		Obesity	 has	 reached	 worldwide	 epidemic	 proportions	 and	 with	 this	 increased	incidence	 of	 obesity,	 comes	 an	 increase	 in	 incidence	 of	 the	 comorbidities	associated	with	 obesity	 such	 as	 diabetes	 and	 cardiovascular	 disease	 (CVD).	 The	underlying	mechanisms	which	connect	these	diseases	are	still	poorly	understood.	One	system	which	has	been	shown	to	be	up-regulated	in	the	setting	of	obesity	and	diabetes	 is	 that	 of	 the	 G-protein	 coupled	 receptor-55/Lysophosphatidylinositol	(GPR55/LPI).	Despite	being	upregulated	 in	 the	setting	of	obesity,	 the	 function	of	GPR55	in	obesity	and	other	disease	states	remains	elusive.	Therefore,	the	present	study	 aimed	 to	1)	 investigate	 the	 role	 of	GPR55	 in	 obesity	by	 characterising	 the	phenotype	of	the	GPR55	knockout	(GPR55-/-)	mouse	when	challenged	with	a	high	fat	diet	(HFD)	intervention,	2)	elucidate	any	effect	of	the	GPR55	knockout	and	HFD	intervention	 on	 the	 myocardial	 infarct	 size	 sustained	 following	 a	 period	 of	ischaemia/reperfusion	(I/R)	and	3)	make	use	of	an	in	vitro	model	to	elucidate	the	mechanisms	 by	 which	 changes	 occur	 in	 the	 adipose	 tissue	 of	 mice	 fed	 a	 HFD.	GPR55-/-	mice	fed	a	HFD	for	12-weeks	gained	significantly	more	weight	in	the	form	of	fat	mass,	compared	to	wild-type	(WT)	controls	and	consequently	become	obese.	Obese	 GPR55-/-	 mice	 displayed	 hypertrophic	 adipose	 tissue	 concurrent	with	 the	significant	 dysregulation	 of	 plasma	 lipids,	 increases	 in	 specific	 circulating	 LPI	species,	increased	lipid	deposition	within	the	liver	and	a	change	in	adipose	tissue	gene	expression	profile.	These	changes	were	not	observed	in	GPR55-/-	mice	 fed	a	standard	 diet	 or	WT	mice	 fed	 a	HFD.	 Following	 a	 period	 of	 I/R,	 the	myocardial	infarct	 size	 in	 hearts	 from	 WT	 HFD	 fed	 mice	 was	 significantly	 smaller	 than	 in	hearts	 from	WT	standard	diet	 fed	mice.	This	reduction	 in	infarct	size	due	to	HFD	intervention	was	not	dependent	on	RISK-pathway	activation	and	was	not	observed	in	hearts	 from	GPR55-/-	mice,	 therefore	demonstrating	 that	 the	cardio-protective	effect	of	a	HFD	on	infarct	size	is	dependent	on	GPR55.	In	vitro	studies	using	3T3-L1	cells	 determined	 that	 the	 changes	 in	 adipose	 tissue	 gene	 expression	 of	HFD	 fed	mice	was	not	due	 to	 enhanced	 stimulation	with	LPI	 or	 via	hypoxic	mechanisms.	The	results	of	these	studies	demonstrate	that	GPR55	has	an	anti-obesity	function	
in	 vivo	 and	 also	 mediates	 the	 cardio-protective	 effect	 of	 a	 HFD	 on	 myocardial	infarct	size,	through	currently	unknown	mechanisms.		
Keywords:	Myocardial	 ischaemia,	Reperfusion,	GPR55,	Lysophosphatidylinositol,	Obesity.		 	
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1.1. The Cardiovascular System 
The	 cardiovascular	 system,	 comprising	 of	 the	 heart	 and	 all	 blood	 vessels,	 is	 the	principal	system	responsible	for	maintaining	body	homeostasis,	with	the	delivery	of	oxygen	and	nutrient	rich	blood,	and	removal	of	metabolism	waste	by-products	to	and	from	tissues.	Oxygenated	blood	from	the	pulmonary	system	is	pumped	via	the	heart	 through	arteries	and	delivered	 to	all	 peripheral	 tissues	by	networks	of	capillaries,	 delivering	 the	 necessary	 nutrients	 and	 oxygen	 by	 diffusion	 through	capillary	membranes;	simultaneously	removing	the	waste	products	of	metabolism	and	returning	to	the	heart	via	veins	in	a	closed	loop	system.		
1.1.1. Prevalence of cardiovascular disease 
Dysregulation	or	failure	of	the	cardiovascular	system	is	common	and	encompasses	many	 disease	 states,	 including:	 coronary	 artery	 disease,	 acute	 myocardial	infarction	 (AMI),	 stroke,	 hypertension,	 atherosclerosis,	 heart	 failure	 and	 others;	these	diseases	are	 collectively	 referred	 to	as	cardiovascular	disease	 (CVD;	World	Health	Organisation	2017).	Each	year	CVD	accounts	for	the	largest	cause	of	death	globally,	 accounting	 for	 32%	 of	 all	 recorded	 deaths	 in	 2015,	 with	 17.7	 million	people	dying	from	CVD	related	causes	 (World	Health	Organisation	2017).	During	2012	in	the	UK	alone,	CVD	and	particularly	coronary	artery	disease,	accounted	for	the	largest	cause	of	death	in	women	(with	28%	of	women	dying	from	CVD)	but	not	men	 (28%	 as	 opposed	 to	 32%	 for	 cancer;	 Bhatnagar	 et	 al.	 2015).	 This	 large	prevalence	 of	 CVD	 is	 reflected	 in	 the	 financial	 burden	 on	 the	 National	 Health	Service	of	England,	where	£6.8	billion	was	spent	 in	2013/2014	on	treating	those	with	CVD	(Bhatnagar	et	al.	2015).	Similarly,	CVD	in	the	USA	is	the	leading	cause	of	death	and	accounted	for	30%	of	all	deaths,	with	around	1	in	3	people	dying	from	CVD	 in	 2014;	 this	 is	 despite	 a	 falling	 trend	 in	 the	 absolute	 number	 of	 people	suffering	with	 CVD	 since	 1979	 (Benjamin	 et	 al.	 2017).	 Although	 the	 risk	 of	 CVD	increases	with	age,	36%	of	the	deaths	reported	in	the	USA	due	to	CVD	were	people	under	the	age	of	75,	therefore	highlighting	the	dangers	of	premature	death	due	to	CVD	(Benjamin	et	al.	2017).	The	cause	of	this	increasing	figure	in	relatively	young	people	is	thought	to	be	a	general	lack	of	exercise	and	physical	health	coupled	with	the	ever-increasing	rise	in	obesity	and	metabolic	syndrome,	a	phenomenon	that	is	
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explored	in	later	sections	of	this	thesis.	Of	the	CVDs,	coronary	heart	disease	is	the	most	prevalent	and	accounted	for	46%	of	all	CVD	related	deaths	in	the	UK	during	2012,	and	20%	of	all	CVD	related	deaths	in	Europe	(latest	data	taken	from	multiple	years;	Bhatnagar	et	al.	2015,	Townsend	et	al.	2016).	Similarly,	in	the	USA,	it	is	estimated	that	an	American	suffers	an	AMI	every	 40	 seconds	 (based	 on	 most	 recent	 data	 from	 the	 American	 Heart	Association;	Benjamin	et	al.	2017).		
1.1.2. Acute myocardial infarction 
Within	 the	 classification	 of	 coronary	 heart	 disease,	 acute	 myocardial	 infarction	(AMI;	 commonly	 referred	 to	 as	 a	 heart	 attack)	 occurs	when	 there	 is	 insufficient	blood	flow	via	the	coronary	arteries	to	the	heart	muscle,	leading	to	ischaemia	and	a	build-up	of	metabolites	within	 the	 tissue;	which	 is	due	 to	either	 reduced	 flow	or	total	blockage	of	an	artery,	both	of	which	 lead	 to	 loss	of	 function	and	eventually	necrosis	 of	 cardiomyocytes.	 The	 cause	 of	 AMI	 is	 usually	 atherosclerosis,	 plaque	formation	 and	 subsequent	 rupture	 within	 the	 coronary	 arteries	 (Jefferson	 and	Topol	2005).	 It	 is	expected	 that	atherosclerosis	and	plaque	 formation	within	 the	coronary	 arteries	 is	 almost	 endemic	within	Western	 society	 due	 to	 a	mixture	 of	genetic	 and	 environmental	 factors	 such	 as	 poor	 diet	 and	 low	 physical	 activity;	subsequently,	 it	 is	 not	 surprising	 that	many	of	 those	 living	with	 coronary	 artery	disease	go	on	to	suffer	an	AMI	(Jefferson	and	Topol	2005).		
1.1.3. Molecular events during AMI 
Upon	 coronary	 artery	 occlusion	 and	 regional	 ischaemia	 of	 the	 cardiac	 tissue,	 a	cascade	of	multiple	mechanisms	begins	 to	unfold	which	 lead	 to	 tissue	damage	 if	left	 untreated.	 However,	 upon	 reperfusion	 of	 the	 tissue	 with	 oxygenated	 blood,	further	injury	to	the	tissue	may	be	initiated,	which	is	independent	of	the	effects	of	ischaemia	 and	 is	 referred	 to	 as	 ‘reperfusion	 injury’.	 Under	 standard	 normoxic	conditions,	 the	 cardiomyocyte	 continuously	 generates	 high	 energy	 adenosine	triphosphate	(ATP),	which	is	required	for	the	maintenance	of	ion	homeostasis	and	heart	 muscle	 contraction,	 via	 aerobic	 glycolysis	 of	 glucose	 and	 the	 electron	
	 4	
transport	 chain	within	 the	mitochondria.	As	 cardiomyocytes	have	a	 low	capacity	for	storage	of	ATP	(Griese	et	al.	1988),	within	the	first	30	seconds	of	ischaemia	and	the	cessation	of	aerobic	processes,	the	mitochondria	can	no	longer	synthesise	ATP	to	the	 level	required	by	the	cell;	 therefore,	 the	 level	of	ATP	begins	to	 fall	and	the	cell	 must	 utilise	 anaerobic	 mechanisms	 to	 ensure	 ATP	 production	 and	 cellular	survival	(Carmeliet	1999,	De	Zwaan,	Daemen	and	Hermens	2001).		Despite	a	failing	of	the	electron	transport	chain	and	reduced	generation	of	ATP	by	mitochondria,	 levels	 of	 ATP	 are	 relatively	 stable	 for	 the	 first	 10-15	 min	 of	ischaemia	 and	 can	 remain	 above	 50%	 of	 normal	 levels	 due	 to	 stimulation	 of	anaerobic	glycolysis	and	the	increased	generation	of	pyruvate.	However,	anaerobic	glycolysis	 also	 produces	 lactate,	 accumulation	 of	 which	 leads	 to	 osmotic	 stress	within	 the	 cells,	 with	 water	 accumulation	 via	 osmosis	 and	 disruption	 of	 the	sarcolemma.	Simultaneously,	a	high	level	of	lactate	inhibits	the	glycolytic	pathway,	preventing	 further	 ATP	 production	 (Carmeliet	 1999,	 De	 Zwaan,	 Daemen	 and	Hermens	 2001).	 A	 major	 consequence	 of	 reduced	 ATP	 production,	 along	 with	reduced	 contractile	 function,	 is	 the	 disruption	 of	 ion	 homeostasis	 within	 the	cardiomyocyte.	
1.1.4. Ion homeostasis disruption during AMI 
The	consequence	of	impaired	oxidative	phosphorylation,	lactate	accumulation	and	a	fall	in	the	level	of	ATP	during	ischaemia	is	the	dysregulation	of	ion	homeostasis,	with	 principal	 increases	 in	 intracellular	 H+,	 Na+	 and	 Ca2+	 concentrations	 and	 an	extracellular	 increase	 in	K+	concentration,	culminating	 in	acidosis	and	impedance	of	 the	 electrical	 conductance	 and	 contraction	 of	 the	 cardiac	 tissue,	 which	 may	result	in	cell	death	(Figure	1.1;	Pie	and	Czubryt	1995).	
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Figure 1.1. Diagram representing a simplified mechanism of cell death in AMI. [ion]i 
represents intracellular ion concentration. [ion]e represents extracellular ion concentration.  
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The	most	rapid	effect	of	ischaemia,	in	terms	of	ion	homeostasis,	is	in	relation	to	the	extracellular	 K+	 concentration,	which	 increases	 rapidly	within	 20	 seconds	 of	 the	onset	 of	 ischaemia,	 plateaus	 after	 10	 min	 and	 then	 steadily	 increases	 further	between	10-15	min	after	the	onset	(Wilde	and	Aksnes	1995).	However,	this	rapid	effect	 is	 only	 observed	 in	 situ	 where	 there	 is	 stimulation	 of	 the	 tissue	 by	 the	sympathetic	 nervous	 system	 and	 the	 absolute	 levels	 of	 extracellular	 K+	 during	these	 phases	 vary	 greatly	 between	 species	 when	 studied	 experimentally	(Carmeliet	1999).	This	extracellular	accumulation	of	K+	occurs	as	a	consequence	of	(1)	 decreased	 volume	 of	 the	 extracellular	 space	 due	 to	 osmosis	 and	 the	accumulation	of	lactate	within	the	cell	(Tranum-Jensen	et	al.	1981),	(2)	a	reduced	influx	of	K+	 into	cells	via	 the	Na+/K+-ATPase	 (Weiss	and	Shine	1986),	and	 (3)	an	increase	in	passive	efflux	of	K+	into	the	extracellular	space	(Carmeliet	1999).	Acidosis,	a	reduction	 in	 intra/extracellular	pH	 to	values	as	 low	as	6.0,	 is	strongly	associated	 with	 ischaemia	 and	 is	 predominantly	 caused	 by	 3	 main	 mechanisms	(Carmeliet	 1999).	 Firstly,	 and	 chiefly,	 acidosis	 occurs	 through	 an	 increased	production	 of	 H+	 ions	 due	 to	 the	 activation	 of	 the	 anaerobic	 glycolytic	 pathway	during	ischaemia,	as	it	has	been	demonstrated	that	when	this	pathway	is	blocked	during	ischaemia,	the	usual	resulting	acidosis	is	also	prevented	(Allen	et	al.	1985).	Secondly,	the	chemical	hydrolysis	of	ATP	naturally	results	in	the	production	of	H+	ions	 and	 finally,	 due	 to	 the	 retention	 of	 CO2	 within	 the	 tissue	 which	 would	normally	be	removed	via	diffusion	into	the	blood,	there	is	a	build	up	of	acidic	ions	(Carmeliet	1999,	Hayashi	et	al.	1992,	Eisner	et	al.	1989).	Intracellular	 sodium	 ion	accumulation	within	 the	cell	occurs	via	both	 the	 inward	movement	of	Na+	through	the	late	INa	channel	(which	also	occurs	under	normoxic	conditions)	and	an	inability	of	the	Na+/K+-ATPase	transporter	to	remove	Na+	from	the	 cytosol,	 due	 to	 the	 reduced	 availability	 of	 ATP	 during	 prolonged	 periods	 of	ischaemia	 (>20	 min;	 Hale	 et	 al.	 2008,	 Hoyer	 et	 al.	 2011).	 Furthermore,	 in	 an	attempt	 to	normalise	 the	 acidic	 intracellular	 environment	 via	 the	 removal	 of	H+	ions,	 the	Na+/H+-exchanger	 is	 activated,	 further	 increasing	 the	 influx	 of	Na+	 into	the	cytosol	(Turer	and	Hill	2010).		Calcium	ion	homeostasis	is	influenced	by	multiple	mechanisms	during	ischaemia;	firstly,	Ca2+	 ions	are	displaced	 from	their	 cellular	binding	sites	due	 to	acidosis	of	
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the	 intracellular	 environment,	 leading	 to	 an	 initial	 increase	 in	 intracellular	 free	Ca2+	(Gambassi	et	al.	1993).	Secondly,	the	increased	concentration	of	intracellular	Na+	 leads	 to	 the	 reversal	 of	 the	 Na+/Ca2+-exchanger,	 which	 under	 normoxic	conditions	 ejects	 Ca2+	 from	 the	 cell	 and	 imports	 Na+	 ions.	 The	 reversal	 of	 the	Na+/Ca2+	exchanger	is	considered	to	be	one	of	the	main	mechanisms	contributing	to	intracellular	overload	of	Ca2+	ions,	an	event	which	is	a	key	contributory	factor	to	the	damage	caused	by	ischaemia/reperfusion	(I/R)	injury	(De	Zwaan,	Daemen	and	Hermens	2001,	Turer	and	Hill	2010,	Haigney	et	al.	1994).		Concomitant	with	the	reversal	of	the	Na+/Ca2+-exchanger,	there	is	reduced	uptake	of	 Ca2+	 by	 the	 sarcoplasmic	 reticulum.	 This	 reduced	 uptake	 of	 Ca2+	 is	 due	 to	 a	reduction	 in	 the	 maximum	 velocity	 of	 uptake	 of	 the	 sarcoplasmic	 Ca2+-ATPase	transporter,	 due	 to	 the	 reduced	 availability	 of	 ATP	 and	 subsequent	 hydrolysis	during	ischaemia	(Carmeliet	1999,	Kaplan	et	al.	1992).	These	three	mechanisms	all	result	 in	 intracellular	 free	 calcium	 overload	 during	 ischaemia	 and	 can	 induce	ventricular	arrhythmias	as	a	consequence	of	the	shortening	of	the	action	potential	that	 regulates	 the	 heart	 contraction.	 In	 addition,	 if	 physiological	 Ca2+	concentrations	 are	 not	 rapidly	 restored	 upon	 reperfusion,	 opening	 of	 the	mitochondrial	permeability	 transition	pore	 (mPTP)	occurs	 initiating	cell	 death,	a	primary	cause	of	reperfusion	injury	(Carmeliet	1999).		The	major	consequences	of	 these	ionic	dysregulations	during	ischaemia	is	hyper-contracture	 of	 myofibrils	 within	 the	 tissue,	 structural	 damage	 to	 mitochondria,	myocardial	 stunning	 and	 an	 increased	 incidence	 of	 arrhythmias	 and	 cell	 death	(Carmeliet	1999,	Turer	and	Hill	2010).	
1.1.5. Myocardial cell death  
Following	 a	 prolonged	 period	 of	 ischaemia	 and	 without	 timely	 reperfusion	 of	blood	 to	 the	 tissue,	 cardiomyocytes	 become	 swollen,	 produce	 high	 amounts	 of	reactive	oxygen	species	(ROS)	due	to	dysregulation	of	mitochondria	and	ultimately	suffer	ultrastructural	damage	to	their	cytoskeleton	and	sarcolemma	which	results	in	physical	 disruption	 and	 cell	 necrosis	 (Buja	2005).	Necrosis	 is	 an	uncontrolled	mechanism	of	cell	death	which	elicits	an	immune	response	due	to	the	unrestricted	release	of	intracellular	components	into	the	interstitial	space	after	the	 loss	of	cell	
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membrane	 integrity.	 This	 form	 of	 cell	 death	 is	 found	within	 the	 central	 zone	 of	ischaemia,	 deep	 within	 the	 tissue	 where	 the	 most	 severe	 injury	 is	 sustained	(Buja2005).	Alternatively,	cells	in	the	peripheral	zone	of	ischaemia	are	less	 likely	to	 suffer	 necrosis	 induced	 damage,	 however,	 due	 to	 the	 gradient	 of	 ischaemia	across	 the	 tissue	 starting	 at	 the	occluded	 artery,	may	die	 via	 apoptosis,	 a	 highly	complex	 and	 sophisticated	 form	of	 cell	 death	 that	 requires	ATP.	During	hypoxia,	the	intrinsic	apoptosis	pathway	is	activated,	whereby	opening	of	the	mPTP	leads	to	the	 loss	 of	 mitochondrial	 membrane	 potential	 and	 the	 release	 of	 pro-apoptotic	proteins	 from	 the	 intermembrane	 space	which	 subsequently	 activate	 a	 series	 of	caspase	enzymes	whose	downstream	effects	are	numerous	but	ultimately	result	in	DNA	fragmentation,	cell	shrinkage	and	death	(Elmore	2007).	Although	it	has	been	demonstrated	in	the	rat	heart	that	apoptosis	contributes	to	the	cell	death	observed	in	 ischaemia	without	 reperfusion	 (Kajstura	et	al.	1996),	 it	 is	widely	 thought	 that	apoptosis	 is	 either	 initiated	 or	 at	 least	 accelerated	 at	 the	 reperfusion	 stage	 of	injury	 due	 to	 its	 dependence	 on	 energy	 and	 ATP	 (Hausenloy	 and	 Yellon	 2004).	Interestingly,	 Zhao	 et	 al.	 (2001)	 demonstrated	 using	 a	 canine	model	 of	 I/R	 that	necrosis	and	apoptosis	occur	simultaneously	after	reperfusion	of	 the	tissue,	with	necrosis	being	the	primary	mode	of	cell	death	up	to	24	hours	post-reperfusion	and	apoptotic	 cell	 death	 occurring	more	 so	 in	 the	 later	 phase,	 up	 to	 72	 hours	 post-reperfusion	(Zhao	et	al.	2001).	It	is	now	understood	that	reperfusion	of	ischaemic	tissue	 may	 paradoxically	 contribute	 to	 cell	 death	 and	 can	 increase	 the	 infarct	sustained	after	a	 period	of	 ischaemia;	 this	phenomenon	 is	known	as	 reperfusion	injury	and	many	studies	have	examined	the	therapeutic	potential	of	intervention	at	this	phase	of	injury.		
1.1.6. Reperfusion injury 
Reperfusion	 of	 the	 tissue	 with	 oxygenated	 blood,	 usually	 by	 pharmacological	thrombolysis	or	primary	percutaneous	coronary	intervention	(in	a	clinical	setting),	is	 the	 most	 efficient	 way	 to	 salvage	 ischaemic	 cells	 that	 are	 not	 yet	apoptotic/necrotic,	restoring	their	function	and	therefore	limiting	the	final	infarct	size	sustained	(Hausenloy	and	Yellon	2004).	However,	reperfusion	itself	may	lead	to	cellular	damage	in	potentially	viable	cells	that	were	not	yet	necrotic/apoptotic	
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and	 can	 significantly	 exacerbate	 the	 infarct	 size	 sustained	 after	 a	 period	 of	ischaemia.	 There	 are	multiple	 explanations	 as	 to	why	 reperfusion	 injury	 occurs,	with	the	leading	mechanisms	being	the	oxygen	paradox,	the	calcium	paradox	and	the	initiation	of	an	inflammatory	response.		
1.1.6.1. The oxygen paradox 
The	oxygen	paradox	 is	 characterised	by	damage	 caused	by	 the	reintroduction	of	oxygen	to	the	previously	ischaemic	tissue,	the	extent	of	which	is	greater	than	the	damage	 that	 would	 have	 occurred	 with	 ischaemia	 alone.	 Since	 multiple	 studies	have	shown	that	reperfusion	generates	reactive	oxygen	species	(ROS)	in	vitro	and	
in	vivo	(reviewed	by	Yellon	and	Hausenloy	2007),	re-oxygenation	injury	is	believed	to	 be	 due	 to	 the	 production	 of	 ROS,	 primarily	 superoxide	 and	 hydroxyl	 free	radicals,	 formed	 from	molecular	 oxygen	within	 the	 cells	 via	 enzymatic	 reactions	including	 via	 the	 NADPH	 oxidase	 and	 xanthine	 oxidase	 systems	 (Yellon	 and	Hausenloy	2007,	Maxwell	and	Lip	1997).	However,	treatment	with	ROS	scavengers	and/or	 antioxidants	 at	 the	 time	 of	 reperfusion	 has	 produced	 mixed	 results	(reviewed	 by	 Marczin	 et	 al.	 2003).	 For	 example,	 the	 ISLAND	 trial,	 which	 used	supplementation	 with	 N-acetylcysteine,	 a	 glutathione	 precursor,	 demonstrated	that	 it	 could	reduce	 infarct	 size	 and	 improve	 left	 ventricular	 function	 in	patients	suffering	 with	 AMI	 (Sochman2002).	 Similarly,	 other	 groups	 have	 also	 reported	better	outcomes	such	as	a	reduction	in	infarct	size	and	arrhythmias	when	treating	patients	presenting	with	 an	AMI	with	 free	 radical	 scavengers	 such	 as	 edaravone	(Tsujita	 et	 al.	 2006,	 Becker	 2004).	 Conversely,	 in	 other	 human	 clinical	 trials,	administration	of	the	human	SOD	enzyme	in	order	to	increase	the	oxidant	capacity	at	 the	 time	 of	 reperfusion	 was	 unable	 to	 confer	 any	 cardiovascular	 benefit	 in	patients	suffering	an	AMI	(Flaherty	et	al.	1994)	and	likewise,	antioxidants	vitamin	E	 and	 beta-carotene	 administered	 long-term	 in	 a	 large	 trial	 of	 men	 who	 had	previously	suffered	an	AMI	failed	to	improve	future	coronary	events	(Rapola	et	al.	1997).		Oxygen	free	radicals	may	be	produced	by	a	number	of	mechanisms	within	the	cell	upon	 reperfusion,	 mostly	 via	 activation	 of	 enzymatic	 reactions	 such	 as	 the	mitochondrial	 cytochrome	oxidase	and	xanthine	oxidase	pathways	which	 lead	 to	
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immediate	cellular	 injury;	however,	 it	 is	also	established	that	neutrophils	rapidly	accumulate	at	 the	site	of	 I/R	 injury	upon	reperfusion	and	also	contribute	 to	ROS	accumulation	in	the	form	of	superoxide	production,	leading	to	delayed	reperfusion	injury	 hours	 or	 often	 days	 after	 the	 initial	 reperfusion	 of	 tissue	 (Yellon	 and	Hausenloy	2007,	Park	and	Lucchesi	1999).	The	cellular	consequence	of	high	ROS	levels	 includes	 DNA	 and	 protein	 damage,	 irreversible	 structural	 damage,	 lipid	peroxidation	 and	 loss	 of	 cellular	 integrity;	 all	 of	 which	 lead	 to	 cell	 death	 via	apoptosis	or	necrosis	depending	on	the	degree	of	injury.	
1.1.6.2. The calcium paradox 
Reperfusion	injury	may	also	be	explained	via	the	calcium	paradox,	which	has	been	demonstrated	 in	 a	 number	 of	 species.	 Reperfusion	 of	 isolated	 hearts	with	 Ca2+-containing	 solutions	 after	 a	 period	 of	 Ca2+-free	 solution	 results	 in	 exacerbated	tissue	damage,	ATP	depletion	and	disruption	of	the	cellular	membrane	(reviewed	by	Hoffman	et	al.	2004).	Following	a	prolonged	period	of	ischaemia,	a	high	level	of	intracellular	Ca2+	are	present	as	a	result	of	 ion	dysregulation	as	discussed	above.	Upon	reperfusion	the	oxygen	consumption	of	the	cells	quickly	returns	to	baseline,	however	 the	 cardiomyocyte	 is	 unable	 to	 remedy	 the	 increase	 in	 intracellular	calcium	 rapidly	 as	 the	 Ca2+-transporters	 of	 the	 sarcoplasmic	 reticulum	 and	mitochondria	 require	 ATP	 and	 therefore	 are	 activated	 secondary	 to	 ATP	production;	 consequently,	 the	 recommencement	 of	 aerobic	 ATP	 production	alongside	 the	 raised	 intracellular	 Ca2+	 leads	 to	 myofibrillar	 activation	 and	hypercontracture	 of	 the	 tissue.	 Hypercontracture,	 defined	 as	 irreversible	 cell	shortening	 beyond	 the	 normal	 range	 of	 contraction	 due	 to	 deformation	 of	 the	cytoskeletal	 components	 of	 the	 cell,	 leads	 to	 cell	 death,	 but	 can	 also	 cause	 cell	death	of	adjacent	cells	due	to	the	physical	mechanical	stress	applied	to	these	cells	and	the	free	movement	of	Ca2+	through	gap	junctions	of	adjoining	cells	leading	to	further	 hypercontracture	 (Piper	 and	 Garcı́a-Dorado	 1999).	 It	 has	 been	demonstrated	 in	 the	 isolated	 rat	 heart	 (Schluter	 et	 al.	 1991),	 isolated	 guinea	pig	heart	(Habazettl	et	al.	1996)	and	the	dog	heart	(Schlack	et	al.	1994)	that	inhibition	of	 the	 contractile	 machinery	 of	 the	 cardiac	 tissue	 during	 early	 reperfusion	 can	effectively	 limit	 the	 infarct	 damage	sustained;	 therefore	hypercontracture	due	 to	
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Ca2+	overload	is	regarded	as	a	primary	mechanism	of	reperfusion	injury	(Hoffman	Jr	et	al.	2004,	Piper	and	Garcı́a-Dorado	1999).		Although	each	pathway	independently	causes	cellular	injury	upon	reperfusion	and	may	 influence	 one	 another,	 the	 oxygen	 and	 calcium	 paradoxes	 converge	 at	 the	level	 of	 the	mitochondria,	 inducing	mitochondrial	 damage,	where	 increased	ROS	and	 the	 high	 concentration	 of	 Ca2+	 are	 crucial	 in	 mediating	 the	 formation	 and	opening	of	the	mPTP.	
1.1.6.3. Neutrophil activation 
Another	contributor	to	reperfusion	injury	is	both	the	accumulation	(at	the	site	of	I/R	 injury)	 and	 subsequent	 activation	 (by	 inflammatory	 molecules	 such	 as	cytokines)	 of	 neutrophils	 (Vinten-Johansen	 2004).	 These	 activated	 neutrophils	play	 multiple	 roles	 in	 mediating	 delayed	 reperfusion	 injury	 by	 causing	 direct	damage	 to	 cells	 via	 further	 generation	 of	 ROS,	 endothelial	 dysfunction	 and	 the	plugging	of	 capillaries	due	 to	excess	aggregation	of	neutrophils	 –	a	phenomenon	known	as	“no-reflow”	(Hoffman	Jr	et	al.	2004).	No-reflow	in	particular,	may	lead	to	further	 tissue	 ischaemia	 due	 to	 the	 blockage	 of	 small	 capillaries	 by	 the	accumulated	 neutrophils,	 whereas	 the	 production	 of	 ROS	 and	 cytokines	 by	activated	 neutrophils	 can	 cause	 cellular	 apoptosis	 and	 cell	 death	 by	 the	mechanisms	already	discussed.		
1.1.7. The RISK pathway in I/R 
As	apoptotic	 cell	death	 is	 initiated	or	accelerated	at	 the	 reperfusion	stage	of	 I/R,	much	 attention	 has	 been	 given	 to	 the	 activation	 of	 endogenous	 cellular	 anti-apoptotic	 pathways	 as	 a	potential	 therapeutic	 strategy	 for	 treating	patients	with	AMI.	These	pathways	principally	 converge	at	 the	 level	of	 two	major	pro-survival	kinases,	 the	 extracellular-signal	 regulated	 kinase	 1/2	 (ERK1/2;	 also	 known	 as	p42/p44	MAPK)	and	Akt	(also	known	as	Protein	Kinase	B)	pathways	(Hausenloy	and	Yellon	2004).	Subsequently,	these	pathways	have	been	collectively	termed	the	‘reperfusion	 injury	 salvage	 kinase’	 (RISK)	 pathway,	 as	 both	 ERK1/2	 and	 Akt	activation	 has	 been	 demonstrated	 to	 confer	 powerful	 cardio-protective	 effects	
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when	activated	at	the	time	of	reperfusion	(Hausenloy	and	Yellon	2004,	Hausenloy	and	Yellon	2007).		
1.1.7.1. The ERK1/2 pathway in I/R 
The	ERK1/2	proteins	are	members	of	a	family	of	serine-threonine	kinases	that	are	principally	responsible	for	regulation	of	cell	cycle,	cell	proliferation,	differentiation	and,	most	relevant	to	I/R	injury,	cell	survival	(Roskoski2012).	The	ERK1/2	kinase	may	 be	 activated	 by	 numerous	 stimuli,	 often	 extracellular	 growth	 factor/ligand	binding	 to	 G-protein	 coupled	 receptors	 that	 activate	 downstream	 kinases	 in	 a	tiered	 kinase	 system	 as	 depicted	 in	 Figure	 1.2.	 However,	 in	 the	 setting	 of	 I/R,	although	activation	of	ERK1/2	has	been	demonstrated	to	confer	cardio-protection,	the	 mechanism	 by	 which	 activation	 occurs	 is	 still	 unclear.	 Activated	 ERK1/2	phosphorylates	 and	 activates	 hundreds	 of	 other	 proteins,	 enzymes	 and	transcription	factors	involved	in	multiple	cellular	processes.	In	the	setting	of	I/R,	it	is	 hypothesised	 that	 ERK1/2	 activation	 confers	 cardio-protection	 by	 the	phosphorylation	and	deactivation	of	a	whole	array	of	pro-apoptotic	proteins.		Two	principal	proteins	 in	mediating	cellular	apoptosis	are	BAD	and	BAX,	both	of	which	are	regulated	by	ERK1/2.	During	apoptosis,	BAD	is	de-phosphorylated	and	BAX	 undergoes	 a	 conformational	 change	 allowing	 its	 translocation	 to	 the	mitochondrial	 membrane;	 these	 changes	 allow	 for	 the	 release	 of	 cytochrome	 c	from	 the	 mitochondria	 and	 subsequent	 cell	 death	 via	 apoptotic	 mechanisms	(Westphal	 et	 al.	 2011).	 However,	 with	 the	 activation	 of	 ERK1/2,	 BAD	 is	phosphorylated,	 which	 sequesters	 it	 away	 from	 the	 mitochondria,	 and	 BAX	 is	unable	to	undergo	its	conformational	change,	thus	preventing	these	proteins	from	their	 pro-apoptotic	 functions	 (Hausenloy	 and	 Yellon	 2004,	 Roskoski2012).	Alternatively,	 it	 has	 also	 been	 demonstrated	 that	 ERK1/2	 may	 promote	 cell	survival	through	its	ability	to	phosphorylate	p90RSK,	a	signal	transducing	protein	that	 is	 able	 to	 regulate	 cAMP-response	 element-binding	 (CREB)	 protein,	 a	transcription	 factor	 that	 regulates	 the	 transcription	 of	 genes	 related	 to	 cellular	survival	(Bonni	et	al.	1999).		
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Figure 1.2. ERK1/2 signalling cascade. ERK1/2 is activated via a series of phosphorylation 
events beginning with extracellular stimulation and subsequent activation of MAP kinase 
proteins in a tiered system of activation.  
1.1.7.2. The Akt pathway in I/R 
The	Akt	protein	 is	a	 serine/threonine	protein	kinase	and	similarly	 to	ERK1/2,	 is	involved	 in	 a	 complex	 system	 of	 downstream	 effects,	 such	 as	 cell	 cycle	 control,	cellular	survival	and	metabolism	via	the	regulation	of	glucose	utilisation	(Cross	et	al.	 2000).	 Activation	 of	 Akt	 is	 dependent	 on	 the	 upstream	 activation	 of	phosphatidylinositol-3-OH	 kinase	 (PI3K;	 Figure	 1.3),	 which	 is	 activated	 by	 the	binding	of	 signalling	molecules	 to	multiple	 receptors,	 including	 those	 for	growth	factors,	G-protein	coupled	receptors,	and	importantly,	the	insulin	receptor.	Again,	similar	 to	 ERK1/2	 activation,	 activation	 of	 the	 PI3K-Akt	 signalling	 cascade	 can	directly	 inhibit	 apoptosis	 by	 the	 phosphorylation	 of	 BAD	 and	 preventing	 the	conformational	 change	 and	 translocation	 of	 BAX	 (Hausenloy	 and	 Yellon	 2004).	Furthermore,	Akt	has	been	shown	to	prevent	cell	death	and	cytochrome	c	release	from	mitochondria	via	a	BAD/BAX-independent	mechanism,	possibly	through	the	inhibition	of	mPTP	opening	(Kennedy	et	al.	1999).		
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A	 large	 array	 of	 hormones	 and	 signalling	molecules	 are	 now	 known	 to	 activate	either	 Akt	 or	 ERK1/2	 and	 therefore	 the	 RISK	 pathway	 during	 the	 reperfusion	phase	of	 I/R,	 including	 leptin,	 insulin	and	 insulin-like	 growth	 factor-1	 (reviewed	extensively	 by	Hausenloy	 and	 Yellon	 2007).	 Furthermore,	 activation	 of	 the	 RISK	pathway	has	also	been	postulated	to	be	a	factor	which	links	the	cardio-protective	effects	 of	 both	 pre	 and	 post-conditioning	on	 the	heart,	 via	 common	mechanisms	which	converge	on	the	mitochondria	and	the	inhibition	of	mPTP	opening.		
	
Figure 1.3. Simplified diagram of PI3K-Akt signalling. PIP2: Phosphatidylinositol 4,5-
bisphosphate, PIP3: Phosphatidylinositol (3,4,5)-trisphosphate, PDK1: phosphoinositide-
dependent protein kinase-1.  
1.1.8. Ischaemic conditioning 
Ischaemic	 conditioning,	 either	 before	 the	 onset	 of	 ischaemia	 (ischaemic	 pre-conditioning;	 IPC)	 or	 at	 the	 time	 and	 after	 reperfusion	 (ischaemic	 post-conditioning;	 IPost),	have	been	shown	 to	be	cardio-protective	and	reduce	 infarct	size	 both	 experimentally	 and	 clinically	 (recently	 reviewed	 extensively	 by	Hausenloy	et	al.	2016).	The	phenomenon	of	IPC	relies	on	several	minutes	of	acute	coronary	occlusion	or	 intermittent	reperfusion	and	ischaemia	at	sub-lethal	 levels	before	the	onset	of	prolonged	ischaemia	and	was	first	described	in	1986	by	Murray	et	 al.	 (Murry,	 Jennings	 and	 Reimer	 1986).	 Although	 IPC	 is	 easily	 induced	
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experimentally,	 it	 is	 much	 more	 difficult	 in	 a	 clinical	 setting	 due	 to	 the	uncontrolled	 nature	 of	 coronary	 heart	 disease	 (CHD)	 and	 AMI	 and	 therefore	clinical	 studies	 have	 been	 limited	 to	 those	 undergoing	 elective	 surgery	 (Heusch	2013).	 However,	 as	 the	 cellular	 pathways	 by	 which	 IPC	 signals	 are	 now	 well	understood,	 including	 the	 RISK,	 survivor	 activating	 factor	 enhancement	 (SAFE;	Lecour	2009)	and	nitric	oxide	(NO)	pathways,	many	studies	have	tested	the	use	of	pharmacological	intervention	(“pharmacological	post-conditioning”)	at	the	time	of	reperfusion	 which	 has	 been	 demonstrated	 to	 act	 via	 RISK/SAFE/NO-dependent	and	independent	pathways	(Heusch	2015).	For	example,	 in	experimental	studies,	exogenous	 application	 of	 hydrogen	 sulphide	 to	 Langendorff-perfused	 rat	 hearts	was	 shown	 to	 limit	 infarct	 size	 in	 the	 setting	 of	 I/R	 via	 a	mechanism	 involving	modulation	of	potassium	channels	 (Johansen,	Ytrehus	and	Baxter	2006).	Further	study	using	hydrogen	sulphide	donor	compounds	has	shown	that	the	mechanism	of	action	is	specific	to	each	compound	and	that	they	reduce	infarct	size	at	the	time	of	reperfusion	due	to	either	activation	of	the	RISK	and	NO	pathways	(Karwi	et	al.	2016)	or	 independent	of	 these	pathways,	possibly	 instead	via	direct	 inhibition	of	mPTP	opening	(Karwi	et	al.	2017).	Clinical	 trials	 that	have	used	pharmacological	post-conditioning	 as	 adjunctive	 therapy	 with	 a	 variety	 of	 possible	 agents	 (for	example	 adenosine	 and	 ciclosporin	 A),	 have	 shown	 mixed	 results,	 with	 many	demonstrating	reduced	 infarct	 sizes	but	no	adjustment	 to	prognosis	or	mortality	(Heusch	2013).	For	example,	the	AMISTAD	and	AMISTAD	II	trials	(using	adenosine	treatment	 adjunctively)	 reported	 reductions	 in	 infarct	 size	 compared	 to	 placebo	controls	(Mahaffey	et	al.	1999,	Ross	et	al.	2005).	However	in	contrast,	another	trial	by	 Fokkema	 et	 al.	 (2009)	 using	 adenosine	 adjunctive	 treatment	 failed	 to	 reduce	infarct	 size	 in	 patients	 suffering	 with	 STEMI	 (Fokkema	 et	 al.	 2009).	 Therefore,	although	pathways	such	as	RISK,	SAFE	and	NO	have	been	demonstrated	to	confer	powerful	cardio-protection	when	activated,	these	pathways	are	not	always	crucial	or	 responsible	 for	 the	 cardio-protection	 offered	 by	 different	 pharmacological	 or	mechanical	interventions.		In	contrast	to	IPC,	IPost	was	not	demonstrated	as	a	concept	until	2003,	when	Zhao	et	 al.	 showed	 that	 3	 cycles	 of	 30	 seconds	 reperfusion	 and	 30	 seconds	 of	 re-occlusion	after	the	onset	of	prolonged	ischaemia	could	reduce	 infarct	size	to	 that	comparable	of	IPC	in	dogs	(Zhao	et	al.	2003).	Where	IPC	delays	the	development	of	
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infarction	by	activation	of	pro-survival	signalling	prior	to	ischaemia,	IPost	reduces	the	lethal	reperfusion	injury	following	ischaemia,	however	both	systems	converge	on	 the	mitochondria	 and	prevent	opening	of	 the	mPTP	via	multiple	mechanisms	and	 pathways	 (Heusch	 2015).	 As	 IPost	 or	 pharmacological	 post-conditioning	occurs	 after	 the	 ischaemic	 period,	 it	 has	 been	 easier	 to	 translate	 to	 a	 clinical	setting,	although	multiple	 trials	have	shown	mixed	results.	Many	 trials	 that	 have	demonstrated	 a	 reduction	 in	 infarct	 size	when	 adopting	 IPost	 adjunctively	 with	percutaneous	coronary	intervention	(reviewed	by	Heusch	2013)	often	have	small	sample	sizes	and	therefore	larger	controlled	trials	would	be	beneficial	to	elucidate	the	 benefits	 of	 IPost	 in	 general	 populations.	 Furthermore,	 whilst	 IPC	 and	 IPost	have	 both	 been	 demonstrated	 to	 reduce	 infarct	 size	 in	 a	 number	 of	 trials	 and	experimental	 studies,	 there	 is	 confounding	 data	 surrounding	 their	 benefit	 in	certain	 disease	 states	 such	 as	 diabetes	 and	 obesity,	 and	 also	 within	 an	 older	population	(Hausenloy	et	al.	2016,	Heusch	2013).	
1.2. Obesity 
Obesity	is	a	disease	state,	characterised	by	excess	adipose	tissue	accumulation	to	an	 extent	 that	 has	 a	 negative	 impact	 on	 health.	 It	 is	 a	 global	 problem	 that	 has	steadily	 increased	 over	 the	 past	 few	 decades	 and	 has	 now	 reached	 epidemic	proportions	 (World	 Health	 Organisation	 2013).	 Adipose	 tissue	 is	 distributed	throughout	 the	 body	 in	 both	 subcutaneous	 and	 visceral	 tissues,	 making	 direct	measurement	of	body	fat	percentage	difficult	 to	 implement	at	a	population	 level;	therefore,	measurements	such	as	Body	Mass	Index	(BMI)	and	waist:hip	ratio	have	been	introduced	to	estimate	such	values.		
1.2.1. Measurement and Assessment of Obesity 
In	 order	 to	 define	 obesity	 in	 a	 medical	 context,	 the	 World	 Health	 Organisation	(WHO)	set	out	guidelines	that	outline	BMI	limits	to	classify	an	individuals’	weight	level	 (World	Health	Organisation	1995).	BMI	 is	 the	most	 common	measurement	used	to	define	weight	status	and	therefore	to	define	obesity.	BMI	is	a	simple,	cost	effective	measurement	that	is	calculated	as	shown	in	Equation	1	as	follows:	
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!"# = %&'(ℎ*	(-()/&'(ℎ*0(1) 	
Equation 1. Calculation of BMI.  
In	1991,	Deurenberg	et.	al.	proposed	that	percentage	body	fat	could	be	accurately	estimated	 from	 BMI	 using	 the	 following	 modelling	 formula	 for	 adults	 where	gender	is	1	for	males	and	0	for	females:	2345*	!637	89*	% = (1.2	 × 	!"#) + (0.23	 × 	2(&) − (10.8	 × 	(&D3&E) − 5.4	
Equation 2. Modelling calculation of body fat percentage in adults using BMI (Deurenberg, 
Weststrate and Seidell 1991). 
Subsequent	WHO	recommendations	(World	Health	Organisation	1995)	state	that,	in	 order	 to	 relate	 a	BMI	 result	 directly	 to	health	 status,	 cut	 off	 points	 should	be	established	 within	 the	 BMI	 scale	 to	 indicate	 the	 health	 status	 of	 an	 individual	(Table	1.1)	rather	than	using	the	Deurenberg	equation	above	and	then	comparing	to	 normal	 fat	 percentages.	 These	 guidelines	 are	 now	 commonplace	 throughout	clinical	medical	practices	and	are	widely	accepted	as	a	quick	and	easy	estimate	of	one’s	weight	status.		
BMI Classification 
<18.5 Underweight 
18.5-24.99 Normal Range 
25-29.99 Overweight 
>30+ Obese 
Table 1.1. Original classification of weight according to BMI by WHO (World Health 
Organisation1995) 
There	are	however,	serious	limitations	of	the	BMI	scale.	Firstly,	the	measurement	does	not	distinguish	between	muscle	and	fat	mass	and	 therefore	those	with	high	muscle	mass,	such	as	body	builders	and	professional	athletes,	may	be	classified	as	obese	using	this	method.	Conversely,	those	with	reduced	muscle	mass,	such	as	the	elderly,	may	be	misclassified	as	being	within	normal	range	despite	their	 fat	mass	being	 increased	 relative	 to	 their	 muscle	 mass.	 Finally,	 whilst	 this	 method	 of	measurement	can	be	applied	globally,	different	ethnic	populations	such	as	those	of	
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an	Asian	decent	have	been	recommended	to	use	varied	BMI	cut-off	values	within	the	scale	(Jih	et	al.	2014),	presumably	due	to	differences	in	fat	deposition	or	body	composition	 variances	 between	 different	 ethnic	 origins	 and	 the	 genetic	underpinning	of	energy	metabolism	and	insulin	signalling.	Other	methods	of	defining	the	weight	status	of	an	individual	may	be	used,	such	as	measuring	 the	 waist	 circumference	 and	 the	 waist:hip	 circumference	 ratio	measurement;	 these	 methods	 help	 to	 eliminate	 error	 caused	 by	 the	 lack	 of	distinguishing	between	muscle	and	fat	weight	when	using	the	BMI	method	alone	(Seidell	and	Flegal	1997).	A	waist	circumference	greater	than	102cm	and	88cm	in	men	and	women,	 respectively,	 is	 indicative	 of	 obesity;	 likewise	 a	waist:hip	 ratio	greater	 than	1.0	and	0.85	 in	men	and	women,	 respectively,	may	 indicate	obesity	(World	 Health	 Organisation2000).	 In	 relation	 to	 suitability	 of	 the	 method	 used,	when	 diagnosing	 obesity	 in	 order	 to	 identify	 cardiovascular	 risk,	 it	 is	 more	appropriate	 to	 use	 sagittal	 abdominal	 diameter	 (Ohrvall,	 Berglund	 and	 Vessby	2000),	waist	circumference	or	wasit:hip	ratio	rather	than	BMI,	as	these	parameters	have	been	identified	as	independent	risk	factors	of	cardiometabolic	diseases	such	as	 myocardial	 infarction	 and	 diabetes,	 even	 after	 correction	 of	 BMI;	 however	despite	this,	many	studies	that	examine	CVD	in	obese	populations	continue	to	use	the	BMI	categories	in	order	to	define	obesity	(Janssen,	Katzmarzyk	and	Ross	2004,	Smith	and	Haslam	2007).		More	 expensive	 and	 technical	methods	 exist	 to	 assess	 obesity,	 for	 example	 body	composition	 scanning	 via	 Dual-Energy	 X-ray	 Absorptiometry,	 Computed	Tomography	and	Magnetic	Resonance	 Imaging.	These	methods	are	more	reliable	than	the	 indirect	methods	such	as	BMI	and	physiological	measurements,	and	are	useful	 in	 validating	 results	 from	 indirect	 methods	 for	 experimental	 studies;	however,	 they	 are	 expensive	 and	 need	 trained	 users	 to	 operate	 the	 machinery	involved	 and	 therefore	 are	 not	 suitable	 in	 everyday	 medical	 clinics	 for	 the	assessment	 of	 obesity.	 These	 scanning	methods	may	 also	not	 be	 appropriate	 for	assessing	obesity	due	 to	 a	number	of	 factors	 such	 as	 radiation	 exposure,	 size	 of	machines	required	and	accuracy	(as	reviewed	by	Duren	et	al.	2008).		
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1.2.2. Prevalence of Obesity  
Obesity	has	reached	global	epidemic	status	throughout	recent	years,	and	the	rate	of	 incidence	throughout	most	populations	continues	to	rise	each	year;	 the	World	Health	 Organisation	 estimates	 that	 1.4	 billion	 adults	 over	 the	 age	 of	 20	 were	overweight	 in	 2011,	 with	 over	 200	 million	 men	 and	 300	 million	 women	 being	classified	as	obese,	a	figure	which	is	predicted	to	increase	with	time	(World	Health	Organisation	2013).	 In	England	 alone,	 a	National	Health	 Service	 (NHS)	 report	 in	2014	 published	 that	 24%	 and	 25%	 of	 male	 and	 female	 adults	 were	 obese,	respectively	(The	Health	and	Social	Care	Information	Centre2014);	 figures	which	are	expected	 to	 continue	 to	 rise,	 reaching	60%,	50%	and	25%	by	2050	 for	men,	women	and	children,	 respectively	 (Butland	et	al.	2007).	 In	 the	United	States,	 the	prevalence	 is	even	more	severe,	having	more	than	doubled	from	13%	in	1960	to	36%	 in	 2010;	 despite	 this	 initial	 surge,	 the	 increase	 in	 prevalence	 has	 begun	 to	slow,	not	showing	any	significant	changes	from	2005	to	2010	in	men,	and	not	since	1999	in	women	(Fryar,	Carroll	and	Ogden2012).		The	burden	of	obesity	 is	not	 limited	 to	 the	personal	health	of	 the	 individual,	but	has	a	large	financial	burden	on	society;	the	cost	of	which	has	risen	in	line	with	the	prevalence.	The	direct	costs	of	obesity	to	the	NHS	was	estimated	as	£480	million	in	1998,	of	which	only	£9.5m	was	spent	directly	treating	obesity,	the	remainder	spent	treating	 the	 resulting	 comorbidities	 (National	 Audit	 Office2001);	 this	 direct	 cost	was	 estimated	 to	 have	 risen	 to	 £4.2	 billion	 in	 2007	 (Butland	 et	 al.	 2007).	 Both	estimates	 of	 direct	 cost	 do	 not	 include	 the	 indirect	 costs	 to	 the	 economy	 as	 a	consequence	of	lost	productivity	and	related	chronic	illnesses,	and	these	values	are	thought	 to	 be	 much	 greater	 and	 comparable	 with	 the	 cost	 to	 the	 economy	 of	tobacco	smoking	(National	Audit	Office	2001).	As	indicated	by	the	economic	cost	of	obesity,	the	greater	problem	to	an	individual’s	health	is	not	the	obese	state	itself,	but	the	associated	comorbidities	that	are	a	result	or	consequence	of	obesity.	
1.2.3. Comorbidities of Obesity and metabolic syndrome 
It	 is	 now	 widely	 acknowledged	 and	 documented	 that	 the	 increased	 mass	 of	adipose	tissue	characteristic	of	obesity	is	associated	with,	and	a	causative	factor	in,	
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the	 development	 of	 a	 large	 number	 of	 comorbidities.	 The	 most	 common	comorbidities	 thought	 to	 be	 a	 direct	 result	 of	 obesity	 are	 hypertension,	dyslipidaemia,	 and	 insulin	 resistance;	 all	 of	 which	 are	 risk	 factors	 for	 the	development	 of	 further	 diseases,	most	 importantly	 cardiovascular	 disease	 (CVD;	Isomaa	 et	 al.	 2001,	 Kopelman	 2007).	 First	 described	 as	 ‘Syndrome	 X’	 in	 1988	(Reaven	1988),	when	clustered	together	these	risk	 factors	may	be	categorised	as	‘metabolic	syndrome’	or	‘insulin	resistance	syndrome’	(Isomaa	et	al.	2001,	Grundy	et	al.	2004);	a	syndrome	which	has	been	characterised	by	the	presence	of	different	risk	 factors	 of	 CVD	 in	 conjunction	 with	 central	 obesity.	 Different	 groups	 use	varying	criteria	for	the	diagnosis	of	metabolic	syndrome,	each	putting	emphasis	on	a	different	risk	factor,	however	all	feature	either	central	obesity,	measured	by	BMI,	waist:hip	ratio	or	waist	circumference,	or	insulin	resistance,	characterised	by	type	2	diabetes	or	glucose	intolerance,	as	the	main	focus	of	the	syndrome	(Isomaa	et	al.	2001,	Grundy	et	al.	2004,	Alberti,	Zimmet	and	Shaw	2006).	In	2006,	a	consensus	on	the	conditions	required	to	diagnose	metabolic	syndrome	were	outlined	by	Alberti	et	al.	and	the	International	Diabetes	Federation,	although	definitions	provided	by	WHO	and	others	are	still	widely	used	(Alberti,	Zimmet	and	Shaw	2006).	Metabolic	syndrome	 is	 defined	 as	 central	 obesity	 plus	 any	 two	 of	 the	 four	 other	comorbidities	as	outlined	by	Alberti	et	al.	in	Table	1.2.	The	major	outcome	of	obesity	and	metabolic	syndrome	is	an	increased	risk	of	CVD,	particularly	as	the	factors	that	make	up	metabolic	syndrome	are	all	independently	associated	with	an	increased	risk	of	CVD.		
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Criteria Defined by 
Central Obesity Increased waist circumference – ethnicity dependent cut-offs 
Raised Triglycerides  ≥ 1.7 mmol/l (150 mg/dl) 
OR specific treatment for this lipid abnormality 
Reduced HDL- 
cholesterol 
< 1.03 mmol/l (40 mg/dl) in males 
< 1.29 mmol/l (50 mg/dl) in females 
OR specific treatment for this lipid abnormality 
Raised blood 
pressure 
Systolic: ≥ 130 mmHg 
OR 
Diastolic: ≥ 85 mmHg 
OR treatment of previously diagnosed hypertension 
Raised fasting 
plasma glucose 
Fasting plasma glucose ≥ 5.6 mmol/l (100 mg/dl) 
OR previously diagnosed Type 2 diabetes 
If > 5.6 mmol/l or 100 mg/dl, oral glucose tolerance test is strongly 
recommended but is not necessary to define presence of the syndrome 
Table 1.2. Conditions for diagnosis of metabolic syndrome. Adapted from Alberti, Zimmet 
and Shaw 2006. 
1.2.4. Obesity and risk of CVD 
In	men,	obesity	alone	has	been	associated	with	increased	coronary	atherosclerosis	(McGill	 et	 al.	 2002),	 and	 central	 obesity	 measured	 by	 subscapular	 skinfold	thickness	 was	 shown	 to	 be	 an	 independent	 predictor	 of	 CHD	 (Donahue	 et	 al.	1987);	 interestingly,	 this	 study	 concluded	 BMI	 was	 not	 significant	 at	 predicting	CHD,	suggesting	central	obesity,	measured	by	anthropomorphic	measurements	 is	more	 important	 than	 the	widely-used	 BMI	 classification	 of	 obesity.	 Similarly,	 in	women,	 it	 has	 been	 found	 that	 obesity,	 defined	 by	 waist:hip	 ratio,	 positively	correlated	with	 incidence	of	CVD	such	as	AMI,	angina	pectoris	and	stroke,	over	a	12-year	 follow	 up	 period	 (Lapidus	 et	 al.	 1984).	 Another	 study	 highlighting	 the	importance	 of	 obesity	 in	 predicting	 CHD	 in	 women,	 states	 that	 even	 a	 mild-to-moderate	 overweight	 status	 increases	 one’s	 risk	 of	 developing	CHD	 significantly	(Manson	et	al.	1990),	supporting	the	use	of	obesity	as	an	independent	risk	factor	for	predicting	CVD.	The	Framingham	Heart	Study	evaluated	obesity	as	a	predictor	of	 a	 range	 of	 CVDs	 such	 as	 angina,	 stroke,	 coronary	 disease,	 congestive	 heart	failure	and	death	from	CVD	in	both	men	and	women	over	a	26-year	period,	finding	that,	 in	 conjunction	 with	 the	 other	 studies,	 obesity	 was	 a	 strong	 predictor	 of	 a	
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number	of	 CVDs	 (independent	 of	 other	 risk	 factors)	 in	both	 sexes	 (Hubert	 et	 al.	1983).	Overall,	these	studies	suggest	that	obesity	is	certainly	an	independent	risk	factor	for	the	development	of	CVD,	even	when	other	factors	such	as	other	diseases,	smoking	 status	 and	 age	 are	 taken	 into	 consideration;	 however,	 it	 must	 be	considered	 that	 other	 co-morbidities	 such	 as	 hypertension	 may	 contribute	towards	the	overall	outcome	of	CVD,	even	if	obesity	is	the	stronger	predictor.	More	recently,	in	2004,	the	INTERHEART	study,	using	acute	myocardial	infarction	(AMI)	as	 an	 outcome,	 described	 nine	 factors	 that	 independently	 increase	 one’s	 risk	 to	CHD;	among	these,	obesity	measured	by	waist:hip	ratio,	but	not	BMI,	is	ranked	one	of	the	highest	predictors	behind	smoking	status,	diabetes	and	hypertension	(Yusuf	et	al.	2004).	The	INTERHEART	study	also	provides	evidence	that	these	risk	factors	have	a	 cumulative	effect	 in	 increasing	one’s	 risk	 to	CHD;	as	 these	 factors	are	 the	main	components	of	metabolic	syndrome,	this	highlights	the	dangers	of	allowing	metabolic	syndrome	and	obesity	to	go	unchecked	(Yusuf	et	al.	2004).	
1.2.5. The Obesity Paradox 
Despite	 the	 evidence	 that	 obesity	 is	 an	 independent	 risk	 factor	 for	 the	development	of	CVD,	in	particular	CHD	and	AMI,	it	has	been	shown	by	a	number	of	cohort	studies	that	patients	with	a	higher	BMI	(overweight	and	obese)	who	suffer	from	CVD	have	 lower	 rates	 of	 cardiac	mortality	 after	 AMI	 and	heart	 failure,	 and	suffer	smaller	infarct	sizes	following	AMI	than	those	with	a	lower	BMI	(within	the	normal	or	underweight	range;	Gruberg	et	al.	2002,	Curtis	et	al	2005,	Pingitore	et	al.	2007).	 This	 phenomenon	 has	 been	 termed	 the	 ‘obesity	 paradox’	 (Gruberg	 et	 al.	2002),	wherein	those	with	a	high	BMI	and	a	higher	risk	of	suffering	cardiovascular	events,	 such	 as	 AMI	 or	 heart	 failure,	 have	 a	 better	 survival	 rate	 in	 the	 years	following	such	an	event,	compared	to	those	of	a	lower	BMI.		Through	 a	 systematic	 review	 of	 the	 available	 cohort	 studies	 in	 2006,	 Romero-Corral	 et	 al.	 describe	 a	U-shaped	or	 J-shaped	 trend,	where	underweight	patients	have	 an	 increased	 relative	 risk	 (RR)	 for	 total	 mortality	 (RR=1.37)	 and	cardiovascular	mortality	(RR=1.45),	overweight	patients	have	a	lower	RR	for	total	mortality	(RR=0.87)	and	cardiovascular	mortality	(RR=0.88),	obese	patients	have	no	increased	risk,	while	those	who	are	morbidly	obese	with	a	BMI	>35	kg/m2,	have	
	 23	
no	increase	in	total	mortality	(RR=1.1)	but	the	highest	increase	in	cardiovascular	mortality	(RR=1.88;	Romero-Corral	et	al.	2006).		This	paradox	has	been	challenged	with	confounding	evidence	from	Bolaños	et	al.	(2009),	who	provide	evidence	for	a	greater	infarct	size	after	AMI	in	obese	subjects	(Iglesias	Bolaños	et	al.	2009),	although	this	study	only	observed	40	male	patients,	limiting	the	conclusions	that	may	be	drawn	from	the	data.	Building	on	the	work	of	Pingitore	 et	 al.	 (2007),	 who	 observed	 smaller	 infarct	 sizes	 in	 obese	 patients	(Pingitore	et	al.	2007),	a	greater	insight	into	the	paradox	was	detailed	by	Cepeda-Valery	et	al.	(2013),	who	associated	greater	infarct	size	in	obese	patients	with	non-ST	 segment	 elevation	myocardial	 infarction	 (NSTEMI)	 and	 conversely,	 a	 smaller	infarct	 size	 in	patients	with	 ST-segment	 elevation	myocardial	 infarction	 (STEMI;	Cepeda-Valery	 et	 al.	 2013);	 thus	 providing	 evidence	 that	 the	 type	 of	 AMI	 is	important	in	determining	the	outcome	in	the	obese	patient	population	and	may	be	useful	as	a	prognosis	tool.	The	discrepancies	between	studies	are	also	possibly	due	to	 the	 assessment	 of	 obesity	 used	 by	 each,	 as	 already	 discussed,	 BMI	 is	 not	considered	 the	 best	 predictor	 of	 CVD,	 yet	 it	 the	 usual	method	 by	which	 studies	have	defined	obesity.		The	underpinning	molecular	mechanisms	by	which	the	obesity	paradox	exists	are	not	fully	understood,	but	one	major	hypothesis	suggests	that	activation	of	the	RISK	pathway	at	the	time	of	reperfusion	reduces	infarct	size,	as	has	been	demonstrated	in	hyperglycaemic	mice	(Xu	et	al.	2004)	and	obese	rats	(Donner	et	al.	2013),	and	is	explored	within	the	following	chapters	of	this	thesis.	Further	research	is	needed	to	explore	 the	molecular	mechanisms	 of	 the	 obesity	 paradox	 in	 order	 to	 elucidate	how	 it	 occurs	 and	 if	 it	 may	 be	 manipulated	 and	 used	 as	 a	 therapeutic	 tool	 in	patients	with	CVD,	particularly	AMI.	
1.2.6. Structure/Function of adipose tissue 
The	main	role	of	adipose	tissue	is	the	storage	of	energy	in	the	form	of	triglycerides	within	mature	 adipocytes,	which	 are	 large	 cylindrical	 cells	 that	make	 up	 around	50%	 of	 the	 total	 adipose	 tissue	 volume.	 The	 remaining	 volume	 consists	 of	 the	‘stromal	vascular	fraction’	of	cells,	containing	fibroblasts,	vascular	cells,	connective	tissues	and	immune	cells,	with	macrophages	alone	constituting	up	to	10%	of	 the	
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total	 cells	 in	 healthy	 individuals	 (Hausman	 1985).	 Mostly	 regulated	 by	 insulin	upon	feeding,	adipose	tissue	absorbs	free	fatty	acids	(FFAs)	from	the	bloodstream,	converting	them	into	triglycerides	 for	storage	within	 large	vesicles	which	occupy	most	of	 the	cellular	space	of	 the	adipocyte.	Conversely,	during	periods	of	 fasting,	adipose	 tissue	 releases	 lipids	 into	 the	 bloodstream	 to	 be	 used	 as	 energy	 for	potentially	 starved	 tissues,	 therefore	maintaining	 the	 energy	 homeostasis	 of	 the	body.	 However,	 in	 the	 past	 decades,	 it	 has	 become	 abundantly	 clear	 that	 the	adipose	 tissue	 is	 not	 only	 an	 organ	 for	 storage	 but	 a	 fully	 functional	 endocrine	organ,	 secreting	 numerous	 hormones,	 termed	 adipokines,	 and	 other	 signalling	molecules	 such	 as	 lipids,	 and	 contributes	 to	 systemic	 oxidative	 stress	 via	 the	production	of	ROS	(Ahima	and	Flier	2000,	Kershaw	and	Flier	2004).		
1.2.7. Adipose tissue as an endocrine organ 
With	the	discovery	of	leptin	in	1994	(Zhang	et	al.	1994),	a	then	unknown	hormone	produced	 principally	 by	 mature	 adipose	 tissue,	 it	 was	 confirmed	 that	 adipose	tissue	was	 indeed	 an	 endocrine	organ	 and	not	merely	 a	 storage	 depot	 of	 excess	energy	 in	 the	 form	 of	 lipids	 as	 previously	 thought.	 Since	 then,	 hundreds	 of	hormones	 and	 other	 signalling	 molecules	 have	 been	 found	 to	 be	 produced	 and	released	 by	 the	 adipose	 tissue	 (Lehr,	 Hartwig	 and	 Sell	 2012)	 and	 are	 termed	adipokines	(some	major	adipokines	are	detailed	in	Table	1.3).	The	most	abundant	and	 well	 characterised	 adipokines	 are	 the	 two	 appetite/metabolism	 altering	adipokines	 adiponectin	 and	 leptin,	 the	 latter	 of	 which	 directly	 links	 peripheral	adipose	tissue	with	the	CNS.	
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Adipokine Function 
Leptin Appetite control via CNS 
Adiponectin Insulin sensitising hormone, anti-inflammatory 
TNFα Modulation of inflammation, antagonist of insulin signalling 
Resistin Promotes insulin resistance 
IL-6 Pro-inflammatory cytokine 
CCL2/MCP-1 Monocyte chemoattractant 
Apolipoprotein E Plasma transportation and metabolism of lipids 
FGF-1 Growth factor – cell survival, division, angiogenesis 
RBP4 Insulin resistance 
Table 1.3. Major known adipokines. TNFα: Tumour necrosis factor-alpha; IL-6: Interleukin-6; 
CCL2/MCP-1: Chemokine ligand 2/Monocyte chemoattractant protein-1; FGF-1: Fibroblast 
growth factor-1; RBP4: Retinol binding protein-4. 
Tumour	 necrosis	 factor-alpha	 (TNFα)	 was	 the	 first	 cytokine	 described	 to	 be	produced	 by	 adipose	 tissue,	 having	 been	 shown	 in	 1993	 to	 be	 produced	 and	released	 by	 adipose	 tissue	 from	 obese	 rodents,	 (Hotamisligil,	 Shargill	 and	Spiegelman	1993).	TNFα	is	primarily	produced	by	activated	macrophages	as	part	of	 the	 acute	 phase	 immune-response	 and	 acts	 upon	 two	 receptors,	 tumour	necrosis	 factor	 receptor-1	 (TNFR1)	 and	 tumour	 necrosis	 factor	 receptor-2	(TNFR2).	 In	 human	 adipose	 tissue,	 TNFα	 is	 expressed	 primarily	 by	 the	 stromal	vascular	fraction	of	cells,	including	macrophages	(although	it	may	be	produced	by	adipocytes)	 and	 is	 expressed	 at	 a	 greater	 level	 within	 subcutaneous	 fat	 depots	compared	 to	 visceral	 fat	 depots	 (Fain	 et	 al.	 2004).	 There	 is	 now	 substantial	evidence	that	this	molecule	is	vital	to	glucose	homeostasis	via	interaction	with	the	insulin	signalling	pathway	and	will	be	discussed	in	further	detail	in	the	subsequent	sections.	Leptin	is	secreted	predominantly	by	subcutaneous	fat	depots	upon	feeding	(Fain	et	al.	2004)	and	acts	as	a	peripheral	signal	of	energy	sufficiency,	supressing	appetite	and	further	intake	of	food	via	its	action	on	the	leptin	receptor	within	the	CNS	and	hypothalamus	 (Friedman	 and	 Halaas	 1998).	 As	 well	 as	 its	 appetite	 controlling	effect,	 leptin	 is	 also	 involved	 in	many	 peripheral	 functions	 such	 as	 proliferation	and	differentiation	of	cells,	angiogenesis	and	modulation	of	immune	cells	and	may	act	on	a	variety	of	tissues/cells	(reviewed	by	Margetic	et	al.	2002).	
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Conversely,	 adiponectin	 (also	 termed	 Acrp30)	 is	 produced	 solely	 by	 mature	adipocytes,	is	released	in	high	levels	into	the	circulating	bloodstream	(Chandran	et	al.	2003)	and	is	inversely	correlated	with	insulin	sensitivity,	obesity	and	diabetes	(Chandran	 et	 al.	 2003,	Diez	 and	 Iglesias	2003a).	 Like	 leptin,	 adiponectin	 acts	 on	other	 peripheral	 tissues	 and	 adiponectin	 receptors	 have	 been	 found	 in	 muscle	tissue	and	the	 liver,	where	activation	 leads	to	tissue	specific	effects	(Yamauchi	et	al.	 2003).	 Within	 the	 liver	 adiponectin	 has	 been	 shown	 to	 enhance	 insulin	signalling	by	increasing	the	 level	of	insulin-receptor	substrate	2	(Awazawa	et	al.)	and	 to	 increase	 the	 rate	 of	 fatty	 acid	 oxidation	 by	 stimulating	 AMP-activated	protein	 kinase	 (Yamauchi	 et	 al.	 2002).	 In	 muscle	 tissue,	 adiponectin	 primarily	stimulates	glucose	utilisation	and	the	upregulation	of	glucose	transporters	but	also	stimulates	the	phosphorylation	of	other	enzymes	such	as	acetyl-CoA	carboxylase-alpha	 (ACCα)	 and	 like	 the	 function	 in	 the	 liver,	 increases	 fatty	 acid	 oxidation	(Yamauchi	et	al.	2002).	
1.2.8. Changes to adipose tissue during obesity 
During	 the	 early	 stages	 of	 development,	 adipose	 tissue	 grows	 via	 hyperplastic	mechanisms,	 resulting	 in	 a	 greater	 number	 of	 adipocytes	 per	 fat	 depot	 and	 a	greater	 capacity	 to	 store	 lipids	 (Spalding	 et	 al.	 2008).	 However,	 in	 obesity,	 the	adipose	tissue	must	adapt	quickly	to	 the	growing	demand	of	 increased	fatty	acid	storage	 and	 therefore	 hypertrophic	 growth	 is	 necessary	 and	 may	 predate	hyperplastic	growth	(or	altogether	replace	it	in	older	subjects),	leading	to	a	greatly	increased	 adipocyte	 cell	 size	 (Spalding	 et	 al.	 2008).	 The	 increase	 in	 cell	 size	associated	with	adipose	tissue	hypertrophy	is	 thought	to	be	a	contributing	factor	in	the	dysregulation	of	adipokines	that	is	observed	in	an	obese	phenotype,	through	a	 variety	 of	 possible	 mechanisms	 such	 as	 cell	 hypoxia,	 an	 increase	 in	 oxidative	stress	and	gene	expression	changes.		It	 is	 understood	 that	 obesity	 results	 in	 increased	 systemic	 oxidative	 stress,	mediated	 primarily	 by	 an	 increase	 in	 reactive	 oxygen	 species	 (ROS)	 produced	within	 adipose	 tissue	 (reviewed	 by	 Greenberg	 and	 Obin	 2006).	 During	 obesity,	ROS	 production	 in	 adipose	 tissue	 is,	 in	 part,	 controlled	 by	 the	 up-regulation	 of	NADPH	 oxidase	 (in	 particular	 the	 NOX4	 isoform)	 in	 adipocytes,	 and	 the	 down	
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regulation	 of	 anti-oxidant	 enzymes:	 superoxide	 dismutase	 (SOD),	 catalase	 and	glutathione	peroxidase	(Furukawa	et	al.	2004,	Griendling,	Sorescu	and	Ushio-Fukai	2000).	However,	it	has	also	been	shown	that	macrophages	accumulate	in	adipose	tissue	 during	 obesity,	 possibly	 due	 to	 the	 dysregulated	 and	 increased	 release	 of	chemotaxic	proteins	 from	adipocytes	 in	response	to	ROS	(Hajer,	van	Haeften	and	Visseren	2008,	Weisberg	et	al.	2003).	These	accumulated	macrophages,	as	well	as	secreting	more	 inflammatory	 and	 chemotaxic	molecules,	may	 directly	 contribute	to	the	increased	ROS	production	found	within	the	setting	of	obesity,	resulting	in	a	vicious	positive	feedback	loop	as	represented	in	Figure	1.4.		Furukawa	et.	al.	(2004)	have	also	shown	an	increase	in	markers	of	oxidative	stress	in	human	subjects	that	was	directly	correlated	with	both	waist	circumference	and	BMI,	 and	 it	 is	 reasonable	 to	 suggest	 this	 is	 a	 direct	 result	 of	 increased	 ROS	production	 by	 the	 accumulated	 adipose	 tissue	 (Furukawa	 et	 al.	 2004).	 A	 direct	result	 of	 this	 increased	oxidative	 stress	 is	 an	 alteration	 in	 adipocyte	 function,	 in	particular	the	endo/paracrine	function	and	release	of	adipokines.	
	
Figure 1.4. Schematic of the progression of adipokine dysregulation and ROS accumulation 
in obesity.  
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1.2.9. Obesity, adipokines and CVD 
Hypertrophic	 adipocytes	 in	 the	 state	 of	 obesity	 are	 characterised	by	 a	disrupted	profile	 of	 adipokine	 secretion;	 particularly	 for	 the	 major	 adipokines	 leptin,	adiponectin,	TNFα	and	 chemokine	 ligand	2/monocyte	chemoattractant	protein	1	(CCL2/MCP-1).	The	causes	of	this	dysregulation	are	not	fully	understood	and	each	adipokine	may	be	differentially	regulated,	however,	the	most	noted	theory	is	that	hypertrophic	adipocytes	cause	adipose	tissue	hypoxia	in	the	state	of	obesity,	which	leads	 to	 increases	 in	oxidative	stress	and	dysregulation	of	 function	as	mentioned	previously	and	reviewed	extensively	by	Hosogai	et	al.	2007.		Furthermore,	 obesity	 may	 have	 a	 direct	 negative	 effect	 on	 the	 heart,	 and	 in	particular	 the	 cardiomyocyte,	 due	 to	 the	 dysregulation	 of	 lipid	 metabolism	 that	accompanies	obesity.	With	the	development	of	insulin	resistance,	the	liver	is	prone	to	increased	lipogenesis	in	order	to	clear	excess	glucose	from	the	bloodstream,	and	the	adipose	tissue	concomitantly	increases	the	rate	of	lipolysis	and	release	of	free	fatty	acids	 (FFAs),	 leading	 to	an	elevated	blood	plasma	 level	of	 triglycerides	 and	FFAs	(Wende	and	Abel	2009).	These	increases	in	FFAs	and	triglycerides	can	lead	to	ectopic	deposition	of	lipids	within	tissues,	including	the	heart.	Whilst	 these	 lipids	may	be	stored	in	small	vesicles	as	triglycerides,	they	are	also	propelled	into	other	pathways	 which	 lead	 to	 dysfunction	 of	 cellular	 components	 such	 as	 the	mitochondria	 and	 other	 signalling	 pathways,	 possibly	 resulting	 in	 apoptosis	 and	ultimately	 cell	 death	 (Wende	 and	 Abel	 2009).	 However,	 there	 is	 mounting	evidence	that	dysfunction	of	adipokine	release	from	adipose	tissue	may	also	have	a	significant	 role	 in	 mediating	 CVD’s	 such	 as	 congestive	 heart	 failure,	 coronary	artery	disease	and	AMI	in	the	setting	of	obesity	(recently	reviewed	by	Smekal	and	Vaclavic	2017).		
1.2.9.1. TNFα 
In	 1993,	 Hotamisligil	 et	 al.	 demonstrated	 that	 TNFα	 mRNA	 and	 protein	 are	upregulated	 in	 the	 state	 of	 obesity	 in	 4	 different	 rodent	 models	 of	 obesity	 and	diabetes,	 and	 subsequent	neutralization	of	TNFα	 sensitised	peripheral	 tissues	 to	insulin	(Hotamisligil,	Shargill	and	Spiegelman	1993).	The	same	group	also	showed	
	 29	
that	increased	TNFα	mRNA	expression	in	adipose	tissue	was	positively	associated	with	hyperinsulinemia	in	obese	women,	and	that	this	increase	was	reversed	with	weight	loss	and	the	restoration	of	normal	insulin	levels	(Hotamisligil	et	al.	1995).	These	 studies	 provided	 the	 first	 evidence	 that	 TNFα	 is	 directly	 associated	 with	energy	metabolism	and	particularly	 the	development	 of	 insulin	 resistance	 in	 the	setting	of	obesity	and	diabetes.	Acting	locally	on	adipose	tissue,	TNFα	may	activate	either	 TNFR1	 or	 TNFR2	 receptors	 on	 adipocytes	 to	 regulate	 a	 plethora	 of	downstream	processes.	In	vitro	studies	using	3T3-L1	cells	have	shown	that	TNFα	prevents	 differentiation	 of	 pre-adipocytes	 into	mature	 adipocytes	 by	 preventing	phosphorylation	 of	 the	 insulin	 receptor,	 an	 effect	 which	 is	 prevented	 with	treatment	of	thiazolidinediones,	anti-diabetic	insulin	sensitising	drugs	(Szalkowski	et	al.	1995,	Peraldi,	Xu	and	Spiegelman	1997).	Furthermore,	TNFα	administration	to	 3T3-L1	 cells	 supresses	 the	 expression	 of	 adipocyte	 genes	 that	 encode	 the	proteins	 necessary	 for	 normal	 insulin	 signalling	 and	 glucose	 homeostasis,	including	insulin	receptor	substrate-1	(IRS-1),	Akt	and	glucose	transporter	type-4	(GLUT4;	 among	 many	 others),	 mediated	 via	 activation	 of	 nuclear	 factor-κΒ	 by	TNFα	(Ruan	et	al.	2002).	Finally,	TNFα	can	 induce	 the	expression	and	release	of	inflammatory	 cytokines	 from	 human	 adipocyte	 cells;	 in	 particular,	 IL-6,	CCL2/MCP-1	 and	 TNFα	 itself	 are	 all	 significantly	 upregulated	 by	 TNFα	administration,	 not	 only	 providing	 evidence	 of	 a	 positive	 feedback	 loop	 within	TNFα-signalling	but	also	suggesting	that	TNFα	may	play	a	crucial	role	in	mediating	the	 chronic	 inflammatory	 state	 observed	 in	 the	 state	 of	 obesity	 (Cawthorn	 and	Sethi	2008).	Despite	the	consistent	findings	that	TNFα	is	upregulated	in	the	setting	of	obesity,	it	is	still	unclear	how	this	upregulation	is	initiated,	although	one	major	theory	 is	 that	 adipose	 tissue	 hypoxia	 (due	 to	 hypertrophy	 of	 adipocytes)	 is	 a	possible	cause,	and	further	work	needs	to	be	carried	out	to	this	end.		Another	consequence	of	TNFα	upregulation	is	the	induction	of	the	gene	encoding	CCL2/MCP-1	 within	 adipocytes,	 a	 chemoattractant	 protein	 responsible	 for	 the	recruitment	of	monocytes	to	the	area	which	undergo	differentiation	into	activated	macrophages.	It	has	been	established	that	there	is	a	chronic	and	systemic	low	level	of	 inflammation	 and	 oxidative	 stress	 in	 the	 adipose	 tissue	 of	 obese	 individuals,	partly	 due	 to	 the	 influx	 of	 ROS	 producing	 monocytes	 into	 adipose	 tissue	 as	 a	consequence	of	the	increase	in	CCL2/MCP-1	expression	by	adipocytes	in	response	
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to	TNFα	(Weisberg	et	al.	2003).	Alongside	 its	 gene	 transcription	 altering	 effects,	 a	 further	 effect	 of	 TNFα	 on	adipose	 tissue	 is	 the	 serine-phosphorylation	 of	 IRS-1	 within	 adipocytes,	 a	consequence	 of	 which	 is	 a	 reduction	 in	 tyrosine	 kinase	 activity	 of	 the	 insulin	receptor,	 therefore	 reducing	 insulin	 sensitivity	 in	 these	 cells	 and	 subsequently	leading	to	insulin	resistance	(Tzanavari,	Giannogonas	and	Karalis	2010).	There	are	a	 number	 of	 other	 suggested	 mechanisms	 by	 which	 TNFα	 induces	 insulin	resistance,	reviewed	by	Cawthorn	and	Sethi	(2008),	and	it	is	now	well	established	that	 excess	 TNFα	 is	 a	 strong	 contributor	 to	 adipokine	 dysregulation	 and	 energy	metabolism	dysregulation	in	the	setting	of	obesity	via	its	actions	on	adipose	tissue	(Cawthorn	and	Sethi	2008).		
1.2.9.2. Leptin 
Leptin	expression	has	been	shown	to	be	directly	correlated	with	adipocyte	cell	size	(Skurk	 et	 al.	 2007)	 and	 therefore	 it	 is	 unsurprising	 that	 this	 molecule	 is	upregulated	in	obese	states,	with	high	levels	of	circulating	leptin	observed	in	obese	subjects	(Considine	et	al.	1996).	Mice	lacking	the	ob	gene,	which	encodes	the	leptin	protein,	 lack	 appetite	 control,	 are	 extremely	 obese	 and	 develop	 diabetes;	 all	 of	these	phenotypic	changes	can	be	reversed	by	administration	of	exogenous	leptin	in	
vivo	(Pelleymounter	et	al.	1995).	The	increased	expression	of	leptin	in	the	state	of	obesity	seems	paradoxical	given	 its	appetite	satiating	effect	on	the	CNS,	however	this	 may	 be	 explained	 by	 the	 development	 of	 leptin	 resistance	 which	 has	 been	observed	 in	mice	 fed	 a	 high	 fat	 diet	 (HFD;	Münzberg,	 Flier	 and	 Bjørbæk	 2004).	Furthermore,	administration	of	exogenous	leptin	does	not	rescue	mice	from	diet-induced	 obesity,	 further	 supporting	 the	 theory	 of	 leptin	 resistance	 (Münzberg,	Flier	and	Bjørbæk	2004).	The	development	of	leptin	resistance	is	thought	to	occur	via	 the	 concomitant	 increase	 in	 the	 expression	 of	 suppressor-of-cytokine-signalling-3	 (SOCS-3),	 a	 potent	 inhibitor	 of	 the	 leptin	 signalling	 pathway	(Münzberg,	 Flier	 and	 Bjørbæk	 2004),	 in	 the	 obese	 state.	 Leptin	 resistance	 is	thought	to	be	secondary	to	the	development	of	obesity	and	not	to	play	a	part	in	the	pathogenesis	of	the	disease,	however	a	resistance	to	leptin	can	make	it	difficult	for	obese	individuals	to	lose	weight	with	dieting	and	to	maintain	any	weight	loss	due	
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to	a	lack	of	appetite	satiation	(Myers	et	al.	2010).	Leptin	 is	 widely	 regarded	 as	 a	 “bad”	 adipokine	 in	 relation	 to	 its	 effects	 when	overexpressed,	particularly	on	the	cardiovascular	system,	as	hyperleptinaemia	has	been	 associated	 with	 hypertension,	 atherosclerosis	 and	 the	 development	 of	metabolic	 syndrome	 (Mattu	 and	 Randeva	 2013).	 It	 has	 been	 shown	 that	 leptin	plays	 a	 significant	 role	 in	 the	 initial	 development	of	 atherosclerosis	 via	 both	 the	induction	 of	mitochondrial	 superoxide	 and	 increases	 in	MCP-1	 production	 via	 a	fatty	 acid	 oxidation	 mechanism	 in	 vascular-endothelial	 cells	 (Yamagishi	 et	 al.	2001).	Not	surprising	therefore,	is	the	discovery	by	Schafer	et	al.	(2004)	that	ob/ob	mice	 (which	do	not	produce	 leptin)	are	 resistant	 to	atherosclerosis	development	compared	to	wild	type	mice,	even	with	continuous	feeding	with	a	pro-atherogenic	diet	and	 the	development	of	obesity	 (Schafer	 et	al.	2004).	These	studies	provide	evidence	that	hyperleptinaemia	is	not	simply	a	by-product	of	atherosclerosis	(as	it	is	with	obesity)	but	actively	contributes	to	the	pathogenesis	of	the	disease.		Despite	 the	 negative	 associations	 of	 leptin	 with	 CVD,	 it	 has	 been	 shown	 that	administration	 of	 leptin	 during	 the	 reperfusion	 phase	 of	 I/R	 in	 Langendorff-perfused	 mouse	 hearts	 reduces	 infarct	 size	 (Smith	 et	 al.	 2006).	 This	 effect	 was	mediated	via	ERK1/2	and	Akt	activation,	i.e.	activation	of	the	RISK	pathway	at	the	time	 of	 reperfusion,	 and	may	 offer	 an	 insight	 into	 the	 obesity	 paradox	 and	why	individuals	 that	 are	 obese	 and	 display	 hyperleptinaemia	 despite	 being	 at	 higher	risk	of	CVD	often	display	better	outcomes	following	an	AMI	(Romero-Corral	et	al.	2006,	Smith	et	al.	2006).		
1.2.9.3. Adiponectin 
Conversely	 to	 leptin	 expression,	 the	 expression	 of	 adiponectin	 is	 inversely	correlated	with	weight	and	is	significantly	down-regulated	 in	the	state	of	obesity	(Arita	 et	 al.	 1999,	 Kern	 et	 al.	 2003)	 and	 interestingly,	 this	 down-regulation	 is	inherently	 reversed	 with	 weight	 loss	 (De	 Rosa	 et	 al.	 2013).	 Moreover,	administration	of	exogenous	adiponectin	 to	 insulin-resistant	mice	 improves	both	glucose	tolerance	and	insulin	resistance	in	the	mice	(Yamauchi	et	al.	2001,	Berg	et	al.	 2001).	 It	 was	 demonstrated	 by	 Hotta	 et	 al.	 (2001)	 that	 a	 reduction	 in	adiponectin	expression	is	strongly	correlated	with	insulin	desensitisation	and	the	
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development	of	type	2	diabetes	in	non-human	primates,	therefore	suggesting	that	adiponectin	 is	 important	 in	maintaining	normal	 insulin	signalling	and	a	 low	level	may	 contribute	 to	 the	 progression	 of	 insulin	 resistance	 (Hotta	 et	 al.	 2001).	Similarly,	 it	 has	 been	 shown	 in	 a	 clinical	 study	 in	 Pima	 Indian	 and	 Caucasian	subjects	that	circulating	adiponectin	concentration	is	strongly	associated	with	the	degree	 of	 insulin	 resistance	 and	 hyperinsulinemia,	 more	 so	 than	 the	 degree	 of	adiposity	 or	 glucose	 tolerance	 in	 these	 subjects	 (Weyer	 et	 al.	 2001).	 This	 data	provides	 evidence	 that	 the	 reduction	 in	 circulating	 adiponectin	 concentration	found	 in	 obesity	 is	 directly	 associated	 with	 the	 development	 of	 the	 insulin	resistance	 that	 has	 long	 been	 associated	 with	 obesity	 and	metabolic	 syndrome.	However,	the	molecular	mechanism	of	this	down-regulation	of	adiponectin	within	obesity	remains	elusive.		In	contrast	to	leptin,	adiponectin	(regarded	as	a	“good”	adipokine)	has	been	shown	to	 possess	 multiple	 anti-inflammatory	 properties	 and	 is	 considered	 anti-atherosclerotic	 due	 to	 its	 ability	 to	 inhibit	 both	 smooth	muscle	 cell	 proliferation	and	 the	 conversion	 of	macrophages	 into	 foam	 cells	 (Smekal	 and	 Vaclavik	 2017,	Okamoto	 et	 al.	 2002).	 However,	 contrasting	 results	 have	 been	 found	 through	multiple	 meta-analyses;	 while	 it	 has	 been	 shown	 in	 some	 clinical	 studies	 that	circulating	 adiponectin	has	no	 association	with	CVD	 (Wu	et	 al.	 2013a,	 Hao	 et	 al.	2013),	 others	 have	 shown	 a	 high	 level	 of	 circulating	 adiponectin	 has	 been	associated	 with	 a	 lower	 risk	 of	 coronary	 heart	 disease	 (Zhang	 et	 al.	 2013).	Therefore,	at	present,	circulating	plasma	adiponectin	levels	cannot	be	used	reliably	to	 predict	 CVD.	 These	 confounding	 results	 may	 be	 due	 to	 the	 complexity	 of	adiponectin	protein	expression,	as	two	different	isoforms	(high	and	low	molecular	weight	 forms)	 of	 adiponectin	 exist,	 both	 of	 which	 form	 multimers	 (mainly	hexamers	 or	 octodecamers)	 within	 the	 circulation	 (Smekal	 and	 Vaclavik	 2017).	Adiponectin	binds	 to	 three	distinct	 receptors,	AdipoR1,	AdipoR2	and	T-cadherin,	the	 latter	 of	 which	 is	 ubiquitously	 expressed	 and	 is	 found	 at	 high	 levels	 in	 the	aorta,	 carotid	arteries	and	cardiomyocytes	(Denzel	et	al.	2010).	T-cadherin	binds	the	high	molecular	weight	form	of	adiponectin	(Hug	et	al.	2004)	and	therefore	it	is	this	 receptor	 and	 adiponectin	 isoform	 that	 is	 thought	 to	 mediate	 the	 cardio-protective	effects	of	adiponectin,	as	the	absence	of	T-cadherin	(and	adiponectin)	in	the	setting	of	I/R	injury	leads	to	a	greater	infarct	size	(Denzel	et	al.	2010).		
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Hearts	from	adiponectin	knockout	mice	are	characterised	by	greater	infarct	sizes	(compared	 to	 control	 mice)	 after	 a	 period	 of	 I/R,	 due	 to	 an	 increased	 protein	expression	of	inducible	nictric	oxide	synthase	and	increases	in	NO	and	superoxide	production,	 an	 effect	 which	 was	 reversed	 via	 administration	 of	 globular	adiponectin	 (Tao	 et	 al.	 2007).	 This	 study	 further	 demonstrated	 that	 adiponectin	exerts	 its	 cardio-protective	 effect	 during	 I/R	 by	 preventing	 oxidative/nitrative	overload	and	cardiomyocyte	apoptosis	during	reperfusion	as	exogenously	applied	adiponectin	 to	 adiponectin	 knockout	 hearts	 resulted	 in	 inhibition	 of	 inducible	nitric	oxide	synthase	and	NADPH	oxidase	2	protein	expression,	and	subsequent	NO	and	superoxide	production	(Tao	et	al.	2007).	
1.3.  The GPR55/LPI system 
G-protein	coupled	receptor-55	 (GPR55)	 is	an	orphan	receptor	 first	discovered	 in	human	brain	tissue	and	cloned	in	1999	by	Sawzdargo	et	al	(1999),	however	it	was	not	until	2006	that	it	emerged	it	had	been	investigated	further	by	GlaxoSmithKline	and	AstraZeneca,	where	it	was	then	postulated	to	be	a	third	cannabinoid	receptor	based	on	its	potential	for	activation	by	cannabinoid	compounds	(Sawzdargo	et	al.	1999,	Baker	 et	 al.	 2006).	 Since	 then,	many	 in	 vitro	 studies	have	 investigated	 the	pharmacology	 of	 the	 receptor,	 with	 many	 confounding	 results.	 However,	 one	consistently	 recognised	 finding	 is	 that	 GPR55	 is	 reliably	 activated	 by	 the	endogenous	lysophospholipid:	lysophosphatidylinositol	(LPI).	
1.3.1. Is GPR55 is an LPI receptor? 
Classification	of	GPR55	has	been	difficult	due	to	its	complex	pharmacology	and	the	contrasting	 and	 inconsistent	 results	 of	 different	 laboratories	 in	 identifying	agonists/antagonists	of	the	receptor.	Ryberg	et	al	(2007)	provided	the	first	in	vitro	evidence	 that	 GPR55	 could	 be	 a	 third	 cannabinoid	 receptor	 as	 it	 can	 bind	 and	induce	GTPγS	activation	upon	stimulation	with	a	number	of	cannabinoid	 ligands,	including	anandamide,	 tetrahydrocannabinol	(Δ9-THC)	and	AM251	(Ryberg	et	al.	2007).	However,	multiple	studies	have	now	produced	conflicting	evidence	using	a	range	 of	 in	 vitro	 systems	 and	 outcome	 measures	 that	 demonstrate	 that	cannabinoid	 compounds	 are	 unreliable	 in	 their	 ability	 to	 activate	 or	 antagonise	
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GPR55	 (reviewed	 extensively	 by	 Ross	 (2009),	 Sharir	 and	 Abood	 (2010)	 and	Balgena	et	al.	 (2011)).	Despite	the	conflicting	evidence	to	support	the	hypothesis	of	 GPR55	 being	 a	 cannabinoid	 receptor,	 one	 consensus	 is	 that	 GPR55	 is	functionally	 activated	by	LPI	 and	 activation	may	 signal	 via	multiple	downstream	pathways	 as	 summarised	 in	 Figure	 1.5	 (Yu	 et	 al.	 2013,	 Obara	 et	 al.	 2011,	Bondarenko	 et	 al.	 2010,	 Oka	 et	 al.	 2010,	 Lauckner	 et	 al.	 2008,	 Henstridge	 et	 al.	2009,	Oka	et	al.	2007).	It	 was	 first	 demonstrated	 by	 Oka	 et	 al.	 (2007)	 that	 activation	 of	 GPR55	 by	 LPI	stimulated	Ca2+	release	and	ERK	activation	in	HEK293	cells	stably	transfected	with	hGPR55	(Oka	et	al.	2007).	Building	on	this	discovery,	Oka	et	al.	then	demonstrated	in	2010	that	LPI	also	induced	p38	MAPK	phosphorylation	that	was	dependent	on	the	 activation	 of	 the	 small	 GTPase,	 RhoA,	 and	 the	 downstream	 Rho-associated	protein	 kinase	 (ROCK;	 Oka	 et	 al.	 2010).	 Further	 studies	 have	 validated	 these	findings	 whilst	 expanding	 the	 signalling	 pathway	 by	 which	 GPR55	 exerts	 its	cellular	 responses.	 Lauckner	 et	 al.	 (2008)	 and	 Obara	 et	 al.	 (2011)	 both	demonstrated	 that	 GPR55	 signals	 via	 Gα12/13	 and	 Gαq	 proteins,	 with	 the	 latter	group	distinguishing	distinct	downstream	effects	of	each	pathway	when	using	rat	adrenal	 cancer	 cell	 line:	 PC-12	 cells	 that	 natively	 express	 GPR55	 (Figure	 1.5;	Obara	 et	 al.	 2011,	 Lauckner	 et	 al.	 2008).	Activation	of	GPR55	may	 indeed	 signal	through	 multiple	 pathways,	 however	 it	 is	 recognised	 that	 GPR55	 activation	principally	leads	to	Ca2+	release	from	intracellular	stores,	such	as	the	endoplasmic	reticulum,	and	subsequent	MAP	kinase	(ERK1/2,	Akt,	p38)	and	transcription	factor	(NFAT,	 CREB	 and	 ATF-2)	 activation,	 depending	 on	 the	 cell	 type	 (Balenga	 et	 al.	2011,	Henstridge	et	al.	2009,	Henstridge	et	al.	2010).		
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Figure 1.5. Summary of possible downstream pathways of GPR55 activation by LPI
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1.3.2. Localisation of GPR55 
GPR55	 was	 first	 identified	 in	 human	 brain	 tissue,	 specifically	 in	 the	 caudate	nucleus	 and	 the	putamen	 (Sawzdargo	 et	 al.	 1999)	 and	 since	 then,	GPR55	mRNA	has	 been	 detected	 in	 multiple	 regions	 of	 the	 rodent	 CNS,	 including	 the	hippocampus,	 frontal	 cortex,	 cerebellum,	 striatum,	 hypothalamus	 and	 the	 brain	stem	(Ryberg	et	al.	2007,	Balenga	et	al.	2011).	At	a	peripheral	level,	GPR55	mRNA	has	 been	 detected	 in	 many	 tissues	 in	 both	 humans	 and	 rodents,	 including	 the	adrenals,	 spleen	 (Ryberg	et	al.	2007),	 liver,	adipose	 tissue,	 (Moreno-Navarrete	et	al.	 2012),	 pancreas	 (Romero-Zerbo	 et	 al.	 2011)	 and	 multiple	 areas	 of	 the	gastrointestinal	 tract	 (Lin	 et	 al.	 2011,	 Schicho	 and	 Storr	 2012,	 Li	 et	 al.	 2013).	Unfortunately,	 the	 corresponding	 protein	 levels	 have	 scarcely	 been	 investigated,	likely	due	to	the	lack	of	commercially	available	antibodies	against	the	protein,	and	therefore	 it	 is	 largely	 unknown	 whether	 mRNA	 levels	 directly	 correlate	 with	protein	 expression	 in	 these	 tissues.	The	 exception	 to	 this	 is	 in	 the	pancreas	 and	adipose	 tissue,	where	 protein	 expression	 of	 GPR55	 has	 been	 detected	 alongside	mRNA	in	both	humans	and	rodents	(Moreno-Navarrete	et	al.	2012,	Romero-Zerbo	et	al.	2011).	Importantly,	using	fluorescent	ligand	binding,	GPR55	protein	has	been	shown	 to	 be	 present	 in	 the	 vasculature	 (Daly	 et	 al.	 2009)	 and	 likewise,	 using	immunohistochemistry,	the	cardiomyocytes	of	the	heart	(Walsh	et	al.	2014).		As	 the	 receptor	 has	 been	 detected	 in	 multiple	 tissues,	 both	 centrally	 and	peripherally,	GPR55	is	thought	to	be	involved	in	multiple	physiological	processes	and	diseases,	including	bone	growth,	cancer,	inflammation,	cardiovascular	disease,	and	metabolism	and	obesity	(reviewed	by	Balenga	et	al.	2011).	
1.3.3. The function of GPR55 
Not	unlike	the	pharmacology	of	GPR55,	the	function	of	GPR55	under	physiological	settings	is	just	as	complex	and	is	still	under	much	investigation;	however,	multiple	studies	have	now	suggested	a	function	for	GPR55	in	a	number	of	different	tissues,	in	both	physiological	and	pathophysiological	states	(Balenga	et	al.	2011,	Arifin	and	Falasca	2016).		GPR55	 mRNA	 expression	 has	 been	 postulated	 to	 be	 highly	 associated	 with	 the	
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aggressiveness	of	cancer	and	the	progression	and	growth	of	tumours	as	GPR55	is	highly	 expressed	 in	 a	 number	 of	 cancerous	 cells	 (Andradas	 et	 al.	 2013).	 An	elevated	GPR55	mRNA	 level	has	also	been	associated	with	 tumour	biopsies	with	higher	 histological	 grades	 and	 subsequently	 lower	 patient	 survival	 rates	(Andradas	 et	 al.	 2011).	 Piñiero	 et	 al.	 (2011)	have	 also	demonstrated	 in	prostate	and	 ovarian	 cancer	 cells	 that	 LPI,	 produced	 via	 cytosolic-phospholipase	 A2	(cPLA2)	 and	 secreted	 through	 the	 ATP-binding	 cassette	 transporter	(ABCC1/MRP1),	 is	 able	 to	 activate	 extracellular	 GPR55	 (as	 shown	 by	 RNA	interference	 and	 pharmacological	 inhibition	 studies)	 and	 its	 subsequent	downstream	 pathways	 including	 ERK1/2	 and	 Akt	 phosphorylation,	 and	 calcium	mobilisation,	all	of	which	 leads	 to	 the	proliferation	of	 the	cells	 (Pineiro,	Maffucci	and	Falasca	2011).		Due	to	the	high	level	of	GPR55	expression	in	the	CNS,	the	role	of	GPR55	has	been	investigated	in	a	number	of	studies	using	cellular	models	of	CNS	cells	including	in	PC-12	 cells,	 where	 it	 was	 found	 to	 influence	 neurite	 retraction	 in	 a	 Gα13-RhoA-dependent	mechanism	(Obara	et	al.	2011),	and	cultured	large	dorsal	root	ganglion	neurons,	 where	 it	 was	 demonstrated	 to	 inhibit	 M-current	 via	 a	 Ca2+-increasing	mechanism	(Lauckner	et	al.	2008).	It	 has	 been	 postulated	 that	 GPR55	 may	 have	 a	 physiological	 function	 in	 the	cardiovascular	 system,	 as	 our	 laboratory	 have	 previously	 demonstrated	 that	mature	 GPR55	 knockout	 (GPR55-/-)	mice	 (as	 compared	 to	 young	GPR55-/-	mice)	are	 characterised	 by	 cardiac	 systolic	 dysfunction	 and	 ventricular	 remodelling,	including	reduced	left	ventricular	wall	thickness	and	increased	collagen	deposition	(Walsh	et	al.	2014).	Furthermore,	our	laboratory	has	also	found	that	application	of	exogenous	LPI	 to	 the	mouse	heart	 during	 a	 Langendorff-perfusion	model	 of	 I/R,	results	 in	 a	 greater	 infarct	 size	 through	 a	 ROCK-dependent	 mechanism	(Robertson-Gray,	manuscript	 submitted	 for	publication).	Whether	GPR55	plays	a	role	in	mediating	hemodynamic	effects	in	the	vasculature	is	also	of	contention,	as	certain	cannabinoid	 ligands,	namely	arachidonyl-2'-chloroethylamide	(ACEA)	and	AM251,	have	been	shown	to	reduce	arterial	blood	pressure	in	vivo	through	GPR55-dependent	 mechanisms	 (based	 on	 data	 from	 in	 vitro	 agonist/antagonist	 data);	however,	as	cannabinoid	compounds	have	controversial	relationships	with	GPR55,	
		 38	
it	would	be	interesting	to	test	the	endogenous	agonist	LPI	in	this	setting	(Walsh	et	al.	2015).		GPR55	 may	 also	 play	 a	 role	 in	 multiple	 other	 biological	 functions	 such	 as	inflammation	 (Staton	 et	 al.	 2008),	 modulation	 of	 pain	 (Deliu	 et	 al.	 2015),	 bone	growth	and	repair	(Whyte	et	al.	2009),	and	metabolic	control,	the	latter	of	which	is	reviewed	 in	detail	 in	 chapter	3	 of	 this	 thesis.	However,	 it	must	 be	noted	 that	 in	these	settings,	the	exact	role	of	GPR55	remains	to	be	conclusively	determined	and	further	work	is	needed	to	elucidate	the	function	and	mechanism	by	which	GPR55	exerts	its	effects	in	vivo.		
1.3.4. Production and metabolism of LPI 
The	endogenous	ligand	of	GPR55,	LPI,	belongs	to	a	subspecies	of	lysophospholipid	with	 an	 inositol	 containing	 head	 group	 and	 was	 originally	 thought	 to	 be	 a	 by-product	 of	 lipid	 metabolism	 with	 no	 bioactive	 role.	 In	 the	 rat	 brain,	 Oka	 et	 al.	(2009)	determined	there	was	37.5	nmol/g	tissue	of	LPI,	of	which	50.5%	was	the	stearic-acid	 containing	 species	 (18:0)	 exclusively	 at	 the	 sn-1	 position	 of	 the	molecule,	 and	 the	 second	 most	 abundant	 species	 (22.1%	 of	 total	 LPI)	 was	 the	arachidonic	 acid	 (20:4)	 containing	 species,	 this	 time	 predominantly	 at	 the	 sn-2	position	of	the	molecule	(Oka	et	al.	2009).	Furthermore,	Oka	et	al.	determined	that	the	2-arachidonyl	LPI	species	of	LPI	(Figure	1.6)	was	the	most	potent	agonist	at	GPR55,	exhibiting	activity	10-15	 times	greater	 than	other	molecules	 and	3	 times	greater	than	that	of	1-stearoyl	LPI	(Oka	et	al.	2009).		
	
Figure 1.6. Molecular structure of 2-arachidonyl lysophosphatidylinositol 
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LPI	 is	 synthesised	 in	 a	 complex	 lipid	 remodelling	 pathway	 (as	 proposed	 by	Yamashita	 et	 al.	 2013)	 starting	 with	 de	 novo	 synthesis	 of	 the	 parent	 molecule	phosphatidylinositol	 (PI),	 the	 predominant	molecular	 species	 of	 which	 is	 the	 1-stearoyl-2-arachidonyl	species	(18:0-20:4	PI).	From	this	parent	molecule,	the	two	most	 abundant	 forms	 of	 LPI	 are	 synthesised	 via	 phospholipases,	 particularly	intracellular	 phospholipase	 A1	 (PLA1)	 and	 phospholipase	 A2	 (PLA2)	 enzymes,	which	hydrolyse	fatty	acids	at	the	sn-1	and	sn-2	positions,	respectively	(Yamashita	et	 al.	 2013).	 Yamashita	 et	 al.	 (2010)	 had	 previously	 demonstrated	 that	 2-arachidonyl	LPI	was	formed	specifically	by	the	PLA1	enzyme	DDHD1/PA-PLA1	in	
vitro	and	it	is	known	that	high	levels	of	DDHD1	are	present	in	the	brain	where	an	abundance	of	LPI	is	also	found	(Yamashita	et	al.	2010).		Evidence	of	the	specific	PLA2	isoform	which	metabolises	PI	into	1-stearoyl	LPI	is	more	limited.	However,	it	has	been	shown	in	rat	thyroid	cells	that	cytosolic	PLA2	(cPLA2)	can	metabolise	PI	 into	LPI,	 although	the	focus	of	 the	authors	was	on	the	other	 generated	 molecules	 in	 their	 study	 (Mariggio	 et	 al.	 2006).	 The	 most	compelling	evidence	to	support	the	involvement	of	cPLA2	in	the	generation	of	LPI	is	the	finding	by	Piñeiro	et	al.	(2011),	who	used	RNA	knockdown	studies	in	cancer	cell	 lines	 to	 demonstrate	 that	 the	 proliferative	 effect	 of	 endogenous	 LPI	 was	dependent	 on	GPR55,	 cPLA2α	and	 the	ABCC1	 transporter	 (Pineiro,	Maffucci	 and	Falasca	 2011).	 This	 is	 also	 the	 only	 study	 to	 have	 examined	 the	 mechanism	 by	which	 LPI	 is	 released	 into	 the	 extracellular	 space,	 although	 Yamitasha	 et	 al.	 did	report	that	45%	of	the	LPI	produced	by	DDHD1	was	released	into	the	cell	medium,	they	did	not	elucidate	or	propose	a	mechanism	by	which	this	occurred	(Yamashita	et	al.	2013).		Much	less	is	known	about	the	degradation	and	subsequent	metabolism	of	LPI	once	it	has	bound	to	GPR55;	multiple	lysophospholipase	enzymes	are	known	to	degrade	LPI	 (Ueda	 et	 al.	 1993,	 Murase	 and	 Okuyama	 1985),	 however	 it	 has	 not	 been	demonstrated	 in	 relevance	 to	 GPR55	 signalling.	 Henstridge	 et	 al.	 (2010)	demonstrated	 using	 HEK293-GPR55	 cells	 that	 upon	 LPI	 stimulation,	 membrane	bound	 GPR55	was	 internalised	within	 intracellular	 vesicles,	 postulating	 a	 signal	termination	mechanism	for	LPI-GPR55,	however	the	fate	of	the	LPI	molecule	was	not	established	(Henstridge	et	al.	2010).		
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1.4. Statement of aims and hypothesis 
Despite	 the	 pharmacology	 of	 the	 GPR55	 receptor	 being	well	 researched	 and	 the	receptor	being	found	in	several	different	tissues	of	both	humans	and	rodents,	the	biological	 function	of	 the	receptor	remains	elusive.	Additionally,	 as	expression	of	GPR55	mRNA	and	plasma	levels	of	LPI	have	been	shown	to	be	regulated	by	leptin	and	nutritional	status	in	rats	(Imbernon	et	al.	2014),	and	both	are	upregulated	in	human	obesity	(Moreno-Navarrete	et	al.	2012),	 this	study	aimed	to	elucidate	the	role	of	GPR55	in	the	setting	of	obesity	in	mice.	Furthermore,	as	our	laboratory	has	previously	detected	GPR55	protein	in	murine	heart	tissue	and	has	demonstrated	a	possible	 role	 of	 GPR55	 by	 showing	 that	 LPI	 applied	 exogenously	 to	 the	 mouse	heart	during	I/R	causes	an	increase	in	infarct	size,	the	present	study	also	aimed	to	further	characterise	the	function	of	GPR55	in	the	heart	in	the	combined	setting	of	I/R	and	obesity.	Thus,	it	is	the	general	hypothesis	of	this	study	that	the	GPR55/LPI	system	plays	an	 important	 functional	 role	 in	 the	development	of	obesity	and	 the	associated	 cardiovascular	 consequences,	 such	 as	 the	 impact	 of	 obesity	 on	 the	outcome	of	AMI.		To	test	this	hypothesis,	the	specific	aims	and	objectives	of	the	present	study	were:	1. To	use	an	in	vivo	study	design	to	compare	and	contrast	the	phenotypic	response	of	wild	type	(WT)	and	GPR55-/-	mice	to	a	12-week	high-fat	diet	intervention	with	specific	reference	to:	a. Body	weight	and	fat	mass	b. Adipose	tissue	histology	and	gene	expression	profile	c. Circulating	and	cardiac	tissue	levels	of	LPI		d. Atherosclerosis	development	e. Lipid	deposition	in	the	heart	and	liver	2. To	use	an	isolated	heart	model	to	observe	any	effect	of	GPR55	knockout	and	intervention	with	a	HFD	on	the	infarct	sustained	after	a	period	of	I/R,	and	to	determine	a	mechanism	by	which	any	changes	occur.		3. To	use	an	in	vitro	model	approach	to	elucidate	the	mechanisms	by	which	any	changes	observed	in	the	adipose	tissue	of	WT	and	GPR55-/-	mice	fed	a	HFD	may	occur.	
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2 : General Methods 
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2.1. In vivo studies 
2.1.1. Animals and husbandry 
All	 in	 vivo	 studies	 were	 carried	 out	 in	 accordance	 with	 the	 Animal	 (Scientific	Procedures)	Act	1986	(ASPA)	under	project	 licenses	60/4231	and	70/8875	with	approval	from	the	Robert	Gordon	University	Animal	Ethics	Committees.	Wild	type	C57BL6/J	(WT)	mice	were	purchased	from	Charles	River	(Tranent,	Scotland,	UK)	at	 4	weeks	 old.	 GPR55	 homozygous	 knockout	mice	 (GPR55-/-;	 bred	 and	 derived	from	 a	 C57BL6/J	 background)	 were	 bred	 at	 the	 Medical	 Research	 Facility	(University	 of	Aberdeen,	UK)	 from	an	 existing	 colony;	 a	 random	selection	of	 the	breeding	 colony	was	 routinely	 genotyped	 to	 confirm	 the	knockout	 of	GPR55.	All	mice	were	 housed	 in	 accordance	with	 the	 ‘Code	of	 Practice	 for	 the	Housing	 and	Care	of	Animals	Bred,	Supplied	or	Used	for	Scientific	Purposes’	as	part	of	ASPA.	All	mice	were	group	housed	with	up	to	10	mice	per	cage	and	held	at	21	±	2°C	and	55	±	10%	humidity	with	a	12	h	 light/dark	 cycle	and	had	access	 to	 food	 and	water	ad	
libitum.	 Animals	 were	 primarily	 housed	 at	 the	 Medical	 Research	 Facility	 and	transferred	 to	holding	 rooms	at	Robert	Gordon	University	 on	 a	weekly	basis	 for	experimentation;	the	mice	were	acclimatised	for	a	minimum	of	30	minutes	before	any	experimental	procedures	were	carried	out.		
2.1.2. High fat diet intervention 
Male	and	female	(Study	1)	or	male	only	(Study	2)	WT	and	GPR55-/-	mice	were	fed	either	a	standard	chow	diet	(SD)	or	high	fat	diet	(HFD)	comprising	of	40%	energy	from	 fat,	 supplied	 by	 Lantmännen	 (“Western	 Diet	 R638	 Semi-synthetic	 feed”;	Kimstad,	Sweden)	for	a	period	of	12	weeks	from	the	age	of	5	weeks	old.	Full	details	of	the	composition	of	both	the	SD	and	HFD,	as	provided	by	the	manufacturers,	can	be	found	in	the	appendix.		
2.1.3. Physiological parameters 
The	body	weight	and	body	composition	(fat	and	lean	mass)	of	individual	mice	was	measured	by	staff	at	the	Medical	Research	Facility.	Body	weights	were	recorded	on	
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a	weekly	basis	throughout	both	dietary	studies.	Body	composition	was	measured	using	an	EchoMRIÔ	analyser	for	live	mice	and	was	conducted	at	the	start	and	end	of	 the	dietary	period	of	Study	1.	Throughout	 the	dietary	 intervention	of	Study	2,	weekly	food	intakes	were	also	measured	by	manually	weighing	the	remaining	food	in	each	cage	twice	weekly	and	calculating	an	average	food	intake	per	mouse	based	on	the	number	of	mice	sharing	each	cage.		
2.1.4. Plasma and tissue harvest 
Mice	were	anaesthetised	with	a	mixture	of	ketamine	 (120	mg	kg−1)	and	xylazine	(16	 mg	 kg−1)	 via	 intraperitoneal	 injection.	 Once	 the	 mice	 were	 under	 deep	anaesthesia	(as	assessed	by	the	absence	of	the	pedal	withdrawal	reflex),	the	heart	was	exposed	through	opening	of	the	thoracic	cavity;	blood	samples	(between	500	–	1000	μl)	were	obtained	via	 cardiac	puncture	of	 the	 right	ventricle	using	a	25G	needle	and	dispensed	 into	a	pre-heparinized	microcentrifuge	 tube	 (adjusted	 to	a	final	concentration	of	heparin	of	20	U.ml-1).	Following	blood	collection,	 the	heart	was	 immediately	removed	via	severing	of	 the	connecting	blood	vessels	 to	ensure	the	 cessation	 of	 circulation	 and	 death	 as	 per	 Schedule	 1	 Code	 of	 Practice	 under	ASPA.	 Tissues	 were	 carefully	 removed	 and	 immediately	 frozen	 in	 cryovials	immersed	 in	 liquid	 nitrogen	 before	 being	 stored	 at	 -80°C	 until	 use.	 Tissues	harvested	in	this	way	included	visceral	adipose	tissue,	liver,	kidneys,	and	the	heart	and	whole	thoracic	aorta	(Study	1	only).	Before	the	separation	of	blood	plasma,	5	µL	of	whole	blood	was	used	to	measure	glucose	levels	using	a	blood	glucose	meter	(Accu-Chek	Aviva	Glucose	Meter,	Roche,	UK).	Blood	samples	were	 centrifuged	at	2000	 xg	 for	 15	minutes	 at	 4°C,	 the	 plasma	 supernatant	 apportioned	 into	 65	 µL	aliquots	 in	clean	microcentrifuge	 tubes	and	 finally	 snap	 frozen	 in	 liquid	nitrogen	and	 subsequently	 stored	 at	 -80°C	 until	 use.	 For	 Primary	 cell	 culture	 detailed	 in	section	2.2.1,	fresh	adipose	tissue	was	required	and	therefore	not	frozen	and	used	immediately	when	harvested	for	this	purpose.		
2.1.5. Heart Isolation and Langendorff perfusion 
For	Study	2,	the	heart	was	removed	via	severing	of	the	great	vessels,	taking	care	to	transect	 the	 aorta	 at	 the	 descending	 section	 keeping	 the	 aortic	 arch	 intact	 to	
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ensure	 enough	 ascending	 aorta	 remained	 to	 be	 cannulated.	 The	 heart	 was	 then	immediately	 submerged	 in	 ice-cold	Krebs-Henseleit	buffer	 (herein	referred	 to	as	Krebs’	 buffer;	 recipe	 in	 Table	 2.1)	 to	 arrest	 the	 heart.	 The	 heart	 was	 then	transferred	 to	 a	 petri	 dish,	 remaining	 submerged	 in	 ice	 cold	 Krebs’	 buffer	 at	 all	times.	Using	a	microscope	for	better	visualisation,	extra	fat	and	connective	tissue	was	quickly	trimmed	from	the	heart	and	the	aorta	cannulated	with	a	23G	blunted	needle	and	fixed	in	place	using	0.12mm	5/0	silk	suture.	The	cannulated	heart	was	attached	to	a	Langendorff	perfusion	set	up	as	shown	in	Figure	2.1	for	the	duration	of	the	experiment.	Hearts	were	retrogradely	perfused	with	Krebs’	buffer	that	was	oxygenated	by	constant	bubbling	of	the	buffer	with	95%	O2	/	5%	CO2	to	maintain	a	pH	 of	 7.4	 and	 kept	 to	 a	 constant	 temperature	 of	 37°C;	 experiments	 were	performed	with	a	constant	flow	setup,	with	a	flow	rate	of	2.5	ml/min	via	use	of	a	peristaltic	 pump	 and	 coronary	 perfusion	 pressure	 measured	 at	 the	 onset	 of	perfusion	to	verify	successful	cannulation	of	the	heart.	 
Component Concentration 
(mM) 
NaCl 119 
KCl 4.7 
KH2PO4 1.18 
MgSO4 2.41 
NaHCO3 25 
CaCl2 2.5 
C6H12O6 (D-glucose) 10.88 
Table 2.1. Krebs-Henseleit Buffer. Buffer was prepared fresh daily, stored at 4°C and sterile 
filtered through a 0.22 µm filter before use to remove any traces of undissolved salts.
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Figure 2.1. Langendorff Perfusion setup
		 46	
2.1.6. Tissue processing for histology 
Tissues	collected	in	section	2.1.4	were	processed	for	histology	in	one	of	two	ways,	either	by	thawing	and	formalin	fixation	followed	by	paraffin	embedding	(FFPE)	for	microtome	 sectioning	 or	 direct	 embedding	 whilst	 frozen	 in	 optimal	 cutting	temperature	medium	(OCT;	Thermo	Scientific,	UK)	for	cryosectioning.	The	method	of	processing	was	dependent	on	 the	downstream	staining	protocol	 intended;	 for	hematoxylin	 and	 eosin	 staining,	 FFPE	 sections	were	 routinely	used,	 however	 for	Oil	 Red	 O	 staining	 of	 lipids,	 frozen	 sections	 were	 used	 to	 avoid	 the	 tissue	processing	steps	of	FFPE	that	would	have	extracted	the	lipids	from	the	sample.	For	 FFPE,	 small	 sections	 of	 tissue	 were	 manually	 sliced	 from	 the	 frozen	 tissue,	allowed	to	thaw	and	fixed	 in	1X	zinc	 formalin	 fixative	(Sigma	Aldrich,	UK)	for	24	hours	at	4°C;	washed	3	times	in	phosphate	buffered	saline	(PBS;	137	mM	NaCl,	10	mM	phosphate	buffer,	2.7	mM	KCl;	made	from	PBS	tablets,	Thermo	Scientific,	UK)	and	placed	into	histocassettes	(Simport,	Canada)	for	autoprocessing	as	detailed	in	Table	2.2	using	a	Citadel	1000	tissue	processor	(Thermo	Scientific,	UK).		
Step Solution Time (min) 
1 75 % Ethanol 30 
2 95 % Ethanol 75 
3 95 % Ethanol 75 
4 100 % Ethanol 60 
5 100 % Ethanol 60 
6 100 % Ethanol 60 
7 Histoclear II 60 
8 Histoclear II 60 
9 Melted paraffin at 60°C 60 
10 Melted paraffin at 60°C Overnight 
11 Melted paraffin at 60°C 60 
Table 2.2. Auto-processing of tissue samples for FFPE histology. Histoclear II purchased from 
National Diagnostics, USA. Following	 the	 completion	 of	 tissue	 processing,	 the	 tissues	 were	 embedded	 into	paraffin	 wax	 blocks	 using	 a	 tissue	 embedding	 centre	 (Histocentre	 2,	 Thermo	Scientific,	 UK)	 ready	 for	 sectioning	 using	 a	 ShandonÔ	 FinesseÔ	 325	 manual	microtome	 (Thermo	 Scientific,	 UK).	 Eight	 µm	 cut	 sections	 were	 transferred	 to	SuperfrostÔ	slides	(Thermo	Scientific,	UK)	by	floating	the	section	in	a	tissue	water	bath	heated	to	37°C	and	mounting	onto	glass	slides.	Finally,	sections	were	dried	at	
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40°C	overnight	 to	 adhere	 the	 tissue	sections	 to	 the	slides.	Fully	processed	slides	were	stored	at	room	temperature	until	used	in	staining	protocols.		When	using	OCT	sectioning,	small	sections	of	frozen	tissue	were	directly	mounted	into	OCT	medium	inside	a	cryostat	(Cryotome	FSE,	Thermo	Scientific,	UK)	set	to	-20°C.	Ten	µm	sections	were	cut	using	the	cryostat	and	immediately	transferred	to	PolysineÔ	 Microscope	 Adhesion	 Slides	 (Thermo	 Scientific,	 UK),	 air	 dried	 for	 5	minutes	 then	 submerged	 in	 zinc	 formalin	 fixative	 for	 10	 minutes	 at	 room	temperature.	 Fixed	 slides	 were	 rinsed	 in	 distilled	 water	 to	 remove	 remaining	formalin	before	being	air	dried	and	then	stored	at	-20°C	until	used	in	staining.		
2.2. In vitro and molecular studies 
2.2.1. Cell culture of primary adipocytes 
In	 order	 to	 isolate	 and	 culture	 primary	 adipocytes,	 a	 modified	 method	 of	Hausman’s	 isolation	 protocol	 was	 used	 (Hausman,	 Park	 and	 Hausman	 2008).	Freshly	 harvested	 adipose	 tissue	 from	 section	 2.1.4	 was	 placed	 in	 1%	 albumin	buffer	(recipe	in	Table	2.3),	before	being	transferred	to	the	cell	culture	laboratory	and	 cleaned	 of	 connective	 tissue	 and	 blood	 vessels	 in	 an	 aseptic	 environment.	Cleaned	 fat	was	minced	with	scissors	 into	small	 pieces	and	 transferred	 to	10	ml	collagenase	buffer	(Albumin	buffer	supplemented	with	1	mg.ml-1	collagenase	type	I;	 Life	Technologies,	UK)	 and	 incubated	 in	 a	water	bath	 at	 37°C	 for	1	hour,	with	constant	agitation	and	vigorous	shaking	every	15	minutes,	 to	digest	extracellular	matrices	and	 tissue.	The	resulting	digest	was	 filtered	 through	250	µm	mesh	 and	centrifuged	 at	 200	 xg	 for	 10	 min	 at	 room	 temperature	 to	 pellet	 the	 stromal	vascular	fraction	(SVF)	containing	pre-adipocytes.	Mature	adipocytes	from	the	top	formed	 layer	 and	 the	 supernatant	 were	 discarded	 and	 the	 SVF	 cells	 washed	 in	medium-199	 without	 foetal	 bovine	 serum	 (FBS)	 followed	 by	 another	centrifugation	 at	 200	 xg	 for	 10	min	 at	 room	 temperature.	 The	 supernatant	was	discarded	and	the	pellet	re-suspended	in	medium-199	without	FBS.	Any	remaining	red	blood	 cells	which	may	have	been	 carried	over	 from	 the	 tissue	digestion	 and	present	 in	 the	 SVF	 were	 lysed	 via	 the	 addition	 of	 sterile	 water	 followed	 by	immediate	addition	of	10X	PBS	(resulting	in	a	1X	PBS	solution).	Finally,	cells	were	
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centrifuged	at	200	xg	and	re-suspended	in	medium-199	with	10%	FBS	(full	recipe	in	 Table	 2.4);	 cells	 were	 counted	 using	 a	 BS1000	 Improved	 Neubauer	haemocytometer	(Hawksley,	UK)	and	seeded	at	a	density	of	1.5	x	105	cells	per	well	of	a	6-well	plate.	Cells	were	maintained	in	an	atmosphere	of	5%	CO2	humidified	air	at	37°C.		
Stock Solution Final Concentration 
10% Bovine Serum Albumin (BSA) 1% 
10X Mixed Salts: 
1.35 M NaCl, 47 mM KCl, 25 mM CaCl2, 12.5mM MgSO4 
1X 
10X HEPES buffer: 
100mM HEPES, 12.5 mM NaH2PO4, 12.5 mM Na2HPO4 
1X 
Table 2.3. Albumin Buffer Recipe. All reagents obtained from Sigma Aldrich, UK. 
Component Final Concentration 
Medium-199 1X 1X 
FBS  
[South American origin; heat inactivated] 
10% 
Fungizone  2.5 µg.ml-1 
Penicillin/Streptomycin  100 µg.ml-1 
Table 2.4. Complete medium-199 recipe for primary cells. All reagents obtained from Gibco, 
Invitrogen, UK.  To	 induce	 differentiation	 of	 primary	 pre-adipocytes	 into	 adipocytes,	 cells	 were	grown	to	confluence	in	medium-199	then	treated	with	medium-199	supplemented	with	 0.25	 µM	 dexamethasone	 (Dex;	 Sigma	 Aldrich,	 UK),	 0.5	 mM	isobutylmethylxanthine	 (IBMX;	 Sigma	 Aldrich,	 UK)	 and	 10	 µg.ml-1	 insulin	 (Life	Technologies,	UK)	for	48	hours.	After	48	hours,	media	was	replaced	with	medium	supplemented	only	with	insulin	(10	µg.ml-1)	until	14	days	post	induction.	Medium	was	fully	replaced	3	times	per	week	with	medium-199	to	provide	fresh	nutrients	to	the	cells.		
2.2.2. Cell culture of 3T3-L1 adipocytes 
3T3-L1	 is	an	adherent	continuous	 fibroblast-like	cell	 line	originally	derived	 from	Swiss	albino	mouse	embryo	in	1974;	these	cells	are	of	a	pre-adipocyte	lineage	and	have	 the	 potential	 to	 accumulate	 lipids	 and	 therefore	 differentiate	 into	 mature	adipocytes	when	chemically	stimulated	(Green	and	Meuth	1974).	3T3-L1	cells	are	not	immortalized	and,	as	such,	are	classed	as	primary	cells	with	a	limited	life-span,	usually	up	to	passage	13-15	before	they	begin	to	lose	the	potential	to	differentiate.	
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These	 cells	 have	 been	 widely	 used	 in	 research	 related	 to	 adipogenesis	 and	metabolic	health	as	a	model	of	adipocytes	and	are	useful	when	primary	adipocytes	from	humans	or	animals	are	not	readily	available	(Poulos,	Dodson	and	Hausman	2010).		3T3-L1	 cells	 were	 purchased	 from	 ECACC	 (distributed	 via	 Sigma	 Aldrich,	 UK;	ECACC	number:	86052701,	lot:	130030,	Passage+8,	previously	frozen	on	6th	Sept	2013)	and	stored	in	the	vapour	phase	of	liquid	nitrogen	for	long	term	storage.	To	revive	cells,	a	vial	of	cells	was	brought	to	37°C	as	quickly	as	possible	using	a	water	bath	before	adding	the	thawed	cells	 to	10	ml	of	complete	pre-adipocyte	medium	(recipe	in	Table	2.5)	pre-warmed	to	37°C.	Diluted	cells	were	centrifuged	at	125	xg	for	5	minutes	at	 room	temperature	and	re-suspended	 in	complete	pre-adipocyte	medium	and	seeded	into	a	75	cm2	tissue	culture	flask	(Nunc,	Fisher,	UK).	3T3-L1	cells	were	 routinely	maintained	 in	 75	 cm2	 tissue	 culture	 flasks	 in	 complete	 pre-adipocyte	 medium	 in	 an	 atmosphere	 of	 8%	 CO2	 humidified	 air	 at	 37°C.	 3T3-L1	cells	were	 sub-cultured	once	 they	 reached	70-80%	confluence	 via	 trypsinization	using	 0.25%	 trypsin-EDTA	 (Invitrogen,	 UK)	 for	 10	min	 at	 37°C;	 suspended	 cells	were	centrifuged	at	125	xg	 for	5	minutes	at	room	temperature	and	re-suspended	in	 complete	 pre-adipocyte	medium	 for	 cell	 counting.	 Cells	were	 counted	 using	 a	trypan	blue	exclusion	method	as	follows:	an	equal	volume	of	cell	suspension	was	mixed	 with	 0.4%	 trypan	 blue	 solution	 (Thermo	 Scientific,	 UK),	 incubated	 for	 5	minutes	and	cells	counted	using	a	BS1000	Improved	Neubauer	haemocytometer;	dead	cells	(stained	blue)	were	excluded	from	the	count	and	viability	calculated	as	a	percentage	of	 total	 cells	 (viability	was	 regularly	>90%).	 Cells	were	 subsequently	seeded	into	appropriate	vessels	for	differentiation	and	experimental	use.	In	order	to	build	a	sizeable	cell	bank	of	3T3-L1	cells,	 a	number	of	vials	were	frozen	down	for	 storage	 during	 the	 routine	 sub-culturing	 of	 cells.	 Cells	 were	 frozen	 at	 a	concentration	of	1	x	106	cells	per	1	ml,	in	‘freezing	medium’	composed	of	complete	pre-adipocyte	medium	supplemented	with	5%	dimethyl	sulfoxide	(DMSO;	Thermo	Scientific,	 UK);	 vials	were	 initially	 frozen	 in	 a	 -80°C	 freezer	 inside	 a	Mr	 Frosty™	Freezing	Container	(Thermo	Scientific,	UK),	in	order	to	freeze	the	cells	at	a	rate	of	-1°C/min.	 Once	 frozen,	 vials	 were	 transferred	 to	 the	 vapour	 phase	 of	 liquid	nitrogen	for	long	term	storage.		
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Component Final Concentration 
DMEM w/ GlutaMAXÔ, pyruvate, 4.5 g/L glucose 1X 
New Born Calf Serum (NBCS)  
[New Zealand origin, heat inactivated] 
10% 
Penicillin/Streptomycin 100 µg.ml-1 
Table 2.5. Complete pre-adipocyte medium. All reagents obtained from Gibco, Invitrogen, 
UK. 3T3-L1	cells	have	been	shown	to	have	variable	 levels	of	differentiation	potential,	with	 variation	 demonstrated	 from	 passage	 number	 and	 the	 culture	 vessel	 used	when	 using	 the	 standard	 differentiation	 procedure	 provided	 by	 ATCC®	 (ATCC	2014,	 Mehra,	 Macdonald	 and	 Pillay	 2007).	 Therefore,	 to	 differentiate	 cells	 into	mature	 adipocytes,	 a	 modified	 method	 including	 the	 use	 of	 rosiglitazone,	 a	peroxisome	 proliferator-activated	 receptor	 gamma	 (PPARγ)	 agonist,	 as	demonstrated	 by	 Zebisch	 et	 al.	 (2012)	 was	 tested	 and	 therefore	 after	 used	(Zebisch	et	al.	2012).	Cells	were	grown	for	2	days	post-confluence	(designated	day	0)	 in	 complete	 pre-adipocyte	 medium	 and	 the	 medium	 replaced	 with	‘differentiation	medium’,	 comprised	of	adipocyte	maintenance	medium	(recipe	 in	
Table	2.6)	supplemented	with	1	µM	Dex,	500	µM	IBMX,	1	µg.ml-1	insulin	and	1	µM	rosiglitazone	 (Sigma	Aldrich,	UK)	 for	 48	hours.	 After	48	 hours,	 the	medium	was	then	replaced	with	‘insulin	medium’,	comprised	of	adipocyte	maintenance	medium	supplemented	with	1	µg.ml-1	insulin	only	until	day	7,	after	which	cells	were	grown	in	 adipocyte	maintenance	medium	 and	 grown	 up	 to	 day	 14.	 This	 differentiation	protocol	 is	 summarised	 in	 Figure	2.2.	 The	medium	was	 fully	 replaced	 every	 two	days,	 where	 appropriate,	 throughout	 differentiation	 and	maintenance	 to	 supply	the	cells	with	fresh	nutrients.	 
Component Final Concentration 
DMEM w/ GlutaMAXÔ, pyruvate, 4.5 g/L glucose 1X 
FBS 
[South American origin, heat inactivated] 
10% 
Penicillin/Streptomycin 100 µg.ml-1 
Table 2.6. Recipe for adipocyte maintenance medium. All reagents obtained from Gibco, 
Invitrogen, UK. 
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	 Figure 2.2. Differentiation protocol of 3T3-L1 cells. Media was refreshed 3 times a week throughout the protocol. 
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2.2.3. Oil Red O stain preparation 
Oil	Red	O	is	a	lysochrome	diazo	dye	used	to	stain	lipids	in	cells	or	sectioned	tissues	and	 is	 therefore	 useful	 in	 determining	 lipid	 accumulation,	 particularly	 in	examining	metabolic	health	status	(Mehlem	et	al.	2013)	or	to	verify	differentiation	of	3T3-L1	cells	as	outlined	in	section	2.2.2.		To	prepare	a	0.5%	stock	solution	of	dye,	0.5	g	of	Oil	Red	O	powder	(Sigma	Aldrich,	UK)	 was	 added	 to	 100	 ml	 isopropanol	 (Certified	 AR,	 Fisher	 Scientific,	 UK),	 the	suspension	vigorously	mixed	using	a	magnetic	stirrer	for	1	hour	and	the	solution	left	overnight	at	4°C.	Stock	solution	was	subsequently	filtered	through	Whatman®,	Grade	1	filter	paper	(Sigma	Aldrich,	UK)	and	stored	at	4°C	until	use.	A	working	dye	solution	 must	 be	 made	 fresh	 before	 use	 and	 is	 prepared	 by	 diluting	 the	 stock	solution	in	distilled	water	in	a	3:2	ratio.		
2.2.4. RNA extraction from tissues and cells 
Total	 RNA	 was	 extracted	 from	 tissues	 and	 cells	 using	 an	 acid-phenol-guanidine	thiocyanate	(Tri-Reagent;	Ambion,	Thermo	Scientific,	UK)	protocol.	Cells	grown	in	monolayer	were	lysed	directly	in	the	plate	or	flask	by	removing	growth	media	and	passing	the	cells	 through	a	pipette	multiple	 times,	adding	an	appropriate	amount	of	 Tri-Reagent.	 Frozen	 tissue	 samples,	 up	 to	 100	 mg,	 were	 first	 crushed	 under	liquid	nitrogen	using	a	pestle,	followed	by	mechanical	homogenisation	in	1	ml	Tri-Reagent	using	a	handheld	homogeniser	(SHM1	handheld	homogeniser;	Stuart,	UK)	fitted	with	 a	 5	mm	 flat	 head	 probe	 (SHM/5;	 Stuart,	 UK)	 at	 a	 constant	 speed,	 in	bursts	 of	 10	 seconds,	 to	 avoid	 heating	 the	 sample.	 Homogenised	 tissue	 and	 cell	lysates	were	incubated	at	room	temperate	for	at	least	5	minutes	before	continuing	with	the	protocol.		Homogenised	tissue	and	cell	 lysates	were	centrifuged	at	12,000	xg	 for	10	min	at	4°C	 to	 pellet	 insoluble	 material	 and	 the	 supernatant	 transferred	 to	 a	 clean	microcentrifuge	 tube.	 For	 differentiated	 3T3-L1	 cells	 and	 adipose	 tissue	homogenates,	a	 layer	of	 fat	accumulates	at	 the	top	of	 the	centrifuged	sample	and	must	 be	 carefully	 aspirated	 or	 avoided	 during	 removal	 of	 the	 supernatant	 to	 a	
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fresh	 tube.	 To	 1	 ml	 of	 homogenate,	 100	 µL	 of	 1-bromo-3-chloropropane	 (BCP;	Acros	Organics,	Fisher,	UK)	was	added,	the	solution	mixed	by	vigorous	shaking	and	allowed	 to	 incubate	 at	 room	 temperature	 for	 15	 min.	 The	 mixed	 solution	 was	centrifuged	at	12,000	xg	 for	10	min	at	4°C	and	the	resulting	clear	aqueous	phase	containing	RNA	was	carefully	 transferred	 to	a	clean	 tube	and	 the	 interphase	and	organic	 phase	 discarded.	 To	 precipitate	 RNA,	 isopropanol	 (Molecular	 Biology	Grade,	Fisher,	UK)	was	added	to	the	aqueous	phase	(500	µL	per	1	ml	Tri-Reagent	used)	 and	 the	 solution	 incubated	 for	 10	 minutes	 at	 room	 temperature	 before	centrifugation	at	12,000	xg	for	10	minutes	at	4°C	to	pellet	the	RNA.	The	resulting	supernatant	 was	 discarded	 and	 the	 RNA	 pellet	 washed	 twice	 with	 1	 ml	 75%	ethanol	(Molecular	Biology	Grade,	Sigma,	UK)	following	centrifugation	at	7,500	xg	for	5	minutes	between	washes.	After	washing,	ethanol	was	carefully	removed	and	the	pellet	air	dried	for	5	min	before	being	re-suspended	in	an	appropriate	volume	of	 Tris-HCl	 (Sigma	Aldrich,	 UK)	 buffer	made	 in	 RNAse/DNAse	 free	 H2O	 (10	mM	Tris-HCl,	pH	8)	by	gentle	pipetting	of	the	sample.	RNA	samples	were	kept	on	ice	for	immediate	analysis	or	stored	at	-80°C	until	use.		RNA	 concentration	 of	 samples	was	 determined	 via	 spectrophotometer	 using	 the	absorbance	 reading	 at	 260	 nm	 and	 the	 following	 the	 equation	 based	 on	 the	extinction	coefficient	for	single	stranded	RNA:		!"#	%&'%(')*+),&'	(./. .123) = 67260	 × 40	./	 × =,1>),&'	?+%)&*	 ÷ 1000	
Equation 3. Determination of RNA concentration. RNA	quality	was	 similarly	 assessed	 via	 absorbance	 readings	 at	 280	nm	and	230	nm,	 giving	 an	 estimation	of	 protein	 and	organic	 compound	 contamination	 in	 the	sample	and	subsequently	calculating	a	260/280	nm	and	260/230	nm	ratios;	RNA	with	 a	 260/280	 ratio	 >1.7	 and	 a	 260/230	 ratio	 >2	 is	 considered	 acceptable	 for	downstream	applications.		RNA	 integrity	was	assessed	each	 time	 a	new	 tissue	or	cell	 type	was	extracted	 to	check	 the	 protocol	 produced	 intact	 RNA	 to	 an	 acceptable	 level.	 Integrity	 was	assessed	 via	 agarose	 gel	 electrophoresis	 in	 1X	 Tris-Borate-EDTA	 buffer	 (TBE,	supplied	as	10X	buffer,	Thermo	Scientific,	UK).	To	prepare	the	gel,	0.5	g	of	agarose	(Fisher,	 UK)	was	 added	 to	 50	ml	 TBE	 buffer	 and	 heated	 in	 a	microwave	 for	 30	
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second	intervals	until	the	agarose	had	fully	melted.	The	gel	solution	was	allowed	to	cool	slightly	before	adding	5	µl	10,000X	Gel-Red	Stain	(Biotium,	USA)	and	pouring	the	gel	into	a	cast	and	inserting	a	well-spacer	comb;	the	gel	was	subsequently	left	to	cool	and	set.	Ten	µL	of	RNA	was	added	to	2	µL	of	6X	loading	dye	(Promega,	UK)	and	10	µL	of	 the	mixture	added	 to	each	well	of	 the	set	gel.	Gels	were	run	 for	45	minutes	 at	 90	 volts	 submerged	 in	 1X	 TBE	 buffer,	 then	 imaged	 using	 a	 PEQLAB	Fusion	FX7	 and	UV	 light	 to	 check	 for	 clear	bands	 corresponding	 to	28S	 and	18S	RNA	with	minimal	smearing	of	the	RNA	sample.		
2.2.5. RT-qPCR  
Reverse	 transcription-real	 time	 (quantitative)	 polymerase	 chain	 reaction	 (RT-qPCR)	is	used	to	quantify	gene	expression	using	total	RNA	as	a	starting	template.	Firstly,	RNA	 is	 reverse	 transcribed	 into	cDNA,	 then	specific	gene	amplification	of	cDNA	 is	 conducted	 using	 nucleotide	 primers	 which	 bind	 only	 to	 the	 gene	 of	interest.	 Using	 SYBR	 green	 chemistry	 (a	 double	 stranded	 DNA	 binding	 dye)	 the	amplification	 of	 cDNA	 can	 be	 measured	 in	 real	 time	 as	 the	 reaction	 progresses	through	cycles,	allowing	for	accurate	measurements	of	gene	expression.		Two	µg	of	RNA	extracted	 from	 tissues	or	 cells	 as	described	 in	 section	 2.2.4	was	reverse	 transcribed	using	nanoScript	2	Reverse	Transcription	Kit	 (PrimerDesign,	UK)	in	a	20	µL	reaction.	Firstly,	2	µg	of	RNA	was	added	to	a	1:1	mixture	of	random	nonamer	 and	 oligo-dT	 primers	 in	 a	 10	 µL	 reaction	 and	 heated	 to	 65°C	 for	 5	minutes,	then	transferred	immediately	to	ice;	this	step	allows	for	the	pre-annealing	of	 nonamer	 and	 oligo-dT	 primers	 to	 the	 RNA	 template.	 Secondly,	 10	 µL	 of	extension	buffer	(recipe	in	Table	2.7)	was	added	to	each	sample	and	subsequently	the	samples	were	heated	to	42°C	for	30	minutes	followed	by	75°C	for	10	minutes	in	a	BioRad	iCycler	(BioRad,	UK).	The	resulting	cDNA	was	stored	at	-20°C	until	use.		
Component Per reaction (µL) 
nanoScript2 4X Buffer 5.0 
dNTP mix 10 mM 1 
RNase/DNAse free H20 3.0 
nanoScipt2 enzyme 1.0 
Final volume 10 µL  
Table 2.7. Reverse transcription extension buffer recipe.  
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qPCR	 was	 performed	 using	 SYBR	 Green	 chemistry	 and	 PrecisionPlus	 2X	 qPCR	MasterMix	 premixed	 with	 SYBR	 Green	 and	 ROX	 (Primer	 Design,	 UK)	 in	 a	MicroAmp®	Fast	Optical	96-Well	Reaction	Plate	(Applied	Biosystems,	UK)	and	an	Applied	Biosystems	HT9700FAST	qPCR	machine.	The	final	reaction	volume	was	20	µL	per	well	in	a	singleplex	assay	consisting	of	cDNA	template	from	RT	reaction,	1X	qPCR	MasterMix	and	250	nM	forward	and	reverse	primers	specific	to	the	gene	of	interest.	The	qPCR	reaction	was	performed	as	described	in	Table	2.8;	melt	 curve	analysis	was	performed	post-PCR	 to	ensure	specificity	of	products	 formed	 in	 the	reaction	as	described	 in	Table	2.9.	All	 reactions	were	carried	out	 in	duplicate	or	triplicate	and	averages	calculated	 from	the	resulting	data.	Data	 is	output	as	cycle	threshold	 (Ct)	 values	which	must	 be	 converted	 to	 fold	 expression	 as	 detailed	 in	section	2.2.6	for	analysis.		
 Hot-Start Cycles x40 Hold 
Temperature (°C) 95 95 60* 4 
Time  2 min 15 sec 60 sec ¥ 
Table 2.8. qPCR reaction conditions. *Data Collection during the 60°C section of each cycle 
through the SYBR channel. 
 Step 1 Step 2* Step 3 
Temperature (°C) 95 60 95 
Time 15 sec 15 sec 15 sec 
Table 2.9. Melt curve conditions. *Ramp rate between step 2 and 3 is set to 2% and data 
collection performed during ramping via SYBR channel. The	 specific	 primers	used	 to	quantify	 each	 gene	of	 interest	were	designed	using	NCBI	 Primer-Blast	 software	 and	 are	 detailed	 in	 Table	 2.10.	 Care	 was	 taken	 to	design	 primers	 of	 an	 approximate	 length	 of	 20	 base	 pairs	 (bp)	with	 GC	 content	between	40-60%	where	possible,	a	melting	temperature	of	60°C,	and	an	amplicon	length	of	80-160	bp.	Primers	were	also	designed	across	exon-exon	junctions	where	possible,	 this	 allows	 for	 amplification	 of	 mRNA	 sequences	 only	 and	 eliminates	signal	 from	 any	 genomic	 DNA	 contamination.	 All	 primers	 were	 ordered	 from	Sigma	Aldrich	as	a	custom	service	other	than	where	indicated,	β-actin	was	used	as	a	control	gene	for	normalisation	of	the	data.		.	
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Gene Ref Seq Forward 5'-3' Reverse 5'-3' Amplicon 
Length 
Acetyl-CoA Carboxylase – alpha (ACCa) NM_133360.2 GGTCTTCGAGTGGATTGGCA CAGCTGCCTTCAGACCATCA 115 
Adiponectin (ADIPOQ) NM_009605.4 CTCCACCCAAGGGAACTTGT AGGACCAAGAAGACCTGCATC 140 
Cluster of differentiation 14 (CD14) NM_009841.3 ACACCACCGCTGTAAAGGAA CACACGCTCCATGGTCGGTA 93 
Fatty Acid Synthase (FASN) NM_007988.3 AAGCGGTCTGGAAAGCTGAA AGGCTGGGTTGATACCTCCA 151 
GPR55 NM_001033290.2 ATGGGAACCATCTGGGCTTG CGAATGAGCAGTTGTCACGC 101 
GPx4 NM_008162.3 
NM_001037741.3 
AGTACAGGGGTTTCGTGTGC TATCGGGCATGCAGATCGAC 97 
Leptin (Lep) NM_008493.3 TGTCGGTTCCTGTGGCTTTG GATACCGACTGCGTGTGTGA 137 
MnSOD NM_013671.3 GCCTGCTCTAATCAGGACCC GTAGTAAGCGTGCTCCCACA 84 
NADPH Oxidase 4 (NOX4) NM_015760.5 ACCTCTGCCTGCTCATTTGG CCTAGGCCCAACATTTGGTGA 112 
β-actin* NM_007393.3 GATGTATGAAGGCTTTGGTC TGTGCACTTTTATTGGTCTC 96 
Table 2.10. Gene specific primers for use in qPCR. *Primers were purchased pre-designed as KiCqStartÔ Primers from Sigma Aldrich. 
		 57	
2.2.6. qPCR primer validation and analysis 
In	 order	 to	 assess	 changes	 in	 gene	 expression	using	RT-qPCR,	 the	2-ΔΔCt	method,	first	described	by	Livak	and	Schmittgen	(Livak	and	Schmittgen	2001)	was	used.	In	order	to	use	this	method,	 the	gene	specific	primers	(detailed	 in	Table	2.10)	must	first	 be	 validated	 for	 use,	 as	 each	 primer	 set	 must	 have	 a	 PCR	 efficiency	approximately	equal	 to	 the	control	primer	 (β-actin).	PCR	efficiencies	are	optimal	when	between	90-110%,	although,	for	the	2-ΔΔCt	method,	it	is	more	important	that	the	 efficiencies	 of	 each	 reaction	 are	 approximately	 equal.	 To	 assess	 primers’	efficiencies,	 serial	dilutions	of	 cDNA	generated	 from	different	 sample	 types	 to	be	measured	 (e.g.	 tissue	 or	 cells)	 were	 used	 to	 produce	 a	 standard	 curve	 of	concentration	against	Ct	value	 for	each	primer	set.	The	efficiency	of	each	primer	set	was	calculated	from	using	the	gradient	of	the	standard	curve	as	in	Equation	4	as	follows:	
%"##$%$&'%( = *10-. /012345678 − 1: 	× 100	
Equation 4. Percentage Efficiency calculation for PCR reactions. To	approximate	how	equal	efficiencies	are	between	control	and	target	primers,	ΔCt	was	calculated	from	the	results	as	follows:	=>? = >?@21057	0565 − >?AB671BC	0565	
Equation 5. ΔCt Calculation The	 ΔCt	 was	 calculated	 for	 each	 serial	 dilution	 point	 and	 a	 semi-logarithmic	regression	 analysis	 plotted	 for	 each	 primer	 set.	 If	 the	 efficiencies	 of	 target	 and	control	primers	were	equal,	the	gradient	of	this	regression	plot	would	be	<0.1	and	the	primer	set	can	be	considered	appropriate	for	use	in	the	2-ΔΔCt	method.		The	 2-ΔΔCt	 method	 is	 based	 on	 the	 principle	 that	 during	 each	 cycle	 of	 the	 PCR	protocol,	 the	 target	 DNA	 sequence	 is	 doubled	 (assuming	 a	 primer	 reaction	efficiency	of	100%).	Relative	gene	expression	can	therefore	be	calculated	based	on	the	cycle	number	taken	to	reach	a	fluorescence	threshold	(the	Ct	value)	compared	to	a	control	gene.	Firstly,	ΔCt	was	calculated	as	in	Equation	5	above	for	each	target	gene	 for	 every	 sample;	 after	 which,	 each	 sample	 was	 normalised	 to	 a	 control	
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sample,	therefore	producing	ΔΔCt	using	Equation	6	below.		∆∆>?	 = 	∆>?75E7	E2FGC5	 −	∆>?HB671BC	E2FGC5	
Equation 6. ΔΔCt Calculation. The	resulting	ΔΔCt	was	used	in	the	final	calculation	detailed	in	Equation	7	below,	based	on	the	principle	of	a	doubling	of	each	product	per	cycle.		IJKL	"MNO&PP$J'	O&KQ?$R&	?J	%J'?OJK	PQSNK& = 2-∆∆A7	
Equation 7. Calculation of fold gene expression.  
2.2.7. Standard protein extraction from cells 
For	extraction	of	total	protein,	cells	were	first	placed	on	ice,	the	medium	removed	and	 washed	 twice	 with	 chilled	 sterile	 PBS	 to	 remove	 residual	 medium,	 then	incubated	 with	 chilled	 1X	 cell	 lysis	 buffer	 (supplied	 as	 10X	 lysis	 buffer,	 Cell	Signalling,	UK;	details	in	Table	2.11)	on	ice	for	5	minutes.	Cells	were	then	scraped	from	the	culture	dish	using	a	Corning	cell	scraper	and	the	solution	transferred	to	a	chilled	microcentrifuge	tube.	The	solution	was	briefly	sonicated	to	disrupt	cellular	membranes	 followed	 by	 centrifugation	 at	 14,000	 xg	 at	 4°C	 for	 10	 minutes;	 the	resulting	 protein	 containing	 supernatant	 was	 transferred	 to	 a	 clean	 tube	 and	subsequently	snap	frozen	in	liquid	nitrogen	and	stored	at	-80°C	until	use.		For	 tissue	 protein	 extraction,	 specific	 protocols	 were	 conducted	 in	 accordance	with	each	individual	experiment	and	are	detailed	as	such	in	the	relevant	sections.	
Component  Concentration  
Tris-HCl (pH 7.5) 20 mM 
NaCl 150 mM 
Na2.EDTA 1 mM 
EGTA 1 mM 
Triton-X100 1% 
Na4P2O7 2.5 mM 
β-glycerophosphate 1 mM 
Na3VO4 1 mM 
Leupeptin 1 µg.ml-1  
Table 2.11. Composition of 1X cell lysis buffer after dilution in distilled H20. 	
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2.2.8. Protein quantification 
Protein	 samples	 extracted	 from	 cells	 or	 tissues	 were	 quantified	 by	 the	 method	originally	described	by	Bradford	(Bradford	1976).	This	method	utilises	the	binding	of	 Coomassie	 Brilliant	 Blue	 G-250	 dye	 to	 proteins	 under	 acidic	 conditions,	resulting	 in	 a	 shift	 absorbance	 of	 the	 dye	 from	 470	 nm	 to	 595	 nm,	 that	 can	 be	subsequently	read	using	a	spectrophotometer	(Bradford	1976).	Protein	containing	solutions	 were	 first	 diluted	 in	 appropriate	 dilution	 buffer	 (the	 same	 buffer	 as	prepared	in)	in	order	to	be	within	the	linear	range	of	the	assay.	For	quantification,	a	standard	curve	of	BSA	was	prepared	(serial	dilutions	ranging	from	0.1	mg.ml-1	to	1.5	mg.ml-1	in	dilution	buffer)	and	plated	alongside	the	experimental	samples.	Five	µL	of	 each	 solution	was	pipetted	 into	 a	96-well	 plate	 in	 triplicate	 and	250	µL	of	Bradford	 Reagent	 (0.01%	 Coomassie	 Brilliant	 Blue	 G-250,	 5%	 methanol,	 8.5%	phosphoric	acid)	was	added	to	each	well	containing	samples.	After	incubation	for	5	min	 at	 room	 temperature,	 absorbance	was	measured	 at	 595nm	 for	 each	 sample	using	a	Synergy	HT	microplate	reader	(Biotek,	USA).	Readings	were	averaged	and	a	 negative	 ‘blank’	 reading	 (dilution	 buffer	 only)	 was	 subtracted	 from	 the	absorbance	values.	A	standard	curve	was	produced	from	the	known	BSA	dilutions,	and	 from	 the	 equation	 of	 this	 curve,	 the	 concentration	 of	 protein	 in	 the	experimental	samples	was	extrapolated.	
2.2.9. SDS-PAGE and Western blotting 
Polyacrylamide	gel	electrophoresis	(PAGE)	is	a	technique	used	to	separate	whole	protein	extracts	 into	 individual	proteins	based	on	their	molecular	weight.	Firstly,	proteins	were	denatured	and	bound	to	sodium	dodecyl	sulphate	(SDS)	in	a	distinct	ratio	of	1.4:1	w/w,	giving	each	denatured	protein	a	negative	charge,	the	strength	of	which	is	based	on	the	size	of	the	denatured	protein.	The	denatured	samples	were	then	 electrophoresed	 through	 a	 poly-acrylamide	 gel	 with	 uniform	 pores,	separating	 the	 proteins	 from	 one	 another	 as	 larger	 molecules	 move	 slower	through	the	gel.		Glass	 plates	 for	 casting	 gels	 were	 washed	 with	 70%	 ethanol	 and	 assembled	immediately	before	preparing	gel	solutions.		
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The	polyacrylamide	resolving	gels	were	prepared	as	follows	in	Table	2.12:	
 Volume (ml) 
dH2O 4.4 
Bisacrylamide/Acrylamide (30%) 3 
1.5 M Tris buffer pH 8.8 2.5 
SDS (20% solution) 0.05 
Tetramethylethylenediamine (TEMED) 0.005 
Ammonium persulphate (10%) 0.05 
Table 2.12. Preparation of Resolving Gel to make 10 ml of gel solution. Tris	buffer	was	prepared	by	dissolving	Trizma	(Sigma	Aldrich,	UK)	in	water	to	the	required	concentration	and	pH	adjusted	via	addition	of	concentrated	hydrochloric	acid.	SDS	(Fisher	Scientific,	UK)	was	dissolved	in	water	to	a	final	concentration	of	20%	w/v.	Bisacrylamide/Acrylamide	solution	(Bio	Rad,	UK)	was	supplied	in	a	30%	w/v	solution.	Ammonium	persulphate	(Sigma	Aldrich,	UK)	was	dissolved	in	water	to	a	final	concentration	of	10%	w/v.	Components	were	 added	 in	 the	 order	 listed	 in	Table	 2.12,	with	 TEMED	 (Sigma	Aldrich,	UK)	and	ammonium	persulphate	added	last	to	catalyse	the	polymerisation	reaction.	 4.5	 ml	 of	 prepared	 gel	 solution	 was	 immediately	 dispensed	 into	 the	casting	apparatus	for	each	gel,	on	top	of	which	was	 layered	a	few	drops	of	water	saturated	 butanol	 in	 order	 to	 protect	 the	 gel	 from	 air	 exposure	 whilst	 setting.	Resolving	gels	were	left	to	set	for	20-30	minutes	at	room	temperature,	after	which	the	butanol	was	poured	off	and	stacking	gel	was	prepared	as	follows	in	Table	2.13	and	added	to	the	resolving	gel	and	a	comb	inserted:	
 Volume for 6% gel (ml) 
dH2O 3.3 
Bisacrylamide/Acrylamide (30%) 1 
1M Tris pH 6.8 0.625 
SDS (20%) 0.025 
TEMED 0.005 
Ammonium persulphate (10%) 0.025 
Table 2.13. Preparation of Stacking Gel to make 5ml of gel solution. Protein	 samples	 were	 prepared	 by	 adding	 2X	 loading	 buffer	 pH	 6.8	 (recipe	 in	
Table	2.14)	to	appropriate	amounts	of	protein	and	heating	to	95°C	for	5	minutes.			
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 Volume (ml) 
1M Tris pH 6.8 1 
1M Dithiothreitol (DTT) 1 
0.1% Bromophenol Blue 2 
Glycerol 2 
10% SDS solution 4 
Table 2.14. Preparation of 2X loading buffer. All reagents purchased from Sigma Aldrich, UK. Following	heating,	samples	were	electrophoresed	at	150	volts	for	60	minutes,	on	a	gel	submerged	in	running	buffer,	prepared	as	10X	buffer	and	diluted	1:10	in	water	before	 use,	 containing	 250	 mM	 Trizma,	 35	 mM	 SDS,	 1.92	 M	 glycine	 (Fisher	Scientific,	UK).		PAGE	separated	proteins	were	 transferred	 to	 a	 polyvinylidene	difluoride	 (PVDF)	membrane,	previously	activated	 in	methanol,	 in	a	wet	 transfer,	 submerged	 in	1X	running	buffer	supplemented	with	20%	methanol	using	a	current	of	360	mA	for	45	minutes.		The	PVDF	membrane	was	washed	 in	1X	TBS	supplemented	with	0.1%	tween-20	(TBS-T,	prepared	from	10X	TBS;	200mM	Tris,	1.37M	NaCl,	pH	7.6)	 for	5	minutes	before	 incubation	 with	 appropriate	 blocking	 buffer	 for	 one	 hour	 at	 room	temperature.	 Following	 blocking,	 the	 membrane	 was	 incubated	 with	 the	appropriate	 primary	 antibody	 at	 4°C	 overnight	 with	 constant	 agitation.	 The	membrane	was	subsequently	washed	3	times	with	TBS-T	for	5	minutes	each	wash	before	 incubation	with	an	appropriate	HRP-conjugated	secondary	 antibody	 for	1	hour	at	room	temperature.		The	membrane	was	again	washed	3	times	for	5	minutes	each	before	detection	of	signal	via	chemiluminescence.	SuperSignal	West	Pico	Chemiluminescent	Substrate	(Thermo	Fisher,	UK)	was	used	as	 instructed	by	 the	manufacturer;	 the	substrates	were	 combined	 1:1	 and	 the	 membrane	 incubated	 in	 working	 solution	 for	 5	minutes	before	securing	the	membrane	between	plastic	protectors	and	viewing	on	a	PEQLAB	Fusion	FX7	CCD	camera	(Vilber,	Germany).	
2.2.10. Quantitative analysis of LPI in plasma and cardiac tissue 
The	 final	extraction	of	LPI	 from	tissues	and	quantitative	measurement	of	LPI	via	LC-MS	was	undertaken	by	Mr	Seshu	Tammireddy	and	Prof	Phillip	Whitfield	of	the	
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Lipidomics	 Research	 Facility	 within	 the	 Department	 of	 Diabetes	 and	Cardiovascular	Science	at	 the	University	of	 the	Highlands	and	 Islands,	 Inverness.	The	 initial	 development	 of	 the	 modified	 extraction	 method	 was	 a	 collaborative	effort	 between	 myself	 and	 the	 above-mentioned	 colleagues,	 all	 of	 whom	contributed	 equally	 to	 the	 development	 of	 the	 method.	 All	 subsequent	 data	analysis	 and	 statistical	 testing	 was	 performed	 by	 myself.	 Tissue	 and	 plasma	samples	were	collected	and	frozen	at	-80°C,	as	described	in	the	relevant	sections	of	each	chapter	and	transported	to	the	University	of	the	Highlands	and	Islands	on	dry	ice	for	analysis.		
2.2.10.1. Materials and Reagents 
LPI	18:0	and	LPI	20:4	standards	and	LPI	17:1	internal	standard	were	all	purchased	from	Avanti	Polar	Lipids,	AL,	USA.	Methanol,	butanol,	isopropanol,	formic	acid	and	ammonium	formate	were	obtained	from	Fisher	Scientific,	UK.	Solvents	were	HPLC	or	 LC-MS	 grade.	 Other	 reagents	were	 purchased	 from	 Sigma	Aldrich,	 UK,	 unless	otherwise	stated.		
2.2.10.2. Lipid Extraction from plasma and cardiac tissue  
All	 lipid	 extractions	were	 performed	 in	 16	mm	 glass	 culture	 tubes	 (10ml)	 with	PTFE	lined	screw	caps	(Fisher	Scientific,	UK).	A	modified	method	of	extraction	was	performed	based	on	the	method	described	by	Baker	et	al.	(Baker	et	al.	2001).	For	tissues,	 the	wet	weight	of	each	heart	 slice	was	measured	with	a	Fisher	Scientific	MH124	analytical	balance.	 Individual	 heart	 slices	were	 then	homogenised	 in	 ice-cold	phosphate	buffered	saline	(PBS)	to	a	final	concentration	of	20mg/ml	using	an	IKA	Digital	Ultra	Turrax	T25	mechanical	homogeniser.	Heart	tissue	homogenates	(100	μl)	or	plasma	samples	(50	μl)	were	spiked	with	50	pmol	LPI	17:1	in	methanol	as	an	internal	standard	(ISTD)	and	300	μl	buffer	containing	30	mM	citric	acid	and	40	mM	disodium	hydrogen	phosphate	was	added	to	each	sample.	Lipids	were	then	extracted	 with	 750	 μl	 butanol	 and	 375	 μl	 water-saturated	 butanol	 (for	 plasma	samples)	 and	 1.5	 ml	 butanol	 and	 750	 μl	 water-saturated	 butanol	 (for	 heart	homogenate)	 [prepared	 by	 mixing	 1-butanol	 and	 HPLC	 grade	 water	 1:1,	 v/v,	centrifuging	 the	 solvent	 mixture	 and	 collecting	 the	 upper	 phase].	 After	
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centrifugation	 at	 2000	 xg	 for	 5	 min	 to	 facilitate	 phase	 separation,	 the	 upper	butanol	phase	was	transferred	to	a	new	glass	tube	and	and	evaporated	to	dryness	under	vacuum	using	a	Genevac	miVac	sample	concentrator.	The	final	lipid	extract	of	each	sample	was	reconstituted	in	200µl	methanol	containing	5mM	ammonium	formate.	
2.2.10.3. LC-MS 
All	 LC-MS	 analyses	 were	 performed	 using	 a	 Thermo	 Exactive	 Orbitrap	 mass	spectrometer	 (Thermo	 Scientific,	 Hemel	Hempsted,	 UK)	 equipped	with	 a	 heated	electrospray	ionization	(HESI)	probe	and	coupled	to	a	Thermo	Accela	1250	ultra-high-pressure	 liquid	 chromatography	 (UHPLC)	 system.	 Samples	 (5	 µL)	 were	injected	 on	 to	 a	 Thermo	Hypersil	 Gold	 C18	 column	 (2.1mm	 x	 100	mm,	 1.9	 μm)	maintained	 at	 50°C.	 Mobile	 phase	 A	 consisted	 of	 water	 containing	 10	 mM	ammonium	formate	and	0.1%	(v/v)	formic	acid.	Mobile	phase	B	consisted	of	90:10	isopropanol/acetonitrile	 containing	 10	 mM	 ammonium	 formate	 and	 0.1%	 (v/v)	formic	acid.	The	initial	conditions	for	analysis	were	65%A/35%B.	The	percentage	of	mobile	 phase	 B	was	 increased	 from	35%-65%	over	 4	min,	 followed	 by	 65%-100%	over	15	min,	held	for	2	min	before	re-equilibration	to	the	starting	conditions	over	6	min.	The	flow	rate	was	400	µl/min.	The	LC	injection	valve	was	switched	to	waste	after	9	min	of	each	run	as	all	LPI	eluted	within	this	time	window.	The	LPI	were	analysed	in	negative	ion	mode	over	the	mass	to	charge	ratio	(m/z)	range	of	250-2000	at	a	resolution	of	100,000	and	1Hz	scan	speed.	The	mass	spectrometer	was	 calibrated	 with	 using	 Thermo	 ESI	 Negative	 Ion	 Calibration	 Solution,	 which	maintained	<5ppm	mass	accuracy.	
2.2.10.4. Data Analysis 
The	data	were	processed	using	Thermo	Xcalibur	2.1	Quan	Browser	software.	 Ion	signals	corresponding	to	the	accurate	m/z	values	for	[M-H]-	ions	of	individual	LPI	molecular	species	(Table	2.15)	were	extracted	from	raw	LC-MS	data	sets.		The	 response	 ratio	 of	 each	 ion	was	 calculated	 and	 the	 concentration	 of	 the	 LPI	species	determined	from	an	appropriate	calibration	curve	run	with	each	batch	of	
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analysis.	For	LPI	species	with	16-18	carbons	a	calibration	curve	based	on	the	peak	height	of	a	LPI	18:0	standard	to	the	LPI	17:1	ISTD	was	used.	For	LPI	species	with	20-22	carbons	a	calibration	curve	based	on	the	peak	height	of	a	LPI	20:4	standard	to	 the	 LPI	 17:1	 ISTD	 was	 used	 (calibration	 curves	 are	 shown	 in	 the	 appendix).	Total	concentrations	of	LPI	were	calculated	from	the	summed	concentrations	of	all	the	molecular	species.	
LPI	species	 m/z	
LPI	16:0	 571.2889	
LPI	16:1	 569.2732	
LPI	17:1	(ISTD)	 583.2900	
LPI	18:0	 599.3202	
LPI	18:1	 597.3045	
LPI	18:2	 595.2889	
LPI	20:1	 625.3358	
LPI	20:2	 623.3202	
LPI	20:3	 621.3045	
LPI	20:4	 619.2889	
LPI	22:4	 647.3202	
LPI	22:5	 645.3045	
LPI	22:6	 643.2889	
Table 2.15. The accurate m/z values for each [M-H]- ion of each individual LPI species.  
2.2.11. General data analysis and statistics 
All	 statistical	 analyses	 were	 performed	 using	 GraphPad	 Prism	 6	 (GraphPad	Software	 Inc,	 USA)	 and	 all	 values	 presented	 are	 group	 means	 ±	 SEM	 unless	otherwise	 stated	 in	 the	 text.	 Group	 sizes	 of	 each	 experimental	 group	 were	predetermined	 based	 on	 power	 calculations	 where	 appropriate	 and	 will	 be	detailed	in	the	relevant	sections	of	each	chapter.	Statistical	analysis	was	performed	on	all	data	with	3	or	more	independent	measurements	per	group.	All	comparisons	between	groups	 involved	the	comparison	of	more	 than	 two	experimental	groups	and	often	with	two	factor	levels	(i.e.	diet	and	strain),	therefore	a	two-way-ANOVA	test	was	 routinely	 used	 to	 test	 for	 significant	 differences	 between	 group	means.	When	the	overall	ANOVA	P-value	was	significant	(p<0.05),	post-hoc	analysis	using	Bonferroni	correction	for	multiple	comparisons	was	performed	as	a	conservative	method	 to	 test	 for	 significant	 differences	 between	 individual	 groups	 within	 the	ANOVA	and	minimise	the	risk	of	producing	a	type	I	error.	Data	sets	were	assumed	to	be	normally	 distributed	 to	 satisfy	 the	 criteria	 of	 the	 two-way-ANOVA	and	 the	
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Brown-Forsythe	 test	of	homogeneity	of	variances	was	performed	on	data	sets	as	part	 of	 the	 ANOVA	 analysis.	 All	 graphs	 were	 produced	 by	 GraphPad	 Prism	software.	
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3 : The phenotypic response of the GPR55-/- mouse to 
high-fat feeding  
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3.1. Introduction 
3.1.1. The GPR55/LPI system and energy homeostasis 
There	 is	 growing	 evidence	 that	 GPR55	 is	 important	 in	 maintaining	 energy	homeostasis	 and	 may	 play	 a	 role	 in	 metabolic	 disorders.	 Regulation	 of	 glucose	homeostasis	 by	 central	 and	 peripheral	 tissues	 is	 fundamental	 to	 maintaining	 a	healthy	cellular	environment	and	a	disruption	or	an	imbalance	of	this	system	leads	to	 obesity,	 type	 2	 diabetes	 and	metabolic	 syndrome	 as	 described	 in	 the	 general	introduction.	GPR55	mRNA	and	protein	have	been	detected	in	a	number	of	tissues	from	mice,	rats	and	humans	that	regulate	metabolism,	including	the	hypothalamus,	white	 adipose	 tissue	 (Ryberg	 et	 al.	 2007),	 islets	 of	 Langerhans	 and	 the	 liver	(Romero-Zerbo	 et	 al.	 2011);	 yet	 surprisingly,	 no	 study	 has	 yet	 looked	 at	 the	expression	 of	 GPR55	 within	 insulin-sensitive	 skeletal	 muscle.	 The	 function	 of	GPR55	in	these	tissues	remains	quite	elusive,	however	emerging	work	has	begun	to	 shed	 light	 on	 the	 issue.	 Romero-Zerbo	 et	 al.	 (2011)	 demonstrated	 using	 rat	tissues	 that	 treatment	 with	 O-1602	 (a	 synthetic	 GPR55	 agonist)	 significantly	enhances	the	response	of	pancreatic	cells	to	release	insulin	when	stimulated	with	glucose,	involving	a	calcium-transient	mechanism	within	the	cells	(Romero-Zerbo	et	al.	2011).	This	effect	was	not	observed	when	using	tissues	 from	GPR55-/-	mice	and	therefore	would	seem	to	be	dependent	on	GPR55	(Romero-Zerbo	et	al.	2011).	The	 ability	 of	 GPR55	 to	 enhance	 insulin	 release	 has	 great	 implications	 for	 the	potential	treatment	of	type	2	diabetes	and	metabolic	syndrome,	however	it	is	also	important	 to	 study	 the	 function	 of	 GPR55	 within	 insulin-sensitive	 tissues.	 As	discussed	and	reviewed	by	Simcocks	et	al.	(2014),	activation	of	GPR55	by	LPI	has	been	shown	by	a	number	of	in	vitro	studies	to	phosphorylate	and	activate	ERK1/2	and	 p38	MAPK;	 two	 proteins	 important	 in	 the	 regulation	 of	 energy	metabolism	within	 skeletal	 muscle	 (Simcocks	 et	 al.	 2014).	 Activated	 ERK1/2	 is	 known	 to	activate	cluster	differentiation	36	(CD36),	thereby	stimulating	fatty	acid	oxidation	within	skeletal	muscle	and	is	also	implicated	in	the	uptake	of	glucose	by	the	muscle	tissue	(Turcotte,	Raney	and	Todd	2005,	Chen	et	al.	2002).	Additionally,	activated	p38	MAPK	in	skeletal	muscle	stimulates	mitochondrial	biogenesis	via	downstream	activation	 of	 peroxisome	 proliferator-activated	 receptor	 gamma	 coactivater	 1-
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alpha	(PGC-1α;	Akimoto	et	al.	2005).	Simcocks	et	al.	hypothesised	that	due	to	these	strong	overlaps	 in	 the	GPR55/LPI	system	and	skeletal	muscle	glucose	utilisation	pathways,	 there	 is	 a	 large	 potential	 for	 these	 systems	 to	 be	 causal	 in	 their	relationship	and	further	work	needs	to	be	conducted	to	assess	this	(Simcocks	et	al.	2014).		It	has	been	shown	in	rats	that	the	GPR55/LPI	system	is	influenced	under	standard	diet	 conditions	 by	 feeding/fasting	 status	 and	 leptin	 treatment;	 with	 an	 inverse-relationship	between	feeding	and	both	GPR55	expression	in	WAT	and	plasma	LPI	levels	(Imbernon	et	al.	2014).	This	study	 is	 the	only	study	 to	have	demonstrated	that	 there	 is	a	 direct	 link	between	 the	GPR55/LPI	system	and	 leptin,	with	 leptin	playing	a	 regulatory	 role	 in	 the	 expression	of	both	GPR55	and	LPI.	As	 leptin	 is	a	principal	 hormone	 in	 regulating	 food	 intake	 and	 therefore	 energy	 homeostasis	(Zhang	et	al.	1994),	 this	 is	 further	evidence	that	GPR55	and	LPI	are	 important	to	energy	 homeostasis	 and	metabolism.	However,	 the	most	 compelling	 evidence	 to	support	 the	 notion	 of	 GPR55/LPI	 system	 involvement	 in	 the	 setting	 of	 energy	metabolism	and	obesity	is	the	study	of	Moreno-Navarette	et	al.	(2012),	in	which	it	was	established	that	plasma	level	of	LPI	and	GPR55	expression	in	visceral	WAT	of	humans	was	strongly	correlated	with	weight,	BMI	and	fat	mass	(Moreno-Navarrete	et	al.	2012).	Furthermore,	the	treatment	of	visceral	WAT	explants	with	LPI	in	this	study	 led	 to	 an	 increase	 in	 lipogenic	 enzymes:	 fatty	 acid	 synthase	 (FASN)	 and	acetyl	 CoA-carboxylase	 (ACCa),	 and	 an	 increase	 in	 PPARγ	 gene	 expression,	 an	important	nuclear	receptor	that	controls	the	differentiation	and	storage	capacity	of	undifferentiated	 and	 mature	 adipocytes,	 respectively	 (Moreno-Navarrete	 et	 al.	2012).	Despite	the	aforementioned	studies,	little	is	known	about	the	role	that	the	GPR55/LPI	system	plays	in	the	setting	of	obesity	and	metabolic	syndrome,	or	what	changes	may	occur	as	a	consequence	of	changes	in	GPR55	receptor	expression	or	LPI	production.		
3.1.2. Aim and Objectives 
The	 hypothesis	 of	 this	 study	 is	 that	 GPR55	 plays	 a	 functional	 role	 in	 metabolic	health	and	that	ablation	of	the	receptor	may	lead	to	dysregulation	of	specific	tissue	functions.	To	test	this	hypothesis,	the	primary	aim	of	the	following	chapter	was	to	
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characterise	and	compare	the	phenotypic	responses	of	male	and	female	GPR55-/-	mice	 to	WT	 controls	 and	 their	 respective	 responses	 to	 a	 12-week	 high	 fat	 diet	(HFD)	 intervention.	 To	 fulfil	 this	 aim,	 primary	 objectives	 included	 physiological	measurements	of	body	weights,	plasma	lipid	profiles	and	body	fat	mass	of	mice.		Further	to	this,	 the	secondary	aim	was	to	 investigate	the	tissue	specific	effects	of	the	HFD	in	the	different	experimental	groups	of	mice;	with	a	main	focus	on	adipose	tissue	 histology	 and	 gene	 expression.	 Other	 tissues	 examined	 to	 a	 lesser	 extent	included	the	heart,	aorta	and	the	liver.		The	final	aim	was	to	examine	the	circulating	plasma	and	cardiac	tissue	levels	of	the	endogenous	GPR55	ligand	LPI,	in	mice	from	each	experimental	group,	in	order	to	assess	any	 influence	of	a	HFD	on	LPI	metabolism	in	the	presence	and	absence	of	GPR55.		
3.2. Methods and experimental design 
3.2.1. In vivo and physiological parameters 
To	measure	 the	 phenotypic	 effect	 of	 a	HFD	on	WT	and	GPR55-/-	mice,	male	 and	female	mice	were	randomly	assigned	to	each	diet	group.	Between	5-7	mice	were	allocated	 to	 each	 group	 as	 detailed	 in	Table	 3.1,	 and	 the	 diet	 commenced	 at	 5	weeks	of	age	as	described	in	section	2.1.2.	Individual	body	weights	were	measured	weekly	and	the	 individual	 fat	mass	assessed	via	EchoMRI™	as	outlined	 in	section	2.1.3.		
 Male Female 
 SD HFD SD HFD 
WT 6 6 6 6 
GPR55-/- 7 5 7 6 
Table 3.1. The number of mice allocated to each experimental group throughout the study. 
3.2.2. Protein array 
A	 protein	 array	 (Mouse	 Adipokine	 Array	 Kit;	 R&D	 Systems,	 ARY013)	 was	conducted	on	adipose	tissue	that	had	been	previously	harvested	as	part	of	a	pilot	study	and	stored	at	 -80°C.	The	array	was	conducted	on	adipose	tissue	from	male	
		 70	
and	female,	WT	and	GPR55-/-	mice	 fed	a	SD	for	12	weeks	and	was	carried	out	to	determine	any	baseline	differences	in	adipokine	expression	between	the	strains	of	mice	before	intervention	with	the	HFD	as	planned	in	this	study.	Eight	arrays	were	conducted	 in	 total	 (two	 independent	adipose	 tissue	samples	were	analysed	 from	each	 of	 the	 four	 experimental	 groups);	 four	 of	 those	 arrays	 (one	 from	 each	experimental	group)	were	conducted	by	another	user	before	the	commencement	of	 this	 study	and	another	 four	were	performed	by	myself	as	part	of	 this	 present	study	to	validate	and	confirm	the	results	of	the	first	user.		To	 extract	 protein	 from	 the	 previously	 frozen	 adipose	 tissue,	 frozen	 tissue	 was	placed	 directly	 into	 PBS	 supplemented	 with	 10	 μg/ml	 protease	 inhibitors:	pepstatin	A,	leupeptin	(Sigma	Aldrich,	UK)	and	aprotinin	(Tocris,	UK)	for	lysis	and	homogenisation.	 Tissue	was	 homogenised	 via	 a	mechanical	 homogeniser	 (SHM1	handheld	 homogeniser;	 Stuart,	 UK)	 fitted	with	 a	 5	mm	 flat	 head	 probe	 (SHM/5;	Stuart,	UK)	 in	bursts	of	15	seconds	until	no	 larger	 fragments	remained.	Triton	X-100	 (Sigma	 Aldrich,	 UK)	was	 added	 to	 a	 final	 concentration	 of	 1%,	 the	mixture	vigorously	 vortexed	 and	 stored	 at	 -80°C	 for	2	hours	 to	 aid	 the	disruption	of	 the	tissue.	After	thawing	at	room	temperature,	the	mixture	was	centrifuged	at	10,000	xg	for	5	minutes	at	4°C	to	clarify	the	solution	and	pellet	cell	debris;	the	supernatant	containing	protein	was	then	transferred	to	a	chilled	microcentrifuge	tube	and	kept	on	 ice	 for	 immediate	use	or	snap	frozen	in	 liquid	nitrogen	and	stored	at	 -80°C.	A	layer	 of	 fat	 was	 present	 on	 top	 of	 the	 supernatant,	 therefore	 care	was	 taken	 to	avoid	 contamination	of	 the	 protein	when	 removing	 the	protein	 containing	 layer.	Protein	concentration	was	determined	as	described	in	section	2.2.8.	The	membranes	provided	in	the	array	kit	have	pre-attached	capture	antibodies	for	38	different	adipokines.	 In	brief,	membranes	were	 incubated	for	1	hr	 in	blocking	buffer	 (Array	 buffer	 6)	 before	 incubation	with	 500	 μg	 of	 adipose	 tissue	 protein	extract	 in	 Array	 buffer	 4	 supplemented	 with	 15	 μl	 detection	 antibody	 cocktail,	overnight	 at	 4°C	with	 constant	 agitation.	Membranes	were	 then	washed	with	1x	wash	buffer,	3	times	for	10	min,	followed	by	incubation	with	diluted	streptavidin-HRP	for	30	min	at	room	temperature.	Finally,	membranes	were	washed	a	further	3	times	 in	 wash	 buffer,	 incubated	 with	 Chemi-reagent	 and	 exposed	 to	 x-ray	 film	(Thermo	Fisher,	UK)	 in	a	dark	room.	Developed	films	were	analysed	using	a	UV-
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white	 light	 filter	 on	 the	 PEQLAB	 Fusion	 FX7	 (Vilber	 Lourmat,	 Germany);	 pixel	density	 of	 each	 capture	 spot	 was	 averaged	 and	 divided	 by	 reference	 spots	provided	to	calculate	relative	concentrations	of	each	adipokine.		
3.2.3. Plasma lipid analysis 
Plasma	from	each	mouse	was	obtained	at	the	end	of	the	12-week	dietary	period	as	described	 in	 section	 2.1.4.	 Plasma	 lipids	 (total	 cholesterol,	 HDL-C,	 LDL-C	 and	Triglycerides)	were	measured	using	colorimetric	assays	on	an	automated	Konelab	60i	 clinical	 analyser	 (Thermo	 Fisher,	 UK)	 as	 per	 the	 instruction	 manual	 and	associated	assay	kits	(all	purchased	from	Thermo	Fisher,	UK).	Each	measurement	was	 conducted	 in	 duplicate	 and	 the	 result	 averaged	 for	 each	 sample.	 Values	 are	expressed	as	absolute	mmol/L	values	as	determined	via	calibration	of	the	analyser	with	the	standards	provided	in	the	assay	kits	as	instructed	by	the	manufacturer.		
3.2.4. Histology 
Adipose,	heart,	aorta	and	liver	tissues	were	harvested	from	mice	at	the	end	of	the	dietary	intervention	as	detailed	in	section	2.1.4.	Adipose	tissue	was	processed	and	sectioned	with	a	10	µm	thickness	using	FFPE	methods	as	described	in	2.1.6.	Heart	and	liver	tissue	was	processed	frozen	via	cryostat	as	described	in	section	2.1.6	and	sectioned	at	a	thickness	of	8	µm.	Aorta	sections	were	trimmed	of	external	fat,	left	whole	and	submerged	in	zinc	formalin	fixative	for	24	hours	at	4°C	ready	for	Oil	Red	O	staining	as	described	below.		
3.2.5. Hematoxylin & Eosin staining 
Hematoxylin	&	Eosin	(H&E)	staining	of	adipose	tissue	was	conducted	to	assess	the	morphology	of	adipose	tissue	obtained	from	each	group	of	mice.	Slides	containing	adipose	 sections	 dried	 overnight	 at	 40°C	 were	 stained	 using	 a	 modified	 H&E	method	described	by	Berry	et	al.	(2014)	and	detailed	in	Table	3.2	below	(Berry	et	al.	2014).		
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Solution Time (Seconds) 
Histoclear II (x3) 20 
100% ethanol (x2) 20 
95% ethanol 15 
H2O 15 
Shandon Gill 3 Hematoxylin (x2) 30 
H2O 45 
0.125% HCl-ethanol 15 
H2O 15 
1% lithium carbonate 15 
H2O 15 
Eosin Y alcoholic 15 
95% ethanol (x3) 15 
100% ethanol (x2) 30 
Histoclear II 60 
Table 3.2. H&E staining protocol of sectioned adipose tissue. Shandon Gill 3 Hematoxylin 
and lithium carbonate was purchased from Thermo Fisher, UK. Eosin Y alcoholic was 
purchased from Sigma Aldrich, UK. Following	 staining,	 slides	 were	 cover-slipped	 with	 Histomount™	 mounting	medium	 (National	 Diagnostics,	 USA)	 and	 allowed	 to	 air	 dry	 before	 imaging	 the	stained	 tissue.	 Imaging	 was	 conducted	 using	 a	 Leica	 DMI4000B	 inverted	microscope	 attached	 to	 a	 Leica	 DFC300FX	 camera	 (Leica	 Camera,	 Germany);	images	were	taken	in	bright	light	and	also	using	a	N2.1	fluorescent	filter	cube.	As	discussed	by	Berry	et	al.	(2014),	using	the	fluorescent	filter	allows	for	automated	cell	 size	 measurements	 using	 the	 freeware,	 Cell	 Profiler	 software	 (Berry	 et	 al.	2014).	This	automated	counting	was	verified	using	a	sample	of	images	and	manual	measurements	 taken	using	 ImageJ	 software	 for	comparison	and	was	 found	 to	be	accurate;	furthermore,	“output”	images	that	are	generated	by	Cell	Profiler	software	were	checked	for	reliability	of	the	method.	Further	details	of	the	output	generated	from	the	automated	counting	can	be	found	in	the	appendix.	
3.2.6. Oil Red O staining 
The	Oil	Red	O	staining	of	sectioned	frozen	heart	and	liver	tissue	was	performed	to	assess	 any	 accumulation	 of	 lipids	 within	 the	 tissues.	 Slides	 containing	 sections	were	brought	to	room	temperature	before	being	submerged	in	Oil	Red	O	working	solution	 (prepared	 as	 described	 in	 section	 2.2.3)	 for	 5	 minutes	 at	 room	temperature.	 Slides	 were	 rinsed	 in	 distilled	 water	 and	 counterstained	 via	
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submersion	 in	Shandon	Gill	3	hematoxylin	 for	15	seconds	 followed	by	rinsing	 in	running	tap	water	for	30	minutes.	Stained	slides	were	cover-slipped	using	aqueous	Hydromount™	 mounting	 medium	 (National	 Diagnostics,	 USA)	 and	 imaged	immediately,	as	Oil	Red	O	will	precipitate	over	time	and	destroy	the	clarity	of	the	sections.	 Imaging	 was	 conducted	 using	 a	 Leica	 DMI4000B	 inverted	 microscope	attached	to	a	Leica	DFC300FX	camera	in	bright	field	mode.	To	quantify	the	degree	of	lipid	staining,	a	colour	thresholding	method	was	applied	using	ImageJ	software	as	described	by	Mehlem	et	 al.	 (2013)	 and	 the	area	stained	by	 the	Oil	Red	O	was	quantified	 as	 a	 percentage	 of	 total	 area	 imaged	 (Mehlem	 et	 al.	 2013).	Quantification	of	 staining	was	performed	on	 two	histological	 sections	 from	 each	individual	mouse	per	group.		To	 visualise	 any	 lipid	 plaque	 formations	 within	 the	 descending	 thoracic	 aorta,	formalin-fixed	 aortas	were	 first	 rinsed	 in	 PBS	 to	 remove	 residual	 formalin,	 then	rinsed	in	70%	isopropanol	before	being	submerged	in	Oil	Red	O	working	solution	for	30	minutes	at	room	temperature.	After	staining,	each	aorta	was	again	rinsed	in	70%	isopropanol	to	remove	excess	stain	and	finally	stored	submerged	in	distilled	water	 until	 imaging.	 To	 image	 the	 stained	 aorta,	 each	 aorta	was	 carefully	 sliced	longitudinally	 under	 a	 microscope	 and	 pinned	 onto	 a	 gel	 surface	 for	 en	 face	imaging	 using	 a	 digital	 camera	 (EOS	 1100D,	 Canon,	 UK)	 attached	 to	 a	stereomicroscope	(Leica	S4E,	Leica	Microsystems	Ltd,	UK),	To	quantify	the	Oil	Red	O	 stain,	 each	 aorta	was	 transferred	 to	 a	well	 of	 a	 96	well	 plate,	 100	μl	 of	 100%	isopropanol	added	to	each	well	and	the	plate	placed	on	a	plate	shaker	for	10	min	to	extract	 the	 dye.	 The	 aortas	 were	 subsequently	 removed	 from	 the	 plate	 and	discarded	and	the	absorbance	of	 the	extracted	dye	of	each	well	measured	at	520	nm	 using	 a	 synergy	 HT	 microplate	 reader.	 A	 standard	 curve	 of	 Oil	 Red	 O	concentration	 vs	 absorbance	 at	 520	 nm	 was	 constructed	 alongside	 the	 sample	readings	 in	 order	 to	 calculate	 an	 absolute	 concentration	of	Oil	 Red	O	dye	 in	 the	extracted	 samples.	 To	 account	 for	 size	 variations	 between	 individual	 aortas,	 the	final	data	was	expressed	as	concentration	of	Oil	Red	O	extracted	per	mm2	of	aorta	for	each	sample	(as	calculated	from	the	en	face	images	using	ImageJ	software)	as	described	by	Nunnari	et	al.	(Nunnari	et	al.	1989),	and	averages	were	calculated	for	each	group.		
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3.2.7. qPCR and gene expression 
To	 assess	 the	 gene	 expression	 of	 several	 selected	 adipokines,	 antioxidant	 genes	and	GPR55	within	adipose	and	heart	tissue,	RNA	was	extracted	from	the	tissue	as	described	 in	section	2.2.4	using	Tri-Reagent	and	a	mechanical	homogeniser.	RNA	was	 reverse	 transcribed	 and	 used	 in	 qPCR	 reactions	 as	 detailed	 in	 2.2.5	 with	primers	 specific	 for	 each	 gene	 of	 interest	 (primer	 details	 also	 in	Table	 2.10	 in	section	2.2.5).		
3.2.8. LPI analysis 
Five	 plasma	 samples	 and	 five	 hearts	 were	 randomly	 selected	 from	 each	 male	experimental	 group	 for	 the	 extraction	 of	 lipids	 and	 analysis	 of	 LPI	 by	 LC-MS,	 as	detailed	 in	 section	0.	LPI	analysis	was	set	up	 to	detect	nine-individual	 species	of	LPI	 based	 on	 the	 different	 acyl	 group	 attached;	 total	 LPI	 was	 calculated	 by	combining	 the	 values	 of	 all	 nine-individual	 species	 together.	 LPI	 values	 are	expressed	in	absolute	pmol.ml-1	or	pmol.mg-1	as	determined	by	standard	curves	of	known	standards	run	as	detailed	in	section	2.2.10.4.	For	comparative	purposes,	the	cardiac	LPI	data	 collected	 in	 this	 experiment	will	 be	presented	 and	 discussed	 in	chapter	4	of	this	thesis.		
3.2.9. Statistical analysis 
Data	is	expressed	as	mean±SEM	unless	otherwise	stated.	Gene	expression	data	was	normalised	 to	 a	 control	 gene	 as	 outlined	 in	 section	 2.2.5	 and	 expressed	 as	 fold-change	compared	to	the	control	WT	SD	fed	group.	
3.3. Results 
3.3.1. Protein array 
The	results	of	the	protein	array	conducted	on	adipose	tissue	harvested	from	male	and	 female	mice	 fed	a	SD	 for	12	weeks	are	 represented	 in	Figure	3.1	and	Figure	3.2,	respectively.	
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Figure 3.1. Relative protein expression of adipokines within adipose tissue of male mice fed a SD for 12 weeks. Bars represent mean values and error bars 
= SD. n=2.  
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Figure 3.2. Relative protein expression of adipokines within adipose tissue of female mice fed a SD for 12 weeks. Bars represent mean group values and 
error bars = SD. n=2.
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There	were	subtle	differences	in	adipokine	profiles	between	male	and	female	mice;	the	 female	 mice	 exhibited	 a	 greater	 expression	 of	 most	 adipokines	 and	 specific	increases	 in	 growth	 factor	 binding	 proteins,	 VEGF	 and	 retinol	 binding	 protein	(RBP4)	 expression.	 Despite	 these	 sex	 differences,	 there	 were	 no	 significant	changes	in	the	expression	of	the	38	measured	adipokines	between	WT	and	GPR55-/-	mice	of	either	sex.	
3.3.2. Physiological parameters 
3.3.2.1. Body weight 
There	were	no	significant	differences	 in	absolute	weight	or	weight	gain	between	WT	control	and	GPR55-/-	mice	 fed	 a	SD	 for	12	weeks	 irrespective	of	 sex	 (Figure	
3.3;	p>0.05).	Male	WT	mice	fed	a	HFD	for	12	weeks	did	not	show	any	accelerated	weight	 gain	 or	 a	 greater	 absolute	 body	 weight	 as	 compared	 to	 their	 WT	 SD	controls	 (Figure	 3.3;	 final	 change	 in	weight:	 13.2±0.5	 g	 vs	 12.4±1.0	 g,	 p>0.05).	Similarly,	 female	WT	mice	 fed	 a	HFD	 for	 12	weeks	 did	not	 show	 any	 significant	differences	in	body	weight	compared	to	their	SD	controls	(final	change	in	weight:	6.7±0.5	g	vs	7.8±1.0	g,	p>0.05).	In	 contrast,	 male	 GPR55-/-	 mice	 fed	 a	 HFD	 for	 12	 weeks	 gained	 weight	 at	 an	accelerated	rate	from	week	7	of	the	dietary	period	(see	Figure	3.3c)	and	exhibited	a	 significantly	 increased	 weight	 gain	 by	 the	 end	 of	 the	 dietary	 intervention	 as	compared	 to	 the	 GPR55-/-	 SD	 fed	 controls	 (Figure	 3.3;	 final	 change	 in	 weight:	19.5±0.9	g	vs	10.2±0.3	g,	p<0.001).	This	increased	weight	gain	resulted	in	a	greater	absolute	body	weight	 at	 the	end	of	 the	dietary	period	 that	 could	be	 classified	as	obese	 (greater	 than	3	 standard	 deviations	 above	 the	mean	of	 the	 SD	 fed	 control	mice).	Female	GPR55-/-	mice	fed	a	HFD	for	12	weeks	also	gained	weight	at	an	accelerated	rate	from	week	10	of	the	dietary	period,	but	to	a	 lesser	extent	than	in	male	mice.	Although	 absolute	body	weight	was	 greater	 in	 the	HFD	mice,	 due	 to	 intra-group	variation	 the	 results	 were	 not	 statistically	 significant	 (Figure	 3.3b	 and	 d;	 final	change	in	weight:	10.9±2.2	g	vs	8.0±0.5	g,	p=0.09).	
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Male	 	 	 	 	 			Female	
	
Figure 3.3. Changes in absolute body weights of (a) male mice and (b) female mice 
throughout the study. Change in body weight of (c) male mice and (d) female mice 
throughout the dietary period. Individual points represent mean group values and error bars 
= SEM. n=5-7 for all groups. *** p<0.001 GPR55-/- HFD vs all other groups, as determined via 
two-way ANOVA and Bonferroni post-hoc analysis.  	 	
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3.3.2.2. Measurement of fat mass via EchoMRI™ 
As	 shown	 by	 Figure	 3.4a	 and	 b,	 the	 fat	 mass	 of	 male	 and	 female	 mice,	 as	 a	percentage	of	total	body	weight,	was	approximately	the	same	(~10%)	regardless	of	strain	 and	 diet	 group	 before	 the	 commencement	 of	 the	 dietary	 intervention	(p>0.05).		At	the	end	of	the	dietary	intervention,	there	were	no	significant	differences	in	fat	mass	percentage	between	control	WT	and	GPR55-/-	SD	fed	mice	irrespective	of	sex	(p>0.05).	Similarly,	male	WT	mice	fed	a	HFD	had	the	same	percentage	of	fat	mass	as	 the	WT	SD	 controls	 (Figure	3.4c;	11.9±1.1	%	vs	10.4±0.6	%,	p>0.05).	 Female	WT	mice	 fed	 a	HFD	also	had	 the	 same	percentage	of	 fat	mass	 as	 the	WT	SD	 fed	controls	(Figure	3.4d;	13.4±1.6	%	vs	10.4±1.2	%,	p>0.05).		In	 contrast,	 male	 GPR55-/-	 mice	 fed	 a	 HFD	 had	 a	 significantly	 greater	 fat	 mass	percentage	 at	 the	 end	 of	 the	 dietary	 period	 compared	 to	 GPR55-/-	 SD	 controls	(Figure	3.4c;	 36.2±1.8	%	vs	10.2±1.3	%,	p<0.0001).	 Female	GPR55-/-	mice	 fed	 a	HFD	also	had	a	significantly	greater	fat	mass	percentage	at	the	end	of	the	dietary	period	 as	 compared	 to	 GPR55-/-	 SD	 controls,	 however	 this	 effect	 was	much	 less	pronounced	 and	 with	 greater	 variability	 compared	 to	 male	 mice	 (Figure	 3.4d;	24.4±5.4	%	vs	10.0±0.5	%,	p<0.01).	These	 results	 mirror	 those	 for	 body	 weight	 data,	 confirming	 that	 the	 increased	weight	 gain	 in	 GPR55-/-	mice	 (of	 both	 sexes)	 in	 response	 to	 a	HFD	 is	 due	 to	 an	increase	in	fat	mass	(as	opposed	to	lean	muscle	or	bone	etc.);	for	reference	the	lean	mass	data	at	the	end	of	the	dietary	period	is	provided	in	Table	3.3.			
 Male Female 
 SD HFD SD HFD 
WT 78.30 ± 0.55 79.90 ± 1.19 80.71 ± 1.67 75.03 ± 2.0 
GPR55-/- 82.62 ± 0.89 57.68 ± 2.3****, #### 80.68 ± 1.3 68.73 ± 4.0# 
Table 3.3. Lean mass as a percentage of total body weight at the end of the dietary period. 
Values are percentages ± SEM. n=5-7 for all groups. **** p<0.0001 vs GPR55-/- SD; # p<0.05 vs 
WT HFD; #### p<0.0001 vs WT HFD as determined via two-way ANOVA and Bonferroni post-
hoc analysis. 
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		 	 							Male	 	 	 	 																		Female	
 
Figure 3.4. Fat mass of (a) male and (b) female mice before the dietary intervention and (c) 
male and (d) female mice after the 12-week dietary intervention. Bars represent mean group 
values and error bars = SEM. n=5-7 for all groups. ** p<0.01 **** p<0.0001 as determined by 
two-way ANOVA and Bonferroni post-hoc analysis. 	
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3.3.2.3. Plasma lipids 
The	 effect	 of	 a	HFD	on	plasma	 lipids	 of	male	WT	and	GPR55-/-	mice	 is	 shown	 in	
Figure	3.5;	 the	decision	 to	study	plasma	 from	male	mice	only	was	based	on	 the	results	of	the	body	weight	and	fat	mass	data	which	demonstrated	the	greatest	and	more	consistent	differences	in	male	mice.	There	were	no	significant	differences	in	plasma	 cholesterol,	 HDL-C,	 LDL-C	 or	 triglycerides	 between	 the	 control	 WT	 and	GPR55-/-	SD	fed	mice	(p>0.05).	Similarly,	WT	mice	fed	a	HFD	for	12	weeks	did	now	show	any	significant	changes	in	any	of	the	measured	plasma	lipids	as	compared	to	the	SD	fed	controls	(p>0.05).		In	contrast,	GPR55-/-	mice	fed	a	HFD	for	12	weeks	exhibited	significant	elevations	in	 plasma	 cholesterol	 (+1.3	mmol/L,	p<0.01),	 HDL-C	 (+1.8	mmol/L,	p<0.01)	 and	LDL-C	 (+0.6	 mmol/L,	 p<0.0001)	 levels	 as	 compared	 to	 the	 GPR55-/-	 SD	 fed	controls.	In	contrast	plasma	triglycerides	(-0.3	mmol/L,	p<0.05)	were	significantly	lower	compared	to	GPR55-/-	SD	fed	controls.		
3.3.3. Plasma LPI levels 
As	 with	 the	 plasma	 lipid	 results,	 only	 plasma	 from	 male	 mice	 was	 studied	 for	plasma	 LPI	 levels,	 for	 the	 reason	 previously	 stated.	 Figure	 3.6	 shows	 a	representative	LC-MS	trace	for	the	detection	of	multiple	LPI	species.	As	shown	in	
Figure	 3.7,	 there	 was	 no	 significant	 difference	 in	 plasma	 levels	 of	 total	 LPI	concentrations	between	control	WT	SD	fed	control	mice	and	GPR55-/-	SD	fed	mice	(p>0.05).	Likewise,	despite	a	trend	towards	an	increase	in	total	LPI	in	plasma	from	WT	mice	fed	a	HFD,	this	result	was	not	statistically	significant	when	compared	to	the	WT	SD	fed	controls	(p>0.05).	In	contrast,	the	plasma	concentration	of	total	LPI	in	GPR55-/-	mice	 fed	a	HFD	was	significantly	 increased	compared	 to	the	GPR55-/-	SD	fed	controls	(2883.8±486.1	pmol.ml-1	vs	1574.4±231.4	pmol.ml-1,	p<0.05).	
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Figure 3.5. Absolute level of plasma lipids from male mice. Bars represent mean group 
values and error bars = SEM. n=4-6 for each group. * p<0.05, ** p<0.01, **** p<0.0001 as 
determined by two-way ANOVA and Bonferroni post-hoc analysis.  
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Figure 3.6. Representative raw LC-MS trace demonstrating the peaks for different LPI species 
in plasma from WT SD fed mice. From top to bottom: Total Ion Chromatogram, 16:0 LPI, 18:0 
LPI, 18:2 LPI, 20:3 LPI, 20:4 LPI, 22:6 LPI, 17:1 LPI internal standard.  
LPI_mouse_Plasma_WT_SD_02 08/09/2016 02:20:02
RT: 0.00 - 9.00 SM: 3B
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0
Time (min)
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
R
e
la
ti
v
e
 A
b
u
n
d
a
n
c
e 0
50
100
0
50
100
0
50
100
5.01
540.33214.75564.3321
0.63
448.9935
5.67
568.36384.61
564.3323
6.42
465.3057
1.12
514.2856
3.03
660.1699
8.58
1370.7826
7.30
764.5536
7.62
579.3920
0.03
378.9192
4.09
316.9485
2.42
499.3079
1.91
501.3235
4.69
571.2905
4.54
0.0000
5.32
599.3221
5.20
0.0000
4.42
595.2909
4.28
595.2906 5.13
0.0000
4.70
621.3059
4.57
621.3063
4.83
621.30643.76
0.0000
2.31
0.0000
4.43
619.2908
4.29
619.2905 4.62
619.2908
4.40
643.2910
4.28
643.29113.14
0.0000
4.50
583.2905
4.35
583.2906
4.70
583.2908
NL: 3.52E7
TIC  MS 
LPI_mouse_Plasma
_WT_SD_02
NL: 6.06E3
m/z= 
571.2864-571.2914 
 MS 
LPI_mouse_Plasma
_WT_SD_02
NL: 2.47E4
m/z= 
599.3177-599.3227 
 MS 
LPI_mouse_Plasma
_WT_SD_02
NL: 6.31E4
m/z= 
595.2864-595.2914 
 MS 
LPI_mouse_Plasma
_WT_SD_02
NL: 2.66E4
m/z= 
621.3020-621.3070 
 MS 
LPI_mouse_Plasma
_WT_SD_02
NL: 2.39E5
m/z= 
619.2864-619.2914 
 MS 
LPI_mouse_Plasma
_WT_SD_02
NL: 7.77E3
m/z= 
643.2864-643.2914 
 MS 
LPI_mouse_Plasma
_WT_SD_02
NL: 1.85E5
m/z= 
583.2864-583.2914 
 MS 
LPI_mouse_Plasma
_WT_SD_02
		 84	
  
Figure 3.7. Total plasma level of LPI in male WT and GPR55-/- mice fed either a SD or HFD for 
12 weeks. Bars are mean group values and error bars = SEM. n=5 for each group. * p<0.05 as 
determined via two-way ANOVA and Bonferroni post-hoc analysis.  		 	
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Seven	molecular	 species	 of	 LPI	were	 detected	within	 the	 plasma	 of	mice	 under	control	 conditions;	 additionally,	 an	 extra	 species	 (22:5	LPI)	was	 detected	 at	 low	levels	only	 after	 intervention	with	a	HFD	 in	both	strains	of	mice	 (see	Table	3.4).	The	 most	 abundant	 LPI	 species	 found	 in	 the	 plasma	 of	 these	 animals	 was	 the	arachidonic	 acid	 (20:4)-containing	 LPI	 species,	 which	 was	 present	 at	approximately	 5-10-fold	 higher	 concentrations	 than	 any	 of	 the	 other	 detected	species.	There	were	no	significant	differences	between	 the	plasma	concentration	of	 individual	 species	 of	 LPI	 of	 GPR55-/-	 SD	 fed	 mice	 compared	 to	 WT	 SD	 fed	controls	(p>0.05	for	all	comparisons).		WT	 mice	 fed	 a	 HFD	 displayed	 a	 significant	 increase	 (~7	 fold)	 in	 the	 plasma	concentration	of	dihomo-γ-linolenic	acid	(DGLA;	20:3)	containing	LPI	compared	to	WT	SD	fed	controls	(p<0.001).	Equally,	the	level	of	20:3-LPI	was	also	significantly	increased	 in	plasma	 from	GPR55-/-	mice	 fed	 a	HFD	 compared	 to	GPR55-/-	 SD	 fed	controls	 (p<0.001).	 There	 was	 also	 an	 approximate	 3-fold	 increase	 in	 18:1-LPI	after	HFD	 feeding	 in	 both	 strains,	 however	 these	 increases	were	 not	 considered	statistically	significant	(p<0.05).	Other	than	the	changes	in	20:3-LPI,	there	were	no	other	significant	differences	between	any	other	species	of	LPI	irrespective	of	diet	or	strain.	Therefore,	the	significant	increase	in	20:3-LPI	in	GPR55-/-	mice	fed	a	HFD	largely	accounts	for	the	increase	observed	in	total	LPI	as	described	above.			
 Group 
LPI Species WT SD WT HFD GPR55-/- SD GPR55-/- HFD 
LPI 16:0 28.8±3.2 12.8±1.6 13.8±1.5 16.6±3.5 
LPI 18:0 97.6±5.8 150.6±6.2 73.8±8.8 171.6±25.7 
LPI 18:1 45.2±2.0 186.6±18.0 23.2±2.7 228.8±49.5 
LPI 18:2 206.2±33.9 66.2±9.6 129.0±15.1 70.4±16.2 
LPI 20:3 186.8±24.2 1210.8±88.7*** 119.6±24.3 1128.4±228.3### 
LPI 20:4 1313.6±104.5 1068.8±72.1 1180.2±181.7 1207.0±175.9 
LPI 22:5 ND 46.2±2.7 ND 46.8±3.9 
LPI 22:6 43.6±4.7 19.6±1.7 34.8±4.2 24.0±4.6 
Table 3.4. Concentration of individual LPI species (pmol.ml-1) in plasma from male mice fed 
either a SD or HFD for 12 weeks. Values are pmol.ml-1 ± SEM, n = 5 for all values. ND = not 
detected. *** p<0.001 vs WT SD; ### p<0.01 vs GPR55-/- SD as determined via two-way 
ANOVA and Bonferroni post-hoc analysis. 
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3.3.4. Adipose tissue  
3.3.4.1. Morphology of adipocytes 
Due	to	the	processing	steps	 involved	 in	preparing	the	adipose	tissue	samples	 for	hematoxylin	and	eosion	staining,	fat	droplets	are	removed	from	the	cells	however	the	 cellular	 membrane	 remains	 intact.	 As	 shown	 by	 the	 hematoxylin	 and	 eosin	stained	adipose	sections	from	male	and	female	mice	in	Figure	3.8	and	Figure	3.9,	the	 tissue	processing	and	sectioning	of	adipose	 tissue	was	successful	and	 largely	maintained	 the	 gross	 structure	 of	 the	 adipose	 tissue,	 therefore	 allowing	 for	accurate	 measurement	 of	 adipocyte	 size.	 As	 expected,	 adipose	 tissue	 from	 both	male	 and	 female	mice	showed	 the	 typical	 rounded	adipocyte	morphology	with	a	small	nucleus	at	the	periphery	of	the	cells.		There	were	 no	 obvious	 differences	 in	morphology	 between	WT	 SD	 fed	 controls	and	 GPR55-/-	 SD	 fed	 mice	 irrespective	 of	 sex.	 Similarly,	 there	 were	 no	 visual	differences	 in	adipocyte	morphology	between	adipocytes	 from	WT	HFD	fed	mice	compared	to	WT	SD	fed	controls	irrespective	of	sex.	However,	it	is	clear	from	the	image	 in	 Figure	 3.8d	 that	 male	 GPR55-/-	 mice	 fed	 a	 HFD	 display	 adipocyte	hypertrophy,	although	the	gross	morphology	of	adipocytes	remained	the	same.		This	adipocyte	hypertrophy	is	also	evident	in	adipose	tissue	from	female	GPR55-/-	mice	 fed	 a	 HFD	 (see	 Figure	 3.9d),	 although	 the	 effect	 was	 not	 as	 marked	 as	observed	in	the	male	mice.				
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Figure 3.8. Representative bright field images at x200 magnification of (a) WT SD, (b) WT HFD, (c) 
GPR55-/- SD and (d) GPR55-/- HFD adipose tissue from male mice stained with haematoxylin and 
eosin. Blue arrows indicate cell membranes and red arrows indicate nuclei. 
 
Figure 3.9. Representative bright field images at x200 magnification of (a) WT SD, (b) WT HFD, (c) 
GPR55-/- SD and (d) GPR55-/- HFD adipose tissue from female mice stained with haematoxylin and 
eosin. Blue arrows indicate cell membranes and red arrows indicate nuclei. 
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Quantification	 of	 adipose	 cell	 size	 (as	 determined	 via	 measuring	 the	 area	 of	individual	 adipocytes	 and	 calculating	 the	 diameter	 of	 each	 cell)	 confirmed	 the	visual	 observations	 described	 above	 (Figure	 3.10).	 There	 were	 no	 significant	differences	in	average	adipose	cell	diameter	between	GPR55-/-	SD	fed	mice	and	WT	SD	 fed	 controls,	 regardless	 of	 sex	 (p>0.05);	 nor	was	 there	 an	 effect	 of	 a	HFD	on	average	adipose	cell	diameter	in	WT	mice,	regardless	of	sex	(p>0.05).	In	contrast,	the	 average	 adipocyte	 cell	 diameter	 in	 male	 GPR55-/-	 mice	 fed	 a	 HFD	 was	significantly	greater	than	adipocytes	in	GPR55-/-	SD	fed	controls	(76.7±26.5	µm	vs	49.4±14.7	µm,	p<0.0001).	Likewise,	 the	average	diameter	of	adipocytes	 in	 female	GPR55-/-	mice	fed	a	HFD	was	significantly	greater	than	adipocytes	in	GPR55-/-	SD	fed	control	mice	(59.3±23.6	µm	vs	41.3±13.0	µm,	p<0.0001).		Frequency	distributions	of	adipocyte	diameters	in	each	group	also	highlighted	the	exaggerated	 effect	 observed	 in	male	GPR55-/-	mice	 compared	 to	 female	GPR55-/-	mice	 fed	 a	 HFD.	 In	 particular,	 there	 was	 a	 greater	 percentage	 of	 hypertrophic	adipocytes	 with	 a	 diameter	 >80	 µm	 in	 male	 GPR55-/-	 mice	 fed	 a	 HFD	 (Figure	
3.10c),	an	effect	which	was	observed	to	a	lesser	extent	in	female	GPR55-/-	mice	fed	a	HFD	(Figure	3.10d).	 	
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Figure 3.10. Average diameter of adipocytes in adipose tissue sections from (a) male and (b) 
female mice. Bars are mean group diameters and error bars = SEM. **** p< 0.0001 as 
determined by two-way ANOVA and Bonferroni post-hoc analysis. Percentage frequency 
distribution charts representing the average percentage of adipocytes of a certain diameter 
within adipose tissue sections from (c) male and (d) female mice. Individual points are mean 
percentage values and error bars = SEM. The number of individual cells measured per group 
ranged from 548-1327, as measured from 2 histology sections from each individual mouse 
per group.  		 	
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3.3.4.2. Gene expression in adipose tissue 
The	expression	of	the	adipokine	leptin	gene	in	adipose	tissue	was	slightly	higher	in	GPR55-/-	SD	fed	mice	compared	to	WT	SD	fed	controls,	however	this	result	was	not	statistically	 significant	 (Figure	 3.11,	 p=0.70).	 In	 response	 to	 HFD,	 leptin	 gene	expression	was	significantly	increased	by	4.8-fold	(p<0.05)	in	adipose	tissue	of	WT	HFD	fed	mice,	compared	to	WT	SD	fed	controls.	The	expression	of	leptin	in	GPR55-/-	 mice	 fed	 a	 HFD	was	 also	 significantly	 increased	 compared	 to	 GPR55-/-	 SD	 fed	controls	(21.7-fold	vs	4.9-fold,	p<0.05).	Like	leptin,	adiponectin	gene	expression	in	adipose	tissue	trended	to	be	higher	in	GPR55-/-	SD	fed	mice	compared	to	WT	SD	fed	controls,	however	the	result	was	not	statistically	significant	(p=0.80).	The	gene	expression	of	adiponectin	was	increased	8-fold	in	adipose	tissue	from	WT	mice	fed	a	HFD	compared	to	WT	SD	fed	controls	(p<0.05).	Finally,	the	gene	expression	of	adiponectin	in	adipose	tissue	from	GPR55-/-	HFD	 fed	mice	was	not	 statistically	 significant	compared	 to	 the	GPR55-/-	 SD	 fed	controls	(p>0.05).		The	 gene	 expression	 of	 the	 antioxidant	 enzyme	 GPx4	 in	 adipose	 tissue	 from	GPR55-/-	 SD	 fed	 mice	 was	 2.9-fold	 higher	 compared	 to	 WT	 SD	 fed	 controls	(p<0.0001).	 Similarly,	 GPx4	 gene	 expression	 was	 increased	 5.9-fold	 in	 adipose	tissue	 from	 WT	 mice	 fed	 a	 HFD	 compared	 to	 WT	 SD	 fed	 controls	 (p<0.0001).	However,	the	gene	expression	of	GPx4	in	adipose	tissue	was	not	further	elevated	by	 HFD	 intervention	 in	 GPR55-/-	 mice	 compared	 to	 those	 fed	 a	 standard	 diet	(p>0.05).		Similar	 to	GPx4	gene	expression,	 the	gene	expression	of	 the	antioxidant	enzyme,	MnSOD,	was	2-fold	higher	in	adipose	tissue	from	GPR55-/-	SD	fed	mice	compared	to	 WT	 SD	 fed	 controls	 (p<0.0001).	 The	 gene	 expression	 of	 MnSOD	 was	 also	increased	3-fold	in	response	to	HFD	in	WT	mice	compared	to	WT	SD	fed	controls	(p<0.0001)	and	2-fold	in	GPR55-/-	HFD	fed	mice	compared	to	GPR55-/-	SD	fed	mice	(p<0.05).			 	
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Figure 3.11. Relative gene expression of selected genes within adipose tissue of male WT 
and GPR55-/- mice fed either a SD or HFD for 12 weeks. Fold-expression normalised to the 
expression of the WT SD fed group. Bars represent mean group values and error bars = SEM. 
n=5-6 for each group. * p<0.05, ** p<0.01, *** p< 0.001, **** p<0.0001 vs WT SD; # p<0.05 vs 
GPR55-/- SD; †† p<0.01 vs WT HFD. P-values determined via two-way ANOVA and Bonferroni 
post-hoc analysis. 
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The	 gene	 expression	 of	 the	 pro-oxidant	 protein	 NOX4	 was	 2.9-fold	 higher	 in	GPR55-/-	 SD	 fed	 mice	 versus	WT	 SD	 fed	 controls	 (p<0.01).	 In	 response	 to	 HFD,	NOX4	gene	expression	was	increased	2.9-fold	in	adipose	tissue	from	WT	HFD	fed	mice	compared	to	WT	SD	fed	controls	(p<0.01).	Conversely,	the	HFD	intervention	did	not	increase	NOX4	expression	any	further	in	GPR55-/-	mice	(p>0.05).		There	were	no	significant	changes	in	expression	of	the	monocyte	marker	CD14	or	FASN	 in	adipose	 tissue,	 regardless	of	 strain	or	diet	 (p>0.05	 for	all	 comparisons).	Similarly,	 there	 were	 no	 significant	 differences	 in	 the	 expression	 of	 ACCα	 in	adipose	tissue	from	GPR55-/-	SD	fed	or	WT	HFD	fed	mice	compared	to	WT	SD	fed	controls	 (p>0.05),	 although	 there	was	 a	 significant	decrease	 in	 the	 expression	of	ACCα	 in	adipose	 tissue	 in	 response	 to	HFD	 in	GPR55-/-	versus	WT	HFD	 fed	mice	(2.6-fold	vs	0.6-fold,	p<0.01).	Finally,	 the	expression	of	GPR55	was	unchanged	 in	response	to	a	HFD	in	WT	mice	(1.33±1.0	 fold	vs	1.10±0.60	 fold,	p>0.05)	and	was	not	detected	in	the	GPR55-/-	mice	as	expected.	
3.3.5. Cardiac tissue 
3.3.5.1. Lipid accumulation in heart tissue 
The	representative	bright	field	images	of	Oil	Red	O	stained	cardiac	tissue	sections	from	 GPR55-/-	 HFD	 fed	 mice	 in	 Figure	 3.12	 show	 that	 there	 was	 no	 positive	staining	 of	 lipid	 droplets	 within	 any	 of	 the	 sections,	 demonstrating	 that	 the	combined	 effect	 of	 GPR55	 deletion	 and	 HFD	 intervention	 had	 no	 effect	 on	 lipid	accumulation	 within	 the	 heart.	 Furthermore,	 the	 gross	 morphology	 of	 cardiac	tissue	appears	unaffected	as	 the	standard	striated	appearance	 is	maintained	and	no	other	unexpected	morphology	is	observed.		
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Figure 3.12. Representative bright field images of heart sections from two male GPR55-/- 
mice fed a HFD for 12 weeks stained with Oil Red O at x200 magnification. Nuclei are 
counterstained with hematoxylin.  		 	
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3.3.5.2. Fatty streak staining in the descending aorta 
As	 shown	 by	 the	 representative	 images	 in	 Figure	 3.13,	 there	 was	 no	 clear	evidence	 of	 fatty	 streak	 formation	 within	 the	 aortae	 of	 mice	 from	 any	 of	 the	experimental	 groups	 and	 only	 generic	 background	 staining	 was	 observed.	Furthermore,	quantification	of	the	extracted	stain	showed	that	all	groups	show	the	same	 level	 of	 background	 staining,	 with	 no	 differences	 observed	 due	 to	 either	strain,	diet	or	sex	(Figure	3.14,	p>0.05).		
3.3.5.3. Gene expression in heart tissue 
As	 shown	 in	 Figure	 3.15,	 GPR55	 deletion	 alone	 had	 no	 effect	 on	 the	 gene	expression	of	GPx4,	MnSOD	and	NOX4	in	heart	tissue	(p>0.05	for	all	comparisons).	Similarly,	a	HFD	intervention	had	no	effect	on	the	gene	expression	of	these	genes	in	either	strain,	or	on	GPR55	gene	expression	in	WT	mice	(p>0.05).		
3.3.6. Liver 
3.3.6.1. Oil Red O stain 
As	shown	by	 the	representative	 images	 (Figure	3.16)	and	quantification	of	 lipid	staining	 (Figure	 3.17),	 there	 was	 a	 distinctive	 staining	 pattern	 of	 lipids	 within	each	 group	 of	mice.	WT	mice	 fed	 either	 a	 SD	 or	 HFD	 displayed	 very	 small	 lipid	droplets,	 both	 of	 which	 covered	 a	 similar	 lipid-positive	 percentage	 area	 of	 total	area	 stained,	 with	 no	 significant	 differences	 between	 them	 (14.2±2.4	 %	 vs	16.9±3.4	%,	p>0.05).	Conversely,	GPR55-/-	mice	fed	a	SD	displayed	a	much	smaller	number	of	 very	 small	 lipid	droplets,	with	only	3.3±0.8	%	of	 the	 section	 staining	positively	 for	 lipid	 compared	 to	 14.2±2.4	 %	 (p<0.05)	 in	 WT	 SD	 fed	 controls	 .	However,	 in	 GPR55-/-	 mice	 fed	 a	 HFD	 there	 was	 extensive	 liver	 steatosis	characterised	 by	 substantial	 numbers	 of	 large	 lipid	 droplets	 such	 that	 the	percentage	 area	 of	 lipid-positive	 tissue	 constituted	 37.9±3.6	 %	 of	 the	 tissue	(p<0.001).		 	
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Figure 3.13. Representative images of Oil Red O stained aortas from male WT and GPR55-/- 
mice fed either a SD or HFD for 12 weeks.  	
	
Figure 3.14. Quantification of Oil Red O staining in the descending aorta from WT and 
GPR55-/- mice fed either a SD or HFD for 12 weeks. Bars are mean group values and errors 
bars = SEM. n=5-7 for all groups.  	 	
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Figure 3.15. Relative gene expression of selected genes within heart tissue of male WT and 
GPR55-/- mice fed either a SD or HFD for 12 weeks. Fold expression is normalised to the WT 
SD fed group. Bars represent mean group values and error bars = SEM. n = 5-6 for each 
group. 
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Figure 3.16. Representative bright field images at x200 magnification of liver sections from 
male (a) WT SD, (b) WT HFD, (c) GPR55-/- SD and (d) GPR55-/- HFD mice stained with Oil Red O 
(lipids) and counterstained with hematoxylin.  
 
Figure 3.17. Quantification of Oil Red O staining in liver sections from male WT and GPR55-/- 
mice fed either a SD or HFD for 12 weeks. Bars represent mean group percentage and error 
bars = SEM. n=5-6 for all groups based on the analysis of 2 individual sections per mouse. * 
p<0.05 vs WT SD, ### p< 0.001 vs GPR55-/- SD, ††† p<0.001 vs WT HFD, as determined by 
two-way ANOVA and Bonferroni post-hoc analysis.   
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3.4. Discussion 
The	main	aim	of	the	present	study	was	to	characterise	and	compare	the	phenotype	of	GPR55-/-	mice	with	C57BL/6J	WT	controls	and	to	elucidate	changes	in	response	to	12-weeks	of	a	HFD	intervention	in	the	two	strains.	To	fulfil	this	aim,	numerous	factors	were	measured	including	body	weight	and	adiposity,	plasma	lipids,	plasma	and	tissue	LPI	 levels,	 tissue	specific	gene	expression,	and	histological	assessment	of	tissue	structure	and	lipid	deposition	in	specific	organs	and	tissues.		The	results	of	the	protein	array	conducted	on	adipose	tissue	from	WT	and	GPR55-/-	mice	 fed	 a	 SD	 for	 12-weeks	 demonstrated	 no	 differences	 in	 adipokine	 profile	between	the	strains.	Furthermore,	the	data	presented	in	this	chapter	demonstrates	that	global	deletion	of	GPR55	does	not	affect	any	of	the	physiological	parameters	measured	in	this	study	under	standard	diet	conditions,	as	indicated	by	the	lack	of	significant	 differences	 in	 body	 weight	 and	 fat	 mass,	 plasma	 lipid	 levels,	 gross	histology	of	adipose	and	heart	tissue,	or	vascular	lipid	deposition	between	groups.	There	 were	 however	 slight	 differences	 in	 the	 gene	 expression	 within	 adipose	tissue,	and	the	degree	of	lipid	deposition	in	the	liver.		When	challenged	with	a	HFD,	WT	mice	display	similar	characteristics	to	both	WT	and	 GPR55-/-	 SD	 fed	 mice,	 only	 displaying	 changes	 in	 plasma	 levels	 of	 LPI	 and	alterations	 in	 adipose	 tissue	 gene	 expression.	 In	 stark	 contrast,	 GPR55-/-	 mice	challenged	 with	 a	 HFD	 display	 increased	 body	 weight	 and	 fat	 mass,	 adipocyte	hypertrophy,	 changes	 in	 plasma	 lipid	 profile	 (consistent	 with	 borderline	dyslipidaemia),	 increased	 plasma	 LPI	 levels,	 alterations	 in	 adipose	 gene	expression,	and	extreme	liver	steatosis.		
3.4.1. The phenotype of GPR55-/- mice fed a SD 
Before	comparisons	could	be	made	about	the	effect	of	a	HFD	in	each	genetic	strain,	it	 was	 first	 necessary	 to	 compare	 the	 phenotype	 of	 the	 GPR55	 knockout	mouse	with	 that	 of	 the	WT	 controls	 under	 control	 conditions	 (i.e.	 fed	 a	 SD)	 in	 order	 to	account	 for	 any	 baseline	 differences	 in	 further	 analyses.	 The	 present	 study	demonstrated	that	GPR55-/-	mice	were	similar	to	WT	mice	in	terms	of	body	weight	gain	 and	 fat	 mass,	 irrespective	 of	 sex;	 this	 is	 in	 agreement	 with	 two	 previous	
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studies	 that	 have	 shown	no	differences	 in	 these	 variables	between	GPR55-/-	 and	WT	age-matched	mice	(Bjursell	et	al.	2016,	Wu	et	al.	2013b).	However,	in	contrast,	Meadows	et	al.	(2016)	showed	that	although	there	was	no	significant	differences	in	the	 body	 weights	 of	 the	 two	 strains	 of	 mice,	 GPR55-/-	 mice	 display	 increased	adiposity	 compared	 to	 WT	 controls,	 leading	 them	 to	 conclude	 that	 deletion	 of	GPR55	 promotes	 obesity	 and	 that	 this	 was	 due	 to	 an	 observed	 decrease	 in	voluntary	 and	 spontaneous	 locomotor	 activity	 (Meadows	et	 al.	 2016).	There	 are	two	possible	explanations	for	the	disparity	between	the	present	results	and	those	of	Meadows	 et	 al.	 Firstly,	 there	 is	 a	 significant	 age	 difference	 between	 the	mice	used	 in	 their	 study	 compared	 to	 the	 present	 study,	with	 the	 former	 using	 older	mice	(16-22	weeks	of	age)	whereas	the	mice	in	the	present	study	were	younger	(4-18	weeks	old),	 suggesting	 there	may	be	an	age-related	obesity	effect	 in	GPR55-/-	mice.	 Secondly,	 the	 composition	 of	 the	 standard	 diet	 used	 by	 Meadows	 et	 al.	consisted	 of	 16%	 energy	 from	 fat,	 compared	 to	 9%	 fat	 in	 the	 diet	 used	 in	 the	present	 study.	While	 this	 is	only	a	moderate	difference	 in	dietary	 composition	 it	could	have	a	significant	impact	on	the	outcome	of	body	weight	and	adiposity	if	the	mice	are	indeed	susceptible	to	obesity	as	suggested	(Meadows	et	al.	2016).		As	 the	 GPR55-/-	 mice	 displayed	 normal	 body	 weight	 and	 fat	 mass,	 it	 is	 not	surprising	that	there	were	no	differences	in	adipose	tissue	histology,	plasma	lipid	levels	 or	 lipid	 deposition	 in	 the	 heart	 or	 aorta;	 however,	 there	 were	 some	interesting	 differences	 in	 gene	 expression	 in	 adipose	 tissue	 from	 GPR55-/-	 mice.	There	are	no	previous	reports	on	adipose	tissue	gene	expression	that	include	the	selected	 genes	 in	 study,	 however	 it	 appears	 from	 the	 data	 that	 control	 GPR55-/-	mice	display	a	gene	expression	profile	similar	to	that	of	WT	and	GPR55-/-	mice	fed	a	 HFD	 (which	 will	 be	 discussed	 further	 in	 subsequent	 sections).	 This	 therefore	suggests	 a	 potential	 “pre-obesity”	 phenotype	 in	 respect	 to	 adipose	 tissue	 gene	expression	in	control	GPR55-/-	mice,	a	phenomenon	which	has	been	suggested	by	another	 study	 using	 C57BL/6J	mice	 in	 predicting	 “high	 and	 low	weight	 gainers”	before	feeding	with	a	HFD	based	on	the	expression	of	a	number	of	different	genes	(Koza	et	al.	2006).		The	expression	levels	of	two	important	adipokine	genes	were	3-fold	higher	in	the	adipose	 tissue	 of	 GPR55-/-	 mice:	 leptin,	 which	 regulates	 food	 intake,	 and	
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adiponectin,	which	modulates	 glucose	 utilization	 and	 fatty	 acid	 oxidation	within	insulin-sensitive	 tissues	 (Klok,	 Jakobsdottir	 and	 Drent	 2007,	 Diez	 and	 Iglesias	2003b).	 Chronic	 increases	 in	 circulating	 leptin	 and	 the	 development	 of	 leptin-resistance	is	considered	a	hallmark	of	chronic	obesity,	however	it	is	still	unknown	whether	leptin	increases	are	a	causative	factor	in	the	development	of	obesity	or	a	consequence	 of	 obesity	 itself	 (Considine	 et	 al.	 1996).	 Opposite	 to	 leptin	 and	 in	contrast	 to	 the	 results	 of	 the	 present	 study,	 adiponectin	 has	 been	 shown	 to	 be	down-regulated	 in	 the	 state	 of	 obesity	 (Kern	 et	 al.	 2003).	 Nonetheless,	 under	standard	 physiological	 conditions,	 adiponectin	 regulates	 fatty	 acid	 oxidation	within	 insulin-sensitive	 tissues	 including	 adipose	 tissue	 and	 the	 liver,	 and	 an	infusion	of	adiponectin	has	previously	been	demonstrated	to	significantly	decrease	the	 fat	 accumulation	 in	 the	 liver	 of	 mice	 with	 diet-induced	 alcoholic	 and	 non-alcoholic	 fatty	 liver	disease	 (Xu	et	al.	 2003).	Hence,	given	 there	 is	an	 increase	 in	adiponectin	gene	expression	 in	 the	adipose	 tissue	of	 the	present	 study,	 this	may	hypothetically	lead	to	greater	oxidation	of	fatty	acids	within	other	insulin-sensitive	tissues	 and	 subsequently	 decreasing	 fat	 storage	 within	 these	 tissues,	 as	 was	observed	 within	 the	 liver	 of	 GPR55-/-	 mice	 fed	 a	 SD	 in	 the	 present	 study	 (see	
Figure	3.17);	 this	 is	 however	 depended	on	 the	 gene	 expression	 translating	 into	protein	which	 is	 released	 into	 the	 circulation	 and	more	work	would	 need	 to	 be	carried	out	to	validate	this	hypothesis.		The	present	study	also	demonstrated	higher	levels	in	the	adipose	tissue	expression	of	 two	genes	encoding	major	antioxidant	enzymes,	GPx4	and	MnSOD,	 in	GPR55-/-	SD	fed	mice.	GPx4	expression	has	been	shown	to	be	increased	in	response	to	fatty	acids	such	as	docosahexaenoic	acid	 (DHA)	and	 linoleic	acid	 in	vitro	using	human	umbilical	vein	endothelial	cells	(HUVEC)	cells	(Sneddon	et	al.	2003),	and	has	also	been	shown	to	be	increased	in	the	pituitary	gland	of	pigs	in	a	model	of	diet	induced	obesity	 (Zhao	 et	 al.	 2015).	 However,	 under	 standard	 diet	 conditions	 changes	 in	GPx4	 expression	 have	 not	 been	 reported	 due	 to	 any	 other	 factors	 (other	 than	dietary	selenium	supplementation).	MnSOD	expression	has	been	demonstrated	to	increase	 in	 rats	 fed	 a	 selenium	 supplemented	 diet,	 leading	 to	 an	 increased	antioxidant	capacity	in	the	liver	when	challenged	with	an	inflammatory	stimulant	(Shilo	 et	 al.	 2008).	 Furthermore,	MnSOD	was	 increased	 in	 the	 adipose	 tissue	 of	Wistar	 rats	 fed	 a	HFD	 for	12-weeks	 and	 it	was	postulated	by	 the	 authors	 of	 the	
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study	 that	 an	 increase	 in	 reactive	 oxygen	 species	 (ROS)	 production	 within	adipocytes	lead	to	the	induction	of	transcription	of	the	MnSOD	gene	(Krautbauer	et	al.	 2014).	These	 increases	 in	GPx4	and	MnSOD	expression	 are	 often	 an	 adaptive	response	 to	 increases	 in	 ROS	 production,	 in	 order	 to	 protect	 the	 cellular	environment	 from	 oxidative	 damage;	 therefore,	 it	 is	 logical	 that	 these	 increases	would	be	an	endogenous	response	to	the	onset	of	obesity	where	a	chronic	level	of	increased	 oxidative	 stress	 occurs.	 This	 therefore	 may	 suggest	 that	 within	 the	adipose	 tissue	 of	 GPR55-/-	 mice	 under	 standard	 diet	 conditions,	 there	 is	 an	increased	 oxidative	 environment	 without	 the	 onset	 of	 obesity,	 but	 it	 is	 unclear	whether	this	may	be	another	 indication	that	GPR55-/-	mice	are	susceptible	to	the	development	of	obesity	as	suggested	by	Meadows	et	al.	and	mentioned	previously	(Meadows	et	al.	2016).	Finally,	in	adipose	tissue	from	GPR55-/-	SD	fed	mice,	there	was	a	3-fold	increase	in	the	 gene	 expression	 of	 the	 pro-oxidant	 enzyme	 NOX4.	 It	 was	 demonstrated	 by	Furukawa	et	al.	(2004)	that	upregulation	of	the	NOX4	enzyme	in	the	adipose	tissue	of	 obese	 (diabetic	 and	 non-diabetic)	 KKAy	 mice	 is	 principally	 responsible	(alongside	decreases	in	antioxidant	gene	expression)	for	the	increase	in	oxidative	stress	 observed	 during	 obesity	 due	 to	 ROS	 generated	 directly	 by	 adipocytes	(Furukawa	et	al.	2004).	It	is	also	likely	that	this	increase	in	NOX4	expression	has	a	direct	 relationship	 with	 the	 increases	 observed	 in	 GPx4	 and	 MnSOD	 within	 the	present	study,	as	each	may	be	modulated	in	order	to	balance	the	oxidative	state	of	the	cellular	environment.	Additionally,	Matsuzawa-Nagata	et	al.	 (2008)	have	 also	demonstrated	that	NOX4	expression	is	increased	in	the	adipose	tissue	of	C57BL/6J	mice	 fed	 a	 HFD	 for	 6	 weeks	 but	 before	 the	 onset	 of	 obesity	 occurs,	 therefore	indicating	that	the	increase	in	NOX4	and	subsequent	oxidative	stress	precedes	the	onset	 of	 obesity	 and	may	 in	 fact	 be	 a	 contributing	 factor	 to	 the	 development	 of	obesity	itself	(Matsuzawa-Nagata	et	al.	2008).	This	again	is	another	example	where	the	 present	 study	 has	 demonstrated	 that	 the	 GPR55	 knockout	 alone	 leads	 to	 an	adipose	 tissue	 gene	 expression	 indicative	 of	 a	 “pre-obese”	 phenotype,	 similar	 to	that	observed	in	obese	mice;	therefore,	it	may	be	that	GPR55-/-	mice	suffer	a	higher	oxidative	stress	within	 tissues,	 similar	 to	 that	of	obese	mice,	which	would	partly	explain	 the	 changes	 in	 gene	 expression	 and	 may	 leave	 the	 mice	 susceptible	 to	obesity.	However,	further	in	vivo/ex	vivo	experimentation	would	need	to	be	carried	
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out	in	order	to	assess	this	hypothesis	and	furthermore,	it	must	be	noted	that	gene	expression	changes	do	not	always	translate	into	changes	in	protein	expression	and	therefore	these	conclusions	must	be	used	cautiously	in	lieu	of	protein	data.		Finally,	the	most	significant	change	in	the	phenotype	of	the	GPR55-/-	control	mice	was	 a	 reduction	 in	 fat	 deposition	 in	 the	 liver,	 indicative	 of	 increased	 fatty	 acid	uptake	and	utilisation	by	other	tissues	or	increased	fatty	acid	oxidation	that	would	correspond	with	previous	findings	that	deletion	of	GPR55	has	an	effect	on	glucose	homeostasis,	 energy	 expenditure	 and	 insulin	 sensitivity	 (Bjursell	 et	 al.	 2016,	Meadows	et	al.	2016),	however	these	other	metabolic	factors	were	not	measured	in	the	present	study.	Bjursell	et	al.	(2016)	postulate	from	their	data	which	shows	that	 GPR55-/-	 mice	 exhibit	 reduced	 energy	 expenditure	 but	 no	 differences	 in	energy	 intake	 or	 body	 weight,	 that	 GPR55-/-	 mice	 may	 have	 enhanced	 energy	utilisation	efficiency	compared	to	WT	mice;	this	hypothesis	would	help	explain	the	finding	of	 the	present	 study	 that	GPR55-/-	mice	display	reduced	 fat	deposition	 in	the	liver,	as	less	glucose	is	transformed	into	fatty	acids	for	storage	in	adipocytes	by	the	liver	and	subsequently	fewer	fatty	acids	deposited	ectopically	within	the	liver	(Bjursell	et	al.	2016).	
3.4.2. The phenotype of WT mice fed a HFD 
Due	 to	 the	 wealth	 of	 research	 already	 conducted	 in	 this	 area	 and	 reviewed	extensively	 by	 Hariri	 and	 Thibault	 (2010),	 one	 might	 expect	 an	 obesogenic	phenotype	 in	 C57BL/6J	mice	 fed	 a	 HFD	 compared	 to	 SD	 fed	 controls;	 however,	high	 fat	 feeding	 for	 12-weeks	 had	 no	 effect	 on	 weight	 gain	 or	 fat	 mass	accumulation	 in	WT	mice	 in	 this	 study	 (Hariri	and	Thibault	2010).	Nevertheless,	this	 is	 in	agreement	with	another	study	 that	used	a	similar	45%	energy	 from	 fat	HFD,	that	also	did	not	demonstrate	any	significant	changes	(<3%	difference)	in	the	body	weight	of	C57BL/6J	mice	fed	a	HFD,	even	after	a	much	longer	dietary	period	of	20	weeks	(Littlejohns	et	al.	2014).	In	contrast,	dietary	intervention	studies	that	have	reported	an	obesogenic	effect	of	a	HFD	in	C57BL/6J	mice	have	used	either	a	60%	energy	from	fat-HFD	or	employed	a	much	longer	study	duration,	such	as	12	months	(with	differences	in	body	weight	being	observed	from	14	weeks	post-diet	onwards),	in	order	to	achieve	this	effect	(Winzell	and	Ahrén	2004,	Yang	et	al.	2014,	
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Jang	2017).		High	 fat	 feeding	 in	WT	mice	 similarly	 failed	 to	 induce	 any	 changes	 in	 adipocyte	histology,	 a	 finding	 that	was	 not	 surprising	 given	 the	 body	weight	 and	 fat	mass	results	 recorded	 in	 these	 mice.	 Similarly,	 there	 were	 no	 observed	 changes	 in	plasma	 lipid	 levels	 in	 WT	 mice,	 a	 finding	 supported	 by	 another	 study	 using	C57BL/6J	 mice	 that	 showed	 no	 significant	 alterations	 to	 plasma	 lipids	 when	feeding	with	a	60%	energy	from	fat-HFD	for	12	weeks,	despite	the	mice	presenting	with	an	obese	phenotype	which	was	not	observed	in	the	present	study	(Jiang	et	al.	2005).	Alterations	in	plasma	lipids	are	often	associated	with	HFD	feeding	in	mice,	however	 similar	 to	 the	body	weight	 results	 described	 above,	 these	 studies	 often	use	 higher	 fat	 content	 diets	 for	 longer	 durations	 to	 achieve	 these	 results	(Kalaivanisailaja,	Manju	and	Nalini	2003,	Williams	et	al.	2014).		There	were	 also	no	differences	 in	 lipid	deposition	within	 the	 aorta	 or	 liver	 (nor	was	 positive	 staining	 identified	 within	 the	 heart)	 between	 WT	 mice	 fed	 a	 HFD	compared	 to	 those	 fed	 a	 SD	 for	12	weeks,	 again	 a	 finding	which	 is	 unsurprising	given	 the	 previous	 results	 relating	 to	 body	 weight,	 fat	 mass	 and	 plasma	 lipid	profiles	 in	 these	 mice,	 in	 which	 dysregulation	 of	 these	 parameters	 is	 usually	 a	causative	factor	of	lipid	deposition	in	other	tissues.		One	 distinct	 change	 observed	 in	 WT	 mice	 fed	 a	 HFD	 was	 the	 gene	 expression	profile	of	selected	genes	within	adipose	tissue,	most	notably	the	adipokines	leptin	and	adiponectin	and	the	antioxidant	genes	GPx4	and	MnSOD.	Leptin	expression	(at	both	 mRNA	 and	 protein	 level)	 and	 leptin	 secretion	 from	 adipocytes	 is	 directly	affected	 by	 adipocyte	 cell	 size	 and	 overall	 mass	 of	 adipose	 tissue,	 with	 a	 much	higher	production	of	leptin	in	adipocytes	greater	than	80	µm	in	diameter	(Skurk	et	al.	 2007),	 and	 circulating	 leptin	 is	 widely	 acknowledged	 to	 be	 increased	 in	 the	setting	of	obesity	(Considine	et	al.	1996).	Despite,	or	possibly	due	to	the	increases	in	leptin	observed	in	obesity,	there	are	data	supporting	the	development	of	leptin	resistance	within	obese	 individuals	(Frederich	et	al.	1995),	which	 leads	to	both	a	further	increase	in	fat	mass	accumulation	and	difficulty	in	maintaining	weight	loss	when	 switching	 to	 a	 low-calorie	 diet	 (Myers	 et	 al.	 2010).	 However,	 the	 present	study	provides	data	to	suggest	that	an	increase	in	leptin	gene	expression	occurs	in	response	to	HFD	feeding	before	the	onset	of	obesity,	since	adipocytes	were	within	
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a	normal	size	range.	The	present	study	also	showed	an	increase	in	the	expression	of	 adiponectin	 with	 HFD	 feeding	 in	 WT	 mice;	 this	 is	 in	 contrast	 with	 existing	literature	 which	 largely	 supports	 the	 opposite	 view.	 Since	 increased	 visceral	obesity	is	associated	with	a	down-regulation	in	adiponectin	gene	expression	in	the	adipose	tissue	from	human	patients	(Kern	et	al.	2003,	Yatagai	et	al.	2003,	Turer	et	al.	 2011)	 and	 C57BL/6J	 mice	 fed	 a	 42%	 calories	 from	 fat-HFD	 for	 4	 months	similarly	exhibit	a	reduction	in	adiponectin	gene	expression	(Barnea	et	al.	2006);	however	as	with	leptin	expression,	the	upregulation	of	adiponectin	observed	in	the	present	 study	 is	 not	 accompanied	 by	 an	 obese	 phenotype.	 These	 results,	 in	similarity	to	the	GPR55-/-	SD	fed	mice,	may	indicate	that	the	WT	HFD	fed	mice	of	the	 present	 study	 are	 in	 a	 “pre-obese”	 state	 in	 terms	 of	 adipose	 tissue	 gene	expression,	and	may	go	on	to	develop	obesity	if	given	enough	time	feeding	with	a	HFD.	Moreover,	it	is	possible	that	a	high	gene	expression	of	leptin	and	adiponectin	within	 adipose	 tissue	 may	 constitute	 a	 novel	 biomarker	 for	 a	 predisposition	 to	developing	obesity.		The	up-regulation	of	antioxidant	gene	expression	within	adipose	tissue	of	WT	mice	fed	 a	HFD	 is	 consistent	with	 literature,	 as	 it	 is	 regarded	 as	 an	 adaptive	 defence	mechanism	 against	 the	 sustained	 low	 level	 of	 oxidative	 stress	 that	 accompanies	HFD	feeding	and	obesity	due	to	increases	in	cellular	ROS	production	(Krautbauer	et	 al.	 2014,	 Rupérez,	 Gil	 and	 Aguilera	 2014).	 Again	 however,	 these	 increases	 in	gene	expression	were	independent	of	obesity	in	the	present	study;	therefore,	these	changes	 within	 adipose	 tissue	 may	 again	 reflect	 a	 potential	 “pre-obese”	 gene	expression	phenotype.	As	previously	discussed	in	reference	to	GPR55-/-	mice	fed	a	SD,	this	raises	the	notion,	at	least	in	the	case	of	oxidative	status,	that	the	molecular	changes	often	described	in	the	state	of	obesity	may	in	fact	be	a	cause	rather	than	a	consequence	 of	 the	 development	 of	 obesity,	 as	 they	 occur	 before	 any	 increased	weight	gain	is	observed.	The	plasma	level	of	20:3-LPI	was	significantly	 increased	with	HFD	feeding	of	WT	mice,	 a	 novel	 finding	 that	 has	 not	 been	 previously	 demonstrated	 in	 rodents.	Imbernon	 et	 al.	 (2014)	 showed	 that	 plasma	 levels	 of	 total	 LPI	 correlated	 with	feeding	 status,	 leptin	 level	 and	 other	 pituitary	 factors	 in	 rats,	 therefore	demonstrating	that	plasma	LPI	levels	are	dynamic	and	depend	on	multiple	factors,	
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however	 their	 study	did	not	 explore	 the	 effects	 of	HFD	 feeding	 (Imbernon	et	 al.	2014).	Higher	total	LPI	levels	were	recorded	in	plasma	from	rats	by	Imernon	et	al.	compared	to	the	present	study	in	mice	(~3500	pmol.ml-1	vs	2000	pmol.ml-1),	and	in	particular	 a	much	 greater	 level	 of	 18:0	 LPI	 (~2500	 pmol.ml-1	 vs	~100 pmol.ml-1); 
however, this difference may be due to species specific differences in LPI profiles 
(Imbernon et al. 2014).	In	human	patients	with	obesity	and	type	2	diabetes,	it	was	shown	that	the	level	of	total	LPI	in	plasma	is	positively	correlated	with	BMI,	body	weight	 and	 fat	 mass	 in	 female	 cohorts;	 however,	 the	 study	 did	 not	 take	 into	account	 possible	 confounding	 factors	 such	 as	 regular	diet	 habits	 and	medication	taken	by	the	subjects	 involved	(Moreno-Navarrete	et	al.	2012).	 In	contrast	 to	the	study	 using	 rats,	 plasma	 levels	 of	 total	 LPI	 only	 reached	 a	 maximum	 of	 ~800	pmol.ml-1	 in	 obese	 patients,	 which	 with	 the	 inclusion	 of	 data	 from	 the	 present	study	would	 suggest	 that	 rats	 exhibit	 the	 greatest	 plasma	 LPI	 level,	 followed	 by	mice	and	then	humans.	Both	the	rat	and	human	studies	only	measured	3	individual	species	of	LPI	(16:0,	18:0	and	20:4),	possibly	due	to	limitations	in	their	extraction	of	 LPI,	 however	 the	 present	 study	 suggests	 that	 plasma	 20:3	 LPI	 is	 the	 most	significantly	affected	by	HFD	 feeding	and	 it	 is	 this	 species	 that	may	have	a	more	important	 role	 in	 the	 setting	 of	 obesity.	 Unfortunately,	 as	 20:3	 LPI	 is	 usually	detected	 at	 extremely	 low	 levels	 under	 control	 conditions	 (and	 unmeasured	 by	previous	 studies),	 little	 is	 known	 of	 the	 pharmacology	 or	 biological	 relevance	 of	this	species	of	LPI.	This	change	in	LPI	profile,	particularly	the	increase	in	20:3	LPI	is	 most	 likely	 explained	 by	 the	 increased	 intake	 of	 dietary	 fats	 and	 changes	 in	acyltransferase	enzyme	profile;	 the	20:3	fatty	acid	(DGLA;	 independent	of	LPI)	 is	produced	from	linoleic	acid	or	more	directly	by	γ-linoleic	acid	(Figure	3.18),	both	of	which	are	expected	to	be	increased	in	a	diet	high	in	fats	(Fan	and	Chapkin	1998).	Furthermore,	 accumulation	of	DGLA	 in	phospholipids	 and	 triglycerides	has	been	documented	 after	 dietary	 supplementation	 with	 high	 fat	 oils	 such	 as	 corn	 oil,	primrose	oil	and	borage	oil	(Chapkin	1992),	therefore	it	is	possible	that	this	excess	DGLA	is	partially	stored	within	LPI	and	would	explain	the	high	 levels	of	20:3	LPI	found	 within	 this	 study.	 It	 may	 also	 explain	 the	 reductions	 in	 18:2-LPI,	 as	 it	 is	converted	to	18:3	and	then	to	20:3	due	to	increases	in	enzyme	activity.		
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Figure 3.18. Metabolism of LA into DGLA in mammalian tissues. LA: Linolenic acid; GLA: γ-
linolenic acid; DGLA: Dihomo-γ-linolenic acid.  	Although	biologically	 active	20:3-LPI	has	not	 been	determined	previously,	 it	 has	been	 demonstrated	 in	 rats	 and	 mice	 that	 dietary	 supplementation	 with	 DGLA	results	in	increases	in	tissue	DGLA	accumulation	and	an	increase	in	prostaglandin-E1	production	(Chapkin	1992,	Umeda-Sawada	et	al.	2006).	From	a	limited	number	of	 human	 studies,	 it	 has	 been	 suggested	 that	 DGLA	may	 have	 anti-inflammatory	properties	(Fan	and	Chapkin	1998).	It	may	be	possible	therefore	that	20:3	LPI	acts	as	a	precursor	to	DGLA	release,	or	indeed	exerts	anti-inflammatory	activity	itself,	however	this	needs	to	be	investigated	further.		Whilst	Moreno-Navarette	 et	 al.	 demonstrated	 a	 positive	 correlation	between	LPI	and	body	weight,	BMI	and	fat	mass,	 it	 is	 the	conclusion	of	 the	present	study	 that	the	plasma	LPI	profile	 (that	 is	 individual	plasma	LPI	 levels	and	particularly	20:3	LPI)	 in	mice	 is	 independent	 of	 these	parameters	 and	 is	more	dependent	 on	 diet	
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alone,	yet	the	total	LPI	level	may	possibly	correlate	with	these	factors,	as	the	non-obese	WT	mice	 fed	 a	HFD	did	not	display	an	 increase	 in	 total	LPI,	yet	 the	obese	GPR55-/-	 mice	 fed	 a	 HFD	 did.	 Moreno-Navarette	 et	 al.	 also	 demonstrated	 that	GPR55	 mRNA	 level	 was	 increased	 in	 the	 adipose	 tissue	 of	 obese	 and	 type	 2	diabetic	 human	 subjects,	 yet	 decreased	 in	 obese	 rats	 and	 obese	 ob/ob	 mice,	concluding	 that	 there	 are	 distinct	 species	 variations	 in	 the	 regulation	 of	 GPR55	(Moreno-Navarrete	et	al.	2012).	In	contrast,	the	present	study	found	no	changes	in	GPR55	mRNA	expression	in	either	adipose	or	heart	tissue	of	WT	mice	due	to	HFD	feeding,	supporting	the	likelihood	of	wide	species	variation	in	GPR55	regulation.	
3.4.3. The phenotype of GPR55-/- mice fed a HFD 
In	 stark	 contrast	 to	 WT	mice,	 GPR55-/-	 mice	 fed	 a	 HFD	 for	 12-weeks	 exhibited	accelerated	weight	gain	and	a	greatly	increased	fat	mass	at	the	end	of	the	dietary	period.	Whilst	 ablation	of	GPR55	alone	has	been	 shown	 to	 increase	 adiposity	 as	previously	 discussed	 (Meadows	 et	 al.	 2016),	 this	 is	 the	 first	 study	 to	 define	 the	phenotypic	response	to	a	HFD	in	GPR55-/-	mice,	providing	support	to	the	assertion	by	Meadows	et	al.	that	GPR55	ablation	causes	susceptibility	to	obesity.	However,	it	also	supports	the	argument	that	there	 is	a	distinct	species	variation	in	the	role	of	the	 GPR55/LPI	 system	 as	 up-regulation	 of	 the	 GPR55/LPI	 system	 has	 been	demonstrated	in	an	obese/type	2	diabetic	human	population,	although	this	may	be	a	response	to	the	development	of	obesity	itself	(Moreno-Navarrete	et	al.	2012).		The	increased	body	weight	and	fat	mass	in	GPR55-/-	HFD	fed	mice	was	associated	with	 adipocyte	 hypertrophy,	 as	 determined	 via	 histological	 staining	 of	 adipose	tissue.	Hypertrophic	obesity	is	largely	associated	with	human	adult	obesity	and	an	increased	risk	of	developing	dyslipidaemia,	insulin	resistance	and	type	2	diabetes,	all	of	which	are	risk	factors	for	the	development	of	CVD	(Gustafson	et	al.	2009).	In	the	present	 study,	GPR55-/-	mice	 fed	 a	HFD	did	present	with	dyslipidaemia,	with	increases	 in	 total	 cholesterol,	 HDL-C	 and	 LDL-C,	 and	 a	 decrease	 in	 triglycerides.	These	 changes	 are	 consistent	 with	 levels	 demonstrated	 in	 previous	 studies	involving	 C57BL/6J	 mice	 which	 have	 been	 fed	 various	 high	 fat	 diets	 containing	different	concentrations	of	cholesterol	 (Nishina	et	al.	1993,	Schreyer,	Wilson	and	LeBoeuf	 1998),	 although	 the	 increases	 in	 plasma	 cholesterol	 were	 much	 less	
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pronounced	than	those	found	in	pro-atherogenic	strains	of	mice	such	as	the	LDL-receptor	deficient	or	ApoE-/-	mouse,	in	which	cholesterol	levels	reach	~18	mmol/L	with	high	fat/high	cholesterol	feeding	(Lichtman	et	al.	1999,	Meir	and	Leitersdorf	2004).	 Therefore,	 given	 that	 HFD	 fed	 GPR55-/-	 mice	 only	 exhibited	 a	 modest	increase	 in	 circulating	 cholesterol,	 it	 is	 perhaps	 not	 surprising	 that	 they	 did	 not	display	any	characteristics	of	atherosclerosis	within	the	12-week	dietary	period.		Interestingly,	 the	alterations	 in	body	weight,	body	composition	and	plasma	lipids	were	 more	 pronounced	 in	 male	 mice	 compared	 to	 female	 mice;	 since	 any	 sex-dependency	 of	 the	 GPR55/LPI	 axis	 is	 currently	 an	 unexplored	 area,	 there	 is	 no	immediate	 explanation	 for	 this.	 However,	 sex-hormones	 have	 both	 direct	 and	indirect	effects	on	adipose	tissue,	leading	to	lipolysis	and	reduced	accumulation	of	fat	in	females	(Mayes	and	Watson	2004),	which	may	help	to	explain	the	observed	differences.	 For	 this	 reason,	 the	 remainder	of	 the	 secondary	phenotypic	 changes	were	examined	only	in	tissues	from	male	mice.		Gene	expression	changes	for	leptin	in	adipose	tissue	from	HFD	fed	GPR55-/-	mice	is	consistent	 with	 the	 literature,	 which	 has	 shown	 that	 leptin	 expression	 directly	correlates	with	adipose	 tissue	mass	and	adipocyte	size	(Skurk	et	al.	2007)	and	is	widely	 acknowledged	 to	 be	 increased	 in	 the	 setting	 of	 obesity	 as	 previously	mentioned	(Considine	et	al.	1996).	 Interestingly,	adiponectin	adipose	tissue	gene	expression	trended	to	be	reduced	(although	not	significantly,	p=0.054)	compared	to	the	HFD	fed	WT	mice,	further	supporting	that	after	the	development	of	obesity	and	 an	 increase	 in	 fat	mass,	 as	 observed	 in	 GPR55-/-	 HFD	 fed	mice,	 adiponectin	expression	 may	 begin	 to	 decrease,	 which	 is	 in	 agreement	 with	 the	 current	literature	 (Hosogai	 et	 al.	 2007,	 Turer	 et	 al.	 2011,	 Nakamura,	 Fuster	 and	Walsh	2014).	Similarly,	the	expression	of	the	antioxidant	genes	GPx4	and	MnSOD,	and	the	pro-oxidant	NOX4	is	relatively	high	in	adipose	tissue	from	GPR55-/-	mice	fed	a	HFD	and	these	levels	are	similar	to	the	expression	levels	found	in	GPR55-/-	SD	fed	and	WT	HFD	fed	mice,	therefore	suggesting	that	these	genes	are	not	associated	with	fat	mass	 but	 most	 likely	 oxidative	 status	 within	 the	 tissue.	 Furthermore,	 these	findings	again	support	the	notion	of	a	“pre-obese”	phenotype	in	terms	of	oxidative	status	 in	 both	 GPR55-/-	mice,	 due	 to	 the	 deletion	 of	 GPR55,	 and	 in	WT	HFD	 fed	mice,	due	 to	the	dietary	 intervention.	However,	as	the	gene	expression	 levels	are	
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unchanged	 in	 obese	 GPR55-/-	 HFD	 fed	mice,	 the	 combined	 effect	 of	 HFD	 feeding	and	 GPR55	 ablation	 are	 not	 additive.	 As	 already	 discussed,	 elevations	 in	antioxidant	 genes	 is	 likely	 a	 defensive	 adaptive	 response	 to	 elevated	 levels	 of	cellular	ROS	that	are	produced	due	 to	high	fat	 feeding	and	obesity,	which	may	in	part	 may	 be	 due	 to	 the	 increase	 in	 NOX4	 gene	 expression,	 as	 observed	 in	 the	present	 study	 (Sneddon	 et	 al.	 2003,	 Krautbauer	 et	 al.	 2014,	 Rupérez,	 Gil	 and	Aguilera	2014).	Of	note	however,	is	that	the	expression	level	of	CD14	(a	monocyte	and	macrophage	marker;	 Ziegler-Heitbrock	 and	Ulevitch	1993)	 in	 adipose	 tissue	remained	 unchanged	 in	 GPR55-/-	 mice	 fed	 a	 HFD;	 therefore	 rejecting	 the	 usual	paradigm	 of	 adipose	 tissue	 inflammation	 and	 recruitment	 of	 immune	 cells	 to	adipose	tissue	in	obesity	(Lee,	Lee	and	Choue	2013,	Berg	and	Scherer	2005).		Interestingly,	there	were	significant	increases	in	total	plasma	levels	of	endogenous	agonist	LPI	in	GPR55-/-	mice	fed	a	HFD,	despite	the	absence	of	the	receptor,	and	as	with	the	response	of	the	WT	mice	to	a	HFD,	this	was	largely	due	to	an	increase	in	20:3	LPI.	Taken	together,	these	results	indicate	that	total	plasma	LPI	level	is	more	directly	associated	with	diet	than	other	factors	such	as	body	weight	or	fat	mass	as	postulated	by	other	studies	(Moreno-Navarrete	et	al.	2012,	Imbernon	et	al.	2014)	and	in	regards	to	plasma	level,	is	not	dependent	on	the	presence	of	GPR55.	HFD	feeding	of	GPR55-/-	mice	induced	marked	liver	steatosis	that	was	not	present	in	WT	HFD	fed	mice,	a	finding	that	is	consistent	with	the	established	link	between	obesity	and	an	increased	risk	of	non-alcoholic	fatty	liver	disease	(NAFLD;	Gholam,	Kotler	 and	 Flancbaum	 2002,	 Ruhl	 and	 Everhart	 2003).	 The	 main	 contributing	factor	 in	NAFLD	is	an	 imbalance	 in	the	rate	of	 fatty	acid	uptake	from	the	plasma	and	the	subsequent	rate	of	fatty	acid	oxidation	and	export	from	the	liver	(reviewed	by	 Fabbrini,	 Sullivan	 and	Klein,	 2010).	 The	 overall	 consequence	 of	 NAFLD	 is	 an	increased	 risk	 of	 hepatic	 fibrosis,	 development	 of	 insulin	 resistance,	 systemic	inflammation	 and	 dyslipidaemia,	 of	 which	 only	 the	 latter	 was	 assessed	 and	existent	in	this	study.	However,	Meadows	et	al.	have	previously	demonstrated	that	GPR55-/-	 mice	 exhibit	 insulin	 resistance	 (without	 HFD	 feeding)	 and	 it	 was	postulated	by	the	authors	that	the	increase	in	genes	encoding	lipogenic	proteins	in	the	liver,	as	observed	in	their	study,	could	lead	to	liver	steatosis,	as	demonstrated	in	the	present	study	when	feeding	with	a	HFD	(Meadows	et	al.	2016).	Therefore,	it	
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is	possible	that	an	upregulation	of	lipogenic	genes	within	the	liver	of	GPR55-/-	mice	causes	 liver	 steatosis	 and	 subsequent	 insulin	 resistance	 upon	 HFD	 feeding	 and	may	play	a	role	in	the	susceptibility	of	these	mice	to	obesity.		
3.5. Conclusion 
This	study	aimed	to	characterise	the	phenotype	of	GPR55-/-	mice	fed	either	a	SD	or	HFD	for	12-weeks	and	to	compare	with	diet-matched	WT	controls.	To	summarise,	GPR55-/-	mice	fed	a	SD	for	12-weeks	show	no	significant	differences	in	phenotype	compared	to	WT	mice	other	than	specific	marked	changes	 in	adipose	tissue	gene	expression	and	reduced	lipid	deposition	within	the	liver.	Similarly,	WT	mice	fed	a	HFD	 displayed	 no	 obesogenic	 phenotype	 after	 the	 12-week	 period;	 only	demonstrating	 changes	 in	 adipose	 gene	 expression	 (similar	 to	 GPR55-/-	 SD	 fed	mice)	and	higher	plasma	levels	of	LPI.	In	contrast,	GPR55-/-	mice	fed	a	HFD	for	12-weeks	display:	severe	obesity	(with	weight	gain	greater	than	3	standard	deviations	from	SD	fed	control	mice)	and	increased	adiposity	due	to	hypertrophic	adipocytes,	increases	 in	 plasma	 LPI	 levels,	 multiple	 alterations	 in	 adipose	 tissue	 gene	expression,	 dyslipidaemia	 and	 marked	 liver	 steatosis.	 However,	 despite	 the	presence	 of	 obesity	 and	 dyslipidaemia,	 this	 phenotype	was	 not	 accompanied	 by	the	development	of	atherosclerosis.		Therefore,	this	chapter	has	demonstrated	that	upon	high-fat	feeding,	GPR55-/-	mice	are	 susceptible	 to	 hypertrophic	 obesity,	 with	 accompanying	 liver	 steatosis,	dyslipidaemia,	 dysregulation	 of	 adipose	 tissue	 gene	 expression	 and	 increased	levels	of	LPI	within	circulating	plasma,	all	of	which	constitute	possible	risk	factors	for	 the	 development	 of	 further	 diseases.	 The	 further	 consequences	 of	 the	 obese	phenotype	in	GPR55-/-	mice,	particularly	on	the	cardiovascular	system	are	yet	to	be	explored	and	will	be	investigated	further	in	the	following	chapter	of	this	thesis.	To	 conclude,	 the	 present	 study	 has	 demonstrated	 an	 “anti-obesity”	 function	 of	GPR55	and	therefore	it	may	be	established	that	GPR55	plays	an	important	role	in	metabolic	 homeostasis	 and	 resistance	 to	 the	 development	 of	 obesity.	 The	mechanism	by	which	GPR55	confers	a	resistance	to	obesity	is	currently	unknown	and	 it	may	be	 via	 a	 central	 or	peripheral	mechanism,	 or	 both,	 and	 further	work	needs	to	be	carried	out	to	evaluate	this	function.		
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the outcome of ischaemia/reperfusion injury in the 
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4.1. Introduction 
4.1.1. Obesity and myocardial infarction 
It	is	well	established	that	obesity	increases	all-cause	mortality	in	humans	(Calle	et	al.	 1999)	 and	 has	 been	 positively	 associated	 with	 the	 development	 of	cardiovascular	 diseases,	 including	 acute	myocardial	 infarction	 (AMI;	 Yusuf	 et	 al.	2004).	Despite	an	 increased	risk	of	developing	cardiovascular	disease	within	 the	obese	population,	 there	 is	 conflicting	 evidence	 as	 to	 the	 severity	 of	 the	outcome	following	an	AMI	in	obese	populations	compared	to	lean	individuals.	Some	studies	have	 recorded	 worse	 outcomes	 in	 patients	 with	 diabetes	 alone	 or	 metabolic	syndrome	 (with	 associated	 obesity),	 in	 terms	 of	 infarct	 size	 and	 in-hospital	complications	(Miki	et	al.	2012,	Clavijo	et	al.	2006).	In	contrast,	other	studies	have	suggested	that	obese	individuals	have	a	better	outcome,	particularly	in	relation	to	infarct	 size	 and	 CV	 related	 mortality,	 as	 compared	 to	 lean	 individuals	 after	suffering	an	AMI	(Bucholz	et	al.	2012,	Das	et	al.	2011,	Das	et	al.	2011,	Mehta	et	al.	2007,	Bucholz	et	al.	2015).	This	effect	has	become	known	as	the	‘obesity	paradox’	(reviewed	in	chapter	1).	The	exact	mechanisms	underlying	the	obesity	paradox	are	still	 unknown	 but	 many	 hypotheses	 have	 been	 put	 forward	 to	 explain	 the	phenomenon,	including	metabolic	pre-conditioning	of	the	heart	tissue	(Hadour	et	al.	 1998), reduced cardiomyocyte lactate production during ischaemia/reperfusion 
(I/R; Ravingerova et al. 2000) and increased activation of the reperfusion injury salvage 
kinase (RISK) pathway at the time of reperfusion (Xu et al. 2004). Other possibilities 
include the dysregulation of adipokines that manifest during obesity, and the effect 
they may have on the cardiovascular system (Berg and Scherer 2005). In particular, 
leptin and adiponectin have both been shown to influence myocardial infarct size 
(Mattu and Randeva 2013, Ouchi, Shibata and Walsh 2006) and both are dysregulated 
in the setting of obesity, with the pro-injurious leptin being increased and the 
protective adiponectin being decreased. 
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4.1.2. The RISK pathway and myocardial infarction 
The	 reperfusion	 injury	 salvage	 kinase	 (RISK)-pathway	 is	 the	 simultaneous	activation	of	multiple	pro-survival	and	anti-apoptotic	pathways,	including	ERK1/2,	Akt	and	PKC,	during	I/R	that	acts	to	moderate	the	extent	of	myocardial	injury	and	is	 the	 central	 mechanism	 behind	 the	 protection	 conferred	 by	 pre	 and	 post-conditioning.	Activation	of	the	ERK	pathway	is	initiated	by	a	large	range	of	stimuli,	including	the	binding	of	many	hormones	and	cytokines	to	extracellular	membrane	receptors,	 physical	 cellular	 stress	 and	 changes	 in	 osmolality	 and	 hypoxia	(Hausenloy	and	Yellon	2007,	Cross	et	al.	2000,	Widmann	et	al.	1999).	Activation	of	the	 ERK	 pathway	 is	 principally	 responsible	 for	 cell	 cycle	 control	 and	 cellular	proliferation,	however	it	has	also	been	shown	to	prevent	cellular	apoptosis	via	the	phosphorylation	 and	 subsequent	 inactivation	 or	 sequestration	 of	 multiple	 pro-apoptotic	 proteins	 such	 as	 caspases,	 BAD	 and	 BAX,	 that	 usually	 lead	 to	 cellular	death	 and	 irreparable	 tissue	 damage	 (Hausenloy	 and	 Yellon	 2004,	 Cross	 et	 al.	2000).		It	 is	understood	that	 I/R	 injury	causes	cell	death	via	both	apoptotic	and	necrotic	mechanisms	 (Yellon	 and	 Baxter	 1999,	 Krijnen	 et	 al.	 2002),	 therefore	 the	importance	of	ERK	kinase	activation	 in	apoptotic	 cell	survival	during	reperfusion	has	been	recognised	and	is	known	 to	be	vital	 in	 the	cardio-protection	offered	by	pre	and	post-ischaemic	conditioning	(Yue	et	al.	2000,	Hausenloy	et	al.	2005).	The	activation	 and	 translocation	 of	 pro-survival	 ERK	 kinases	 during	ischaemia/reperfusion	was	 first	 demonstrated	 in	perfused	 rat	 hearts	 in	1997	by	Mizukami	and	Yoshida	(Mizukami	and	Yoshida	1997)	and	was	later	demonstrated	to	 be	 important	 in	 the	 survival	 of	 isolated	 rat	 cardiomyocytes	 in	 response	 to	reduced	energy	(glucose)	and	hypoxia	(1%	oxygen)	as	a	model	of	I/R	injury	(Yue	et	al.	2000).		Parallel	 to	 the	 importance	of	ERK	activation	 is	 the	 concomitant	 activation	of	 the	anti-apoptotic	 PI3K-Akt	 pathway	 during	 I/R.	 Like	 ERK	 kinase,	 this	 pathway	 is	usually	 activated	 via	 ligand	 binding	 of	 G-protein	 coupled	 receptors	 and	 other	receptor-mediated	 signals	 such	 as	 growth	 factor	 stimulation	 (Cross	 et	 al.	 2000)	and	results	in	the	activation	of	many	diverse	downstream	pathways.	For	example,	
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Akt	activation	 is	able	to	confer	cell	survival	via	multiple	anti-apoptosis	pathways	involving	 the	phosphorylation	and	 inactivation	of	 pro-apoptotic	 proteins	such	as	BAD	(Datta	et	al.	1997)	and	BAX	(Yamaguchi	and	Hong-Gang	2001),	the	inhibition	of	 mitochondrial	 permeability	 transition	 pore	 (mPTP)	 opening,	 and	 the	subsequent	release	of	cytochrome	c,	caspase	activation	(Kennedy	et	al.	1999)	and	by	activation	of	PKC	(Le	Good	et	al.	1998).		Lastly,	as	activation	of	GPR55	has	been	demonstrated	to	activate	both	ERK1/2	and	Akt	signalling	in	various	cell	systems,	it	is	possible	that	a	lack	of	this	receptor,	as	in	GPR55-/-	mice,	may	have	a	negative	effect	on	the	outcome	of	cardiac	I/R	due	to	a	reduced	activation	of	the	RISK	pathway.	
4.1.3. Aims and Objectives 
The	 data	 presented	 in	 the	 previous	 chapter	 has	 shown	 that	 GPR55-/-	 mice	 are	susceptible	 to	 obesity,	 as	 an	 obese	 phenotype	 develops	 in	 these	 mice	 upon	intervention	with	a	high	fat	diet	(HFD)	over	a	period	of	12	weeks,	a	phenomenon	not	present	in	WT	mice.	In	addition	to	increased	fat	mass,	GPR55-/-	mice	fed	a	HFD	exhibit	 modest	 dyslipidaemia,	 dysregulation	 of	 adipose	 tissue	 specific	 genes	(including	 leptin	 and	 adiponectin),	 liver	 steatosis	 and	 alterations	 in	 the	 plasma	levels	 of	 the	 endogenous	GPR55	 ligand	LPI,	 as	 compared	 to	GPR55-/-	 SD	 fed	 and	WT	HFD	fed	controls.	The	primary	aims	of	the	present	study	were	to:	1)	determine	whether	deletion	of	GPR55	 influences	 the	 outcome	 of	myocardial	 I/R	 injury,	 in	 terms	 of	 infarct	 size,	and	2)	determine	whether	HFD	feeding	influences	the	outcome	of	myocardial	I/R,	and	3)	To	 elucidate	 the	mechanism(s)	behind	 any	observed	 changes.	To	do	 this,	isolated	hearts	from	both	WT	and	GPR55-/-	mice	administered	either	a	SD	or	HFD	were	subjected	to	global	ischaemia	followed	by	reperfusion	and	myocardial	tissue	injury	(infarct	size)	was	measured.	To	determine	whether	alterations	in	activation	of	the	RISK	pathway	was	involved	in	any	observed	differences	in	infarct	size,	both	Akt	 and	 ERK	 activation	 were	 examined	 in	 the	 infarcted	 heart	 tissue.	 Finally,	 to	examine	 whether	 GPR55,	 diet	 or	 I/R	 influences	 LPI	 levels	 in	 the	 heart,	 cardiac	tissue	 levels	 of	 LPI	 were	 measured	 in	 an	 attempt	 to	 further	 clarify	 the	mechanism(s)	underlying	any	differences	observed	in	infarct	size.	
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4.2. Methods 
4.2.1. In vivo and physiological parameters  
WT	and	GPR55-/-	mice	were	randomly	allocated	to	receive	either	SD	or	HFD	(n=10	per	group)	as	described	in	section	2.1.2.	Power	calculations	performed	previously	and	 included	as	part	of	 the	Home	Office	project	 licence	70/8875	 indicate	 that	 to	detect	 an	18%	difference	 in	 infarct	 size	with	 a	 standard	deviation	of	 10%	and	 a	power	of	85%,	minimum	group	sizes	of	8	would	be	required,	therefore	group	sizes	of	10	were	used	to	allow	for	exclusions	and	ANOVA	analysis.	Based	on	the	results	of	the	previous	chapter,	which	demonstrated	that	female	GPR55-/-	mice	were	less	sensitive	 to	 the	 obesogenic	 effects	 of	 HFD,	 only	 male	 mice	 were	 used	 for	 these	experiments.	Body	weights	and	food	intakes	of	individual	mice	were	measured	on	a	weekly	basis	as	described	in	section	2.1.3.	
4.2.2. Surgical procedure 
Mice	were	anaesthetised,	the	chest	cavity	opened	and	blood	withdrawn	by	cardiac	puncture	 as	 described	 in	 section	 2.1.4,	 for	 later	 analysis	 of	 circulating	 plasma	levels	of	LPI.	The	heart	was	then	removed	and	attached	to	a	Langendorff	perfusion	apparatus	as	detailed	in	section	2.1.5.	
4.2.3. Langendorff-perfusion of hearts 
4.2.3.1. Rationalisation of the Langendorff method 
In	1895	Oscar	Langendorff	was	the	first	to	describe	a	method	of	isolating	and	using	a	mammalian	 heart	 perfusion	 preparation	 in	 order	 to	 study	 heart	 physiology	 ex	
vivo	(Zimmer	1998).	Over	the	subsequent	100	years	the	method	has	been	refined	and	 advanced,	 although	 the	 underlying	 principle	 remains	 the	 same.	 Using	 a	retrograde	perfusion	apparatus,	 the	isolated	heart	may	be	kept	alive	and	beating,	through	cannulation	of	the	heart	via	the	aorta	and	delivery	of	perfusion	buffer	to	the	 coronary	 circulation,	 allowing	 for	 measurement	 of	 numerous	 physiological	parameters	with	 good	 reproducibility	 (Bell,	 Mocanu	 and	 Yellon	 2011).	 Sumeray	
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and	 Yellon	 (1998)	 characterised	 and	 validated	 a	 modified	 Langendorff	 method	using	 the	 murine	 heart	 and	 a	 global	 ischaemia	 protocol	 to	 measure	 I/R	 injury	outcomes	(Sumeray	and	Yellon	1998),	a	method	which	is	now	widely	employed	to	measure	 the	 effect	 of	 different	 stimuli	 (including	 pharmacological	 intervention,	gene	deletion/activation,	diet	 intervention	and	pre-conditioning)	on	the	outcome	of	 I/R	 injury.	 The	main	 advantages	 of	 this	 adapted	 Langendorff	method	 include	relative	 simplicity	 (as	 compared	 to	 in	 vivo	 working	 heart	 models),	 low	 cost,	reproducibility	 and	 removal	 of	 confounding	 factors,	 such	 as	 neuronal	 and	hormonal	input,	when	studying	molecular	mechanisms	in	the	heart.		
4.2.3.2. Langendorff setup 
Once	 hearts	 were	 successfully	 cannulated	 and	 attached	 to	 the	 Langendorff	apparatus	as	described	in	section	2.1.5,	the	hearts	were	perfused	for	a	minimum	of	15	 mins	 to	 stabilise;	 hearts	 were	 considered	 stable	 once	 they	 displayed	 a	consistent	 perfusion	 pressure	 within	 the	 range	 60-90	 mmHg.	 Hearts	 were	excluded	 from	 analysis	 if	 they	 did	 not	 display	 a	 perfusion	 pressure	 within	 the	specified	 range	 after	 the	 stabilisation	 period.	 After	 stabilisation,	 hearts	 were	subjected	to	30	min	global	ischaemia	by	completely	stopping	the	flow	of	perfusate	into	the	aortic	cannula	using	a	two-way	tap,	after	which	they	were	reperfused	for	30	 minutes.	 At	 the	 end	 of	 the	 experimental	 procedure,	 hearts	 were	 quickly	detached	 from	 the	 cannula,	wrapped	 in	 foil	 and	placed	 in	 a	 -20°C	 freezer	 for	30	minutes	 in	 order	 to	 semi-freeze	 the	hearts,	making	 them	easier	 to	 section.	 Once	semi-frozen,	hearts	were	sectioned	into	3	transverse	slices	as	shown	in	Figure	4.1	and	 the	 middle	 slice	 stained	 with	 Triphenyl	 tetrazolium	 chloride	 (TTC)	 to	determine	 infarct	 size	 (as	 described	 below).	 The	 two	 remaining	 slices	 were	immediately	transferred	into	cryovials,	snap	frozen	in	liquid	nitrogen	and	stored	at	-80°C	until	used	for	extraction	and	analysis	of	LPI,	or	protein	extraction	for	ELISA.		
4.2.3.3. TTC staining of heart slices 
For	 the	 staining	 of	 heart	 tissue,	 the	 refined	 method	 of	 Bohl	 et	 al.	 (2009)	 (i.e.	without	 the	use	of	Evans	Blue	dye)	was	used,	as	while	Evans	Blue	 is	 required	 to	delineate	area	at	risk	in	hearts	subjected	to	regional	ischaemia,	this	is	not	essential	
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when	performing	global	ischaemia	protocols	(Bohl	et	al.	2009).	The	heart	slice	was	submerged	in	1%	w/v	TTC	(Fisher,	UK)	in	PBS	for	30	minutes	at	37°C.	TTC	is	able	to	cross	cellular	membranes	where	 it	 is	 then	metabolised	by	viable	 tissue	 into	a	red	 formazan	 precipitate,	whereas	 in	necrotic	 or	 dead	 tissue	 TTC	 remains	 in	 its	white	 un-metabolised	 form	 and	 therefore	 can	 be	 used	 to	 distinguish	 between	infarcted	 or	 viable	 tissue	 (Fishbein	 et	 al.	 1981).	 The	 stained	 sections	were	 then	immersed	 in	 zinc	 formalin	 fixative	 for	 1	 hour	 before	 imaging	 the	 slice	 by	sandwiching	it	between	two	glass	slides	and	taking	images	with	a	digital	camera.		In	order	to	analyse	and	quantify	the	amount	of	staining,	images	were	coded	by	an	independent	 observer	 to	 enable	 blinded	 analysis	 to	 reduce	 any	 subjective	 bias.	Planimetric	 analysis	 of	 the	 images	 was	 performed	 using	 ImageJ	 software	 and	 a	colour	 thresholding	 method	 to	 identify	 differentially	 stained	 regions	 and	subsequently	measure	 the	 area	 of	 the	 different	 regions	 (i.e.	 viable	 and	 infarcted	tissue).	Infarct	size	was	quantified	as	a	percentage	of	total	ventricular	area.	A	10%	random	sample	of	images	was	analysed	by	another	user	to	confirm	the	consistency	of	the	method.			 	
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Figure 4.1. Illustration demonstrating the sectioning of the heart for analysis. The heart was 
sectioned transversely into 3 approximately equal slices; the atria and remaining aorta were 
discarded. Section 1 was used for protein extraction/analysis; section 2 was used for TTC 
staining and infarct analysis; section 3 was used for LPI extraction/analysis. 	 	
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4.2.4. Determination of the extent of RISK pathway activation 
following I/R 
Slices	from	four	hearts	from	each	experimental	group	were	randomly	selected	and	analysed	for	total	and	phosphorylated	ERK	and	Akt	using	commercially	available	ELISA	 kits.	 Protein	 extraction	 was	 performed	 according	 to	 the	 manufacturer’s	instructions;	 heart	 tissue	 was	 homogenised	 in	 1	 ml	 of	 chilled	 extraction	 buffer	using	a	handheld	homogeniser.	The	tissue	homogenate	was	incubated	on	ice	for	20	minutes	 and	 then	 centrifuged	 at	 14,000	 xg	 for	 10	minutes	 at	 4°C.	 The	 resulting	supernatant	was	transferred	to	a	clean	chilled	microcentrifuge	tube	and	stored	at	-80°C	until	use	in	the	assay.		Both	 ELISA	 kits	 (ab176660;	 ERK1/2	 (pT202/Y204)	 +	 Total	 ERK1/2	 SimpleStep	ELISA™	and	 ab176657;	 AKT	1/2/3	pS473	 +	 AKT1	SimpleStep™	ELISA	Kit)	were	purchased	from	Abcam,	UK.	For	the	assay,	reagents	were	prepared	as	 instructed	 in	the	datasheets.	10X	wash	buffer	was	diluted	to	1X	using	distilled	water;	antibodies	were	mixed	in	a	1:1	ratio	before	use	 and	 lyophilized	ERK1/2	 (pT202/Y204)	 control	 lysate	 and	 lyophilized	AKT	control	lysate	were	reconstituted	in	250	µL	water	each	and	subsequently	used	to	 create	 standard	 curves	 via	 serial	 dilution	 of	 the	 stock	 solution	 in	 1X	 cell	extraction	buffer.		The	total	protein	content	of	samples	was	determined	via	the	Bradford	method	as	described	in	section	2.2.8	and	the	protein	concentration	was	adjusted	to	0.5	mg.ml-1	by	diluting	the	sample	in	an	appropriate	amount	of	1X	cell	extraction	buffer.	To	conduct	the	ELISA,	50	µL	aliquots	of	the	samples	and	standards	were	added	in	duplicate	to	 the	wells	of	 the	provided	96-well	plates,	 to	which	50	µL	of	antibody	cocktail	was	added	and	the	plates	incubated	for	1	hour	at	room	temperature	on	a	plate	shaker	(400	rpm).	After	incubation,	wells	were	washed	with	350	µL	1X	wash	buffer	 3	 times	 and	 the	 plates	 inverted	 and	 any	 remaining	 liquid	 blotted	 against	paper	towels.	Following	washing,	100	µL	of	TMB	substrate	was	added	 to	each	of	the	wells	and	the	plates	incubated	at	room	temperature	for	15	minutes	in	the	dark.	Finally,	100	µL	of	stop	solution	was	added	to	each	well	and	the	absorbance	of	each	
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well	read	at	450	nm	using	a	Biotek	microplate	reader.		
4.2.5. LPI analysis 
Slices	were	randomly	selected	from	five	hearts	from	each	experimental	group	for	the	extraction	of	 lipids	and	analysis	of	LPI	by	LC-MS,	as	detailed	 in	section	0.	LPI	analysis	was	set	up	to	detect	nine-individual	species	of	LPI	based	on	the	different	acyl	group	attached;	total	LPI	was	calculated	by	combining	the	absolute	values	of	all	nine-individual	species	together.		For	 comparative	 purposes,	 the	 cardiac	 LPI	 data	 collected	 in	 the	 experiment	performed	in	chapter	3	of	this	thesis	is	presented	here	to	enable	a	comparison	of	LPI	levels	and	thus	determination	of	the	effect	of	I/R	on	LPI	levels	within	the	heart.		
4.2.6. Statistical analysis 
For	quantification	of	infarct	size,	the	infarcted	tissue	(as	defined	by	white	staining)	was	expressed	as	a	percentage	of	 total	ventricular	area.	LPI	data	 is	expressed	as	mean	absolute	pmol.mg-1	values	as	determined	from	standard	curves	constructed	using	LPI	standards	as	described	in	chapter	2.	ELISA	data	is	expressed	as	both	raw	optical	density	values	(a.u)	and	the	ratio	of	phosphorylated	protein/total	protein.	All	 variables	 were	 analysed	 using	 two-way	 ANOVA	 with	 Bonferroni	 post-hoc	analysis	 (where	 appropriate).	 All	 values	 are	 expressed	 as	 mean±SEM	 of	 n	observations;	p	values	<0.05	was	considered	statistically	significant.		
4.3. Results 
4.3.1. Body weight and food intakes 
Consistent	with	the	results	of	chapter	3,	the	GPR55-/-	HFD	fed	mice	gained	weight	at	an	accelerated	rate	compared	to	the	other	groups	(Figure	4.2a	and	Figure	4.2b)	although	 the	 weight	 gain	 was	 less	 pronounced	 in	 this	 study	 and	 statistical	significance	was	only	detected	between	the	GPR55-/-	SD	and	GPR55-/-	HFD	groups	(final	change	in	weights:	9.51±0.47	g	vs	14.28±1.05	g,	p<0.01).		
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Weekly	 (Figure	4.3a)	and	 total	 averaged	 (Figure	4.3b)	 food	 intake	show	that	 the	intake	of	 food	 for	 each	 group	was	within	 the	 expected	 range	of	 2.5-5	 g	 and	was	relatively	consistent	 throughout	 the	period	of	dietary	 intervention.	However,	 the	averaged	total	intakes	across	the	full	13	weeks	in	both	the	WT	HFD	and	GPR55-/-	HFD	fed	mice	were	lower	than	in	the	SD	fed	controls	(2.95±0.06	g	vs	3.39±0.07	g,	
p<0.001	and	2.90±0.05	g	vs	3.33±0.05	g,	p<0.001).	
4.3.2. Infarct size 
TTC	staining	of	heart	slices	resulted	in	well-defined	areas	of	viable	healthy	tissue	(stained	 red)	 and	 infarcted	 and	damaged	 tissue	 (stained	white;	 Figure	4.4).	 This	good	definition	of	staining	allowed	for	a	reliable	colour	thresholding	method	to	be	applied	to	the	analysis,	which	proved	to	be	consistent	when	tested	between	users.		One	heart	from	each	of	the	WT	SD	and	WT	HFD	groups	was	excluded	from	analysis	due	to	damage	sustained	during	the	cannulation	of	the	aorta,	resulting	in	a	low	and	inconsistent	perfusion	pressure	after	the	stabilisation	period	(<60	mmHg).	As	the	results	of	the	infarct	analysis	show	in	Figure	4.5,	hearts	from	the	control	WT	SD	fed	mice	 exhibited	 an	 infarct	 size	 of	 37.0±1.6%	of	 total	 tissue	 area.	 Similarly,	 hearts	from	GPR55-/-	SD	fed	mice	had	similar	infarct	sizes	when	compared	to	their	WT	SD	counterpart	 (35.8±2.5%;	p>0.05).	 Conversely,	 hearts	 from	 the	WT	HFD	 fed	mice	had	significantly	smaller	infarcts	(27.5±1.8%;	p<0.05)	compared	to	hearts	from	the	WT	SD	fed	group,	whereas	 infarct	size	 in	hearts	 from	the	GPR55-/-	HFD	 fed	mice	was	similar	to	those	fed	a	SD	(33.6±2.9%;	p>0.05).	
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Figure 4.2. The (a) absolute body weight and (b) change in body weight of male WT and 
GPR55-/- mice fed a SD or HFD for 13-weeks. Error bars = SEM and n =10 for all groups ** 
p<0.01 vs GPR55-/- SD as determined via two-way ANOVA and Bonferroni post-hoc analysis. 	  
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Figure 4.3. Food intakes of male WT and GPR55-/- mice fed a SD or HFD for 13-weeks. (a) Food 
intake over time for each group of mice. (b) Bar chart of average food intake of each group 
over the full 13-week period. Error bars = SEM. *** p<0.001 as determined by two way-
ANOVA and Bonferroni post-hoc analysis.  
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Figure 4.4. Representative images of sectioned and TTC stained hearts after completion of 
the I/R protocol; white staining indicates necrotic (infarcted) tissue and red staining indicates 
viable tissue. 	
	
Figure 4.5. Bar chart of myocardial infarct size as a percentage of total area. Error bars = SEM. 
n=9-10 for each group. * p<0.05 as determined by two-way ANOVA and Bonferroni post-hoc 
analysis. 	  
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4.3.3. Total and activated ERK and Akt 
The	level	of	total	ERK1/2	protein	(Figure	4.6a)	was	similar	in	hearts	from	WT	and	GPR55-/-	SD	fed	mice	(0.23±0.02	OD	vs	0.19±0.01	OD,	p>0.05).	Despite	the	level	of	total	ERK1/2	tending	to	increase	in	both	strains	subjected	to	the	HFD,	there	were	no	statistically	significant	differences	between	WT	and	GPR55-/-	groups	(0.30±0.04	OD	vs	0.28±0.05	OD,	p>0.05).		The	 ratio	 of	 p-ERK/Total	 ERK,	 which	 is	 representative	 of	 the	 level	 of	 ERK	activation	 (Figure	 4.6b),	 indicated	 there	 were	 no	 significant	 changes	 in	 ERK	activation	in	hearts	from	either	strain	of	mice,	irrespective	of	diet	(p>0.05).		
Similar to the findings with total ERK1/2, the level of total Akt1	 (Figure	 4.7a)	was	similar	 in	 hearts	 from	 both	 WT	 and	 GPR55-/-	 SD	 fed	 mice	 (1.49±0.30	 OD	 vs	1.08±0.09	 OD,	 p>0.05).	 However,	 total	 Akt1	 was	 significantly	 lower	 in	 GPR55-/-	HFD	fed	mice	compared	to	WT	mice	on	the	same	diet	(0.67±0.07	OD	vs	2.01±0.17	OD,	p>0.001).	Despite this decrease in total Akt1, the ratio of p-Akt1/2/3 to total Akt1, 
and therefore activation of Akt, did not differ between hearts from the different 
groups,	irrespective	of	strain	or	diet	(p>0.05;	Figure	4.7b).Important	to	note	is	that	the	values	recorded	for	p-Akt1/2/3	were	extremely	low	(although	within	the	limit	of	detection)	across	all	groups	and	therefore	may	indicate	little	or	no	activation	of	Akt	proteins.	  
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Figure 4.6. Total ERK1/2 levels (a) and Ratio of p-ERK/Total ERK1/2 (b) in cardiac tissue from 
male mice fed either a SD or HFD for 12-weeks and subjected to the I/R protocol. Error bars = 
SEM and n = 4 for all groups. 
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Figure 4.7. Total Akt1 levels (a) and Ratio of p-Akt1/2/3 / Total Akt1(b) in cardiac tissue from 
male mice fed either a SD or HFD for 12-weeks and subjected to the I/R protocol. Error bars = 
SEM and n = 4 for all groups. *** p< 0.001 as determined via two-way ANOVA and Bonferroni 
post-hoc analysis. 	
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4.3.4. LPI concentration in control (non-infarcted) hearts 
A	representative	raw	LC-MS	trace	of	different	LPI	species	 is	shown	in	Figure	4.8.	The	 cardiac	 tissue	 concentration	 of	 total	 LPI	was	 significantly	 lower	 in	 GPR55-/-	mice	 fed	 a	 SD	 compared	 to	 WT	 controls	 (Figure	 4.9;	 41.2±3.1	 pmol.mg-1	 vs	72.9±3.9	 pmol.mg-1,	 p<0.01).	 There	 were	 no	 significant	 differences	 in	 total	 LPI	concentrations	 between	 WT	 mice	 fed	 a	 SD	 or	 a	 HFD	 (p>0.05);	 however,	 when	challenged	with	a	HFD	intervention,	LPI	concentrations	 from	GPR55-/-	mice	were	increased	to	a	level	similar	to	that	observed	in	WT	SD	mice	and	were	significantly	greater	when	 compared	 to	 the	 GPR55-/-	 SD	 fed	 controls	 (69.6±4.5	 pmol.mg-1	 vs	41.2±3.1	pmol.mg-1,	p<0.05).		Nine	 different	molecular	 species	 of	 LPI	were	 detected	within	 heart	 tissue	 under	control	conditions,	as	opposed	to	the	seven	detected	in	plasma	(chapter	3,	section	3.3.3),	the	most	abundant	species	being	20:4	LPI,	followed	by	18:0	LPI	(see	Table	4.1).	The	lower	level	of	total	LPI	observed	in	GPR55-/-	mice	fed	a	SD	can	be	largely	accounted	 for	by	a	 reduction	 in	 these	 two	species	of	LPI	within	 the	heart	 tissue.	Similar	 to	 the	 findings	 in	plasma	 (chapter	3,	 section	3.3.3),	WT	mice	 exhibited	 a	significant	increase	in	cardiac	20:3	LPI,	alongside	a	small	but	significant	reduction	in	18:2	LPI	 in	response	 to	HFD.	 In	contrast,	 the	 increase	 in	total	LPI	observed	in	response	to	HFD	in	GPR55-/-	mice	is	largely	due	to	replenishment	of	the	18:0	LPI	and	 20:4	 LPI	 species;	 although,	 there	 was	 also	 a	 significant	 but	 less	 marked	increase	in	20:3	LPI	in	comparison	to	WT	mice	fed	a	HFD.		
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Figure 4.8. Representative raw LC-MS trace demonstrating the peaks for different LPI species 
in non-infarcted heart tissue from WT SD fed mice. From top to bottom: Total Ion 
Chromatogram, 16:0 LPI, 18:0 LPI, 18:2 LPI, 20:3 LPI, 20:4 LPI, 22:6 LPI, 17:1 LPI internal 
standard.  
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Figure 4.9. Total LPI level within non-infarcted cardiac tissue of male WT and GPR55-/- mice 
fed either a SD or HFD for 12 weeks (from chapter 3). Bars are mean group values and error 
bars = SEM. n=5 for each group. ** p< 0.01 vs WT SD; # p< 0.05 vs GPR55-/- SD, as determined 
via two-way ANOVA and Bonferroni post-hoc analysis. 	 	
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4.3.5. LPI levels in infarcted hearts 
The	same	nine	molecular	species	of	LPI	detected	in	control	cardiac	tissue	were	also	detected	 in	 infarcted	 tissue	 and	 similarly,	 the	most	 abundant	 of	 these	were	 the	arachidonic	 acid	 (20:4)	 and	 stearic	 acid	 (18:0)	 containing	 species	 (see	Table	4.2	for	individual	values).	In	contrast	to	the	levels	of	20:4	and	18:0	LPI,	the	other	seven	species	were	 detectable	 but	were	 present	 at	 concentrations	 of	 <	 5	 pmol.mg-1	 in	infarcted	 tissue	 from	 control	WT	SD	 fed	mice.	Tissue	 concentrations	of	 18:0	LPI	were	not	affected	by	either	strain	nor	diet,	however	the	concentrations	of	20:4	LPI	were	significantly	increased	in	response	to	HFD	in	WT	mice	(p<0.001).	The	trend	was	 similar	 in	 hearts	 from	 the	 GPR55-/-	mice	 however	 the	 differences	were	 not	considered	statistically	significant	between	the	SD	fed	and	HFD	fed	mice	(19.6±2.2	pmol.mg-1	vs	27.1±5.0	pmol.mg-1,	p>0.05).		Consistent	with	the	findings	in	non-infarcted	hearts,	the	most	significant	effect	of	HFD	 intervention	 was	 an	 increase	 in	 cardiac	 tissue	 levels	 of	 20:3	 LPI	 species,	which	was	 observed	 to	 be	 increased	 in	 hearts	 from	both	WT	 and	GPR55-/-	mice	(Table	4.2).	The	 total	 level	 of	 LPI	 in	 infarcted	hearts	 from	WT	SD	 fed	mice	was	 significantly	reduced	 after	 the	 I/R	 protocol,	 compared	 to	 control	 hearts	 collected	 as	 part	 of	chapter	3	(Figure	4.10a;	72.9±3.9	pmol.mg-1	vs	31.6±0.9	pmol.mg-1,	p<0.001).	This	I/R	induced	reduction	in	total	LPI	was	not	observed	in	infarcted	hearts	from	any	of	the	other	groups.		The	 I/R	 induced	 reduction	 in	 total	 LPI	 in	 hearts	 from	 WT	 SD	 fed	 mice	 was	predominately	due	 to	a	substantial	reduction	 in	20:4	LPI	(Figure	4.10b;	34.5±2.4	pmol.mg-1	vs	10.4±1.5	pmol.mg-1,	p<0.001).	Also	reflecting	the	total	level	of	LPI,	the	other	groups	did	not	have	significant	differences	in	20:4	LPI	between	control	and	infarcted	hearts,	also	irrespective	of	diet	(Figure	4.10b;	p>0.05).	
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 Group 
LPI Species WT SD WT HFD GPR55-/- SD GPR55-/- HFD 
LPI 16:0 1.74±0.12 1.22±0.11 1.10±0.07 1.22±0.11 
LPI 18:0 22.42±1.58 20.22±1.36 17.44±0.85* 23.84±1.54### 
LPI 18:1 2.08±0.1 3.02±0.25 1.18±0.12 2.26±0.15 
LPI 18:2 6.00±0.31 1.08±0.14* 2.96±0.23 0.68±0.07 
LPI 20:3 3.32±0.28 19.78±2.8*** 1.32±0.19 15.06±1.26####, † 
LPI 20:4 34.46+2.37 33.72±3.93 16.00±1.81**** 25.70±2.00####, †††† 
LPI 22:4 0.24+0.02 0.18±0.04 0.10±0.03 0.12±0.02 
LPI 22:5 1.02±0.10 0.50±0.07 0.38±0.09 0.40±0.05 
LPI 22:6 1.64±0.14 0.36±0.02 0.74±0.16 0.32±0.04 
Table 4.1. Concentration of individual LPI species in control heart tissue from male mice fed 
either a SD or HFD for 12 weeks and collected as part of the previous phenotype chapter of 
this thesis. Values are pmol.mg-1 wet weight tissue ± SEM, n = 5 for all values. * p<0.05, *** 
p<0.001, **** p<0.0001 vs WT SD; ### p<0.001, #### p<0.0001 vs GPR55-/- SD, † p<0.05, †††† 
p<0.0001 vs WT HFD as determined via two-way ANOVA and Bonferroni post-hoc analysis. 	
  Group 
LPI Species WT SD WT HFD GPR55-/- SD GPR55-/- HFD 
16:0 1.46 ± 0.6 1.00 ± 0.17 1.00 ± 0.23 0.84 ± 0.12 
18:0 19.56 ± 4.50 19.44 ± 3.68 17.00 ± 3.53 14.12 ± 2.59 
18:1 1.86 ± 0.89 2.50 ± 0.39 1.14 ± 0.2 2.10 ± 0.19 
18:2 4.74 ± 2.37 0.78 ± 0.13 2.94 ± 0.27 0.78 ± 0.1 
20:3 2.10 ± 1.28 13.38 ± 2.65* 1.58 ± 0.2 13.70 ± 2.50## 
20:4 10.38 ± 1.53 24.44 ± 5.43*** 19.60 ± 2.23 27.08 ± 5.01 
22:4 0.18 ± 0.08 0.14 ± 0.02 0.18 ± 0.02 0.14 ± 0.04 
22:5 0.60 ± 0.35 0.36 ± 0.11 0.68 ± 0.12 0.30 ± 0.08 
22:6 1.08 ± 0.59 0.28 ± 0.07 1.30 ± 0.21 0.34 ± 0.10 
Table 4.2. Concentration of individual LPI species in infarcted cardiac tissue. Values are 
pmol.mg-1wet weight tissue ± SEM, n = 5 for all values. * p<0.05 vs WT SD; *** p<0.001 vs WT 
SD; ## p<0.01 vs GPR55-/- SD as determined via two-way ANOVA and Bonferroni post-hoc 
analysis. 
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Figure 4.10. The (a) total level of LPI in cardiac tissue from control hearts (from chapter 3) vs 
infarcted hearts, and (b) level of 20:4 LPI in cardiac tissue from control hearts vs infarcted 
hearts. Error bars = SEM and n=5 for all groups. *** p<0.001 vs WT SD control; as determined 
via two-way ANOVA and Bonferroni post-hoc analysis. 	
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4.4. Discussion 
The	 results	 of	 chapter	3	 established	 an	 accelerated	obesogenic	phenotype	of	 the	GPR55	 knockout	 mouse	 when	 challenged	 with	 a	 high	 fat	 diet.	 To	 further	investigate	 the	 impact	 of	 this	 on	 the	 heart’s	 response	 to	 I/R	 injury,	 a	 series	 of	experiments	were	performed	to	determine	whether	the	obese	phenotype	seen	in	the	 GPR55-/-	mice	was	 accompanied	 by	 any	 alteration	 in	 infarct	 size	 following	 a	period	of	global	I/R	in	isolated	Langendorff-perfused	hearts.	The	data	presented	in	this	 chapter	 demonstrates	 that	 under	 standard	 diet	 conditions,	 the	 GPR55	knockout	alone	has	no	effect	on	myocardial	infarct	size	sustained	after	a	period	of	global	 I/R.	 In	 contrast,	WT	mice	 fed	 a	HFD	 sustain	 a	 smaller	 cardiac	 infarct	 size	compared	 to	 their	 SD	 fed	 controls	 following	 a	 period	 of	 global	 I/R;	 a	 cardio-protective	effect	of	the	HFD,	which	is	abrogated	in	hearts	from	GPR55-/-	mice	 fed	the	same	HFD.		
4.4.1. The cardio-protective effects of a high fat diet 
As	 shown	 by	 the	 results	 of	 section	 4.3.2,	 high	 fat	 feeding	 in	 WT	 mice	 was	associated	with	a	cardio-protective	effect	as	evidenced	by	the	significant	reduction	in	 myocardial	 infarct	 size.	 In	 contrast,	 this	 HFD	 induced	 cardio-protection	 was	absent	 in	 GPR55-/-	 mice	 suggesting	 the	 involvement	 of	 a	 GPR55-dependent	mechanism.	 These	 findings	 were	 unexpected	 and	 further	 molecular	characterisation	was	carried	out	to	determine	if	the	observed	effects	were	due	to	changes	 in	 activation	 of	 the	 cardio-protective	 RISK	 pathway	 (due	 to	 the	 overlap	between	the	GPR55	and	RISK	pathways)	or	differences	in	the	tissue	levels	of	LPI,	the	endogenous	ligand	of	GPR55.		Activation	of	the	RISK	pathway	is	understood	to	be	important	in	reducing	infarct	size	during	reperfusion	and	is	thought	to	be	fundamental	to	the	cardio-protection	offered	by	pre-	 and	post-ischaemic	 conditioning	 and	 is	 principally	dependent	 on	both	 Akt	 and	 ERK1/2	 activation	 (Hausenloy	 and	 Yellon	 2007).	 Furthermore,	 as	previous	 work	 has	 demonstrated	 that	 GPR55	 signals	 via	 both	 ERK1/2	 and	 Akt	kinases	 (Hausenloy	 and	 Yellon	 2007,	 Henstridge	 et	 al.	 2010),	 the	 RISK	 pathway	was	 investigated	 as	 a	 possible	 mechanism	 for	 the	 GPR55-dependent	 cardio-
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protection	in	hearts	from	WT	HFD	mice.		Although	 not	 statistically	 significant,	 the	 level	 of	 total	 ERK	 and	 Akt	 tended	 to	increase	in	hearts	from	WT	mice	fed	a	HFD;	however,	the	level	of	both	ERK	and	Akt	activation	remained	largely	unchanged	due	to	the	diet	intervention.	Therefore,	this	study	 suggests	 that	 the	 reduction	 in	 infarct	 size	 in	 hearts	 from	 the	WT	HFD	 fed	mice	 is	 not	 due	 to	 upregulation	 or	 activation	 of	 the	 RISK	 pathway.	 This	 is	 in	agreement	with	another	study	conducted	by	Salie	et	 al.	 (2014)	using	rats,	which	has	shown	reductions	 in	myocardial	 infarct	size	but	no	changes	 in	RISK	pathway	activation	 during	 early	 reperfusion	 after	 a	HFD	 intervention	 and	 subsequent	 35	min	regional	ischaemia	using	a	working	heart	model	(Salie,	Huisamen	and	Lochner	2014).	 In	 this	 instance,	 the	 authors	hypothesise	 two	main	 explanations:	 that	 the	hearts	are	‘metabolically	preconditioned’,	particularly	by	high	levels	of	circulating	insulin,	 which	 has	 been	 shown	 to	 be	 cardio-protective	 (Hausenloy	 and	 Yellon	2007);	 or	 by	 a	 hypothetical	 involvement	 of	 the	 renin-angiotensin	 system,	 as	observed	in	early	overfeeding	of	infant	rats	(Granado	et	al.	2012).	To	the	contrary,	it	 has	 also	 been	 demonstrated	 that	 obesity	 promotes	 cardio-protection	 to	 I/R	injury	via	modulation	of	the	RISK	pathway,	however	this	study	was	conducted	in	already	 insulin-insensitive	 rats	 which	 may	 account	 for	 the	 disparity	 between	studies	 (Donner	 et	 al.	 2013).	 It	 is	 important	 to	 note	 that	 one	 limitation	 of	 the	present	study	is	that	the	measurement	of	RISK	pathway	activation	was	conducted	after	30	minutes	reperfusion,	as	there	is	a	possibility	that	this	length	of	reperfusion	is	 too	 long	 to	 detect	 active	 RISK	 pathway	 phosphorylation	 events	 and	unfortunately,	 there	 are	 no	 sham-perfused	 heart	 data	 available	 to	 compare	baseline	RISK	pathway	activation	in	this	study.		Another	possibility	is	that	there	may	be	a	direct	cardio-protective	effect	of	the	diet	on	the	heart,	which	is	lost	in	the	presence	of	the	obese	phenotype	that	is	observed	only	 in	 GPR55-/-	 HFD	 fed	mice;	 however,	 this	 seems	 unlikely	 given	 that	 obesity	itself	has	been	shown	to	be	cardio-protective	in	the	setting	of	I/R	and	heart	failure	in	both	 experimental	 and	 clinical	 settings	 (Curtis	 et	 al	 2005,	Donner	 et	 al.	 2013,	Salie,	 Huisamen	 and	 Lochner	 2014).	 It	 has	 been	 suggested	 that	 a	HFD	mediates	cardio-protection	by	 ‘metabolically	conditioning’	 the	heart	 through	high	 levels	of	insulin	 or	 by	 activation	 of	 the	 renin-angiotensin	 system	 as	 previously	 stated;	
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however,	neither	of	these	mechanisms	would	explain	why	the	cardio-protection	is	lost	with	 the	deletion	of	GPR55	 (or	by	 the	presence	of	 the	obese	phenotype),	 as	neither	system	is	thought	to	be	mediated	via	this	receptor.	Furthermore,	using	the	isolated	heart	system	as	employed	in	this	thesis	removes	the	circulating	hormonal	influences	which	may	 be	 present	 in	 a	 working-heart	model	 and	 therefore	 these	explanations	are	not	as	relevant	to	the	present	results.	
4.4.2. RISK pathway activation in GPR55-/- mice 
Despite	 no	 significant	 differences,	 activation	 of	 ERK	 appears	 to	 be	 impaired	 in	hearts	from	the	GPR55-/-	mice	(see	Figure	4.6).	As	activation	of	GPR55	by	LPI	has	been	shown	to	activate	the	ERK	pathway	in	a	number	of	in	vitro	systems	(Oka	et	al.	2007,	Henstridge	et	al.	2010,	Kapur	et	al.	2009),	it	is	logical	to	expect	this	reduced	ERK	activation	in	hearts	lacking	GPR55;	however,	this	did	not	lead	to	any	increases	in	 infarct	 size	due	 to	 reduced	RISK	pathway	 activation	 in	 the	GPR55-/-	 hearts	 as	one	 might	 expect.	 Nevertheless,	 as	 there	 is	 no	 directly	 comparable	 data	 from	sham-perfused	 hearts	 it	 is	 difficult	 to	 suggest	 how	 significant	 a	 reduction	 in	activation	 this	 is,	 as	 the	 level	 of	 activation	 may	 still	 be	 enough	 to	 promote	 cell	survival.		
There was a large significant difference	between	total	Akt	levels	in	hearts	from	WT	HFD	 and	GPR55-/-	 HFD	 fed	mice	 (see	 Figure	 4.7b).	 However,	 this	 reduction	was	mirrored	 in	 a	 reduction in p-Akt, hence the overall ratio and level of activation 
remained largely unchanged between the different groups. Unlike ERK activation, 
activation of GPR55 has only been previously demonstrated by Pineiro et al. (2011) to 
signal via Akt in cancer cell lines stimulated with LPI; therefore, less is known about the 
endogenous GPR55-Akt signalling potential in other cell or tissue systems such as the 
heart and this pathway needs to be studied further (Pineiro, Maffucci and Falasca 
2011). As with the findings of RISK pathway activation in hearts from WT mice, the 
present results suggest that the RISK pathway is not influenced by either diet or GPR55 
and does not play an integral role in mediating the damage caused by I/R in the 
present study. 
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4.4.3. Changes in cardiac tissue levels of LPI in response to 
both I/R and diet 
Unlike	 plasma	 LPI	 levels	 which	 were	 similar	 in	 WT	 and	 GPR55-/-	 mice	 (data	presented	in	chapter	3),	non-infarcted	cardiac	tissue	levels	of	total	LPI	were	lower	in	GPR55-/-	mice,	 largely	due	 to	 a	 reduced	 level	 of	 20:4	 and	 18:0	LPI	 (see	Table	4.1).	As	these	two	species	of	LPI	have	been	shown	to	be	the	most	potent	agonists	of	the	 GPR55	 receptor	 (Oka	 et	 al.	 2009),	 the	 decrease	 in	 heart	 tissue	 level	 of	 LPI	observed	in	GPR55-/-	mice	may	suggest	that	a	positive	feedback	mechanism	exists	between	 the	 activation	 of	 GPR55	 by	 LPI	 and	 the	 further	 production	 of	 LPI	 at	 a	cellular	level,	that	is	inactivated	due	to	the	absence	of	the	receptor.	Indeed,	GPR55	activation	 by	 LPI	 is	 known	 to	 stimulate	 activation	 of	 PLC,	 thus	 increasing	intracellular	calcium	and	the	activation	of	calcium	dependent-cPLA2	(Lauckner	et	al.	2008),	a	key	enzyme	in	the	production	and	metabolism	of	LPI,	as	described	in	chapter	1	(Yamashita	et	al.	2013).	The	present	finding	would	therefore	support	the	notion	 of	 a	 possible	 positive-feedback	 loop	 within	 the	 GPR55/LPI	 system.	 HFD	feeding	of	GPR55-/-	mice	attenuated	the	reduction	of	LPI	observed	in	GPR55-/-	SD	fed	 mice	 compared	 to	 WT	 controls,	 although	 the	 levels	 did	 not	 reach	 the	 same	elevation	as	observed	 in	WT	HFD	 fed	mice;	 further	suggesting	 the	existence	of	a	cellular	positive	feedback	mechanism	which	is	tissue	specific	and	can	be	influenced	by	dietary	intervention.	Although	 the	 total	 level	 of	 LPI	 tended	 to	 increase	with	HFD	 feeding	 in	 infarcted	hearts	from	both	strains	of	mice	(see	Figure	4.10a),	the	combined	results	were	not	significantly	 different	 unless	 the	 individual	 LPI	 species	 were	 considered	separately,	therefore	representing	a	change	in	LPI	profile.	As	described	in	section	4.3.5,	the	most	abundant	LPI	species	found	within	the	infarcted	heart	tissue	from	SD	 fed	 mice	 was	 arachidonic	 (20:4)	 and	 stearic	 acid	 (18:0)	 containing	 LPI	 (see	Table	 4.2).	 The	 influence	 of	 HFD	 feeding	 on	 individual	 LPI	 species	 is	 most	significant	 to	 the	 concentration	 of	 the	 DGLA	 (20:3)	 containing	 LPI,	 which	 is	significantly	increased	in	infarcted	hearts	from	both	the	WT	and	GPR55-/-	HFD	fed	mice.	 This	 is	 in	 direct	 agreement	 with	 the	 results	 from	 control	 heart	 tissues	presented	 in	section	4.3.4,	which	show	an	almost	 identical	pattern	of	LPI	species	concentrations,	including	the	increases	in	20:3-LPI	in	hearts	from	WT	and	GPR55-/-	
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HFD	fed	mice.	There	were	no	significant	differences	between	total	or	individually	measured	LPI	species	in	infarcted	tissue	between	the	WT	and	GPR55-/-	groups	fed	either	a	SD	or	HFD,	and	similar	to	WT	mice,	the	GPR55-/-	mice	exhibited	the	same	increases	in	20:4	and	20:3-LPI	when	challenged	by	a	HFD	intervention.	However,	a	resistance	 to	 I/R	damage	 is	not	observed	 in	 the	obese	GPR55-/-	HFD	 fed	mice	as	compared	 to	 the	WT	HFD	 fed	mice,	 therefore	supporting	 the	hypothesis	 that	 the	cardio-protective	 effect	 of	 a	 HFD,	 possibly	 through	 sustaining	 a	 high	 level	 of	endogenous	20:4-LPI	and	an	increase	in	20:3-LPI	is	dependent	on	the	presence	of	GPR55.	The	most	significant	effect	of	the	I/R	protocol	on	LPI	levels	is	to	the	concentration	of	 20:4-LPI	 in	 infarcted	heart	 tissue	 from	WT	SD	 fed	mice,	which	 is	 significantly	lower	than	the	 level	 from	control	hearts	of	WT	SD	fed	mice	and	accounts	 for	the	decrease	in	total	LPI	observed	in	infarcted	hearts	compared	to	control	hearts	(see	Figure	4.10a	and	b).	As	the	high	 level	of	20:4-LPI	 is	sustained	in	hearts	 from	the	WT	 HFD,	 and	 20:4-LPI	 is	 known	 to	 be	 the	 strongest	 agonist	 at	 GPR55	 of	 the	various	LPI	species	(Oka	et	al.	2009),	it	is	likely	to	be	this	molecule	which	exerts	a	cardio-protective	 effect	 via	 action	 at	 GPR55,	 however	 the	 increase	 in	 20:3-LPI	must	not	be	disregarded	either.	As	the	most	significant	change	due	to	diet	was	the	increase	 in	 20:3-LPI,	 it	 may	 also	 be	 this	 molecule	 that	 mediates	 the	 cardio-protection	 offered	 by	 a	 HFD;	 unfortunately	 to	 date,	 little	 is	 known	 about	 this	molecule	as	it	is	usually	present	at	extremely	low	levels	under	control	conditions	and	has	not	been	studied	for	any	biological	activity.	It	is	most	likely	a	combination	of	the	20:4	and	20:3-LPI	species	that	confer	protection	against	I/R	injury	and	it	is	possible	 that	 the	 increase	 in	 the	20:3	 species	 is	necessary	 to	sustain	 the	 level	of	20:4-LPI	that	was	observed	in	the	infarcted	heart	tissue	from	WT	HFD	fed	mice.		
4.4.4. Proposed mechanism of cardio-protection offered by 
the GPR55/LPI system 
As	 discussed,	 the	 data	 presented	 in	 this	 study	 provides	 evidence	 that	 a	 HFD	intervention	offers	protection	against	 I/R	 injury,	possibly	 through	an	 increase	 in	20:4	and	20:3-LPI	and	hypothetical	activation	of	GPR55	within	the	cardiac	tissue.	This	 conclusion	 needs	 to	 be	 investigated	 further,	 however	 it	 is	 possible	 to	
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hypothesize	a	mechanism	by	which	this	protection	may	occur.	What	is	striking	is	that	 this	data	 is	 in	direct	 contrast	with	data	collected	within	our	 laboratory	 that	shows	LPI	applied	exogenously	to	the	 isolated	mouse	heart	 increases	 infarct	 size	using	 the	 same	 I/R	 protocol	 (Robertson-Gray,	 manuscript	 submitted	 for	publication).	 This	 conflict	 between	 a	 cardio-protective	 effect	 of	 endogenous	 LPI	and	 a	 damaging	 effect	 of	 exogenous	 LPI	 could	 be	 explained	 by	 the	 downstream	action	 of	 LPI	 on	 GPR55	 being	 dependent	 on	 the	 location	 of	 the	 receptor	 it	 is	activating	or	by	the	particular	species	of	LPI	involved.		Yu	et	al.	(2013)	have	previously	shown	that	in	the	cardiomyocyte	GPR55	receptors	are	 located	 on	 both	 the	 sarcolemmal	 and	 endolysosomal	 membranes	 (Yu	 et	 al.	2013).	This	differential	location	of	the	receptor	determines	the	downstream	result	of	 LPI	 activating	 GPR55,	with	 both	 receptors	mobilising	 Ca2+	 ions	 (the	 principal	action	 of	 GPR55	 reported	 by	 many	 studies)	 but	 having	 opposite	 downstream	effects	on	the	membrane	potential	of	the	cell.	Yu	et	al.	determined	that	activation	of	sarmolemmal	GPR55	leads	to	a	large	sustained	increase	in	intracellular	Ca2+	and	depolarisation	of	the	cell;	in	contrast,	activation	of	endolysosomal	GPR55	causes	a	small	 transient	 increase	 in	 intracellular	Ca2+,	which	 leads	 to	hyperpolarisation	of	the	 cell	 (Yu	 et	 al.	 2013).	 Cardiomyocyte	 hyperpolarisation,	 has	 been	 a	 desired	target	of	drug	therapy	for	reducing	infarct	size	for	decades	(reviewed	extensively	by	 Grover	 and	 Garlid	 2000).	 Hyperpolarisation,	 induced	 by	 pharmacological	opening	 of	 K+	 channels,	 has	 been	 shown	 in	 a	 number	 of	 studies	 to	 reduce	 the	damage	sustained	during	 I/R	due	 to	prevention	of	 intracellular	calcium	overload	and	a	salvage	of	ATP	(Maskal	et	al.	1995,	Tsuchida	et	al.	2002,	Kersten	et	al.	2000).	Thus,	 exogenously	 applied	 LPI	 acting	 via	 sarcolemmal	 receptors	 would	 have	 a	detrimental	 effect	 on	 tissue	 integrity	 by	 contributing	 to	 intracellular	 calcium	overload,	 while	 endogenously	 generated	 intracellular	 LPI	 would	 be	 cardio-protective	 by	 activating	 endolysosomal	 receptors,	 causing	 cellular	hyperpolarisation	 and	 producing	 a	 resistance	 to	 depolarisation	 and	 subsequent	events	leading	to	cellular	death	(Figure	4.11).		One	other	important	factor	is	the	species	of	LPI	which	may	be	activating	GPR55,	as	different	species	have	been	shown	to	have	different	GPR55	agonist	activity	(Oka	et	al.	 2009).	 The	 present	 study	 has	 demonstrated	 a	 large	 shift	 in	 the	 ratio	 of	
		 140	
20:4/20:3	 LPI	 and	 it	 may	 be	 conceivable	 that	 20:3-LPI	 exhibits	 different	downstream	 signalling	 to	 that	 of	 20:4-LPI;	 unfortunately,	 to	 date	 no	 study	 has	analysed	 the	 activity,	 pharmacology	 or	 abundance	 of	 20:3-LPI	 in	 either	endogenous	or	model	cell	systems	and	therefore	this	may	be	an	opportune	area	for	further	investigation.			
	
Figure 4.11. Diagram representing the differential effects of intracellular vs sarcolemmal 
GPR55 activation. Adapted from Yu et al. (2013). SR: Sarcoplasmic reticulum, EL: 
Endolysosome, RyR: Ryanadine receptor, LTCC: L-type calcium channel, IP3: inositol 
triphosphate.  	 	
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4.4.5. The impact of obesity on infarct size 
The	principal	finding	of	these	experiments	was	that	hearts	from	WT	HFD	fed	mice	sustain	 an	 almost	 10%	 smaller	 average	 infarct	 size	 compared	 to	 their	 SD	 fed	controls,	however	these	mice	were	not	obese,	unlike	the	GPR55-/-	HFD	fed	mice,	in	which	no	cardio-protection	was	observed.	The	paradoxical	phenomenon	of	obesity	improving	 resistance	 to	 myocardial	 infarct	 damage	 (‘the	 obesity	 paradox’)	 has	been	previously	documented	 in	 rats	using	similar	 isolated	heart	protocols	 (Salie,	Huisamen	and	Lochner	2014,	Kristiansen	et	al.	2004)	and	in	a	number	of	human	clinical	 studies	 (Pingitore	 et	 al.	 2007,	 Cepeda-Valery	 et	 al.	 2013).	 Despite	 these	findings,	 the	 obesity	 paradox	 remains	 contentious	 as	 some	 studies	 have	demonstrated	 that	 high	 fat	 diet	 feeding	 leads	 to	 an	 increased	 susceptibility	 to	myocardial	 damage	 using	 in	 vivo	 (Clark	 et	 al.	 2011)	 and	 ex	 vivo	 models	 of	 I/R	(Thakker	et	al.	2008,	du	Toit	et	al.	2008).	The	authors	of	these	studies	attribute	the	difference	 in	 findings	 between	 studies	 to	 the	 diverse	 experimental	 protocols;	including	 using	 different	 I/R	 timings,	 different	 strains	 of	 animals,	 and	 most	importantly,	different	types	and	durations	of	dietary	intervention.	Furthermore,	it	may	be	difficult	 to	draw	direct	 comparisons	between	 clinical	 studies	 and	 in	 vivo	experiments	due	to	the	un-controlled	nature	of	many	human	studies	compared	to	
in	 vivo	 experimentation	 regarding	 exclusion	 criteria	 (or	 lack	 thereof)	 including	parameters	such	as	accounting	for	current	medications,	diet	and	previous	illness.		The	mechanism	underlying	the	cardio-protective	effect	of	diet	induced	obesity	on	myocardial	infarction	is	not	fully	understood	and	many	hypotheses	exist	to	clarify	the	 phenomenon.	 Hadour	 et	 al.	 (1998)	 first	 proposed	 that	 hearts	 from	 induced	type	I-diabetic	rabbits	were	 ‘metabolically	preconditioned’,	although	they	did	not	propose	 the	 possible	 mechanism	 by	 which	 this	 occurs	 (Hadour	 et	 al.	 1998).	Building	 on	 that	 study,	 Ravingerova	 et	 al.	 (2000)	 suggested	 that	 a	 reduction	 in	lactate	 production	 in	 early	 diabetic	 hearts	 during	 ischaemia	 may	 reduce	 the	damage	 sustained	 during	 reperfusion	 due	 to	 attenuation	 of	 Ca2+	 overload	(Ravingerova	et	al.	2000).	More	recently,	Donner	et	al.	(2013)	demonstrated	that	obesity	 improves	 the	 outcome	 of	 I/R	 in	 hearts	 from	 insulin-insensitive	 rats,	through	modulation	of	the	RISK	pathway	via	Akt,	ERK1/2	and	eNOS	(Donner	et	al.	2013).	Although	most	 of	 these	 studies	have	 focused	on	 the	diabetic	 heart,	many	
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similarities	such	as	increases	in	circulating	insulin,	free	fatty	acids	and	alterations	in	 plasma	 lipids	 are	 also	 found	within	 the	 setting	 of	 obesity	without	 associated	diabetes.	 Other	 proposed	 mechanisms	 underlying	 cardio-protection	 observed	within	obesity	and	diabetes	have	 included	acute	 increases	 in	 insulin	(Jonassen	et	al.	2001),	nitric	oxide	 (Gao	et	al.	2002)	and	an	 increase	 in	activation	of	 the	RISK	pathway	at	the	time	of	reperfusion	(Xu	et	al.	2004).		As	 the	only	mice	 to	 show	overt	 obesity	 in	 this	 study	were	 the	GPR55-/-	HFD	 fed	mice,	and	no	reduction	in	infarct	size	after	a	period	of	global	I/R	was	observed	in	these	mice,	it	is	the	conclusion	of	the	present	study	that	the	obesity	paradox	is	not	evident	 in	 these	mice	 and	 the	 cardio-protective	 effect	 of	 a	HFD	 on	 I/R	 injury	 is	independent	of	the	obese-phenotype	and	dependent	on	GPR55.	 
4.5. Conclusions 
To	summarise,	 the	present	 study	aimed	 to	expand	on	 the	results	of	 the	previous	chapter,	 elucidating	 any	 effect	 of	 a	HFD	 intervention	 and	GPR55	deletion	on	 the	damage	 sustained	 to	 cardiac	 tissue	 following	 a	 period	 of	 I/R.	 The	 results	 of	 the	HFD	 intervention	presented	 in	 this	 study	were	consistent	with	 the	results	of	 the	previous	 chapter;	 therefore,	 the	 results	 of	 this	 chapter	 ought	 to	 be	 directly	relatable	to	the	findings	of	chapter	3.		In	 the	 present	 study,	 it	 was	 established	 that	 HFD	 feeding	 for	 12	 weeks	 could	significantly	 reduce	 the	 damage	 to	 cardiac	 tissue	 caused	 by	 I/R	 in	 WT	 mice.	However,	this	effect	is	not	present	in	hearts	from	GPR55-/-	mice;	hence,	 the	effect	of	 the	HFD	would	 seem	 to	 be	 dependent	 on	 GPR55.	 As	 the	 activation	 of	 GPR55	signals	 through	a	complex	network	of	 systems,	 including	 the	 activation	of	MAPK	proteins	 such	 as	 ERK,	 it	was	 logical	 to	 explore	 the	 possibility	 of	 enhanced	 RISK	pathway	 activation	 within	 the	 infarcted	 hearts.	 However,	 after	 measuring	 the	levels	and	activation	of	both	ERK	and	Akt	in	hearts	from	all	groups	of	mice,	it	was	determined	that	the	reduced	infarct	size	observed	in	the	hearts	from	the	WT	HFD	fed	mice	was	not	due	to	 increased	RISK	pathway	activation.	Therefore,	 from	this	data	 it	was	 concluded	 that	 the	 reduction	 in	 infarct	 size	 in	 hearts	 from	WT	HFD	animals	is	due	to	a	currently	unknown	mechanism	involving	GPR55.		
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As	the	results	of	chapter	3	also	revealed	a	significant	increase	in	the	plasma	levels	of	LPI,	the	endogenous	agonist	of	the	GPR55,	it	was	hypothesised	that	this	increase	in	the	level	of	LPI	may	possibly	influence	the	outcome	of	infarct	size.	The	evidence	presented	in	this	chapter	of	the	thesis	would	suggest	this	hypothesis	could	be	true,	as	the	level	of	LPI	found	within	infarcted	heart	tissue	from	the	WT	SD	fed	mice	was	much	lower	than	that	within	the	tissue	from	the	WT	HFD	fed	mice.	As	the	level	of	LPI	is	also	sustained	in	the	infarcted	heart	tissue	from	GPR55-/-	mice	but	no	cardio-protective	 effect	 of	 diet	 is	 observed,	 this	 confirms	 that	 the	 selective	 cardio-protective	 effect	 of	 the	 endogenous	 LPI	 is	 mediated	 via	 GPR55.	 It	 is	 feasible	 to	propose	that	the	sustained	increase	in	LPI	found	within	the	infarcted	heart	tissue	of	WT	 HFD	 fed	 mice	 would	 allow	 for	 a	 greater	 or	 sustained	 agonistic	 effect	 on	intracellular	GPR55,	 leading	to	the	reduction	in	tissue	damage	that	was	observed	in	 this	 study.	 Further	 mechanistic	 studies,	 possibly	 through	 pharmacological	intervention,	should	be	conducted	in	order	to	substantiate	this	assertion	further.			 	
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5 : In vitro approach to elucidating the mechanisms 
underlying the phenotypic changes observed in the 
adipose tissue of HFD fed mice. 
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5.1. Introduction  
The	results	of	 chapter	3	 firstly	established	 that	HFD	 feeding	of	WT	and	GPR55-/-	mice	 leads	 to	 adipocyte	 hypertrophy	 (in	 GPR55-/-	 mice)	 and	 a	 dysregulation	 in	gene	expression	of	key	adipokines	and	antioxidant	enzymes	within	adipose	tissue.	Furthermore,	 the	 results	 of	 chapter	 4	 established	 that	 this	 HFD	 intervention	produced	 a	 cardio-protective	 effect	 on	 the	 response	 to	 I/R	 injury	 in	 the	 hearts	from	WT	 mice,	 an	 effect	 which	 was	 abrogated	 with	 deletion	 of	 GPR55	 and	 the	onset	 of	 obesity.	 The	 underlying	 mechanism	 behind	 the	 changes	 in	 gene	expression	within	 adipose	 tissue	 and	 subsequent	 effects	 on	 the	heart	 upon	HFD	feeding	are	currently	unknown.		The	 primary	 function	 of	 adipocytes	 is	 to	 store	 excess	 energy	 in	 the	 form	 of	triglycerides	 and,	 upon	 stimulation,	 to	 release	 them	when	needed;	 however	 it	 is	now	widely	 known	 that	 adipose	 tissue,	 consisting	 of	 adipocytes,	 pre-adipocytes	and	immune	cells	such	as	macrophages,	act	together	as	an	endocrine	organ	(Ahima	and	Flier	2000).	As	described	 in	the	general	 introduction	(chapter	1),	adipocytes	secrete	 a	 number	 of	 inflammatory	 markers	 such	 as	 TNF-α,	 IL-6	 and	 IL-10,	 and	adipokine	 hormones	 such	 as	 leptin	 and	 adiponectin	 (Fain	 et	 al.	 2004).	 These	molecules	may	influence	other	systems	within	the	human	body	and	in	particular	the	 cardiovascular	 system,	 especially	 in	 the	 setting	 of	 obesity,	 where	 the	production	 and	 release	 of	 several	 of	 these	 molecules	 becomes	 dysregulated,	leading	to	a	systemic	low	level	of	inflammation	and	oxidative	stress.		The	underlying	mechanism(s)	behind	adipokine	dysregulation	within	the	state	of	obesity	is	a	contentious	subject	as	discussed	in	the	general	introduction	(Chapter	1);	however,	despite	the	cause	remaining	elusive,	it	is	well	established	that	in	the	state	of	obesity,	the	expression	of	adipokines	is	dysregulated	(Antuna-Puente	et	al.	2008).	 The	 main	 theory	 to	 explain	 the	 effect	 of	 obesity	 on	 adipokine	 gene	expression	 is	 that	 of	 increased	 oxidative	 stress	within	 the	 adipose	 tissue	 due	 to	hypertrophy	of	 adipocytes	 and	 subsequent	hypoxia	 of	 the	 cells	within	 the	 tissue	(Furukawa	et	al.	2004,	Hosogai	et	al.	2007).	However,	as	the	present	study	has	also	demonstrated	the	importance	of	GPR55	in	conferring	protection	against	obesity	in	mice	 when	 challenged	 with	 a	 HFD,	 another	 avenue	 of	 possibility	 is	 that	 the	
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endogenous	 GPR55	 agonist	 LPI	 may	 influence	 adipokine	 expression,	 a	phenomenon	 which	 has	 been	 previously	 demonstrated	 in	 another	 study	 using	adipose	 tissue	 explants	 from	human	 subjects	 (Moreno-Navarrete	 et	 al.	 2012).	 In	order	 to	 explore	 these	 two	 possible	 mechanisms,	 in	 vitro	 models	 of	 adipocytes	become	 an	 attractive	 way	 of	 elucidating	 the	 molecular	 changes	 that	 were	observed.		Primary	adipocytes	can	be	 isolated	from	foetal,	 and	to	a	 lesser	extent,	adult	mice	(Hausman,	Park	and	Hausman	2008)	as	pre-adipocytes;	fibroblast-like	cells	which	when	stimulated	with	a	cocktail	of	hormones	and	chemicals	can	differentiate	 into	mature	 adipocytes	 (Ruiz-Ojeda	 et	 al.	 2016).	 Primary	 cells	 offer	 a	 number	 of	advantages	over	immortalised	cell	lines;	in	particular,	they	can	be	harvested	from	specific	depots	(visceral	vs	subcutaneous)	and	keep	the	genetic	characteristics	of	the	 host	 animal	 (such	 as	 gene	 knockouts	 or	 alterations	 due	 to	 interventions).	However,	 primary	 cells	 can	 be	 difficult	 to	 harvest	 and	 differentiate	 due	 to	 the	abundance	 of	 these	 cells	 within	 mature	 adipose	 tissue	 and	 fragility	 of	 the	 pre-adipocyte	cells	once	cultured	(Hausman,	Park	and	Hausman	2008).	Furthermore,	these	 primary	 isolated	 cells	 do	not	propagate	 under	 culture	 conditions	 and	only	survive	 for	 a	 limited	 time,	 therefore	 a	 constant	 supply	 of	 mice	 must	 be	 readily	available	 to	 harvest	 multiple	 cell	 batches	 for	 experiments.	 An	 alternative	 to	primary	adipocytes	 is	 that	of	model	 cell	 lines,	multiple	of	which	exist	 for	murine	white	 adipocytes,	 such	 as	 3T3-L1,	 3T3-F442A	 and	 OP9	 stromal	 cells;	 the	 most	abundantly	used	and	characterised	is	that	of	the	3T3-L1	cell	line	(Ruiz-Ojeda	et	al.	2016).	The	3T3-L1	 cells	 are	derived	 from	disaggregated	17-	 to	19-day-old	 Swiss	3T3	mouse	 embryos	 and	 similar	 to	primary	pre-adipocytes,	 display	 a	 fibroblast-like	phenotype	and	appearance,	and	can	be	differentiated	 into	mature	 lipid-filled	adipocytes	 with	 the	 use	 of	 an	 appropriate	 hormone	 cocktail	 (Green	 and	 Meuth	1974).	Although	the	advantages	of	using	primary	cells	are	lost	with	the	use	of	3T3-L1	 cells,	 the	 significant	 advantage	 of	 their	 use	 is	 their	 ability	 to	 survive	 a	 high	number	 of	 passages	 and	 to	 provide	 a	 homogenous	 culture	 of	 cells	 that	 should	respond	consistently	to	different	stimuli.	Additionally,	as	multiple	cultures	may	be	set	up	from	one	batch	of	cells,	this	eliminates	the	need	for	a	live	colony	of	mice	and	subsequently	the	cost	and	time	of	harvesting	primary	cells.	Finally,	as	the	3T3-L1	cells	are	the	most	well	characterised	of	the	cell	models,	use	similar	protocols	to	the	
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others	 (with	 no	 significant	 disadvantage	 to	 their	 use)	 and	 most	 work	 studying	obesity	 and	 adipogenesis	 has	 been	 done	 using	 these	 cells,	 they	 are	 the	 most	attractive	model	for	use	in	the	present	study.		
5.1.1. Aims and Objectives 
The	 aim	 of	 the	 following	 experiments	 was	 to	 first	 reliably	 isolate	 and	 culture	primary	adipocytes	 from	WT	and	GPR55-/-	mice	 to	use	as	a	 cell	 culture	model	of	adipose	tissue,	whereby	molecular	mechanisms	of	phenotypic	changes	observed	in	chapter	 3,	 particularly	 at	 the	 level	 of	 gene	 expression,	 could	 be	 elucidated.	Whereby	the	primary	aim	could	not	be	fulfilled,	3T3-L1	cells	were	employed	as	a	model	 cell-line	 instead.	 The	 secondary	 aim	 was	 therefore	 to	 characterise	differentiated	 3T3-L1	 cells	 and	 subsequently	 use	 these	 cells	 as	 a	 model	 of	adipoctyes.	 In	 order	 to	 investigate	 the	 mechanisms	 underlying	 the	 phenotypic	changes	observed	in	the	adipose	tissue	of	mice	from	chapter	3,	it	was	hypothesized	that	 1)	 LPI	 or	hypoxia	 applied	 to	 adipocytes	 influences	 gene	 expression	 changes	within	the	cell	and	2)	these	changes	are	the	result	of	increased	oxidative	stress	and	ROS	generation	within	the	cells.	The	results	of	these	experiments	will	be	compared	to	the	results	of	adipose	tissue	gene	expression	from	chapter	3	in	order	to	resolve	if	 these	 hypotheses	may	 explain	 the	 phenotypic	 changes	 observed	 in	 the	 in	 vivo	experiments.		
5.2. Methods 
5.2.1. Primary cell culture 
Cells	were	isolated	and	cultured	as	described	in	section	2.2.1	in	6-well	plates	in	2	ml	 of	 medium	 per	 well	 in	 preparation	 for	 differentiation.	 Following	 the	differentiation	 procedure,	 cells	 were	 imaged	 using	 a	 Leica	 DMI4000B	 inverted	microscope	attached	to	a	Leica	DFC300FX	camera	(Leica	Camera,	Germany)	before	and	after	staining	with	Oil	Red	O	to	assess	the	 level	of	successfully	differentiated	cells.	The	experiment	was	performed	on	4	separate	occasions	using	adipose	tissue	from	4	individual	mice.		
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5.2.2. 3T3-L1 cell culture 
3T3-L1	cells	were	grown	and	routinely	maintained	as	outlined	in	section	2.2.2	 in	75	cm2	tissue	culture	flasks.	For	gene	expression	and	protein	level	experiments,	8	x	104	 cells	 were	 seeded	 into	 each	 well	 of	 a	 6-well	 tissue	 culture	 plate	 in	 2	 ml	 of	complete	pre-adipocyte	medium.	For	flow	cytometry	experiments,	1.25	x	105	cells	were	 seeded	 into	25	 cm2	 tissue	 culture	 flasks	 in	5	ml	 of	 complete	pre-adipocyte	medium.	To	compare	 the	reliability	of	 each	differentiation	method,	 for	 the	 initial	differentiation	 experiment,	 cells	 were	 differentiated	 using	 the	 standard	 method	(without	1	µM	rosiglitazone)	and	the	modified	method	(with	1	µM	rosiglitazone).	For	 all	 subsequent	 experiments,	 cells	 were	 routinely	 differentiated	 using	 the	modified	differentiation	protocol	outlined	in	section	2.2.2.		
5.2.3. Differentiation and characterisation  
5.2.3.1.  Oil Red O staining 
In	 order	 to	 assess	 the	 successful	 differentiation	 of	 primary	 pre-adipocytes	 and	3T3-L1	cells	into	mature	adipocytes	over	a	14	day	period,	Oil	Red	O	dye	was	used	to	 visualise	 accumulated	 lipids.	 Before	 staining,	 images	 were	 taken	 of	 cells	throughout	 the	 differentiation	 protocol,	 using	 a	 Leica	 DMI4000B	 inverted	microscope	 attached	 to	 a	 Leica	 DFC300FX	 camera,	 to	 characterise	 the	morphological	 changes	occurring	during	differentiation.	To	 stain	 cells,	Oil	 Red	O	working	solution	was	prepared	as	outlined	in	section	2.2.3	and	differentiated	cells	or	controls	were	stained	using	the	following	protocol.	Firstly,	media	was	removed	from	cells	and	the	cell	layer	carefully	washed	with	PBS	followed	by	incubation	with	zinc	formalin	fixative	(Sigma	Aldrich,	UK)	for	30	minutes	at	room	temperature	to	fix	 the	cells.	Zinc	 formalin	 fixative	was	removed	and	 the	cells	washed	 twice	with	PBS	 to	 remove	 any	 residual	 fixative.	 Cells	 were	 subsequently	 incubated	 in	 60%	isopropanol	for	5	minutes	before	staining	with	the	Oil	Red	O	working	solution	for	1	hour	at	room	temperature.	To	remove	residual	staining	solution,	plates	containing	stained	cells	were	rinsed	with	running	tap	water	(in	the	centre	of	the	plate,	so	as	not	 to	 disrupt	 the	 cell	 layer)	 until	 the	 water	 ran	 clear.	 Primary	 cells	 were	 also	counterstained	with	 hematoxylin	 by	 incubation	with	Harris	Hematoxylin	 (Sigma	
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Aldrich,	UK)	for	1	minute	before	rinsing	in	tap	water	as	above.	Stained	cells	were	photographed	using	a	digital	 camera.	Oil	Red	O	dye	was	extracted	 from	the	 cells	using	1	ml	100%	isopropanol	and	100	µL	of	 the	resulting	solution	transferred	to	duplicate	wells	 of	 a	 96-well	 plate	 and	 absorbance	measured	 at	 520	 nm	 using	 a	Synergy	HT	microplate	reader.		
5.2.3.2. Gene expression of differentiating 3T3-L1 cells 
To	 further	 characterise	 the	 differentiation	 process	 of	 3T3-L1	 cells	 into	 mature	adipocytes,	 gene	 expression	 of	 selected	 adipokine,	 inflammatory	 and	 oxidative	stress	related	genes	were	profiled	over	a	14	day	period.	RNA	was	extracted	from	differentiating	 cells	 at	 day	0,	 7,	 10	 and	14	 as	 outlined	 in	 section	2.2.4.	 Extracted	RNA	 was	 then	 reverse	 transcribed	 and	 used	 in	 qPCR	 reactions	 as	 detailed	 in	section	 2.2.5	 with	 primers	 specific	 to	 leptin	 and	 adiponectin.	 To	 further	characterise	 the	 differentiating	 3T3-L1	 cells,	 other	 selected	 genes	 were	 also	profiled	 including	 the	 antioxidant	 genes	MnSOD	and	GPx4,	 the	pro-oxidant	 gene	NOX4	 and	 finally	 GPR55	 gene	 expression	 levels	 were	 also	 measured.	 RNA	 was	extracted	 from	 duplicate	 wells	 per	 day	 and	 the	 experiment	 completed	independently	3	times	using	a	different	passage	of	cells	each	time.	
5.2.4. 3T3-L1 response to LPI treatment 
5.2.4.1. Gene Expression 
To	 evaluate	 the	 gene	 expression	 response	 of	 differentiated	 3T3-L1	 cells	 to	treatment	with	LPI,	 cells	were	 grown	and	differentiated	 as	 in	 section	5.2.2	 in	6-well	 plates.	 On	 day	 10	 of	 differentiation,	 cells	 were	 treated	 for	 24	 hours	 with	complete	adipocyte	maintenance	medium	supplemented	with	either	1	µM	LPI	(LPI	sodium	salt	from	soybean	extract,	Sigma,	UK),	0.1%	DMSO	(as	a	vehicle	control)	or	1	 µg.ml-1	 LPS	 (Lipopolysaccharides	 from	Escherichia	 coli	 026:B6;	 Sigma	 Aldrich,	UK)	 to	 measure	 any	 response	 to	 an	 inflammatory	 stimulant.	 After	 24	 hours	treatment,	 RNA	was	 extracted	 from	 cells	 as	 per	 section	 2.2.4	 and	 used	 in	 qPCR	reactions	as	detailed	in	section	2.2.5.	RNA	was	extracted	from	duplicate	wells	per	experiment	 and	 the	 experiment	 repeated	 2-3	 independent	 times	 using	 cells	 of	 a	
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different	passage	number.		
5.2.4.2. ROS generation and accumulation  
To	 assess	 ROS	 generation	 and	 accumulation	 in	 differentiated	 3T3-L1	 cells	 upon	stimulation	 with	 LPI,	 a	 separate	 flow	 cytometry	 experiment	 was	 conducted	 as	follows.	Firstly,	cells	were	grown	and	differentiated	as	outlined	in	section	5.2.2	in	25	cm2	flasks.	On	day	10	of	differentiation,	media	was	removed	and	the	cells	rinsed	with	 PBS	 before	 incubation	 with	 1	 µM	 5-(and	 6-)chloromethyl-2',7'-dichlorodihydrofluorescein	 diacetate,	 acetyl	 ester	 (CM-H2DCFDA,	 Thermo	 Fisher,	UK)	 in	PBS	 for	45	minutes	 at	 37°C	 in	 a	 cell	 culture	 incubator.	 CM-H2DCFDA	 is	 a	non-specific	free	radical	sensor	which	freely	diffuses	into	cells	where	it	is	cleaved	by	intracellular	esterases,	trapping	it	within	the	cell	where	it	may	be	subsequently	oxidised	 by	 ROS.	 Once	 oxidised,	 CM-H2DCFDA	 produces	 a	 fluorescent	 product	which	may	be	measured	via	flow	cytometry.	After	cell	loading	of	the	dye,	cells	were	washed	with	PBS	 to	 remove	 residual	 solution	 and	 then	 trypsinised	using	0.25%	Tryspin-EDTA	for	10	minutes	at	37°C.	Cells	were	re-suspended	in	complete	DMEM	medium	 and	 centrifuged	 at	 125	 xg	 for	 5	 minutes	 before	 being	 washed	 in	 PBS,	followed	by	a	second	centrifugation.	Finally	cells	were	re-suspended	in	PBS	with	or	without	treatments	(1	µM	LPI,	1	µg.ml-1	LPS	or	500	µM	hydrogen	peroxide	[H2O2,	30%	 w/v,	 stabilised;	 Sigma	 Aldrich,	 UK])	 for	 30	 min	 at	 37°C.	 Cells	 were	subsequently	transferred	to	ice	and	were	ran	on	a	Beckman	Coulter	Epics	XL-MCL	flow	 cytometer	 (Beckman	 Coulter,	 UK)	 using	 the	 settings	 in	 Table	 5.1	 below;	fluorescent	data	was	captured	using	the	FL-1	FITC	channel,	acquisition	was	limited	to	300	seconds	with	a	max	events	limit	of	10,000.		
Parameter	 Volts	 Gain	
Forward	
Scatter	
40	 1	
Side	Scatter	 190	 5	
FL-1	(FITC)	 540	 1	
AUX	 500	 10	
Table 5.1. Flow Cytometry acquisition settings.  	
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5.2.5. 3T3-L1 response to hypoxia mimetic CoCl2 and H2O2  
5.2.5.1. Gene expression 
To	measure	 the	effect	of	hypoxia	on	differentiated	3T3-L1	 cells	gene	expression,	cells	were	grown	and	differentiated	in	6-well	plates	as	described	in	section	5.2.2.	To	 induce	 hypoxia,	 hypoxia	 mimetic	 compound	 cobalt	 chloride	 (CoCl2;	 Sigma	Aldrich,	UK)	was	used	 as	 a	 treatment;	 this	 compound	has	been	 shown	 to	mimic	hypoxia	via	 stabilisation	of	 the	HIF-1α	protein	 (Piret	et	al.	2002,	Wu	and	Yotnda	2011).	Another	treatment,	hydrogen	peroxide,	was	also	used	to	challenge	the	cells	and	measure	the	effect	of	non-specific	ROS	on	gene	expression.	In	conjunction	with	both	 treatments,	 cells	 were	 pre-treated	 with	 or	 without	 trolox	 ((±)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic	 acid;	 Sigma	 Aldrich,	 UK),	 a	 soluble	antioxidant	which	provides	a	measure	of	defence	against	the	accumulation	of	ROS,	in	 order	 to	 determine	 if	 the	 effects	 of	 hypoxia	 or	 ROS	 treatment	 could	 be	attenuated	by	pre-treatment	with	an	antioxidant.		On	day	9	of	differentiation,	cells	were	incubated	overnight	in	serum-free	adipocyte	maintenance	medium	to	synchronise	all	cells	to	the	same	phase	of	the	cell	cycle.	On	day	 10,	 cells	were	 subsequently	 incubated	 in	 serum-free	 adipocyte	maintenance	medium	supplemented	with	300	µM	CoCl2	or	500	µM	H2O2	 for	24	hours,	with	or	without	 a	 2	 hour	 pre-treatment	 with	 200	 µM	 trolox	 (cells	 without	 trolox	 were	treated	with	ethanol	as	vehicle	control).	After	24	hour	treatment,	cells	had	either	their	RNA	or	protein	extracted	as	detailed	in	sections	2.2.4	and	2.2.7,	respectively.	All	 treatments	 were	 conducted	 in	 duplicate	 wells	 per	 experiment	 and	 3	independent	 experiments	 were	 carried	 out	 using	 cells	 of	 a	 different	 passage	number.		Extracted	RNA	was	used	to	profile	selected	gene	expression	changes	in	response	to	the	hypoxic	stimulus	via	methods	described	in	sections	2.2.5	and	2.2.6.	Extracted	protein	was	used	to	measure	HIF-1α	protein	levels	using	ELISA	and	western	blot	as	described	below.		
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5.2.5.2. HIF-1α ELISA and western blot 
Protein	levels	of	HIF-1α	were	first	determined	using	a	Human/Mouse	Total	HIF-1α	DuoSet®	IC	ELISA	kit	(DYC1935-2;	R&D	Systems,	UK)	and	Ancillary	Reagent	Kit	2	(R&D	Systems,	UK).	To	better	visualise	HIF-1α	protein	and	to	confirm	the	results	of	the	ELISA,	a	single	western	blot	experiment	was	carried	out.		To	perform	the	ELISA,	reagents	were	prepared	as	instructed	in	the	data	sheet.	25X	wash	buffer	was	diluted	to	1X	in	distilled	water	and	reagent	diluent	was	prepared	by	 adding	 BSA	 to	 1X	 wash	 buffer	 at	 a	 final	 concentration	 of	 5%	 w/v.	 HIF-1α	capture	antibody	was	reconstituted	in	200	µL	PBS	to	a	final	concentration	of	720	µg.ml-1.	HIF-1α	detection	antibody	was	reconstituted	in	1	ml	of	reagent	diluent	to	a	final	 concentration	 of	 3.6	 µg.ml-1.	 Human/Mouse	 Total	 HIF-1α	 Standard	 was	reconstituted	in	500	µL	reagent	diluent	to	a	final	concentration	of	160	ng.ml-1	and	a	7	point	serial	dilution	in	reagent	diluent	(125	pg.ml-1	–	8000	pg.ml-1)	was	produced	to	construct	a	standard	curve.	Streptavidin-HRP	was	diluted	in	reagent	diluent	as	instructed	on	the	vial	(1:200)	directly	before	use.	Substrate	solution	was	prepared	directly	before	use	by	 combining	colour	 reagent	A	and	 colour	 reagent	B	 in	 a	1:1	ratio.	All	reagents	were	stored	at	4°C	for	a	period	no	longer	than	1	month	except	the	HIF-1α	standard	which	was	prepared	fresh	before	use	and	stored	at	-80°C.		To	perform	the	ELISA,	each	well	of	a	96-well	microplate	was	coated	with	100	µL	of	capture	antibody	at	a	concentration	of	4	µg.ml-1	in	PBS	and	incubated	overnight	at	room	 temperature.	 The	wells	 were	 then	washed	with	 350	 µL	 1X	wash	 buffer	 3	times,	 taking	 care	 to	 remove	 all	 liquid	 after	 each	 wash.	 The	 wells	 were	 then	blocked	with	300	µL	reagent	diluent	for	1	hour	at	room	temperature	on	a	Heidolph	Titramax	 100	 plate	 shaker	 (Heidolph	 Instruments,	 UK)	 set	 to	 400	 rpm	 before	being	 washed	 again	 with	 350	 µL	 1X	 wash	 buffer	 3	 times.	 1-100	 µL	 of	 protein	samples	or	standards	were	added	to	wells	in	duplicate	and	the	plate	incubated	for	2	 hours	 at	 room	 temperature	 on	 a	 plate	 shaker	 set	 to	 400	 rpm,	 followed	 by	 3	washes	 with	 350	 µL	 1X	 wash	 buffer.	 1-100	 µL	 of	 detection	 antibody	 at	 a	concentration	of	100	ng.ml-1	 in	 reagent	diluent	was	 then	added	 to	each	well	 and	the	plate	incubated	for	a	further	2	hours	at	room	temperature	on	a	plate	shaker	set	to	400	 rpm.	The	wells	were	 subsequently	washed	3	 times	with	350	µL	1X	wash	
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buffer	before	incubating	the	plate	for	20	minutes	at	room	temperature	in	the	dark	with	100	µL	diluted	streptavidin-HRP	in	each	well.	The	wells	were	washed	a	final	3	times	with	350	µL	1X	wash	buffer;	100	µL	substrate	solution	added	 to	each	well	and	the	plate	 incubated	for	20	minutes	at	room	temperature	 in	the	dark.	Finally,	50	µL	stop	solution	was	added	to	each	well	and	the	absorbance	read	at	450	nm	and	540	nm	using	a	Synergy	HT	microplate	reader.		Duplicate	wells	were	averaged	and	the	absorbance	reading	at	540	nm	subtracted	from	 the	450	nm	absorbance	 reading	 to	 account	 for	 optical	 imperfections	of	 the	plate,	 followed	 by	 subtraction	 of	 the	 negative	 control	 blank	 absorbance	 value.	 A	standard	curve	was	produced	from	the	known	concentrations	of	HIF-1α	standard	and	 a	 four-parameter	 logistic	 curve-fit	 model	 applied	 to	 the	 points.	 From	 this	curve,	 unknown	 values	 were	 calculated	 from	 the	 absorbance	 readings.	 Protein	concentration	was	 corrected	 for	 total	 protein	 in	 each	 sample,	 as	 determined	 via	Bradford	assay	as	outlined	in	2.2.8,	and	data	expressed	as	pg.ml-1	of	total	protein.		The	SDS-PAGE	and	western	blot	of	protein	samples	was	performed	as	outlined	in	section	 2.2.9	 using	 the	 reagent	 diluent	 as	 blocking	 buffer	 and	 the	 detection	antibody	 from	 the	 ELISA	 kit	 as	 the	 primary	 antibody	 at	 a	 concentration	 of	 200	ng.ml-1	 in	 reagent	 diluent.	 Diluted	 streptavidin-HRP	 was	 used	 at	 the	 same	concentration	as	the	ELISA	and	used	as	the	secondary	HRP-conjugate.	Bands	were	visualised	using	chemiluminescence	as	outlined	in	section	2.2.9.		
5.2.6. Data analysis 
Oil	 Red	 O	 staining	 was	 quantified	 using	 absorbance	 readings	 normalised	 to	 a	control	well	of	undifferentiated	cells	for	each	time-point.	Gene	expression	data	was	analysed	as	detailed	 in	section	2.2.6	and	normalised	to	a	control	sample	 for	each	experiment.	One-way	ANOVA	with	Bonferroni	post-hoc	analysis	was	performed	on	analysed	data	with	3	or	more	groups.	Two-way	ANOVA	with	Bonferroni	post-hoc	analysis	was	used	to	analyse	gene	expression	data	 from	the	hypoxia	study	which	contained	treatment	with	and	without	Trolox.	In	all	instances,	p	values	<0.05	were	considered	statistically	significant.			 	
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5.3. Results 
5.3.1. Primary cell isolation and differentiation 
The	 SVF	 of	 cells	 was	 successfully	 isolated	 and	 adhered	 to	 culture	 plates	 as	 per	protocol;	when	seeded	at	1.5	x	105	cells	per	well,	the	culture	reached	confluence	in	approximately	48	hours	as	demonstrated	by	the	representative	image	of	day	0	in	
Figure	 5.1.	 Upon	 differentiation,	 cells	 began	 to	 adopt	 a	 rounded	morphology	 as	expected	 2	 days	 post-differentiation,	 however	 after	 changing	 to	 insulin	supplemented	media,	cells	begin	to	lose	integrity	by	day	6,	detach	from	the	culture	dish	and	appear	to	cluster	together	(Figure	5.1).	This	clustering	and	loss	of	a	stable	monolayer	leads	to	cell	death;	the	amount	of	clustering	and	detachment	increases	with	time,	as	observed	up	to	21	days	post-differentiation	and	shown	in	Figure	5.1.	Staining	of	differentiated	cultures	with	Oil	Red	O	as	shown	by	the	representative	image	 in	 Figure	 5.2	 highlights	 that	 these	 clustered	 cells	 stain	 positive	 for	 lipid	deposition,	 however	 the	 cultures	 were	 unstable	 and	 results	 could	 not	 be	reproduced	 reliably	 between	 experiments	 due	 to	 the	 detachment	 of	 the	 cells	clusters.		
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Figure 5.1. Light microscope images at x5 magnification of primary SVF cells at Day 0, Day 2, Day 6 and Day 21 of differentiation. Yellow arrows indicate 
examples of cellular clustering. 
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Figure 5.2. Light microscopy image at x50 magnification of 21 day-differentiated primary 
SVF cells stained with Oil Red O and counterstained with hematoxylin. Inlayed image 
highlights zoomed region with positive Oil Red O staining.  	 	
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5.3.2. Differentiation of 3T3-L1 cells 
When	cultured,	as	described	in	section	2.2.2,	3T3-L1	cells	became	confluent	within	2	days	and	therefore	ready	to	differentiate	4	days	after	the	initial	plating	of	cells.	As	 shown	 by	 representative	 images	 in	 Figure	 5.3,	 cells	 show	 morphological	changes	 at	 day	 3	 as	 they	 begin	 to	 adopt	 a	 more	 rounded	 shape	 and	 begin	 to	synthesise	 and	 accumulate	 lipid	 droplets.	 From	 day	 7	 of	 the	 differentiation	protocol,	 the	vast	majority	of	 cells	are	 observed	 to	contain	multiple	 lipid	droplet	formations	and	can	be	presumed	differentiated.	As	shown	in	Figure	5.3,	this	lipid	droplet	formation	increases	with	time,	with	Day	10	showing	many	clustered	lipid	droplets	per	cell;	finally,	by	day	14	these	lipid	droplets	not	only	further	increased	in	 number	 but	 many	 have	 also	 fused	 together	 producing	 much	 larger	 lipid	depositions	 per	 cell	 (Figure	 5.4).	 This	 same	 pattern	 of	 differentiation	 was	observed	when	 using	 the	 standard	 differentiation	 procedure,	without	 the	 use	 of	rosiglitazone,	 however	 it	was	observed	 to	be	much	 less	 reliable	 in	 achieving	 full	differentiation	of	the	culture	dish	as	shown	by	the	representative	image	in	Figure	
5.5;	where	some	areas	of	the	cell	culture	remain	undifferentiated	without	the	use	of	 rosiglitazone	 (as	 shown	by	highlighted	 areas	 in	 image	A)	compared	with	 cells	differentiated	with	rosiglitazone	(as	shown	in	image	B).			
5.3.2.1. Oil Red O staining of differentiated cells 
Oil	Red	O	staining	of	culture	plates	as	shown	in	Figure	5.6	illustrates	the	increased	lipid	 accumulation	 over	 time	 during	 the	 differentiation	 protocol	 up	 to	 day	 14.	Control	 cells	which	were	 un-differentiated	 and	 grown	 in	 adipocyte	maintenance	medium	 are	 almost	 completely	 devoid	 of	 Oil	 Red	 O	 stain,	 demonstrating	 no	accumulation	of	lipids	within	cells.	Consistent	with	the	light	microscope	images	in	
Figure	5.3,	no	Oil	Red	O	staining	is	observed	at	day	3	of	differentiation,	however	positive	staining	for	lipid	accumulation	appears	from	day	7	of	differentiation	and	the	 intensity	 of	 staining	 increases	 at	 day	 10	 and	 day	 14.	 Absorbance	 of	 the	extracted	Oil	Red	O	dye,	as	 shown	by	 the	graph	 in	Figure	5.7,	demonstrates	 the	amount	of	Oil	Red	O	staining	 increased	with	time	up	to	day	14	of	differentiation,	consistent	 with	 the	 staining	 of	 culture	 plates	 in	 Figure	 5.6.	
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Figure 5.3. Representative light microscope images at x100 magnification of 3T3-L1 cells at different time points of differentiation when using the 
modified differentiation protocol containing rosiglitazone. 
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Figure 5.4. Representative light microscope images at x200 magnification of 3T3-L1 cells at 
(a) day 10 and (b) day 14 of differentiation when using the modified differentiation protocol 
containing rosiglitazone.  
100 μm 
A 
B 
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Figure 5.5. Representative light microscope images at x100 magnification of 3T3-L1 cells 
differentiated for 7 days (A) without, and (B) with rosiglitazone in the differentiation medium. 
Red dashed lines indicate areas of largely undifferentiated cells.  	 	
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Figure 5.6. Representative images of Oil Red O staining of differentiated 3T3-L1 cells at 
different time points throughout the differentiation protocol. Control cells were un-
differentiated and grown in adipocyte maintenance medium, differentiation of cells was 
performed with and without rosiglitazone in the differentiation media. 
 
Figure 5.7. Absorbance of extracted Oil Red O dye solution at 520 nm normalised to 
undifferentiated control of each time point. Bars represent mean values and error bars = SD, 
n=2 for all groups.  
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Although	differentiation	without	 rosiglitazone	produced	varying	 levels	of	 culture	differentiation	 as	 described	 in	 section	 5.3.2,	 the	 difference	 in	 lipid	 accumulation	(as	 indicated	by	 the	 intensity	of	Oil	Red	O	stain)	between	cultures	differentiated	with	and	without	rosiglitazone	was	not	significantly	different	in	this	study	(Figure	5.7).	
5.3.2.2. Gene expression in 3T3-L1 cells throughout 
differentiation 
In	order	to	further	characterise	and	confirm	the	differentiation	of	3T3-L1	cells	into	mature	adipocytes,	a	number	of	selected	genes	were	profiled	for	their	expression	levels	 throughout	 the	 differentiation	 procedure.	Figure	 5.8	 shows	 expression	 of	these	 selected	 genes	 in	 differentiating	 3T3-L1	 cells	 over	 a	 period	 of	 14	 days	 as	detailed	in	section	5.2.3.2.		The	gene	expression	level	of	adipokines	leptin	and	adiponectin	is	shown	in	Figure	5.8a	 and	 Figure	 5.8b,	 respectively.	 Both	 leptin	 and	 adiponectin	 gene	 expression	was	undetectable	at	day	0	and	therefore	data	were	normalised	to	day	7	expression.	Leptin	 gene	 expression	 significantly	 increased	on	day	10	 and	day	14	by	9.3	 fold	and	 8.5	 fold,	 respectively	 (p<0.01).	 Similarly,	 adiponectin	 gene	 expression	 was	significantly	increased	on	day	10	and	day	14	by	5.9	fold	and	5.5	fold,	respectively	(p<0.05).	 For	 both	 leptin	 and	 adiponectin,	 the	 difference	 in	 expression	 between	day	10	and	day	14	was	not	significant	(p>0.05).		The	 gene	 expression	 level	 of	 antioxidant	 enzymes	MnSOD	and	GPx4	 is	 shown	 in	Figure	 5.8c	 and	 d,	 respectively.	 Both	 MnSOD	 and	 GPx4	 gene	 expression	 was	detected	at	baseline	day	0	and	therefore	data	were	normalised	to	the	day	0	levels	for	each	time	point.	The	gene	expression	of	MnSOD	increased	on	day	7,	day	10	and	day	14	by	8.8,	12.0	and	11.3	fold,	respectively;	the	increase	observed	on	day	7	was	not	 considered	 significant	 however	 the	 increases	 at	 day	 10	 and	 day	 14	 were	statistically	 significant	 (p<0.05).	 Similarly,	 gene	 expression	 level	 of	 GPx4	 was	significantly	 increased	on	days	7,	10	and	14	by	6.7,	6.6	and	8.4	 fold,	respectively	(p<0.01).		
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Figure 5.8. Gene expression levels of 3T3-L1 cells during differentiation. Relative mRNA level 
of (a) leptin, (b) adiponectin, (c) MnSOD, (d) GPx4, (e) NOX4 and (f) GPR55. Dots represent 
individual experiments, horizontal lines represent the mean and error bars represent SEM. * 
p<0.05, # p<0.01 compared to Day 0 or Day 7 control as determined by one-way ANOVA and 
Bonferroni post-hoc analysis. n=3-4 for all experiments.  
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Conversely	 to	 the	antioxidant	enzymes,	expression	 level	of	 pro-oxidant	NOX4,	as	shown	in	Figure	5.8e,	was	significantly	decreased	on	days	7,	10	and	14	to	0.3,	0.5	and	0.3	fold,	respectively	(p<0.01).		Finally,	gene	expression	level	of	GPR55	is	shown	in	Figure	5.8f;	GPR55	expression	was	shown	 to	be	unchanged	 throughout	 the	differentiation	procedure	at	all	 time	points	 (p>0.05).	 As	 compared	 to	 the	 other	 genes	 measured,	 the	 variability	 of	GPR55	 gene	 expression	 was	 much	 greater	 between	 independent	 samples;	 this	observed	variation	 is	 likely	due	to	the	very	 low	expression	of	GPR55	(Ct	value	of	32-34)	which	leads	to	greater	changes	in	fold	expression	despite	small	changes	in	absolute	expression.	
5.3.3. Treatment of 3T3-L1 cells with LPI 
5.3.3.1. Gene expression  
The	gene	expression	 level	of	selected	genes	 in	10	day	differentiated	3T3-L1	cells	treated	with	0.1%	DMSO,	1	µM	LPI	 or	1	mg.ml-1	 LPS	 for	24	hours	 as	detailed	 in	section	5.2.4,	is	shown	in	Figure	5.9.	As	shown	by	graphs	in	Figure	5.9a	and	b,	the	level	 of	 gene	 expression	 of	 the	 antioxidant	 enzymes	 GPx4	 and	 MnSOD	was	 not	altered	by	treatment	with	either	LPI	or	LPS.	Similarly,	the	gene	expression	level	of	pro-oxidant	 NOX4	 was	 not	 altered	 by	 treatment	 with	 LPI	 or	 LPS,	 as	 shown	 in	
Figure	 5.9c.	 Finally,	 GPR55	 expression	 level	was	 also	 not	 altered	 by	 LPI	 or	 LPS	treatment;	 as	with	previous	 experiments,	GPR55	expression	 level	was	extremely	low,	 leading	to	undetectable	 levels	 in	two	experiments	when	treating	with	DMSO	and	LPI.			 	
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Figure 5.9. Gene expression levels in 3T3-L1 cells when treated with 0.1% DMSO, 1 µM LPI or 
1 mg.ml-1 LPS for 24 hours. Relative mRNA level of (a) GPx4, (b) MnSOD, (c) NOX4 and (d) 
GPR55. Dots represent individual experiments, horizontal lines represent the mean and error 
bars represent SEM. n = 2-3 for all experiments other than GPR55, where levels were not 
detected in 2 experiments when using DMSO and LPI treatments. 
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5.3.3.2. ROS generation  
The	 level	of	ROS	accumulation	 in	10	day	differentiated	3T3-L1	cells	 treated	with	500	µM	H2O2,	1	µM	LPI	or	1	mg.ml-1	LPS	for	30	mins,	as	detailed	in	section	5.2.4,	is	shown	by	 the	histograms	 in	Figure	5.10.	 Treatment	 of	 cells	with	H2O2	 (used	 as	positive	 control)	 increased	 positive	 staining	 events	 (i.e.	 ROS	 production)	 from	36.59%	to	79.07%	of	total	measured	cells	as	shown	in	Figure	5.10b.	Unlike	H2O2,	1	 µM	 LPI	 or	 1	 mg.ml-1	 LPS	 were	 unable	 to	 elicit	 an	 increase	 in	 positive	 events	measured	(Figure	5.10c&d;	34.1%	and	24.74%	vs	36.59%	control,	respectively),	therefore	 suggesting	no	 increase	 in	ROS	generation	 compared	 to	 control	 treated	cells.	Due	to	time	restrictions	and	the	finding	that	LPI	and	LPS	had	no	effect	on	ROS	accumulation,	 this	experiment	was	only	performed	once	 and	 therefore	statistical	analysis	was	not	performed.		
5.3.4. Treatment with CoCl2 and H2O2  
5.3.4.1. HIF-1α protein expression 
The	 level	of	HIF-1α	protein	expression	 in	10-day	differentiated	3T3-L1	cells	 that	were	 treated	 with	 CoCl2	 or	 H202	 for	 24	 hours	 (with	 and	without	 pre-treatment	with	the	antioxidant	trolox)	was	assessed	by	quantitative	ELISA	and	by	qualitative	western	blot	analysis:	results	are	presented	 in	Figure	5.11	a	and	b,	respectively.	As	 shown	 by	 both	 the	 ELISA	 and	 western	 blot,	 the	 level	 of	 HIF-1α	 protein	 is	consistently	high	in	all	treatment	groups,	including	the	control	(»150	pg.mg-1	total	protein),	 and	 treatment	with	 CoCl2	 did	 not	 significantly	 increase	 this	 level	 (158	pg.mg-1	 vs	 168	 pg.mg-1,	 p>0.05).	 The	 level	 of	 HIF-1α	 is	 slightly	 increased	 in	 the	H2O2	 treatment	 group,	 however	 this	was	 also	not	 significant	 (234	pg.ml-1	 vs	 158	pg.ml-1,	p>0.05).		
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Figure 5.10. Histogram plots of FL-1 channel intensity and number of events when 
measuring cells loaded with CM-H2DCFDA and untreated (a) control, or treated with (b) 500 
µM H2O2, (c) 1 µM LPI and (d) 1 mg.ml-1 LPS. Number of positive events (%) were defined 
using the centre of the control peak which is shown as a black peak on each histogram.  
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Figure 5.11. (a) HIF-1α protein expression in 3T3-L1 cells 10 days’ post-differentiation after 
24-hours treatment with 300 µM CoCl2 or 500 µM H2O2, with and without 2-hour pre-
treatment with 300 µM trolox, as determined via ELISA. Bars represent mean values and error 
bars represent SEM. n = 3 for all treatments. (b) Western blot of protein extracts from one 
ELISA experiment, alongside untreated and CoCl2 treated cell lysates from different cell lines 
for HIF-1α expression (1: control MDA-MB-231 cells; 2: MDA-MB-231 cells treated with CoCl2 
for 4 hours; 3: control SH-SY5Y cells; 4: SH-SY5Y cells treated with CoCl2 for 4 hours) blotted 
with detection (anti-HIF-1α) antibody from ELISA kit.  	 	
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The	 results	 from	 western	 blot	 analysis	 confirm	 these	 data,	 as	 the	 three	 lanes	representing	the	different	treatments	all	show	similar	high	level	of	HIF-1α	protein.	In	addition,	cell	 lysates	 from	different	cell	 lines	(MDA-MB-231,	breast	 cancer	cell	line	(lane	1)	and	SH-SY5Y,	neuroblastoma	cell	line	(lane	3)	of	western	blot	picture	in	Figure	5.11b	were	used	as	control	for	basal	expression	of	HIF-1α.	Induction	of	HIF-1α	 by	 CoCl2	 in	 cell	 lysates	 from	 these	 two	 cell	 lines	 (lanes	 2	 and	 4	 of	 the	western	 blot	 in	 Figure	 5.11b)	 is	 evidenced	 by	 strong	 bands	 compared	 to	untreated	cells	(lanes	1	and	3	in	Figure	5.11b).	
5.3.4.2. Gene expression 
The	gene	expression	 level	of	selected	genes	 in	10	day	differentiated	3T3-L1	cells	treated	with	CoCl2	or	H2O2	for	24	hours,	with	and	without	2	hours	pre-treatment	with	trolox,	is	shown	by	the	bar	graphs	in	Figure	5.12.	The	gene	expression	level	of	leptin	is	shown	in	Figure	5.12a.	CoCl2	treatment	significantly	decreased	expression	of	 leptin	 to	0.042	 fold	 (p<0.01);	whereas	pre-treatment	with	 trolox	did	not	alter	this	decrease	in	expression	(0.038	vs	0.042	fold,	p>0.05).	H2O2	treatment	alone	did	not	significantly	change	gene	expression,	however	with	pre-treatment	with	trolox	the	level	of	leptin	was	significantly	decreased	to	0.45	fold	(p<0.01).		Adiponectin	 gene	 expression	 level	 is	 shown	 in	 Figure	 5.12b.	 CoCl2	 treatment	significantly	 decreased	 the	 expression	 of	 adiponectin	 to	 0.27	 fold	 (p<0.01);	 pre-treatment	 with	 trolox	 slightly	 attenuated	 the	 reduction	 observed	 with	 CoCl2	treatment	but	was	not	statistically	significant	(0.37	vs	0.27	fold,	p>0.05).	Similar	to	adiponectin	 expression,	 H2O2	 treatment	 did	 not	 induce	 any	 significant	 changes	alone,	 however	when	 cells	were	pre-treated	with	 trolox	 the	 level	 of	 adiponectin	gene	expression	was	significantly	decreased	to	0.59	fold	(p<0.01).		The	 gene	 expression	 level	 of	 GPx4	 and	 NOX4	 is	 shown	 in	 Figure	 5.12c	 and	 d,	respectively.	For	both	genes,	neither	CoCl2	nor	H2O2	treatment	significantly	altered	the	 levels	of	gene	expression	 (p>0.05)	and	 this	was	unchanged	by	pre-treatment	with	trolox	(p>0.05).			 	
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Figure 5.12. Gene expression levels in 3T3-L1 cells 10 days post-differentiation after 24 hours 
treatment with 300 µM CoCl2 or 500 µM H2O2, with and without 2 hour pre-treatment with 
300 µM trolox. Relative mRNA level of (a) leptin, (b) adiponectin, (c) GPx4, (d) NOX4 and (e) 
GPR55. Bars represent mean values and error bars represent SEM. # p<0.01 vs appropriate 
control as determined via two-way ANOVA and Bonferroni post-hoc analysis. n = 3 for all 
experiments.  	 	
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Finally,	 the	 gene	 expression	 level	 of	GPR55	 is	 shown	 in	Figure	5.12e.	Treatment	with	CoCl2	alone	increased	expression	of	GPR55	by	1.98	fold,	however	this	was	not	statistically	 significant	 (p>0.05).	 Similarly,	 treatment	 with	 H2O2	 increased	 the	expression	 of	 GPR55	 by	 1.82	 fold	 but	 was	 also	 not	 significant	 (p>0.05).	 Pre-treatment	 with	 trolox	 had	 no	 significant	 effect	 with	 either	 treatment	 despite	attenuating	 the	 increase	 of	 1.98	 fold	 to	 0.6	 fold	 in	 the	 CoCl2	 treatment	 group	(p>0.05).	 The	 lack	 of	 significant	 changes	 may	 be	 due	 to	 the	 large	 variances	between	individual	experiments,	possibly	due	to	the	 low	level	of	absolute	GPR55	expression.	
5.4. Discussion  
As	the	results	presented	in	chapter	3	and	4	demonstrated	an	altered	phenotype	of	WT	and	GPR55-/-	mice	 fed	a	HFD,	 including	significant	changes	 in	adipose	 tissue	gene	expression	profiles	and	histology	(in	GPR55-/-	HFD	fed	mice),	the	first	series	of	 experiments	 presented	 in	 this	 chapter	 aimed	 to	 isolate	 and	 culture	 primary	adipocytes	 for	use	 as	 a	model	 of	 adipose	 tissue,	whereby	 characterisation	of	 the	phenotypic	changes	observed	in	vivo	could	be	carried	out.		Primary	 SVF	 cells	 isolated	 by	 the	 method	 of	 Hausman	 (Hausman,	 Park	 and	Hausman	 2008),	 successfully	 adhered	 to	 culture	 flasks	 and	 grew	 as	 expected	 as	shown	 in	 Figure	 5.1;	 however,	 difficulties	 arose	 when	 attempts	 were	 made	 to	differentiate	the	isolated	cells	into	mature	adipocytes,	namely:	cell	death	and	loss	of	culture	stability	(see	Figure	5.2).	The	inability	to	reliably	differentiate	SVF	cells	to	mature	 adipocytes	 is	most	 likely	 due	 to	 the	 nature	 of	 the	 isolated	 cells,	 pre-adipocytes	cells	versus	fibroblasts.	Pre-adipocytes	constitute	a	small	amount	of	the	total	SVF	cells	and	are	morphologically	identical	to	fibroblast	cells;	hence,	it	is	not	possible	to	reliably	assess	the	number	of	pre-adipocytes	present	in	culture	that	are	able	 to	 successfully	 differentiate	 into	 mature	 adipocytes	 (Geloen,	 Roy	 and	Bukowiecki	1989,	Ntambi	and	Young-Cheul	2000).	Due	to	the	advanced	age	of	the	mice	 used	 in	 these	 experiments,	 it	 is	 likely	 that	 the	 number	 of	 pre-adipocytes	present	in	the	adipose	tissue	is	greatly	reduced	compared	to	mice	at	birth,	which	are	 recommended	 in	 the	 protocol	 (Hausman,	 Park	 and	 Hausman	 2008).	Consequently,	 the	 number	 of	 isolated	 pre-adipocyte	 cells	 is	 very	 small	 and	 the	
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chance	 of	 survival	 and	 differentiation	 is	 very	 limited.	 After	 unsuccessful	consecutive	attempts	to	optimise	the	isolation	and	differentiation	protocol,	it	was	decided	that	a	cell	line	model	of	adipocytes	could	be	used	as	an	alternative	system	in	subsequent	experiments	as	discussed	in	the	introduction	(section	5.1).		
5.4.1. Characterisation of differentiating 3T3-L1 cells 
Although	 3T3-L1	 cells	 have	 been	 extensively	 used	 in	 the	 study	 of	 adipocytes,	recent	commercially	available	stocks	have	been	reported	to	have	lost	their	ability	to	successfully	differentiate	(ATCC	2014,	Zebisch	et	al.	2012).	It	was	therefore	very	important	 to	 characterise	 the	 newly	 acquired	 cells	 and	 test	 their	 ability	 to	differentiate	before	being	employed	in	further	experiments.		The	morphological	changes	observed	in	3T3-L1	cells	upon	differentiation	using	the	modified	method	 and	 the	 addition	of	 rosiglitazone,	 as	described	 in	 section	2.2.2,	are	 consistent	 with	 mature	 adipocyte	 morphology.	 Similarly,	 Oil	 red	 O	 staining	confirmed	accumulation	of	lipids	within	the	cultured	cells	following	differentiation	and	 is	 consistent	with	 findings	of	Zebisch	et	al.	 (2012)	when	using	 this	modified	method	(Zebisch	et	al.	2012).		Leptin	 and	 adiponectin	 are	 two	 of	 the	 most	 well	 characterised	 adipokines	produced	 by	 mature	 adipocytes;	 their	 gene	 expression	 levels	 were	 therefore	measured	 to	 further	 confirm	 the	 differentiation	 of	 3T3-L1	 cells	 into	 mature	adipocytes.	Consistent	with	the	literature	surrounding	successful	differentiation	of	3T3-L1	 cells,	 the	 expression	 of	 these	 genes	 was	 undetectable	 before	 cell	differentiation	 and	 increased	 over	 time,	 reaching	 a	 plateau	 on	 the	 10th	 day	 of	differentiation	(Mehra,	Macdonald	and	Pillay	2007,	Zebisch	et	al.	2012,	Sheng	et	al.	2014).		Although	 it	 has	 been	 reported	 that	 ROS	 is	 an	 important	 component	 of	 the	differentiation	pathway	of	pre-adipocytes	to	adipocytes	(Lee	et	al.	2009)	and	that	the	levels	of	ROS	produced	by	differentiated	3T3-L1	correlates	with	the	extent	of	differentiation	 (Furukawa	et	 al.	2004),	very	 few	studies	have	examined	 the	gene	expression	 of	 antioxidant	 enzymes	 and	 therefore	 antioxidant	 status	 in	differentiated	3T3-L1	cells.	The	results	of	 this	 study	demonstrate	 that,	 similar	 to	
		 173	
adiponectin	 and	 leptin	 gene	 expression,	 the	 gene	 expression	 level	 of	 the	antioxidant	 enzymes	 MnSOD	 and	 GPx4	 increases	 over	 time	 following	differentiation	of	3T3-L1	cells,	again	plateauing	after	day	10	of	differentiation.	The	increase	 in	MnSOD	gene	 expression	observed	 in	 this	 study	 is	 in	 agreement	with	upregulation	of	MnSOD,	Cu/ZnSOD	and	catalase	enzymes	in	3T3-L1	cells,	reported	in	another	study	(Kojima	et	al.	2010),	which	leads	to	resistance	to	oxidative	stress.	The	 observed	 up-regulation	 of	MnSOD	 gene	 expression	 is	 unsurprising	 as	 it	 has	been	 extensively	documented	 that	 this	 enzyme	may	be	up-regulated	 at	 the	 gene	expression	and	protein	activity	level	by	many	processes	and	is	reviewed	by	Candas	and	Li	(Candas	and	Li	2013).	Crucially,	MnSOD	gene	expression	has	been	shown	to	be	 upregulated	 by	 induction	 of	 p53	 via	 a	 ROS-ERK-dependent	 pathway	 in	 NB4	cells,	a	human	cancer	cell	line	with	characteristics	of	promyelocytic	leukemia	cells	(Li	et	al.	2010),	a	possible	mechanism	by	which	it	could	be	upregulated	in	3T3-L1	cells	 due	 to	 the	 increase	 in	 ROS	 generation	 throughout	 the	 differentiation	 into	mature	 adipocytes.	 The	 increase	 in	 GPx4	 gene	 expression	 throughout	differentiation,	although	not	altogether	surprising,	 is	nevertheless	a	novel	finding	within	 this	 cell	 type.	 Although	 GPx	 enzymes	 are	 largely	 regulated	 via	 selenium	status	(Flohe,	Wingender	and	Brigelius-Flohe	1997),	it	has	been	demonstrated	that	GPx4	 expression	may	 be	 regulated	 by	 fatty	 acids,	 cytokines	 and	 antioxidants	 in	endothelial	 cells	 (Sneddon	 et	 al.	 2003);	 suggesting	 many	 possible,	 currently	uncharacterised,	routes	by	which	this	enzyme	may	be	upregulated.	It	is	logical	to	postulate	 that	 the	 observed	 increase	 in	 antioxidant	 gene	 expression	 during	differentiation	enables	 the	cells	 to	adapt	 to	the	 large	amounts	of	oxidative	stress	produced	throughout	the	differentiation	of	pre-adipocytes	into	mature	adipocytes,	thus	preventing	cellular	death	due	to	oxidative	damage.		The	pro-oxidant	NOX4	enzyme	is	important	in	the	generation	of	cellular	ROS	and	upregulation	 of	 this	 enzyme	 and	 subsequent	 increases	 in	 ROS	 generation	 have	been	implicated	in	cardiovascular	disease,	metabolic	control	and	obesity	(Kuroda	et	al.	2010,	Li	et	al.	2012).	It	is	therefore	reasonable	to	expect	an	increase	in	NOX4	gene	expression	(as	observed	in	the	adipose	tissue	of	mice	fed	a	HFD	in	chapter	3),	as	an	increase	in	ROS	generation	is	crucial	to	the	differentiation	process.	However,	the	gene	expression	level	of	NOX4	observed	in	this	study	is	significantly	decreased	throughout	 the	 differentiation	 period.	 Even	 if	 counterintuitive,	 this	 finding	 is	
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consistent	 with	 another	 study	 in	 which	 decreased	 NOX4	 gene	 expression	 is	described	 as	 a	 ‘hallmark	 of	 adipocyte	 differentiation’	 and	 is	 strongly	 correlated	with	 decreased	 NOX4	 protein	 expression	 in	 both	 3T3-L1	 cells	 and	 primary	adipocytes	(Mouche	et	al.	2007).	This	is	in	direct	contrast	to	a	study	by	Schröder	et	al.	 (2009)	 which	 describes	 NOX4	 as	 a	 ‘switch	 between	 differentiation	 and	proliferation’	 and	 demonstrates	 increases	 in	 NOX4	 expression	 in	 response	 to	insulin	 treatment	 and	 differentiation	 in	 3T3-L1	 cells	 (Schröder	 et	 al.	 2009).	Therefore,	 it	 is	 undetermined	 if	 the	ROS	which	 is	 produced	 throughout	 the	 later	stages	 of	 differentiation	 and	 in	 differentiated	 3T3-L1	 cells	 is	 due	 to	 increases	 in	NOX4	 gene	 expression	 or	 due	 to	 a	 different	 currently	 unknown	 pathway,	nevertheless	 the	 results	 of	 this	 study	 would	 support	 the	 latter	 hypothesis	(Furukawa	et	al.	2004,	Lee	et	al.	2009).	This	combined	evidence	of	an	 increase	 in	Oil	red	O	staining	and	gene	expression	changes,	 specifically	 increases	 in	 leptin	 and	 adiponectin,	 confirms	 the	 successful	differentiation	of	3T3-L1	cells	over	a	period	of	14	days.	However,	despite	further	increase	in	Oil	Red	O	staining	at	day	14,	microscope	images	and	the	plateauing	of	gene	 expression	demonstrate	 that	 3T3-L1	 cells	 had	 accumulated	 sufficient	 lipids	and	 were	 fully	 differentiated	 into	 mature	 adipocytes	 by	 day	 10	 of	 the	differentiation	protocol.	All	subsequent	experiments	were	therefore	conducted	on	10	day	differentiated	 cells.	 Similarly,	although	 the	extent	of	Oil	Red	O	staining	 is	unchanged	 between	 the	 standard	 and	 modified	 differentiation	 methods,	 the	modified	method	was	more	 reliable	 in	 achieving	 a	more	 homogenous	 culture	 of	differentiated	cells,	whereby	there	were	no	visible	areas	of	undifferentiated	cells;	therefore,	the	modified	method	was	chosen	for	use	in	all	subsequent	experiments.	
5.4.2. LPI treatment on gene expression and ROS levels in 3T3-
L1 cells 
Although	Moreno-Navarette	et	al.	 (2012)	have	previously	demonstrated	an	effect	of	exogenous	LPI	on	human	visceral	WAT	explant	gene	expression,	the	effect	of	LPI	on	3T3-L1	cells	is	currently	unexplored,	as	is	the	mechanism	by	which	LPI	exerts	its	effect	on	gene	expression	within	adipose	tissue	(Moreno-Navarrete	et	al.	2012).	This	study	has	previously	demonstrated	in	chapter	3	that	a	HFD	causes	changes	in	
		 175	
gene	 expression	within	 visceral	WAT	 and	 increases	 in	 circulating	 plasma	 LPI	 in	both	WT	and	GPR55-/-	mice.	It	was	therefore	important	to	test,	using	a	cell	system,	the	hypothesis	that:	changes	observed	in	the	WAT	of	mice	fed	a	HFD	could	be	due	to	 the	 effect	 of	 LPI	 on	 adipocytes,	 possibly	 via	 ROS	 production	 and	 associated	changes	in	signalling	pathways.		As	described	in	section	5.3.3,	neither	LPI	nor	LPS	were	able	to	induce	any	changes	in	 3T3-L1	 gene	 expression	 of	 the	 antioxidant	 GPx4	 or	 MnSOD	 genes,	 the	 pro-oxidant	 NOX4	 gene,	 or	 the	 GPR55	 gene;	 therefore,	 suggesting	 that	 the	 changes	observed	 in	 the	 in	 vivo	 study	 were	 not	 due	 to	 a	 gene	 altering	 effect	 of	 LPI	 on	mature	adipocytes.	As	the	data	from	Moreno-Navarette	et	al.	(2012)	suggests	that	LPI	 does	 have	 gene	 expression	 altering	 effects	 within	 cultured	 human	 WAT	explants,	including	increases	in	leptin,	adiponectin	(although	not	significantly)	and	GPR55	mRNA	expression,	it	could	be	that	this	effect	is	via	another	cell	type	found	within	adipose	tissue,	although	no	other	studies	have	examined	the	effect	of	LPI	on	individual	 cell	 types	 such	 as	 fibroblasts,	 immune	 cells	 or	 pre-adipocytes	 to	 date	(Moreno-Navarrete	et	 al.	2012).	Alternatively,	 it	may	be	 that	 the	effect	of	LPI	on	adipocytes	 is	 species	 specific,	 since	 although	 GPR55	 mRNA	 is	 detected	 in	 both	human	 and	 rodent	 WAT,	 the	 level	 of	 GPR55	 gene	 expression	 found	 within	 this	study	 in	 both	 differentiated	murine	 3T3-L1	 cells	 and	 the	WAT	 of	WT	mice	 was	extremely	low	(and	at	times	undetectable).	Therefore,	it	may	be	that	human	WAT	contains	a	higher	level	of	GPR55	expression	and	therefore	has	a	greater	potential	for	 LPI	 to	 exert	 an	 effect	 via	 its	 action	 on	 the	 subsequently	 translated	 GPR55	protein	(Moreno-Navarrete	et	al.	2012,	Imbernon	et	al.	2014).	This	 study	 has	 also	 elucidated	 that	 LPI	 does	 not	 induce	 the	 generation	 of	 ROS	within	 3T3-L1	 cells,	 as	 no	 increases	 in	 fluorescence	 were	 observed	 in	 the	treatment	 of	 3T3-L1	 cells	with	LPI	 as	 observed	 in	 section	5.3.3.2.	However,	 it	 is	likely	 that	any	potential	 increase	 in	ROS	due	 to	 treatment	with	LPI	was	not	high	enough	to	be	counteracted	by	the	high	level	of	antioxidant	enzymes	present	in	the	cells	 (as	 opposed	 to	H2O2	 treatment),	 as	 demonstrated	 in	 this	 study	by	 the	 high	gene	expression	of	antioxidant	genes	in	differentiated	3T3-L1	cells.		
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5.4.3. The effect of CoCl2 and H2O2 treatment in 3T3-L1 cells 
As	multiple	studies	have	shown	that	hypoxia	is	a	significant	mechanism	by	which	dysregulation	 of	 adipokine	 production/secretion	 occurs	 in	 obesity	 and	 HFD	feeding	 (Chen	 et	 al.	 2006,	Wang,	Wood	and	Trayhurn	2007,	Ye	 et	 al.	 2007),	 this	study	aimed	to	elucidate	whether	the	changes	observed	in	gene	expression	within	WAT	 of	WT	 and	 GPR55-/-	 mice	 fed	 a	HFD	 from	 chapter	 3	was	 due	 to	 a	 hypoxic	environment	 created	 in	 adipose	 tissue	 which	 then	 alters	 the	 metabolism	 of	adipocytes.		The	 use	 of	 CoCl2	 is	 widely	 used	 as	 a	 hypoxia	 mimetic	 compound	 and	 has	successfully	been	employed	in	a	vast	array	of	culture	models,	including	the	3T3-L1	cell	line	(Piret	et	al.	2002,	Wu	and	Yotnda	2011,	Kamiya	et	al.	2010).	The	hypoxic	effect	 of	 cobalt	 is	 achieved	 by	 activation	 of	 a	 number	 of	 possible	 pathways,	 all	involving	the	stabilisation	of	the	HIF-1α	protein.	The	HIF-1α	gene	is	continuously	expressed	 and	 translated	 under	 normoxic	 conditions,	 however	 the	 protein	 is	readily	 ubiquitinated	 and	 thus	 targeted	 for	 degradation,	 preventing	 it	 from	translocating	 to	 the	 nucleus,	 dimerising	 with	 HIF-1β	 and	 initiating	 its	transcriptional	activity.	Triantafyllou	et	al.	(2006)	demonstrated	that	cobalt	largely	exerts	 its	 effects	 via	 a	 ROS	 induced-MAPK	 activation	 pathway,	 leading	 to	 the	stabilisation	of	HIF-1α	(Triantafyllou	et	al.	2006).	Activation	of	the	MAPK	pathway	is	contrary	to	the	initial	proposal	that	addition	of	Co2+	ions	simply	replaces	the	Fe2+	ion	present	 in	 the	prolyl	hydrolases	 responsible	 for	 the	hydroxylation	of	proline	residues	in	HIF-1α	that	are	required	for	the	ubiquitination	and	degradation	of	the	protein,	therefore	leading	to	their	inactivation	and	subsequent	stabilisation	of	HIF-1α	(Schofield	and	Ratcliffe	2004).	Alternatively,	it	has	also	been	shown	that	cobalt	may	 regulate	 HIF-1α	 stabilisation	 via	 depletion	 of	 intracellular	 ascorbate,	 a	cofactor	 required	 for	 the	 activity	 of	 the	prolyl	 hydroxylases	which	 target	HIF-1α	(Salnikow	et	al.	2004).	Finally,	it	has	also	been	shown	that	cobalt	can	directly	bind	to	HIF-1α,	preventing	the	binding	of	HIF-1α	to	pVHL	and	therefore	preventing	the	ubiquitination	 and	 degradation	 of	 the	 protein	 (Yuan	 et	 al.	 2003).	 However,	 the	mechanism	 by	 which	 cobalt	 principally	 works	 to	 stabilise	 HIF-1α	 is	 not	 fully	understood	 and	 it	 is	 most	 likely	 a	 combination	 of	 these	 effects	 and	 may	 be	determined	by	tissue	or	cell	type.		
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The	 HIF-1α	 protein	 level	 in	 this	 study,	 as	 described	 in	 section	 5.3.4.1,	 was	surprisingly	 high	 as	 it	 was	 expected	 that,	 under	 normoxic	 conditions,	 protein	levels	would	be	very	 low	or	undetectable	as	demonstrated	 in	other	studies	using	3T3-L1	 cells	 (Mihai	 and	 Schröder	 2014)	 and	 other	 cellular	 systems	 (Wu	 and	Yotnda	2011).	The	 lack	of	an	 increase	 in	HIF-1α	protein	 in	cobalt	 treated	cells	 is	possibly	due	 to	 this	already	high	 (and	possibly	maximal)	 level	of	HIF-1α	protein	within	 the	 3T3-L1	 cells	 under	 control	 conditions.	 The	 results	 obtained	 are	therefore	 difficult	 to	 interpret,	 and	 several	 hypotheses	 could	 be	 suggested	 to	explain	the	high	HIF-1α	protein	expression.	A	primary	mechanism	by	which	HIF-1α	 is	 stabilised	 is	 via	 a	ROS	 dependant	mechanism	and	 as	3T3-L1	 cells	 produce	ROS	 as	 part	 of	 their	 differentiation	 into	 mature	 adipocytes	 (Triantafyllou	 et	 al.	2006),	HIF-1α	may	be	 stabilised	due	 to	 activation	of	 this	 pathway.	 Secondly,	 the	size	 of	 the	 cells	 combined	with	 the	 extremely	 large	 lipid	 droplet	 formations	 (as	seen	in	Figure	5.3)	could	potentially	cause	a	hypoxic	microenvironment	within	the	cell	 culture,	 a	 phenomenon	 typically	 observed	 in	 many	 forms	 of	 cancerous	tumours,	 although	 to	 a	 much	 greater	 extent	 than	 would	 be	 expected	 in	 culture	(Semenza	2016).	Finally,	another	cause	of	HIF-1α	stabilisation	may	be	due	to	the	protocol	used,	as	the	trolox	employed	in	this	experiment	was	initially	dissolved	in	ethanol	 and	 control	 cells	 were	 treated	 with	 an	 ethanol	 as	 a	 vehicle	 control.	Although	 it	 seems	 unlikely,	 as	 the	 final	 concentration	 of	 ethanol	 in	 cell	 culture	media	 was	 kept	 below	 1%	 v/v,	 ethanol	 has	 been	 shown	 to	 induce	 HIF-1α	 and	hypoxia	in	the	liver	during	chronic	feeding	of	ethanol	in	mice	(at	a	concentration	up	 to	 6.2%	v/v)	 in	 vivo	 and	 also	 in	 cellular	 application	of	 100	mM	 ethanol	 in	 in	
vitro	 models	 of	 acute	 ethanol	 treatment	 using	 liver	 sinusoidal	 endothelial	 cells	(Wang	et	al.	2013,	Yeligar,	Tsukamoto	and	Kalra	2009).	Although	unlikely,	in	order	to	 confirm	 if	 ethanol	 was	 having	 an	 effect	 on	 the	 induction	 of	 HIF-1α,	 further	experiments	would	need	to	be	conducted	to	explore	this	theory.		As	the	high	level	of	HIF-1α	in	normoxic	control	cells	was	high,	it	becomes	difficult	to	discern	 if	 true	hypoxia	was	achieved	 in	 the	3T3-L1	cells	upon	 treatment	with	cobalt;	 however,	 changes	 in	 gene	 expression	of	 several	 genes	was	observed	 and	will	be	discussed,	keeping	 in	mind	 that	a	 true	model	of	hypoxia	may	or	may	not	have	been	achieved	in	this	experiment.		
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Firstly,	 a	 large	 decrease	 in	 gene	 expression	 was	 observed	 for	 the	 adipokine	adiponectin	(0.27	fold)	when	treating	3T3-L1	cells	with	cobalt.	Adiponectin	gene	expression	 was	 significantly	 reduced	 upon	 treatment	 with	 cobalt,	 a	 finding	consistent	with	existing	literature	that	has	used	both	in	vivo	and	in	vitro	methods	to	demonstrate	that	the	reduction	in	adiponectin	gene	expression	during	obesity	is	largely	caused	by	hypoxia	of	the	adipose	tissue	(Chen	et	al.	2006,	Ye	et	al.	2007).	Using	an	in	vivo	HFD	intervention	in	mice,	Ye	et	al.	(2007)	showed	that	obesity	is	associated	with	hypoxia	of	the	adipose	tissue,	resulting	in	changes	in	inflammatory	gene	expression	(including	adiponectin).	This	effect	was	confirmed	by	treatment	of	isolated	primary	adipocytes	and	in	vitro	culture	of	3T3-L1	cells	treated	with	either	1%	oxygen	or	75	µM	CoCl2,	therefore	supporting	the	findings	of	the	current	study	in	regards	to	adiponectin	gene	expression	(Ye	et	al.	2007).	Similarly,	 this	 study	 observed	 a	 marked	 decrease	 (to	 0.042	 fold)	 in	 leptin	 gene	expression	upon	treatment	with	cobalt.	This	decrease	is	contrary	to	studies	which	have	 observed	 increases	 in	 both	 leptin	 gene	 expression	 and	 protein	 secretion	during	 hypoxia	 (or	 treatment	with	 cobalt)	 from	 3T3-L1	 cells	 (Wang,	Wood	 and	Trayhurn	2007,	Grosfeld	et	al.	2002).	Leptin	has	also	been	shown	to	be	expressed	during	hypoxia	in	non-adipose	cells	such	as	human	coronary	artery	smooth	cells,	
via	 induction	of	angiotensin	 II,	ROS,	 and	 the	 JNK	pathway	(Chiu,	Wang	and	Shyu	2014),	 and	 similarly,	 it	 was	 determined	 that	 the	 leptin	 gene	 has	 a	 hypoxia-response-element	 (HRE)	 in	 the	 promotor	 region	 that	 directly	 binds	 to	 activated	HIF-1α	 in	 skin	 dermal	 fibroblast-like	 cells	 (Ambrosini	 et	 al.	 2002).	 Given	 these	previous	 findings,	 it	 is	 surprising	 that	 leptin	was	 significantly	down-regulated	 in	response	to	cobalt	treatment	in	3T3-L1	cells;	however,	it	has	also	been	reported	in	rat	primary	adipocytes	that	hypoxia	(10%	oxygen	for	48	hours)	can	downregulate	leptin	 expression	 and	 secretion	 (Yasumasu,	 Takahara	 and	 Nakashima	 2002).	 It	may	 be	 that	 the	 link	 between	 leptin	 and	 hypoxia	 could	 be	 more	 complex	 than	initially	 thought	 and	 it	 is	 possibly	 subtle	 changes	 in	 experimental	 protocols	 that	are	the	cause	of	such	discrepancies	between	studies,	or	as	previously	mentioned,	it	may	 be	 that	 true	 hypoxia	 was	 not	 achieved	 and	 the	 effect	 on	 leptin	 expression	observed	in	the	present	study	is	another	effect	of	direct	treatment	with	cobalt.		As	 hypoxia	 and	 cobalt	 treatment	 (and	 hydrogen	 peroxide)	 have	 been	 shown	 to	
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induce	ROS	and	stabilisation	of	HIF-1α	(Triantafyllou	et	al.	2006),	this	may	lead	to	downstream	effects	via	either	direct	 hypoxia	 responses	 (such	as	HRE	binding	by	HIF-1α)	or	by	indirect	ROS	effects	(Ambrosini	et	al.	2002).	The	changes	observed	in	 both	 adiponectin	 and	 leptin	 gene	 expression	 following	 treatment	 with	 either	cobalt	 or	 hydrogen	 peroxide	 were	 not	 attenuated	 by	 pre-treatment	 with	 the	antioxidant	trolox;	therefore,	it	is	unlikely	that	the	changes	are	due	to	an	oxidative	stress	 response.	 Alternatively,	 it	 must	 be	 considered	 that	 the	 ROS	 scavenging	mechanism	by	which	trolox	works	is	not	suitable	to	counteract	the	effects	caused	by	 cobalt	 or	 hydrogen	 peroxide	 treatment,	 although	 this	 antioxidant	 has	demonstrated	a	ROS	scavenging	effect	in	other	studies.		As	 a	 previous	 study	 has	 shown	 that	 hypoxia	 and	 cobalt	 treatment	 can	downregulate	 the	 gene	 expression	 of	 antioxidant	 enzymes,	 such	 as	 extracellular	SOD	 (EC-SOD)	 but	 not	 MnSOD	 or	 CuSOD,	 by	 a	 JNK-TNFα	 mediated	 pathway	(Kamiya	 et	 al.	 2010),	 the	 present	 study	 examined	 the	 effect	 of	 cobalt	 on	 the	expression	of	 another	 antioxidant	 enzyme,	GPx4.	No	 significant	 changes	 in	GPx4	expression	 were	 observed	 upon	 treatment	 with	 cobalt,	 therefore	 it	 can	 be	concluded	that	GPx4	is	differentially	regulated	to	other	antioxidant	genes	such	as	EC-SOD	 in	 3T3-L1	 cells	 and	 is	 not	 affected	 by	 treatment	 with	 cobalt.	 The	 data	supports	the	notion	that	mitochondria	bound	enzymes	such	as	MnSOD	and	GPx4	may	be	differentially	regulated	compared	to	extracellularly	released	enzymes	(EC-SOD)	and	are	less	likely	influenced	by	changes	in	oxygen	availability.		Similarly,	 no	 changes	 were	 observed	 in	 the	 gene	 expression	 of	 NOX4,	 a	 more	surprising	find	as	it	has	been	shown	that	NOX4	is	a	direct	target	of	activated	HIF-1α	in	pulmonary	artery	smooth-muscle	cells	under	hypoxic	conditions	(Diebold	et	al.	2010)	and	levels	of	NOX4	were	increased	in	the	adipose	tissue	of	mice	fed	a	HFD	as	discussed	 in	chapter	3.	 It	must	be	considered	 that	as	HIF-1α	 is	already	highly	expressed	 in	 the	 normoxic	 3T3-L1	 cells,	 it	 may	 be	 that	 HIF-1α	 is	 inducing	 the	maximal	expression	of	NOX4	in	control	cells	and	therefore	increases	would	not	be	observed	 with	 treatment	 with	 hypoxia	 or	 cobalt.	 However,	 the	 results	 of	 the	differentiation	protocol	(Figure	5.8)	would	suggest	otherwise,	as	NOX4	expression	is	observed	to	be	higher	in	non-differentiated	cells,	it	would	be	expected	that	these	cells	retain	their	ability	to	express	NOX4	at	higher	levels	once	differentiated.		
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Finally,	 no	 significant	 changes	 were	 observed	 in	 GPR55	 gene	 expression	 with	treatment	 of	 cobalt.	 If	 true	 hypoxia	 was	 achieved	 in	 this	 experiment,	 this	 data	would	suggest	that	there	is	no	link	between	hypoxia	and	GPR55	regulation,	a	novel	finding	 as	no	other	 studies	have	 examined	GPR55	 in	 the	paradigm	of	 hypoxia	 in	any	cell	type	to	date.	However,	if	no	true	hypoxia	exists	in	this	experiment	then	it	must	be	concluded	only	 that	 cobalt	 treatment	has	no	effect	on	GPR55	regulation	within	3T3-L1	adipocytes.	
5.5. Conclusions 
To	 summarise,	 the	 present	 study	 aimed	 to	 elucidate	 the	 possible	 mechanisms	behind	the	changes	observed	within	the	adipose	tissue	of	mice	fed	a	high	fat	diet	as	presented	and	discussed	in	chapter	3.	Two	possible	mechanisms	were	explored	to	explain	these	changes,	 that	the	 increase	observed	in	circulating	LPI	could	 lead	to	changes	 in	 gene	 expression	 within	 adipocytes	 and	 the	 theory	 of	 adipose	 tissue	hypoxia	 and	 oxidative	 stress	 leading	 to	 gene	 expression	 changes.	 As	 discussed	above,	 attempts	 at	 the	 isolation	 and	 differentiation	 of	 primary	 pre-adipocytes	proved	unsuccessful,	therefore	the	3T3-L1	adipocyte	cell	model	was	used	in	place.	The	 treatment	 of	 3T3-L1	 cells	 with	 LPI	 demonstrated	 no	 changes	 in	 ROS	accumulation	 or	 gene	 expression	 of	 the	 studied	 genes,	 therefore	 disproving	 the	original	 LPI	 hypothesis.	 The	 induction	 of	 hypoxia	 using	 cobalt	 chloride	 proved	problematic	due	to	the	already	high	level	of	HIF-1α	expression	within	the	control	3T3-L1	 cells.	 However,	 treatment	with	 cobalt	 did	 lead	 to	 some	 gene	 expression	changes;	although,	the	changes	do	not	mirror	those	found	within	the	adipose	tissue	of	 mice	 fed	 a	 high	 fat	 diet	 (nor	 do	 the	 results	 of	 the	 control	 cells	 which	 are	expressing	HIf-1α).	Therefore,	it	is	likely	that	the	adipose	tissue	changes	observed	in	mice	 fed	 a	 HFD	 are	 not	 due	 to	 adipose	 tissue	 hypoxia,	 despite	 the	 advanced	hypertrophy	of	the	tissue	as	discussed	in	chapter	3.	However,	it	must	be	noted	that	due	to	the	limitations	already	discussed	in	relation	to	the	protocols	used,	it	may	be	that	 the	 cell	 system	utilised	was	 not	 suitable	 to	 explore	 these	 changes	 fully	 and	further	work	using	a	different	cell	system	would	need	to	be	explored	to	draw	any	solid	conclusions	on	this	data.	To	conclude,	further	experiments	should	be	carried	out	to	explain	the	changes	observed	within	the	adipose	tissue	of	mice	fed	a	HFD,	as	
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the	mechanisms	explored	 in	this	chapter	such	as	LPI	 level	and	hypoxia	are	 likely	not	involved.	
		 182	
6 : General Discussion 
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6.1. Main findings 
6.1.1. Characterisation of the GPR55-/- mouse 
When	 fed	a	 standard	diet,	GPR55-/-	mice	did	not	present	any	differences	 in	body	weight	or	fat	mass	compared	to	WT	controls,	a	finding	consistent	with	a	number	of	other	 studies	 that	 have	 used	 GPR55-/-	 mice	 and	 shown	 no	 difference	 in	physiological	 parameters	 (Bjursell	 et	 al.	 2016,	 Wu	 et	 al.	 2013b).	 However,	 this	finding	contrasts	with	another	study	that	specifically	examined	energy	metabolism	in	GPR55-/-	mice	by	Meadows	et	al.	(2016),	which	demonstrated	that	older	GPR55-/-	mice	(6	months	old)	develop	increased	adiposity,	even	when	fed	with	a	standard	diet	(Meadows	et	al.	2016).	These	differences	between	studies	are	likely	due	to	the	length	of	 the	study	and	subsequent	age	of	 the	mice	or	 the	specific	diets	used,	as	even	 “standard	diets”	vary	greatly	 in	nutritional	 composition	between	 individual	suppliers	 and	 there	 is	 no	 universally	 accepted	 measure	 to	 which	 a	 diet	 must	comply	to	be	considered	standard.		The	present	 study	has	shown	 that	under	standard	diet	 conditions,	GPR55-/-	mice	are	 characterised	by	 significant	differences	 in	 the	 gene	 expression	of	 adipokines	and	 antioxidant	 enzymes	within	 the	 adipose	 tissue	 compared	 to	WT	mice	 fed	 a	standard	diet	and	which	are	more	akin	to	the	gene	expression	profile	of	WT	mice	fed	 a	 HFD	 seen	 in	 both	 the	 present	 study	 and	 others	 (Krautbauer	 et	 al.	 2014,	Rupérez,	Gil	and	Aguilera	2014).	These	findings	suggest	that	GPR55-/-	mice	have	a	“pre-obese”	gene	expression	profile,	possibly	due	 to	 increases	 in	oxidative	stress	within	the	adipose	tissue.		
6.1.2. GPR55 mediates a resistance to obesity in vivo  
Although	 the	 role	 of	 GPR55	 in	 energy	 expenditure	 and	 metabolism	 has	 been	investigated	by	Meadows	et	al.	under	standard	diet	conditions,	where	ablation	of	GPR55	 was	 shown	 to	 induce	 insulin	 resistance	 and	 higher	 adiposity	 in	 adult	GPR55-/-	mice,	 the	 present	 study	 is	 the	 first	 to	 examine	 the	 phenotypic	 changes	that	occur	in	the	GPR55-/-	mouse	upon	feeding	with	a	HFD	(Meadows	et	al.	2016).	Meadows	et	al.	postulated	from	their	data	that	GPR55-/-	mice	would	be	susceptible	
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to	obesity,	a	hypothesis	which	the	present	study	has	confirmed,	as	GPR55-/-	mice	fed	a	HFD	gained	significantly	greater	weight	and	fat	mass	than	WT	controls	over	the	same	dietary	period.		The	 present	 study	 has	 also	 demonstrated	 that	 GPR55	 expression	 in	 murine	adipose	 tissue	 is	 not	 regulated	 by	 HFD	 feeding,	 which	 is	 in	 contrast	 to	 another	study	by	Imbernon	et	al.	(2014),	which	demonstrated	that	GPR55	expression	in	rat	adipose	tissue	is	regulated	by	nutritional	status	and	leptin	(fed	and	fasted	states),	pituitary	factors	and	sex	(Imbernon	et	al.	2014).	Although	these	differences	may	be	due	 to	 species	 specific	 differences,	 the	 present	 study	 is	 in	 agreement	 with	Imbernon	 et	 al.	 in	 regards	 to	 circulating	 LPI	 levels,	 as	 in	 the	 present	 study	circulating	LPI,	and	particularly	the	20:3	species	of	LPI,	was	increased	in	both	non-obese	 WT	 and	 obese	 GPR55-/-	 mice	 after	 feeding	 with	 a	 HFD.	 Together	 these	findings	suggest	that	plasma	LPI	level	is	not	dependent	on	GPR55	expression	and	is	associated	with	diet,	and	not	body	weight	or	fat	mass,	which	has	been	suggested	previously	 in	a	 study	examining	GPR55	 in	human	patients	 (Moreno-Navarrete	et	al.	2012,	Imbernon	et	al.	2014).	The	 GPR55-/-	 mouse,	 when	 challenged	 with	 a	 HFD,	 presents	 with	 hypertrophic	obesity,	liver	steatosis,	increases	in	circulating	plasma	LPI	and	mild	dyslipidaemia	without	the	onset	of	atherosclerosis.	Meadows	et	al.	have	previously	demonstrated	that	GPR55-/-	mice	are	insulin	resistant,	and	therefore	the	findings	from	this	thesis	add	further	support	to	the	notion	that	the	HFD	fed	GPR55-/-	mouse	may	represent	a	potential	model	of	human	adult	obesity	and	metabolic	syndrome.	However,	 the	GPR55/LPI	 system	 would	 appear	 to	 be	 differentially	 regulated	 in	 humans	 and	rodents,	 as	 it	 has	 been	 shown	 that	 both	 adipose	 tissue	 GPR55	 expression	 and	plasma	LPI	 levels	are	 increased	 in	human	patients	 that	present	with	obesity	and	type	 2	 diabetes,	 a	 finding	 opposite	 to	 that	 in	 rodents	 (Moreno-Navarrete	 et	 al.	2012,	Imbernon	et	al.	2014).		Since	WT	mice	fed	the	same	HFD	did	not	present	with	increased	body	weight,	fat	mass	or	other	characteristics	associated	with	obesity	over	the	same	dietary	period,	this	 study	 has	 provided	 strong	 evidence	 that	 GPR55	 mediates	 a	 resistance	 to	obesity	 in	 vivo;	 however,	 it	 is	 still	 unknown	by	what	mechanism(s)	 this	 function	occurs	and	further	work	needs	to	be	conducted	to	elucidate	this	phenomenon.		
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6.1.3. GPR55 and the outcome of I/R 
6.1.3.1. GPR55 deletion alone does not affect I/R outcome 
To	investigate	the	effect	of	GPR55	on	the	outcome	of	I/R,	a	Langendorff	perfusion	setup	 was	 utilised	 using	 hearts	 from	 GPR55-/-	 mice.	 It	 was	 demonstrated	 that	hearts	from	GPR55-/-	mice	do	not	show	any	differences	in	infarct	size	compared	to	hearts	 from	 WT	 mice,	 a	 finding	 which	 supports	 the	 previous	 findings	 of	 our	laboratory	 (Robertson-Gray,	 manuscript	 submitted	 for	 publication)	 and	 that	demonstrates	that	under	control	conditions,	GPR55	plays	no	functional	role	in	the	outcome	of	 I/R.	Furthermore,	as	these	experiements	were	carried	out	 in	 isolated	hearts,	only	LPI	generated	by	the	cardiomyocyte	would	have	a	functional	effect	on	the	 outcome	 of	 I/R	 injury;	 however,	 as	 there	 were	 no	 observed	 differences	 in	infarct	size,	the	data	further	supports	the	notion	that	the	GPR55/LPI	system	is	not	functionally	active	under	control	conditions	in	the	setting	of	I/R.		
6.1.3.2. GPR55 mediates the cardio-protective effect of a HFD 
on I/R injury 
Although	 the	WT	mice	 used	 in	 the	 present	 study	 did	 not	 develop	 obesity	 when	challenged	 with	 a	 HFD,	 the	 hearts	 from	 these	 mice	 had	 smaller	 infarcts	 after	 a	period	of	I/R	compared	to	hearts	from	SD	fed	controls,	suggesting	that	molecular	changes	may	have	occurred	in	the	heart	due	to	the	HFD	intervention.	The	obesity	paradox,	 an	 effect	 by	 which	 obese	 individuals	 display	 better	 cardiovascular	outcomes	after	a	period	of	I/R,	has	been	demonstrated	in	both	rodents	(Donner	et	al.	2013,	Salie,	Huisamen	and	Lochner	2014)	and	human	patients	 (Gruberg	et	al.	2002)	 previously.	 The	 obesity	 paradox	 is	 thought	 to	 occur	 via	 metabolic	preconditioning	of	 the	heart	with	 insulin	or	other	hormones,	or	via	 an	 increased	induction	 of	 the	 RISK	 pathway	 at	 the	 time	 of	 reperfusion,	 although	 results	 of	independent	groups	have	been	conflicting	(Hausenloy	and	Yellon	2007,	Donner	et	al.	 2013,	 Salie,	 Huisamen	 and	 Lochner	 2014).	 These	 cardio-protective	metabolic	effects	could	therefore,	in	theory,	precede	the	onset	of	obesity	when	using	a	HFD	intervention	 as	 employed	 in	 the	 present	 study	 and	 consequently	 it	 may	 be	
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postulated	 that	 these	 mice	 are	 in	 a	 metabolically	 conditioned	 state	 that	 may	precede	the	development	of	obesity	due	to	intervention	with	a	HFD.	In	contrast	to	the	 study	 of	 Donner	 et	 al.	 (2013)	 and	 in	 agreement	with	 Salie	 et	 al.	 (2014),	 the	present	study	established	that	the	RISK	pathway	was	not	up-regulated	in	infarcted	hearts	 from	 WT	 mice	 fed	 a	 HFD,	 despite	 exhibiteing	 a	 smaller	 infarct	 size,	suggesting	that	the	cardio-protection	offered	by	a	HFD	is	conferred	via	another,	as	yet	 undefined,	 mechanism	 (Donner	 et	 al.	 2013,	 Salie,	 Huisamen	 and	 Lochner	2014).		Crucially,	 the	 present	 study	 has	 demonstrated	 for	 the	 first	 time	 that	 the	 cardio-protective	effect	of	HFD	feeding	on	the	outcome	of	I/R	injury,	as	evidenced	in	WT	mice,	 is	 lost	 in	 hearts	 from	 obese	 GPR55-/-	mice.	 Therefore,	 this	 study	 implies	 a	direct	 role	 for	 GPR55	 in	 the	 cardio-protection	 conferred	 by	 HFD	 feeding	 on	 the	outcome	 of	 I/R	 injury,	 a	 novel	 function	 of	 GPR55.	 The	 possible	 mechanism	 by	which	GPR55	is	cardio-protective	remains	elusive,	however	as	discussed	in	section	4.4.4,	it	is	possible	that	the	diet-induced	increases	in	20:3	LPI	alongside	sustained	levels	 of	 20:4	 LPI,	 result	 in	 activation	 of	 intracellular	 GPR55,	 leading	 to	hyperpolarisation	 of	 cardiomyocytes	 during	 I/R	 and	 subsequently	 an	 increased	resistance	to	I/R	damage.		
6.1.3.3. I/R injury results in a loss of 20:4 LPI in WT SD fed mice 
The	 lysophospholipid	 LPI	 is	 the	 proposed	 endogenous	 ligand	 of	 the	 GPR55	receptor,	 however	 little	 focus	 has	 been	 given	 to	 the	 biological	 relevance	 of	 this	molecule.	 To	 investigate	 the	 effect	 of	 I/R	 and	 diet	 on	 LPI	 levels	 within	 cardiac	tissue,	 LPI	 was	 measured	 in	 control	 hearts	 and	 hearts	 that	 underwent	 the	 I/R	protocol.	The	present	study	found	that	20:4	LPI	was	specifically	and	significantly	reduced	in	infarcted	heart	tissue	from	WT	SD	fed	mice.	This	is	a	completely	novel	finding,	consistent	with	existing	literature	that	describes	a	depletion	of	membrane	phospholipids	 after	 a	period	of	 I/R	which	 leads	 to	 cell	 instability	 and	death	 (De	Windt	et	al.	1998).	The	finding	that	depletion	of	20:4	LPI	was	not	observed	in	WT	HFD	 fed	mice	 (which	 exhibited	 smaller	myocardial	 infarct	 sizes)	 suggests	 that	 a	HFD	prevents	the	I/R-induced	depletion	in	20:4	LPI,	possibly	due	to	the	increased	production	of	20:3	LPI	and	via	a	currently	unknown	mechanism.	
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6.1.4. LPI does not mediate gene altering effects in 3T3-L1 
adipocytes 
As	Moreno-Navarette	 et	 al.	 (2012)	 have	 previously	 shown,	 LPI	 is	 able	 to	 induce	gene	expression	changes	in	human	adipose	tissue	explants,	in	particular	leptin	and	FASN,	 alongside	 an	 increase	 in	GPR55	gene	 expression	 (Moreno-Navarrete	 et	 al.	2012).	The	present	study	aimed	to	elucidate	if	the	phenotypic	changes	observed	in	the	adipose	tissue	of	mice	fed	a	HFD	were	due	to	the	influence	of	LPI	on	adipocytes	(Moreno-Navarrete	et	al.	2012).	It	was	demonstrated	using	differentiated	3T3-L1	adipocytes	 that	 LPI	 does	 not	 have	 any	 effect	 on	 the	 gene	 expression	 of	multiple	genes	 including	 GPR55,	 GPx4	 and	 NOX4,	 which	 is	 in	 contrast	 to	 the	 study	 of	Moreno-Navarette	 et	 al.	 This	 difference	 between	 studies	 may	 be	 due	 to	 species	differences	in	GPR55	expression	and	function,	as	3T3-L1	cells	represent	a	murine	adipocyte	 cell	model	 which,	 under	 basal	 conditions,	 express	 a	 very	 low	 level	 of	GPR55	mRNA.	Moreover,	 LPI	may	 have	 exerted	 an	 effect	 on	 non-adipocyte	 cells	(such	 as	 immune	 cells	 or	 fibroblasts)	 in	 human	 adipose	 tissue,	 which	 are	 not	present	within	 a	 homogenous	 3T3-L1	 cell	 culture.	 Despite	 these	 differences,	 the	results	of	the	present	study	confirm	that	the	gene	expression	changes	observed	in	the	 adipose	 tissue	 of	HFD	 fed	mice	 is	 unlikely	 to	 be	 due	 to	 any	 effect	 of	 LPI	 on	adipocytes	but	via	another	unknown	mechanism.		
6.1.5. Hypoxia mimetic CoCl2 does not replicate the gene 
expression changes found in the adipose tissue of HFD 
mice 
Another	aim	of	the	present	study	was	to	determine	if	the	changes	in	adipose	tissue	gene	 expression	 observed	 in	 HFD	 fed	 mice	 was	 due	 to	 hypoxia	 of	 the	 adipose	tissue,	as	has	been	demonstrated	in	a	number	of	studies	(Chen	et	al.	2006,	Wang,	Wood	and	Trayhurn	2007,	Ye	et	al.	2007).	To	fulfil	this	aim,	differentiated	3T3-L1	cells	were	treated	with	CoCl2,	a	chemical	hypoxia	mimetic	that	has	been	shown	to	replicate	 hypoxia	 in	 many	 different	 cell	 culture	 models,	 including	 3T3-L1	 cells	(Piret	et	al.	2002,	Wu	and	Yotnda	2011,	Kamiya	et	al.	2010).	Unfortunately,	when	confirming	the	hypoxia	mimetic	effect	of	CoCl2	treatment,	namely	the	induction	of	
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HIF-1α,	this	protein	was	found	to	be	highly	expressed	in	untreated	control	cells,	in	direct	 contrast	 to	 other	 studies	 that	 have	 employed	 this	 strategy	 in	3T3-L1	 cells	(Ye	 et	 al.	 2007).	 Despite	 this,	 CoCl2	 treatment	 was	 able	 to	 induce	 some	 gene	expression	 changes	 in	 3T3-L1	 cells	 that	 were	 similar	 to	 the	 findings	 of	 another	study	i.e.	a	decrease	in	adiponectin	expression	(Ye	et	al.	2007),	but	these	changes	did	not	mimic	the	findings	of	the	HFD	intervention	study	conducted	in	chapter	3,	therefore	 implying	 that	 the	changes	observed	 in	vivo	were	not	due	 to	hypoxia	of	the	adipocytes,	despite	the	hypertrophy	of	the	adipose	tissue	observed	in	GPR55-/-	HFD	 fed	mice.	 This	 particular	 finding	 is	 contentious	 due	 to	 the	 reliability	 of	 the	CoCl2	 treatment	 in	 inducing	 true	 hypoxia	 as	 discussed,	 therefore,	 further	 work	would	need	to	be	carried	out	to	substantiate	these	findings.		
6.2. Future work 
6.2.1. Confirmation of the GPR55-/- phenotype 
Alongside	the	physiological	measurements	such	as	body	weight	and	fat	mass,	the	present	 study	has	 focused	on	describing	 the	gene	expression	changes	 in	adipose	tissue,	 and	 whilst	 this	 offers	 significant	 insight	 into	 the	 molecular	 changes	 that	occur	in	response	to	deletion	of	GPR55,	it	would	be	insightful	to	examine	the	same	targets	at	a	protein	and	secretion	level,	particularly	for	the	adipokines	leptin	and	adiponectin,	in	order	to	confirm	that	the	changes	described	in	this	study	translate	to	functional	protein	changes	able	to	exert	subsequent	systemic	effects.		
6.2.2. The mechanism of GPR55 dependent changes 
This	study	has	described	the	multiple	phenotypic	changes	that	occur	in	vivo	due	to	intervention	with	a	HFD	in	GPR55-/-	mice	do	not	occur	in	WT	mice,	although	the	in	
vitro	 use	 of	 3T3-L1	 cells	 was	 not	 able	 to	 elucidate	 the	 pathways	 behind	 these	changes;	 therefore,	 the	 underlying	 mechanisms	 remain	 unknown.	 Employing	GPR55-/-	 mice	 in	 further	 in	 vivo	 studies	 and	 measuring	 levels	 of	 ROS,	 oxidative	stress	and	tissue	hypoxia	could	be	used	to	explore	in	more	depth	why	deletion	of	GPR55	 leads	 to	 susceptibility	 to	 obesity.	 Furthermore,	 through	 using	 in	 vitro	models	of	different	systems,	such	as	isolated	cardiomyocytes	and	hepatic	cells,	and	
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molecular	 approaches	 such	 as	 GPR55	 antagonist	 studies	 or	 RNA	 interference,	 it	would	be	possible	 to	 further	 investigate	the	effect	of	LPI	and	GPR55	on	different	cellular	 processes	 including	 gene/protein	 expression,	 glucose	 utilisation	 and	insulin	signalling.		
6.2.3. Exploring the effect of intracellular vs extracellular LPI 
on I/R injury 
As	proposed	by	the	present	study,	the	localisation	of	GPR55	and	subsequently	the	site	 of	 GPR55	 activation	 may	 play	 a	 crucial	 role	 in	 mediating	 either	 a	 cardio-protective	or	detrimental	effect	on	the	outcome	of	I/R	injury.	Therefore,	it	would	be	 interesting	 to	 explore	 this	 theory	 further	 using	 in	 vitro	 or	 in	 vivo/ex	 vivo	approaches.	However,	producing	or	artificially	inducing	intracellular	LPI	release	is	currently	a	challenge	as	the	endogenous	mechanism	of	LPI	production	 is	still	not	fully	 understood	 and	 appears	 to	 overlap	 with	 many	 other	 lipid	 metabolism	pathways;	similarly,	microinjection	of	LPI	into	individual	cells	(as	performed	by	Yu	et	 al.	 2013)	would	 not	 be	 appropriate	when	 trying	 to	measure	 gene	 or	 protein	expression	changes	in	response	to	I/R	in	the	whole	heart.		
6.3. Conclusion 
This	study	has	characterised	the	response	of	GPR55-/-	mouse	to	a	HFD	intervention	and	 has	 described	 the	 obesogenic	 phenotype	 which	 develops	 in	 these	 mice,	including	 the	 development	 of	 hypertrophic	 obesity,	 mild	 dyslipidaemia,	 adipose	tissue	 gene	 expression	 changes,	 liver	 steatosis	 and	 alterations	 in	 circulating	 and	cardiac	tissue	levels	of	LPI.	These	data	therefore	suggest	a	functional	role	of	GPR55	in	energy	metabolism	and	utilisation.	Moreover,	 it	has	been	established,	using	an	isolated	Langendorff-perfused	heart	preparation,	 that	the	cardio-protective	effect	of	 a	HFD	 on	 the	 outcome	 of	 I/R	 injury	 is	 dependent	 on	 the	 presence	 of	 GPR55.	Therefore,	GPR55	may	constitute	a	potential	 therapeutic	 target	 for	the	treatment	of	AMI.	The	mechanisms	behind	these	GPR55-dependent	effects	are	still	unknown	although	they	are	unlikely	to	be	due	to	any	effect	of	LPI	or	hypoxia	on	adipocytes	and	 further	 mechanistic	 studies	 need	 to	 be	 employed	 to	 elucidate	 these	mechanisms.		
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Figure i.i. Composition of the Standard diet used in both studies. 
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Figure i.ii. Composition of the HFD used in both studies. 
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Western Diet R638 Semi-synthetic feed 
 
Ingredients: 
Cornstarch, cocoa butter, casein, glucose, icing sugar, cellulose flour, minerals, vitamins, 
cholesterol 
 
Energy calculation 
semi-synthetic feed 
 
Feed: Semi-synthetic feed, R638 
 
 Content (%)          Factor          kJ/100 g          Energy (%) 
Raw protein 17.2 15.466 265.40 17.0 
Fat 21.0 29.687 623.43 40 
Crude fibre 3.9 2.926 11.26 0.7 
Ash 4.1 - -  - 
Water 10.0 - -  - 
NFE 43.9 15.048 660.46 42.3 
Total 100.0  1560.55 100.0 
 
 
Energy value 15.6 Mj/kg 
  
Analysis 
  Unit  Content 
Protein N*6.25   %  17.2  
Fat as per EC   %  21 
Crude fibre    %  3.9 
Ash    %  4.1 
Water    %  10 
NFE    %  43.9 
Phosphorus   % 0.4 
Iron    mg/kg  350 
Calcium    %  0.5 
Copper    mg/kg  8 
Magnesium   %  0.05 
Manganese   mg/kg  70 
Sodium    %  0.3 
Selenium    mg/kg  0.23 
Zinc    mg/kg  30 
Cholesterol    %  0.15 
Vitamin A    IE/kg  12000 
D    IE/kg  1500 
E    mg/kg  42 
K3    mg/kg  0.7 
B1    mg/kg  4 
B2    mg/kg  12 
B6    mg/kg  6 
B12    mg/kg  0.02 
Pantothenic acid   mg/kg  12 
Folic acid    mg/kg  0.5 
Niacin    mg/kg  40 
Biotin    mg/kg  0.3 
Vitamin C    mg/kg  500 
Choline    mg/kg  1000 
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Figure i.iii. Representative images showing the "output" generated by the automated cell 
counting using CellProfiler Software. First image is of adipose tissue from WT SD fed mice, 
second image is of adipose tissue from WT HFD fed mice. 
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Figure i.iv. Representative images showing the "output" generated by the automated cell 
counting using CellProfiler Software. First image is of adipose tissue from GPR55-/- SD fed 
mice, second image is of adipose tissue from GPR55-/- HFD fed mice. 	 	
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Molar ratio Peak area   Area ratio to ISTD 
  LPI 17:1  LPI 18:0 LPI 20:4   LPI 18:0 LPI 20:4 
              
0.0 592532 ND ND   0 0 
0.1 643387 50403 57064   0.1 0.1 
0.2 599959 173036 79641   0.3 0.1 
0.5 621668 450396 374073   0.7 0.6 
1.0 650834 921316 812259   1.4 1.2 
2.0 626643 1768641 1494670   2.8 2.4 
5.0 541084 4010946 3333209   7.4 6.2 
Figure i.v. Peak area of 17:1, 18:0 and 20:4 LPI species at different molar ratios and 
calculation of calibration curves for absolute quantification of different LPI species 
	
Figure i.vi. Calibration curve plot of 18:0 and 20:4 LPI standards. 			
y = 1.4704x
R² = 0.9994
y = 1.2263x
R² = 0.9993
0
1
2
3
4
5
6
7
8
0.0 1.0 2.0 3.0 4.0 5.0 6.0
Ar
ea
 ra
tio
 to
 IS
TD
Molar ratio to ISTD
LPI 18:0 LPI 20:4 Linear (LPI 18:0) Linear (LPI 20:4)
